<SEC-DOCUMENT>0001171843-17-002415.txt : 20170428
<SEC-HEADER>0001171843-17-002415.hdr.sgml : 20170428
<ACCEPTANCE-DATETIME>20170428161017
ACCESSION NUMBER:		0001171843-17-002415
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20170613
FILED AS OF DATE:		20170428
DATE AS OF CHANGE:		20170428
EFFECTIVENESS DATE:		20170428

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Anika Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000898437
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				043145961
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14027
		FILM NUMBER:		17795555

	BUSINESS ADDRESS:	
		STREET 1:		32 WIGGINS AVENUE
		CITY:			BEDFORD
		STATE:			MA
		ZIP:			01730
		BUSINESS PHONE:		(781) 457-9000

	MAIL ADDRESS:	
		STREET 1:		32 WIGGINS AVENUE
		CITY:			BEDFORD
		STATE:			MA
		ZIP:			01730

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANIKA THERAPEUTICS INC
		DATE OF NAME CHANGE:	19970114

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANIKA RESEARCH INC
		DATE OF NAME CHANGE:	19930309
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>def14a_042817.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-size: 16pt"><B>UNITED STATES</B></FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-size: 16pt"><B>SECURITIES AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Washington, D.C. 20549</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-size: 16pt"><B>SCHEDULE 14A</B></FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Proxy Statement Pursuant to Section 14(a) of</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">the Securities Exchange Act of 1934 (Amendment No.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">Filed by the Registrant [X]</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">Filed by a Party other than the Registrant [&nbsp;&nbsp; ]</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">Check the appropriate box:</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; width: 5%">[&nbsp;&nbsp; ]</TD>
    <TD STYLE="vertical-align: top; width: 95%">Preliminary Proxy Statement</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">[&nbsp;&nbsp; ]</TD>
    <TD STYLE="vertical-align: top"><B>Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</B></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">[X]</TD>
    <TD STYLE="vertical-align: top">Definitive Proxy Statement</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">[&nbsp;&nbsp; ]</TD>
    <TD STYLE="vertical-align: top">Definitive Additional Materials</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">[&nbsp;&nbsp; ]</TD>
    <TD STYLE="vertical-align: top">Soliciting Material Pursuant to &sect;240.14a-12</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 100%; text-align: center"><FONT STYLE="font-size: 12pt"><B>ANIKA THERAPEUTICS, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">(Name of Registrant as Specified in Its Charter)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3">Payment of Filing Fee (Check the appropriate box):</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>[X]</TD>
    <TD COLSPAN="2">No fee required.</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>[&nbsp;&nbsp; ]</TD>
    <TD COLSPAN="2">Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and&nbsp;0-11.</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%">(1)</TD>
    <TD STYLE="vertical-align: top; width: 90%; border-bottom: black 1pt solid">
        <P STYLE="font-size: 10pt; margin: 0pt 0">Title of each class of securities to which transaction applies:</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">(2)</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid">
        <P STYLE="font-size: 10pt; margin: 0pt 0">Aggregate number of securities to which transaction applies:</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">(3)</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid">
        <P STYLE="font-size: 10pt; margin: 0pt 0">Per unit price or other underlying value of transaction computed pursuant to Exchange
        Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">(4)</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid">
        <P STYLE="font-size: 10pt; margin: 0pt 0">Proposed maximum aggregate value of transaction:</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">(5)</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid">
        <P STYLE="font-size: 10pt; margin: 0pt 0">Total fee paid:</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>[&nbsp;&nbsp; ]</TD>
    <TD COLSPAN="2">Fee paid previously with preliminary materials.</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">[&nbsp;&nbsp; ]</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom">Check box if any part of the fee is offset as provided by Exchange Act Rule&nbsp;0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">(1)</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid">
        <P STYLE="font-size: 10pt; margin: 0pt 0">Amount Previously Paid:</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">(2)</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid">
        <P STYLE="font-size: 10pt; margin: 0pt 0">Form, Schedule or Registration Statement No.:</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">(3)</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid">
        <P STYLE="font-size: 10pt; margin: 0pt 0">Filing Party:</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">(4)</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid">
        <P STYLE="font-size: 10pt; margin: 0pt 0">Date Filed:</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Anika Therapeutics,&nbsp;Inc.</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>32 Wiggins Avenue</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Bedford, Massachusetts 01730</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><I>Notice of Annual Meeting of Stockholders to be Held on June
13, 2017</I></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The 2017 Annual Meeting of Stockholders (including any adjournments
or postponements, the &ldquo;Annual Meeting&rdquo;) of Anika Therapeutics,&nbsp;Inc., a Massachusetts corporation (the &quot;Company&quot;),
will be held at the Company&rsquo;s corporate headquarters, 32 Wiggins Avenue, Bedford, Massachusetts 01730, on Tuesday, June 13,
2017, at 11:30&nbsp;a.m. local time to consider and vote upon the following matters:</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="vertical-align: top; width: 3%">1.</TD>
    <TD STYLE="width: 97%">Election of two Class&nbsp;III directors;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">2.</TD>
    <TD>Approval of the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">3.</TD>
    <TD>Ratification of the appointment of Deloitte &amp; Touche LLP as the Company&rsquo;s independent registered public accounting firm for the 2017 fiscal year;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">4.</TD>
    <TD>Advisory vote to approve executive compensation as disclosed in this proxy statement; </TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">5.</TD>
    <TD>Advisory vote on the frequency of future advisory votes on executive compensation; and </TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">6.</TD>
    <TD>Any other matters that may properly come before the Annual Meeting.</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Only stockholders of record of common stock, par value $0.01 per
share, at the close of business on April 17, 2017, the record date, will be entitled to receive notice of and to vote at the Annual
Meeting.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">All stockholders are cordially invited to attend the Annual
Meeting in person. To assure your representation at the Annual Meeting, the Board of Directors urges you to vote via the Internet
at <U>www.proxyvote.com</U> by following the instructions on the Notice Regarding the Availability of Proxy Materials you receive
in the mail or, if you have requested a proxy card by mail, by signing, voting, and returning your proxy card in the enclosed envelope.&nbsp;You
may also vote via telephone by visiting <U>www.proxyvote.com</U> and following the instructions on the website or, if you have
requested the proxy materials by mail, by following the instructions on the proxy card. For specific instructions on how to vote
your shares, please review the instructions for each of these voting options that are detailed in this Notice and in the accompanying
proxy statement, which the Company expects to begin mailing or otherwise providing to its stockholders on or about April 28, 2017.
If you attend the Annual Meeting, you may vote in person even if you have previously returned your proxy card or have voted via
the Internet or by telephone.<B>&nbsp;Regardless of the number of shares you own, your vote is important</B>.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">In addition to their availability at <U>www.proxyvote.com</U>, the
proxy statement and a form of proxy card, together with the Company&rsquo;s Annual Report on Form 10-K for the fiscal year ended
December 31, 2016, are available for viewing, printing, and downloading at <U>http://www.anikatherapeutics.com/proxy</U>.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%">By Order of the Board of Directors,</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><img src="cheung_sig.jpg"></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Sylvia Cheung</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><I>Chief Financial Officer&nbsp;&amp; Secretary</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Bedford, Massachusetts</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>April 28, 2017</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">WHETHER OR NOT YOU PLAN TO ATTEND THE MEETING IN PERSON, YOU ARE
REQUESTED TO COMPLETE YOUR PROXY CARD AS INDICATED ABOVE.<B><I>&nbsp;YOUR PROXY IS REVOCABLE UP TO THE TIME SET FORTH IN THE PROXY
STATEMENT, AND, IF YOU ATTEND THE ANNUAL MEETING, YOU MAY VOTE IN PERSON EVEN IF YOU HAVE PREVIOUSLY COMPLETED YOUR PROXY CARD.</I></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>2017 Proxy</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Table of Contents</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 87%">&nbsp;&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; width: 10%">Page</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">Number</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">2017 Proxy Statement</TD>
    <TD STYLE="text-align: center">1</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">Proposal 1: Election of Directors</TD>
    <TD STYLE="text-align: center">9</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Information Regarding the Directors</TD>
    <TD STYLE="text-align: center">9</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>The Board&rsquo;s Role in Risk Oversight</TD>
    <TD STYLE="text-align: center">11</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Board Leadership Structure</TD>
    <TD STYLE="text-align: center">11</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Corporate Governance, Board Matters, and Committees</TD>
    <TD STYLE="text-align: center">11</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Communications with the Board of Directors</TD>
    <TD STYLE="text-align: center">14</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Code of Business Conduct</TD>
    <TD STYLE="text-align: center">14</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Majority Voting in Uncontested Director Elections Policy</TD>
    <TD STYLE="text-align: center">14</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Transactions with Related Persons and Conflict of Interest Policy</TD>
    <TD STYLE="text-align: center">14</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">Beneficial Ownership of Common Stock</TD>
    <TD STYLE="text-align: center">16</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Section&nbsp;16(a) Beneficial Ownership Reporting Compliance</TD>
    <TD STYLE="text-align: center">17</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">Executive Officers</TD>
    <TD STYLE="text-align: center">18</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">Compensation Discussion and Analysis</TD>
    <TD STYLE="text-align: center">19</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Philosophy and Process</TD>
    <TD STYLE="text-align: center">19</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Components of Compensation</TD>
    <TD STYLE="text-align: center">20</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Agreements with Named Executive Officers</TD>
    <TD STYLE="text-align: center">22</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Second Amended and Restated 2003 Stock Option and Incentive Plan, as Amended</TD>
    <TD STYLE="text-align: center">23</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Risk Considerations in Our Compensation Programs</TD>
    <TD STYLE="text-align: center">23</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">Compensation Committee Report</TD>
    <TD STYLE="text-align: center">24</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">Executive Compensation</TD>
    <TD STYLE="text-align: center">25</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Summary Compensation</TD>
    <TD STYLE="text-align: center">25</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Option Grants and Plan Awards in 2016</TD>
    <TD STYLE="text-align: center">26</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Discussion of Summary Compensation and Grants of Plan-Based Awards Tables</TD>
    <TD STYLE="text-align: center">26</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Outstanding Equity Awards at December&nbsp;31, 2016</TD>
    <TD STYLE="text-align: center">27</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>2016 Equity Award Exercises and Stock Vested</TD>
    <TD STYLE="text-align: center">28</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Potential Payments Upon Termination or Change in Control</TD>
    <TD STYLE="text-align: center">28</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Directors&rsquo; Compensation</TD>
    <TD STYLE="text-align: center">29</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Board of Directors and Executive Officer Stock Retention Guidelines</TD>
    <TD STYLE="text-align: center">29</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Compensation Committee Interlocks and Insider Participation</TD>
    <TD STYLE="text-align: center">30</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">Proposal 2: Approval of the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan</TD>
    <TD STYLE="text-align: center">31</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">Audit Committee Report</TD>
    <TD STYLE="text-align: center">38</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">Proposal 3: Ratification of Appointment of Independent Registered Public Accounting Firm</TD>
    <TD STYLE="text-align: center">39</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">Proposal 4: Advisory Vote on Executive Compensation</TD>
    <TD STYLE="text-align: center">41</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">Proposal 5: Frequency of Advisory Votes on Executive Compensation</TD>
    <TD STYLE="text-align: center">42</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">Other Matters</TD>
    <TD STYLE="text-align: center">43</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">Stockholder Proposals</TD>
    <TD STYLE="text-align: center">43</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">Appendix A: Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan</TD>
    <TD STYLE="text-align: center">44</TD></TR>
</TABLE>


<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">References in this proxy statement to &ldquo;we,&rdquo;
&ldquo;us,&rdquo; &ldquo;our,&rdquo; &ldquo;our company,&rdquo; and other similar references refer to Anika Therapeutics, Inc.
and its subsidiaries, unless the context requires otherwise.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">ANIKA, ANIKA THERAPEUTICS, CINGAL, ORTHOVISC,
and MONOVISC are our registered trademarks. This proxy statement also contains a registered trademark that is the property of another
company and is licensed exclusively to us.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: middle">
    <TD STYLE="border-top: Black 1.5pt solid; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="font-size: 12pt; font-weight: bold; text-align: center; border-top: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1.5pt solid; border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="font-size: 12pt; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="font-size: 12pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 14pt">2017 Proxy Summary</FONT></TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="font-size: 12pt; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="font-style: italic; text-align: left">This summary highlights information contained elsewhere in this proxy statement. This summary does not contain all of the information that you should consider, and you should read the entire proxy statement carefully before voting.&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="font-style: italic; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="font-style: italic; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; vertical-align: middle; text-align: left"><FONT STYLE="font-size: 12pt">Annual Meeting
    of Stockholders</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; vertical-align: middle; text-align: left">Time&nbsp;and&nbsp;Date</TD>
    <TD STYLE="vertical-align: middle">11:30 a.m. (ET)</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="width: 2%; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-weight: bold; vertical-align: middle; text-align: left; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 15%">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; text-align: left; width: 36%">June 13, 2017</TD>
    <TD STYLE="vertical-align: bottom; width: 35%">&nbsp;</TD>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 2%; border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-weight: bold; vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; vertical-align: middle; text-align: left">Place</TD>
    <TD STYLE="vertical-align: middle">32 Wiggins Avenue</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-weight: bold; vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">Bedford, Massachusetts</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-weight: bold; vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; vertical-align: middle; text-align: left">Record Date</TD>
    <TD STYLE="vertical-align: middle; text-align: left">April 17, 2017</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; vertical-align: middle; text-align: left">Voting</TD>
    <TD COLSPAN="3" STYLE="vertical-align: middle; text-align: left">Stockholders of record of Anika Therapeutics, Inc. common stock at the close of business on April 17, 2017, the record date, will be entitled to vote at the Annual Meeting. Each outstanding share is entitled to one vote.</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-weight: bold; vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; vertical-align: middle; text-align: left">Outstanding Shares</TD>
    <TD STYLE="vertical-align: middle">14,654,590 (as of April 17, 2017)</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-weight: bold; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-weight: bold; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; vertical-align: middle"><FONT STYLE="font-size: 12pt">Annual Meeting Agenda&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; text-align: center; border-bottom: Black 1.1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; font-weight: bold; vertical-align: middle; text-align: left"><FONT STYLE="font-size: 8pt">Board
    Vote Recommendation</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: left">Proposal 1:&nbsp;&nbsp;Election of Directors</TD>
    <TD STYLE="text-align: left">FOR each Director Nominee</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: left">Proposal 2:&nbsp;&nbsp;Approval of 2017 Omnibus Incentive Plan</TD>
    <TD STYLE="text-align: left">FOR</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: left">Proposal 3:&nbsp;&nbsp;Ratification of Auditors for 2017</TD>
    <TD STYLE="text-align: left">FOR</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: left">Proposal 4:&nbsp;&nbsp;Advisory &ldquo;Say on Pay&rdquo; Vote</TD>
    <TD STYLE="text-align: left">FOR</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: left">Proposal 5:&nbsp;&nbsp;Advisory &ldquo;Say on Frequency&rdquo; Vote</TD>
    <TD STYLE="text-align: left">FOR ONE YEAR</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; vertical-align: middle; text-align: left"><FONT STYLE="font-size: 12pt">How to Cast
    Your Vote&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: middle; text-align: left">You can vote by any of the following methods:</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;&bull;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: middle">Internet (http://www.proxyvote.com)&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;&bull;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: middle">Telephone 1-800-690-6903</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;&bull;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: middle">Completing, signing and returning your proxy or voting instruction card to the Secretary prior to the Annual Meeting</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;&bull;</TD>
    <TD COLSPAN="4" STYLE="vertical-align: middle">In person, at the Annual Meeting: If you are a stockholder of record, your
    admission ticket is a copy of  your proxy card. If your shares are held in the name of a broker, nominee or other
    intermediary, you must bring proof of ownership with you to the Annual Meeting.</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: middle">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: middle">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: middle">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: middle">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: middle">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: middle">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; text-align: center">1</TD>
    <TD STYLE="border-right: Black 1.5pt solid; border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 2%; border-top: Black 1.5pt solid; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="width: 17%; border-top: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="width: 5%; border-top: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="width: 7%; border-top: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="width: 15%; border-top: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="width: 17%; border-top: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="width: 8%; border-top: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="width: 18%; border-top: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="width: 9%; border-top: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="width: 2%; border-top: Black 1.5pt solid; border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="font-weight: bold; vertical-align: middle"><FONT STYLE="font-size: 12pt">Proposal 1:&nbsp;&nbsp;Election
    of Directors</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-weight: bold; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-weight: bold; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; vertical-align: bottom; border-bottom: Black 1.1pt solid"><FONT STYLE="font-size: 8pt">Director
    Nominee</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: Black 1.1pt solid"><FONT STYLE="font-size: 8pt">Age</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 1.1pt solid; vertical-align: bottom"><FONT STYLE="font-size: 8pt">Director
    <BR>
    Since</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left; vertical-align: bottom; border-bottom: Black 1.1pt solid"><FONT STYLE="font-size: 8pt">Occupation</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 1.1pt solid; vertical-align: bottom"><FONT STYLE="font-size: 8pt">Experience
    / <BR>
    Qualifications</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left; vertical-align: bottom; border-bottom: Black 1.1pt solid"><FONT STYLE="font-size: 8pt">Independent</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left; vertical-align: bottom; border-bottom: Black 1.1pt solid"><FONT STYLE="font-size: 8pt">Committee
    <BR>
    Memberships</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left; vertical-align: bottom; border-bottom: Black 1.1pt solid"><FONT STYLE="font-size: 8pt">Other
    <BR>
Boards</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom; border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt">Charles H. Sherwood, Ph.D.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 8pt">70</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 8pt">2002</FONT></TD>
    <TD STYLE="vertical-align: middle"><FONT STYLE="font-size: 8pt">President and Chief Executive Officer of Anika Therapeutics,
    Inc.</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt">&#9679; Leadership<BR>
<FONT STYLE="font-size: 8pt">&#9679; Company &amp;&nbsp;&nbsp;Industry&nbsp;&nbsp;Experience</FONT></FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt">No</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt">None</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt">None</FONT></TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt">Steven E. Wheeler</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 8pt">70</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 8pt">1993</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt">President of Wheeler &amp; Co.</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 8pt">&#9679; Leadership</FONT></P>
                                                      <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&#9679; General&nbsp;&nbsp;Experience</FONT></FONT></P></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt">Yes</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 8pt">&#9679; Governance and&nbsp;&nbsp;Nominating&nbsp;&nbsp;(Chair)</FONT></P>
                                                             <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&#9679; Compensation</FONT></FONT></P></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt">&#9679; HFF, Inc.</FONT></TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-style: italic; vertical-align: middle; text-align: left">Board Recommendation<FONT STYLE="font-size: 10pt; font-weight: normal; font-style: normal">:</FONT></TD>
    <TD COLSPAN="5" STYLE="vertical-align: middle; text-align: left">The Board recommends a vote &ldquo;FOR&rdquo; the reelection of Dr. Sherwood and Mr. Wheeler.&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-style: italic; vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-style: italic; vertical-align: top; text-align: left">Vote Required for Approval<FONT STYLE="font-size: 10pt; font-weight: normal; font-style: normal">:</FONT></TD>
    <TD COLSPAN="5" STYLE="vertical-align: middle; text-align: left">Affirmative vote of a majority of votes cast by holders of common stock.&nbsp;&nbsp;Abstentions and broker non-votes will not be treated as votes cast and will have no impact on the proposal, except to the extent that failure to vote for an individual results in another individual receiving a larger percentage of votes.</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-style: italic; vertical-align: top; text-align: left">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-style: italic; vertical-align: top; text-align: left">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-style: italic; vertical-align: top; text-align: left">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-style: italic; vertical-align: top; text-align: left">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-style: italic; vertical-align: top; text-align: left">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-style: italic; vertical-align: top; text-align: left">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-style: italic; vertical-align: top; text-align: left">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-style: italic; vertical-align: top; text-align: left">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-style: italic; vertical-align: top; text-align: left">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-style: italic; vertical-align: top; text-align: left">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-style: italic; vertical-align: top; text-align: left">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-style: italic; vertical-align: top; text-align: left">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-style: italic; vertical-align: top; text-align: left">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-style: italic; vertical-align: top; text-align: left">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-style: italic; vertical-align: top; text-align: left">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-style: italic; vertical-align: top; text-align: left">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-style: italic; vertical-align: top; text-align: left">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-style: italic; vertical-align: top; text-align: left">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-style: italic; vertical-align: top; text-align: left">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-style: italic; vertical-align: top; text-align: left">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-style: italic; vertical-align: top; text-align: left">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-style: italic; vertical-align: top; text-align: left">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-style: italic; vertical-align: top; text-align: left">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-style: italic; vertical-align: top; text-align: left">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-style: italic; vertical-align: top; text-align: left">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-style: italic; vertical-align: top; text-align: left">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="8" STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; text-align: center">2</TD>
    <TD STYLE="border-right: Black 1.5pt solid; border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>



<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: middle">
    <TD STYLE="border-top: Black 1.5pt solid; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: left; border-top: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1.5pt solid; border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 12pt">Proposal 2:&nbsp;&nbsp;Approval
    of Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan</FONT></TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="width: 2%; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-weight: bold; vertical-align: middle; text-align: left; width: 31%">&nbsp;</TD>
    <TD STYLE="font-weight: bold; vertical-align: middle; text-align: left; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 63%">&nbsp;</TD>
    <TD STYLE="width: 2%; border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; vertical-align: middle; border-bottom: black 1pt solid"><FONT STYLE="font-size: 8pt">Key Plan
    Provisions</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; vertical-align: middle; border-bottom: black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">Summary
    Description</FONT></TD>
    <TD STYLE="border-right: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">Shares reserved</TD>
    <TD COLSPAN="2">Up to 1,200,000 shares of common stock, representing approximately 8% of the fully diluted common stock outstanding as of April 17, 2017, are available for grant.</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">Multiple award types</TD>
    <TD COLSPAN="2">Various types of awards may be granted as compensation tools to motivate our workforce, including incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, and other types of share and cash-based awards.</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">Minimum vesting requirements</TD>
    <TD COLSPAN="2">Awards must have a vesting period of at least 1 year, except that:</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;&bull;</TD>
    <TD STYLE="text-align: left">up to 5% of the share pool can be granted without a minimum vesting period,</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;&bull;</TD>
    <TD STYLE="text-align: left">awards may be accelerated due to a participant&rsquo;s death or disability, and</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;&bull;</TD>
    <TD STYLE="text-align: left">awards may provide for acceleration upon a change in control of our company.</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">Maximum award terms</TD>
    <TD COLSPAN="2">Awards may have terms of up to 10 years.</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">Director limits</TD>
    <TD COLSPAN="2">The plan specifies annual limits on the value of awards that may be granted to non-employee directors.</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">No repricing</TD>
    <TD COLSPAN="2">Awards may not be repriced without stockholder approval.</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">No transferability</TD>
    <TD COLSPAN="2">Awards generally may not be transferred, except by will or laws of descent and distribution.</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">Tax deductible awards</TD>
    <TD COLSPAN="2">Awards may qualify as &ldquo;performance-based&rdquo; compensation under Section 162(m) of the Internal Revenue Code.</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">Board Recommendation:</TD>
    <TD COLSPAN="2" STYLE="text-align: left">The Board recommends a vote &ldquo;FOR&rdquo; approval of the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan.&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">Vote Required for Approval<FONT STYLE="font-size: 10pt; font-weight: normal; font-style: normal">:&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: left">Affirmative vote of a majority of shares of common stock present or represented at the Annual Meeting.</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: middle; text-align: left">Abstentions and broker non-votes, if any, will not be treated as votes cast and will have no impact on this proposal.</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: Black 1.5pt solid; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom; text-align: center; border-bottom: Black 1.5pt solid">3</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; border-right: Black 1.5pt solid">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 2%; border-top: Black 1.5pt solid; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="width: 29%; border-top: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="width: 67%; border-top: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="width: 2%; border-top: Black 1.5pt solid; border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; vertical-align: middle"><FONT STYLE="font-size: 12pt">Proposal 3:&nbsp;&nbsp;Ratification
    of Auditors for 2017</FONT></TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: middle">The Audit Committee has approved the retention of Deloitte &amp; Touche LLP as our independent registered public accounting firm to examine and review our consolidated financial statements and the effectiveness of our internal control over financial reporting as of, and for the fiscal year ending, December 31, 2017.&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">Board Recommendation:</TD>
    <TD STYLE="vertical-align: middle">The Board recommends a vote &ldquo;FOR&rdquo; the ratification of Deloitte &amp; Touche LLP as our independent registered public accounting firm for the 2017 fiscal year.</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">Vote Required for Approval:</TD>
    <TD STYLE="vertical-align: middle">Affirmative vote of the holders of a majority of the shares of common stock present or represented at the Annual Meeting and voting on the matter.&nbsp;&nbsp;Because this proposal is considered a routine matter, broker non-votes will be counted.</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; vertical-align: top; border-bottom: Black 1.5pt solid">4</TD>
    <TD STYLE="border-right: Black 1.5pt solid; border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 2%; border-left: Black 1.5pt solid; border-top: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="width: 27%; border-top: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="width: 2%; border-top: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="width: 28%; border-top: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="width: 2%; border-top: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="width: 37%; border-top: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="width: 2%; border-top: Black 1.5pt solid; border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="font-weight: bold; vertical-align: middle; text-align: left"><FONT STYLE="font-size: 12pt">Proposal 4:&nbsp;&nbsp;Advisory &ldquo;Say on Pay&rdquo; Vote&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-weight: bold; vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="font-weight: bold; vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="vertical-align: middle; text-align: left">The overall objective of our executive compensation policy is to attract and retain highly qualified executive officers and to motivate those officers to provide superior performance for the benefit of our company and stockholders.</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; vertical-align: middle; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">Compensation
    Element</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; vertical-align: middle; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Description&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; vertical-align: middle; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Objectives</FONT></TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">Base Salary</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;&bull;</TD>
    <TD STYLE="vertical-align: top; text-align: left">Fixed cash compensation&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;&bull;</TD>
    <TD STYLE="vertical-align: middle; text-align: left">Appropriate level of fixed compensation based on role, responsibility, performance, and competitive market practices</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">Cash Bonuses</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;&bull;</TD>
    <TD STYLE="vertical-align: top; text-align: left">Annual cash award based on performance of company and individual&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;&bull;</TD>
    <TD STYLE="vertical-align: middle; text-align: left">Reward the achievement of financial results, organizational development, business and technical development, and contribution to shareholder value</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;&bull;</TD>
    <TD STYLE="vertical-align: top; text-align: left">Prorated in the year of hire if employment begins before October 1</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;&bull;</TD>
    <TD STYLE="vertical-align: middle; text-align: left">Encourage retention</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">Equity Based Grants</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;&bull;</TD>
    <TD STYLE="vertical-align: top; text-align: left">Grants of stock options or other forms of equity securities, under the Second Amended 2003 Plan</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;&bull;</TD>
    <TD STYLE="vertical-align: middle">Provide executive officers with opportunity to be compensated based on common stock price increases</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;&bull;</TD>
    <TD STYLE="vertical-align: top; text-align: left">Includes stock appreciation rights, restricted stock awards, and performance-based equity awards</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: White; border-left: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="29" STYLE="font-size: 10pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Summary
    Compensation Table</FONT></TD>
    <TD STYLE="background-color: White; border-right: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: White; border-left: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="29" STYLE="font-size: 10pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="background-color: White; border-right: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: White; border-left: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><FONT STYLE="font-size: 8pt">Name
    and Principal Position</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><FONT STYLE="font-size: 8pt">Year</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1.1pt solid"><FONT STYLE="font-size: 8pt">Salary
</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1.1pt solid"><FONT STYLE="font-size: 8pt">Bonus</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1.1pt solid"><FONT STYLE="font-size: 8pt">Option
</FONT><BR> <FONT STYLE="font-size: 8pt">Awards</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1.1pt solid"><FONT STYLE="font-size: 8pt">Stock
</FONT><BR> <FONT STYLE="font-size: 8pt">Awards</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1.1pt solid"><FONT STYLE="font-size: 8pt">All
Other </FONT><BR> <FONT STYLE="font-size: 8pt">Compensation</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><FONT STYLE="font-size: 8pt">Total</FONT></TD>
    <TD STYLE="background-color: White; border-right: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 2%; background-color: White; border-left: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 35%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">Charles H. Sherwood, Ph.D.</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 4%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">2016</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 6%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">601,586</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 6%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">496,308</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 6%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">1,519,778</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 6%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">861,286</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 6%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">52,060</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 6%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">3,531,018</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 2%; background-color: White; border-right: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White; border-left: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">President and Chief</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">2015</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">581,242</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">508,587</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">864,043</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">535,815</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">52,118</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">2,541,805</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="background-color: White; border-right: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White; border-left: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">Executive Officer</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">2014</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">564,313</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">434,521</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">694,130</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">496,310</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">41,093</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">2,230,367</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="background-color: White; border-right: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White; border-left: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="background-color: White; border-right: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White; border-left: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">Ed Ahn, Ph.D.</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">2016</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">315,675</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">156,259</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">439,830</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">301,069</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">18,720</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">1,231,553</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="background-color: White; border-right: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White; border-left: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">Chief Technology and</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">2015</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">305,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">137,250</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">43,953</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">18,720</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">504,923</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="background-color: White; border-right: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White; border-left: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">Strategy Officer</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">2014</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">43,404</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">733,170</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">2,164</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">778,738</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="background-color: White; border-right: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White; border-left: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="background-color: White; border-right: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White; border-left: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: left"><FONT STYLE="font-size: 8pt">Dana Alexander<FONT STYLE="font-weight: normal; font-style: normal"><SUP>&nbsp;</SUP></FONT></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">2016</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">285,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">76,950</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">759,247</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">13,187</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">1,134,384</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="background-color: White; border-right: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White; border-left: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">Chief Operations Officer</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="background-color: White; border-right: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White; border-left: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="background-color: White; border-right: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White; border-left: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">Sylvia Cheung</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">2016</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">346,942</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">171,736</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">439,830</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">301,069</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">18,720</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">1,278,297</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="background-color: White; border-right: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White; border-left: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">Chief Financial Officer</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">2015</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">335,210</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">188,556</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">289,996</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">264,931</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">18,720</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">1,097,413</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="background-color: White; border-right: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White; border-left: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">2014</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">307,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">151,965</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">247,519</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">195,322</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">13,719</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">915,525</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="background-color: White; border-right: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White; border-left: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="background-color: White; border-right: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White; border-left: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">Richard Hague</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">2016</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">315,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">127,575</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">439,830</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">301,069</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">84,799</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">1,268,273</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="background-color: White; border-right: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White; border-left: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">Chief Commerical Officer</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">2015</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">48,462</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">727,650</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">24,831</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">800,943</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="background-color: White; border-right: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White; border-left: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="background-color: White; border-right: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White; border-left: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">Stephen Mascioli, M.D., MPH</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">2016</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">350,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">759,247</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">27,473</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">1,136,720</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="background-color: White; border-right: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White; border-left: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">Chief Medical Officer</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="background-color: White; border-right: Black 1.5pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>


<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-style: italic; vertical-align: middle; text-align: left">* Additional information contained within this proxy statement.</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; text-align: justify; width: 27%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 69%">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid; width: 2%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; vertical-align: top; text-align: left; padding-left: 20pt">Board Recommendation<FONT STYLE="font-size: 10pt; font-weight: normal; font-style: normal">:</FONT></TD>
    <TD STYLE="vertical-align: middle; text-align: left">The Board recommends a vote &ldquo;FOR&rdquo;&nbsp;the approval of executive compensation for the 2016 fiscal year.</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD NOWRAP STYLE="font-style: italic; vertical-align: top; text-align: left; padding-left: 20pt">Vote Required for Approval<FONT STYLE="font-size: 10pt; font-weight: normal; font-style: normal">:&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: middle; text-align: left">Affirmative vote of the holders of a majority of the shares of common stock present or represented at the Annual Meeting and voting on the matter.&nbsp;&nbsp;Abstentions and broker non-votes will not be treated as votes cast and will have no impact on this proposal. This vote is required by law, but it will not be binding on us or the Board of Directors.</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: middle; text-align: center; border-bottom: Black 1.5pt solid">5</TD>
    <TD STYLE="border-right: Black 1.5pt solid; border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 2%; border-left: Black 1.5pt solid; border-top: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="width: 27%; border-top: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="width: 69%; border-top: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="width: 2%; border-right: Black 1.5pt solid; border-top: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; vertical-align: middle"><FONT STYLE="font-size: 12pt">Proposal 5:&nbsp;&nbsp;Advisory
    &ldquo;Say on Frequency&rdquo; Vote</FONT></TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-weight: bold; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: middle">We have been requesting advisory votes on executive compensation on an annual basis. Securities and Exchange Commission rules require that every six years we submit to stockholders a vote with respect to how frequently we should submit &ldquo;say-on-pay&rdquo; votes to stockholders in the future.&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">Board Recommendation<FONT STYLE="font-size: 10pt; font-weight: normal; font-style: normal">:&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: middle">The Board recommends an advisory vote for &ldquo;ONE YEAR&rdquo; on the frequency of future advisory votes on executive compensation to indicate approval of an advisory vote to include a vote on executive compensation in our proxy statement on an annual basis.</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">Vote Required for Approval<FONT STYLE="font-size: 10pt; font-weight: normal; font-style: normal">:</FONT></TD>
    <TD STYLE="vertical-align: middle">Affirmative vote of the holders of a majority of the shares of common stock present or represented at the Annual Meeting and voting on the matter. Abstentions and broker non-votes will not be treated as votes cast and will have no impact on this proposal. This vote is required by law, but it will not be binding on us or the Board of Directors&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; vertical-align: top; border-bottom: Black 1.5pt solid">6</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; border-right: Black 1.5pt solid">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Anika Therapeutics,&nbsp;Inc.</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>32 Wiggins Avenue</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Bedford, Massachusetts 01730</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><I>Proxy Statement for</I></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><I>2017 Annual Meeting of Stockholders</I></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><I>To be Held on Tuesday, June&nbsp;13, 2017</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">This proxy statement is furnished in connection with the solicitation
of proxies by the Board of Directors of Anika Therapeutics,&nbsp;Inc., a Massachusetts corporation, for use at the 2017 Annual
Meeting of Stockholders (the &ldquo;Annual Meeting&rdquo;) to be held at our corporate headquarters, 32 Wiggins Avenue, Bedford,
Massachusetts 01730, on Tuesday, June 13, 2017, at 11:30&nbsp;a.m. local time. At the Annual Meeting, the stockholders will be
asked to consider and vote upon the following matters:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="vertical-align: top; width: 4%">1.</TD>
    <TD STYLE="width: 96%">Election of two Class&nbsp;III directors;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">2.</TD>
    <TD>Approval of the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">3.</TD>
    <TD>Ratification of the appointment of Deloitte &amp; Touche LLP as our independent registered public accounting firm for 2017;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">4.</TD>
    <TD>Advisory vote to approve executive compensation as disclosed in this proxy statement; </TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">5.</TD>
    <TD>Advisory vote on the frequency of future advisory votes on executive compensation; and </TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">6.</TD>
    <TD>Any other matters that may properly come before the Annual Meeting.</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Proposal 1 relates solely to the election of
two&nbsp;Class&nbsp;III directors nominated by the Board of Directors and does not include any other matter relating to the election
of directors, including without limitation, the election of directors nominated by any stockholder.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">This proxy statement, the accompanying notice of the Annual Meeting,
the form of proxy, and our Annual Report are first being made available to stockholders on or about April 28, 2017. Our Annual
Report, however, is not a part of the proxy solicitation materials. The Board of Directors has fixed the close of business on April
17, 2017 as the record date for the determination of stockholders entitled to receive notice of and to vote at the Annual Meeting.
Only stockholders of record of our common stock, par value $0.01 per share, at the close of business on the record date will be
entitled to receive notice of and to vote at the Annual Meeting. As of the record date, there were 14,654,590 shares of common
stock outstanding and entitled to vote at the Annual Meeting. Holders of common stock as of the close of business on the record
date will be entitled to one vote per share.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">This year, pursuant to rules adopted by the Securities and Exchange
Commission (the &ldquo;SEC&rdquo;), we have again elected to provide access to our proxy materials over the Internet. Accordingly,
we have sent a Notice Regarding the Availability of Proxy Materials (the &ldquo;Notice&rdquo;) to certain of our stockholders (excluding
those stockholders who previously have requested that they receive electronic or paper copies of our proxy materials). Stockholders
have the ability to access our proxy materials on the website referred to in the Notice or to request a printed set of our proxy
materials at no charge. Instructions on how to access our proxy materials over the Internet and how to request a printed copy of
our proxy materials may be found in the Notice. In addition, stockholders may request to receive proxy materials in printed form
by mail or electronically by email on an ongoing basis. We believe this process will expedite your receipt of our proxy materials
and reduce the environmental impact of our Annual Meeting.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">You may vote via the Internet at <U>www.proxyvote.com</U> by following
the instructions in the Notice you received in the mail and which are also provided on that website, or, if you have requested
a proxy card by mail, by signing, voting, and returning your proxy card. You may also vote via telephone by visiting <U>www.proxyvote.com</U>
and following the instructions on the website, or, if you have requested the proxy materials by mail, by following the instructions
on the proxy card. If you attend the Annual Meeting, you may vote in person even if you have previously voted by telephone, via
the Internet, or returned a proxy card by mail.&nbsp;If you hold your shares in street name, you will receive instructions from
your broker, bank, or other nominee that you must follow in order to have your shares voted.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Any proxy given pursuant to this solicitation may be revoked by the
person giving it at any time before it is voted. Proxies may be revoked by: (a)&nbsp;filing with our Secretary, before the taking
of the vote at the Annual Meeting, a written notice of revocation bearing a later date than the proxy; (b)&nbsp;properly casting
a new vote via the Internet or by telephone at any time before the closure of the Internet or telephone voting facilities; (c)&nbsp;duly
completing a later-dated proxy relating to the same shares and delivering it to our Secretary before the taking of the vote at
the Annual Meeting; or (d)&nbsp;attending the Annual Meeting and voting in person (although attendance at the Annual Meeting will
not in and of itself constitute a revocation of a proxy). Any written notice of revocation or subsequent proxy should be sent so
as to be delivered to Anika Therapeutics,&nbsp;Inc., 32 Wiggins Avenue, Bedford, Massachusetts 01730, Attention: Secretary, before
the taking of the vote at the Annual Meeting.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 10; Options: NewSection; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><B>All properly authorized proxies received and not revoked prior
to or at the Annual Meeting will be voted in accordance with the stockholders&rsquo; instructions by the persons named as proxies.
If no voting instructions are specified, properly executed proxies will be voted (i) &ldquo;for&rdquo; the election of the nominees
for director listed in this proxy statement, (ii) &ldquo;for&rdquo; the approval of the Anika Therapeutics, Inc. 2017 Omnibus Incentive
Plan, (iii) &quot;for&quot; the ratification of the appointment of Deloitte &amp; Touche LLP as our independent registered public
accounting firm for the 2017 fiscal year, (iv) &ldquo;for&rdquo; the approval of the resolution regarding the compensation of the
Named Executive Officers, and (v) &ldquo;one (1) year&rdquo; indicating approval of an advisory vote to include a vote on executive
compensation in our proxy statement on an annual basis.&nbsp;If other matters are validly presented, proxies will be voted in accordance
with the discretion of the persons named as proxies.</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The presence, in person or by proxy, of holders of at least a majority
of the total number of outstanding shares of common stock entitled to vote is necessary to constitute a quorum for the transaction
of business at the Annual Meeting. Shares held of record by stockholders or their nominees who do not return a signed and dated
proxy or attend the Annual Meeting in person will not be considered present or represented at the Annual Meeting and will not be
counted in determining the presence of a quorum. Proxies withholding authority or marked as abstaining from a particular matter
will be treated as present for purposes of determining whether a quorum is present for the Annual Meeting, but will not be counted
as voting on any proposal for which authority is withheld or an abstention is indicated. If your common stock is held by a broker,
bank, or other nominee (<I>i.e.</I>,&nbsp;in &ldquo;street name&rdquo;) and you fail to give instructions as to how you want your
shares voted, the broker, bank, or other nominee generally may vote your shares on routine matters, but not on non-routine matters.
If the organization does not receive instructions from you on how to vote your shares on a non-routine matter, it will inform the
inspector of the election that it does not have the authority to vote on this matter with respect to your shares. This is referred
to as a &ldquo;broker non-vote.&rdquo; The only routine matter expected to be voted on at the 2017 Annual Meeting is the ratification
of our independent auditor for 2017. Each other proposal is considered non-routine, and broker non-votes will have no impact on
the approval of the proposal. Instead, broker non-votes will be counted only for the purpose of determining the presence or absence
of a quorum for the transaction of business. &nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">At the Annual Meeting, Proposal 1 requires, with respect to each
director, the affirmative vote of a majority of votes cast at the Annual Meeting by the holders of common stock pursuant to our
Majority Voting in Uncontested Director Elections Policy. In accordance with this policy, if a director in an uncontested election
does not receive at least the majority of the votes cast (including votes &ldquo;for&rdquo; and votes &ldquo;withheld&rdquo;),
such director is required to promptly tender his resignation from the Board of Directors. The Majority Voting in Uncontested Director
Elections Policy is described below in the section captioned &ldquo;Majority Voting in Uncontested Director Elections Policy&rdquo;
on page 14. For each of Proposals 2 through 5, the affirmative vote of the holders of a majority of shares of common stock present
or represented at the Annual Meeting and voting on the matter is required. With respect to Proposal 5, however, if none of the
frequency options receives the affirmative vote of the holders of a majority of the shares present or represented and voting, the
option receiving the greatest number of votes will be considered the frequency recommended by the stockholders.&nbsp;With respect
to each of Proposals 2 through 4, stockholders may vote &ldquo;for,&rdquo; &ldquo;against,&rdquo; or &ldquo;abstain.&rdquo;&nbsp;With
respect to Proposal 5, stockholders may either vote to recommend an advisory vote every one, two, or three years or abstain from
voting.&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.75in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><B>Important Notice Regarding the Availability of Proxy Materials
for the 2017 Annual Meeting of Stockholders to be held on June 13, 2017 at 11:30 a.m. at 32 Wiggins Avenue, Bedford, Massachusetts
01730:</B>&nbsp;This proxy statement, a form of proxy card, and our Annual Report to Stockholders are available at<I>&nbsp;<U>http://www.anikatherapeutics.com/proxy</U>.</I>
In addition, directions to the 2017 Annual Meeting of Stockholders are also available at<I>&nbsp;<U>http://www.anikatherapeutics.com/proxy</U>.</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>PROPOSAL 1:</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>ELECTION OF DIRECTORS</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Board of Directors is currently comprised of six directors and
is divided into three classes: Class&nbsp;I, Class&nbsp;II, and Class&nbsp;III. Each class of directors serves for a three-year
term with one class of directors being elected by our stockholders at each annual meeting. Dr. Sherwood and Mr. Wheeler serve as
Class&nbsp;III Directors with a term of office expiring at the 2017 Annual Meeting. Dr. Bower and Mr. Thompson serve as Class&nbsp;I
Directors with a term of office expiring at the 2018 Annual Meeting. Mr. Land and Dr. Larsen serve as Class&nbsp;II Directors with
a term of office expiring at the 2019 Annual Meeting.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Dr. Sherwood and Mr. Wheeler are our Board&rsquo;s nominees for election
to the Board at the 2017 Annual Meeting. The Class&nbsp;III Directors will be elected to hold office until the 2020 Annual Meeting
and until their successors are duly elected and qualified. Unless otherwise instructed, the persons named in the accompanying proxy
will vote, as permitted by our Amended and Restated By-laws, to elect Dr. Sherwood and Mr. Wheeler as Class&nbsp;III Directors.
If either of the Class&nbsp;III Directors becomes unavailable or declines to serve, the persons acting under the accompanying proxy
may vote the proxy for the election of a substitute in their discretion. The Board has no reason to believe that any of the nominees
will be unable or unwilling to serve if elected. There are no arrangements or understandings between any nominee and any other
person pursuant to which such nominee was selected.&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Vote Required</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">At the 2017 Annual Meeting, the election of a director requires the
affirmative vote of a majority of votes cast by the holders of common stock entitled to vote at the election pursuant to our Majority
Voting in Uncontested Director Elections Policy, which is described more particularly in the section titled &ldquo;Majority Voting
in Uncontested Director Elections Policy&rdquo; on page 14 of this Proxy Statement. Abstentions and broker non-votes, if any, will
not be treated as votes cast and will have no impact on the proposal, except to the extent that failure to vote for an individual
in the election of directors results in another individual receiving a larger percentage of votes.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Board Recommendation</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><B>THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE &ldquo;FOR&rdquo;
THE ELECTION OF EACH OF THE DIRECTOR NOMINEES.</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Information Regarding the Directors</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The following table sets forth the name of each current director,
including the nominees for Class&nbsp;III Director, his age, and the year in which he became a director of Anika Therapeutics,
Inc.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="3" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Director</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Term</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid; text-align: left; vertical-align: bottom">Director Name</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Age</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Since</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Expires</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 10pt">Class&nbsp;I Directors:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; font-size: 10pt; text-align: left; padding-left: 10pt">Joseph L. Bower</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="width: 8%; font-size: 10pt; text-align: center">78</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">1993</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">2018</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Jeffery S. Thompson</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">51</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2011</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2018</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 10pt">Class&nbsp;II Directors:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Raymond J. Land</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">72</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2006</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2019</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Glenn R. Larsen, Ph.D.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">62</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2015</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2019</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 10pt">Class III Directors:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Charles H. Sherwood, Ph.D.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">70</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2002</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2017</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Steven E. Wheeler</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">70</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1993</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2017</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.25in; margin: 0pt 0">&#9;<I>Joseph L. Bower, D.B.A.</I>, joined the Board of Directors
in February 1993 and has served as lead director since April 2005.&nbsp;Since July 2014, he has been the Donald Kirk David Professor
Emeritus at Harvard Business School. From 2008 through 2014, he was the Baker Foundation Professor of Business Administration at
Harvard Business School, and prior to 2008, he was the Donald Kirk David Professor of Business Administration. Throughout his tenure,
Dr. Bower also served in many administrative roles at Harvard Business School, including as Senior Associate Dean. Dr. Bower also
serves as a director of Loews Corporation and the New America High Income Fund, Inc. During the past five years, Dr. Bower also
served as a director of Brown Shoe Company, Inc. and Sonesta International Hotels Corporation. He holds an A.B., as well an M.B.A.
and a D.B.A. from Harvard University.&nbsp;Dr. Bower brings to the Board more than four decades of experience in business strategy,
corporate governance, leadership, and management, during which time he has written books about and taught these subjects at the
Harvard Business School. Additionally, he has consulted with numerous organizations on matters related to strategy, organizational
development, and succession planning. As a result, we believe he is well suited for his roles as Lead Director and as Chairperson
of the Compensation Committee. Dr. Bower also serves on the Audit Committee.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><I>Raymond J. Land</I> became a member of the Board of Directors
in January 2006. He also serves as chairman of the Board of Directors and interim Chief Financial Officer of BioAmber, Inc., a
publicly traded company developing chemicals from renewable feedstocks, and a director and chairman of the Audit Committee of Mountain
View Pharmaceuticals, Inc., a privately held company specializing in biopharmaceuticals. From 2008 through 2010, Mr. Land served
as the Senior Vice President and Chief Financial Officer of Clarient, Inc., an advanced molecular diagnostics company. From June
2007 to June 2008, he was&nbsp;the Senior Vice President and Chief Financial Officer of Safeguard Scientifics, Inc., a venture
capital firm.&nbsp;Prior to Safeguard Scientifics, Inc., Mr. Land held executive management and Chief Financial Officer positions
at Medcenter Solutions, Inc., a pharmaceutical marketing company where&nbsp;he was also a board member,&nbsp;and Orchid Cellmark,
a provider of DNA testing services. Mr. Land previously served as Senior Vice President and Chief Financial Officer for&nbsp;Genencor
International, Inc., a biotechnology company focusing on bioproducts and healthcare, from 1997 until its acquisition&nbsp;in April
2005. From 1991 to 1996, he served as Senior Vice President and Chief Financial Officer for&nbsp;West Pharmaceutical Services,
Inc. Previously, Mr. Land was with Campbell Soup Company, Inc. where for nine years he held increasingly senior financial positions
and also served as General Manager of a frozen food division. Prior to joining Campbell Soup, he was with Coopers and Lybrand for
nine years. Mr. Land is a retired Certified Public Accountant and has a B.S. degree in accounting and finance from Temple University.&nbsp;Mr.
Land's qualifications for membership on the Board include his extensive prior experience as chief financial officer at multiple
companies, including several in the life science industry.&nbsp;He serves as the Chairperson and designated financial expert on
the Audit Committee and as a member of the Governance and Nominating Committee.</P>

<P STYLE="font-size: 10pt; text-indent: 0.25in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><I>Glenn R. Larsen, Ph.D.</I>, joined the Board of Directors in February
2015. He is currently President and Chief Executive Officer of Aquinnah Pharmaceuticals, Inc., a pharmaceutical company focused
on the development of treatments for ALS and neurodegenerative diseases, which he co-founded in February 2014. He is also a co-founder
and Chairman of the Board of Directors of 180 Therapeutics L.P., a clinical stage musculoskeletal drug development company focusing
on treating fibrosis, which he co-founded in 2013. He previously served as Chief Scientific Officer and Executive Vice President
of Research and Development at SpringLeaf Therapeutics, Inc., a producer of combination drug delivery devices, from 2010 through
2013 and as Chief Operating Officer and Executive Vice President of Research and Development, and as a member of the board of directors,
at Hydra Biosciences, Inc., a biopharmaceutical company, from 2003 through 2010. During his prior employment at Wyeth (now Pfizer)/Genetics
Institute, Dr. Larsen served in various drug discovery and development leadership positions, including Vice President Musculoskeletal
Sciences where he directed Wyeth&rsquo;s second-largest therapeutic area with responsibility for Enbrel, an anti-TNF therapeutic
with multi-billion dollar annual sales used to treat rheumatoid arthritis and other diseases. Dr. Larsen received his Ph.D. in
Biochemistry from Stony Brook University and a PMD from Harvard University Business School. Dr. Larsen&rsquo;s qualifications for
membership on the Board include his strong scientific background in pharmaceuticals, biotech, orthopedics, and regenerative medicine,
and his extensive experience in management, product development, and business development at multiple companies in the life science
industry, all of which provide the Board of Directors with innovative product and commercial development perspectives and insights.
He serves as a member of the Compensation Committee and a member of the Governance and Nominating Committee.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><I>Charles H.&nbsp;Sherwood, Ph.D.</I>, was appointed Chief Executive
Officer of Anika Therapeutics in March 2002, and simultaneously became a member of the Board of Directors. Dr.&nbsp;Sherwood has
served as President since June 2001. Dr.&nbsp;Sherwood previously served as Anika Therapeutics&rsquo; Chief Operating Officer beginning
in June 2001, Vice President of Research and Development beginning in April 2000, and Vice President of Process Development and
Engineering beginning in April 1998. Dr.&nbsp;Sherwood served as a consultant to Anika Therapeutics from January 1998 to April
1998. From 1995 to 1997, Dr.&nbsp;Sherwood was Senior Director of Medical Device Research and Development for Chiron Vision. In
April 1995, Chiron Vision acquired IOLAB Corporation, a division of Johnson&nbsp;&amp; Johnson where Dr.&nbsp;Sherwood had been
Executive Director of Research and Development from 1993 to 1995, Director of Materials Characterization from 1989 to 1993, and
Manager/Section Head from 1982 to 1989. Dr.&nbsp;Sherwood was also a part-time faculty member in the Department of Chemistry at
the California State Polytechnic University, Pomona, California from 1984 to 1987. Dr.&nbsp;Sherwood received a B.S. in Chemical
Engineering from Cornell University, and an M.S. and Ph.D. in Polymer Science and Engineering from the University of Massachusetts,
Amherst. Dr.&nbsp;Sherwood also received a Certificate in Management from Claremont Graduate School. Dr. Sherwood brings to the
Board an exceptional understanding of all aspects of our business given his role as our President and Chief Executive Officer,
and he provides invaluable insight to the Board with respect to their decision-making functions.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><I>Jeffery S. Thompson</I> joined the Board of Directors in January
2011. He is a Partner with HealthEdge Investment Partners, LLC (&ldquo;HealthEdge&rdquo;), a Tampa, Florida based private equity
firm that provides strategic capital exclusively in the healthcare industry. Mr. Thompson currently serves as a director for various
HealthEdge affiliated companies including AMC, Formulated Solutions, Santus, MNG Laboratories, Columbus Group, and Data Dimensions,
LLC. Mr. Thompson also serves as a non-executive director for Sinclair Pharma, plc, a publicly traded, London-based, international
aesthetic dermatology company. Prior to joining Anika, he served as President, Chief Executive Officer and Chairman of Advanced
Bio-Technologies and Enaltus, HealthEdge portfolio companies specializing in skincare solutions. Mr. Thompson also served as a
director and the Chief Operating Officer for Stiefel Laboratories, Inc. (&ldquo;Stiefel&rdquo;), an independent pharmaceutical
company specializing in dermatology. Prior to his Chief Operating Officer role, he was Stiefel&rsquo;s Senior Vice President of
U.S. Business Services and President of Glades Pharmaceuticals. Earlier in his career, Mr. Thompson held sales and business management
positions at Bausch &amp; Lomb Pharmaceuticals and SmithKline Beecham. Mr. Thompson holds a B.S. in general science from the University
of Pittsburgh. Mr. Thompson&rsquo;s qualifications for membership on the Board include his prior experience in running a pharmaceutical
company and his knowledge of the medical device industry, both of which provide the Board with product and business development
perspectives and insights. He serves on the Audit Committee and the Compensation Committee.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><I>Steven E. Wheeler</I> joined the Board of Directors in 1993. Since
1997, he has been the President of Wheeler &amp; Co., a private investment firm.&nbsp;He is also currently a director of HFF, Inc.
During the past five years, Mr. Wheeler also served as a director of Bariston Partners, LLC, a private equity investment firm,
and PingTone Communications, Inc., a privately-held VOIP telephone services provider.&nbsp;Between 1993 and 1996, he was Managing
Director and a director of Copley Real Estate Advisors and President, Chief Executive Officer, and a director of Copley Properties,
Inc., a publicly traded real estate investment trust. From 1991 to 1993, he was Chairman and Chief Executive Officer of Hancock
Realty Investors, which manages an equity real estate portfolio. Earlier, he was an Executive Vice President of Bank of New England
Corporation from 1990 to 1991. Mr. Wheeler received a B.S. in engineering from the University of Virginia, an M.S. in nuclear engineering
from the University of Michigan, and an M.B.A. from Harvard University Business School. Mr. Wheeler brings to the Board a broad
understanding of business and finance matters, as well as over 20 years of experience as a member of the Board. He serves as a
member of the Compensation Committee and as Chairperson of the Governance and Nominating Committee.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>The Board&rsquo;s Role in Risk Oversight</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The role of the Board of Directors in our risk oversight process
includes receiving reports from management or a Board committee chairperson on areas of material risk to our Company, including
operational, financial, commercial, legal, regulatory, strategic, and reputational risks. The Board has delegated primary responsibility
to the Audit Committee to review these reports and discuss with management the process by which management assesses and manages
our risk exposure, risk management, and risk mitigation strategies. The Audit Committee also works with other committees to assess
areas of risk under the particular purview of those committees. When the Audit Committee receives a report from management or another
committee, the Chairperson of the Audit Committee reports on his or her review of the report to the full Board. This enables the
Board and its committees to coordinate the risk oversight role to ensure that all directors receive all significant risk-related
information. The Board also administers its risk oversight function through the required approval by the Board (or a committee
of the Board) of significant transactions and other material decisions and through regular periodic reports from our independent
registered public accounting firm and other outside consultants regarding various areas of potential risk, including, among others,
those relating to our internal controls and financial reporting. In addition, as part of its charter, the Audit Committee discusses
with management and our independent registered public accounting firm significant risks and exposures, as well as the steps management
has taken to minimize those risks.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Board Leadership Structure</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Dr. Bower serves as the Lead Director of the Board of Directors.&nbsp;Separating
the Lead Director role and the Chief Executive Officer role allows our Chief Executive Officer to focus on the strategic management
of our day-to-day business, while allowing the Lead Director to focus on leading our Board in its fundamental role of providing
advice to and independently overseeing management. The Board recognizes the time, effort, and energy that the Chief Executive Officer
is required to devote to his position in the current business environment, as well as the commitment required to serve as our Lead
Director, particularly as the Board&rsquo;s oversight responsibilities continue to grow. The Board believes that having separate
positions, with an independent, non-executive director serving as the Lead Director, is the appropriate leadership structure for
our Company at this time and allows the Board to fulfill its role with appropriate independence.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Corporate Governance, Board Matters, and Committees</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Board of Directors has determined that each of its members, except
for Dr.&nbsp;Sherwood, is &ldquo;independent&rdquo; within the meaning of the director independence standards of the NASDAQ Stock
Market, Inc. (&ldquo;NASDAQ&rdquo;) and the SEC. The Board based these determinations primarily on a review of the responses of
each director to questions regarding employment and compensation history, affiliations, and family and other relationships, and
on other relevant discussions with the directors.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Independent directors meet periodically in executive sessions without
management participation. The executive sessions generally occur in connection with regularly scheduled meetings of the Board and
committees of the Board, and at other times the independent directors deem appropriate. The executive sessions are chaired either
by the Lead Director or by the Chairperson of the Board committee having jurisdiction over the particular subject matter to be
discussed at the particular meeting or portion of a meeting.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Board reviews matters related to our corporate governance annually
at a regularly scheduled meeting of the Board. This includes an evaluation of our by-laws, committee charters, shareholder rights
plan, and other matters related to our governance. During this review, the Board assesses input from management and outside consultants
to discern whether any actions should be taken on any of these topics. Furthermore, the Board conducts periodic evaluations that
focus on the effectiveness of the Board as a whole and of its committees. Board members complete a detailed questionnaire that
(a)&nbsp;provides for quantitative rankings in key areas and (b) seeks subjective comments in each of those areas. In addition,
members of each Board committee complete a detailed questionnaire to evaluate how well their committee is operating and to make
suggestions for improvement. The evaluation process is managed by the Chairperson of the Nominating and Governance Committee, with
advice from outside counsel. Outside counsel conducts separate, confidential interviews with each of the directors to follow-up
on responses and comments reflected in the questionnaires. An anonymized summary of the principal findings from the questionnaires
and interviews is prepared by outside counsel and is used as the basis for self-assessment discussions by the Board and its committees.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Board met four times during 2016. No director attended less than
80% of the aggregate of (1)&nbsp;the total number of Board meetings and (2)&nbsp;the total number of meetings held by all committees
on which such director served. Our Annual Meetings of Stockholders are generally held to coincide with the Board&rsquo;s regularly
scheduled meetings. Directors are encouraged to attend the Annual Meeting. Each of the then-current directors attended the 2016
Annual Meeting of Stockholders.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Board currently has three standing committees:</P>

<P STYLE="font-size: 10pt; text-indent: 0.75in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 4%; text-align: center">&#9679;</TD>
    <TD STYLE="width: 94%">Audit Committee;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&#9679;</TD>
    <TD>Compensation Committee; and</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&#9679;</TD>
    <TD>Governance and Nominating Committee.</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Board has adopted a written charter for each of the Audit Committee,
the Compensation Committee, and the Governance and Nominating Committee, which are reviewed at least yearly by each of the committees.
You can find links to these materials in the corporate governance section of our website at<I>&nbsp;<U>http://www.anikatherapeutics.com</U></I>.
Please note that the information contained on the website is not incorporated by reference in, or considered to be a part of, this
proxy statement.&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><I>Audit Committee.</I> The current members of the Audit Committee
are Mr.&nbsp;Land, as Chairperson, Dr.&nbsp;Bower, and Mr. Thompson. Mr.&nbsp;Land, Dr.&nbsp;Bower, and Mr. Thompson served on
the Audit Committee throughout 2016. The Board has determined that each member of the Audit Committee meets the independence requirements
promulgated by NASDAQ and the SEC, including Rule&nbsp;10A-3(b)(1) under the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange
Act&rdquo;). In addition, the Board has determined that each member of the Audit Committee is financially literate and has the
requisite financial sophistication to serve on the committee. The Board has also determined that Mr.&nbsp;Land qualifies as an
&ldquo;audit committee financial expert&rdquo; under the rules of the SEC. Stockholders should understand that this designation
is a disclosure requirement of the SEC related to Mr.&nbsp;Land&rsquo;s experience and understanding with respect to certain accounting
and auditing matters. The designation does not impose upon Mr.&nbsp;Land any duties, obligations, or liability that are greater
than those that are generally imposed on him as a member of the Audit Committee and the Board, and his designation as an audit
committee financial expert pursuant to this SEC requirement does not affect the duties, obligations, or liability of any other
member of the Audit Committee or the Board.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The purposes of the Audit Committee are, among other things, to (1)&nbsp;oversee
our accounting and financial reporting processes and the audits of our financial statements, (2)&nbsp;take, or recommend that the
Board take, appropriate action to oversee the qualifications, independence, and performance of our independent registered public
accounting firm, (3) lead the review of our risk management processes and exposure to risk, and (4)&nbsp;prepare an Audit Committee
report as required by the SEC to be included in our annual proxy statement. The Audit Committee has direct authority to appoint,
retain, oversee and, when appropriate, terminate our independent registered public accounting firm. The Audit Committee also has
the responsibility to confer with the independent registered public accounting firm regarding the scope, method, and result of
the audit of our books and records, to report the same to the Board of Directors, and to establish and monitor a policy relative
to non-audit services provided by the independent registered public accounting firm in order to ensure the firm&rsquo;s independence.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Audit Committee holds separate sessions of its meetings, outside
the presence of management, with our independent auditors in conjunction with each regularly scheduled Audit Committee meeting
in which the independent auditors participate. The Audit Committee met twelve times during 2016.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><I>Compensation Committee.</I> The current members of the Compensation
Committee are Dr.&nbsp;Bower, as Chairperson, Dr. Larsen, Mr. Thompson, and Mr.&nbsp;Wheeler, each of whom is independent for purposes
of NASDAQ listing standards and the SEC. Messrs.&nbsp;Thompson and Wheeler and Dr. Bower and Dr. Larsen served on the Compensation
Committee throughout 2016. The Compensation Committee, among other things, exercises on behalf of the Board all of the Board&rsquo;s
responsibilities relating to the development and implementation of our compensation programs which provide incentives that further
our long-term strategic plan with the goal of enhancing enduring stockholder value, including: (1) managing our overall compensation
structure, policies, and programs, (2)&nbsp;reviewing and approving corporate goals and objectives relevant to the compensation
of our Chief Executive Officer and other executive officers, (3) reviewing the performance of and determining the compensation
of our Chief Executive Officer, (4)&nbsp;reviewing the performance of and determining, with the advice and assistance of the Chief
Executive Officer, the compensation of our executive officers other than the Chief Executive Officer, (5) annually reviewing and
recommending to the Board compensation for non-employee directors, (6)&nbsp;overseeing our overall compensation programs, including
granting awards under our stock option and equity incentive plan, (7)&nbsp;preparing a report on executive compensation to be included
in our annual proxy statement, and (8) appointing, retaining, compensating, terminating, and overseeing the work of any compensation
consultant or other compensation adviser, as well as considering the independence of any compensation consultant or other compensation
adviser. The Compensation Committee met six times during 2016.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><I>Governance and Nominating Committee.</I>&nbsp;The current members
of the Governance and Nominating Committee are Mr.&nbsp;Wheeler, as Chairperson, Mr. Land, and Dr. Larsen, each of whom is independent
for purposes of NASDAQ listing standards and the SEC. Messrs.&nbsp;Wheeler and Land and Dr. Larsen served on the Governance and
Nominating Committee throughout 2016. The Governance and Nominating Committee is primarily responsible for (1)&nbsp;recommending
to the Board the criteria for Board and committee membership, (2)&nbsp;identifying, evaluating, and recommending nominees to stand
for election as directors at each Annual Meeting of Stockholders, including incumbent directors and candidates recommended by stockholders,
(3) matters related to executive and Board succession, (4) coordinating the evaluation of the Board and its committees, and (5)
Board education programs. The Governance and Nominating Committee met five times during 2016.&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">When considering candidates for director, the Governance and Nominating
Committee takes into account a number of factors, including the following minimum qualifications: the nominee shall have the highest
personal and professional integrity, shall have demonstrated exceptional ability and judgment, and shall be most effective, in
conjunction with the other members of the Board, in collectively serving the long-term interests of the stockholders. In addition,
the Governance and Nominating Committee will take into consideration such other factors as it deems appropriate, including any
direct experience in the biotechnology, pharmaceutical, and/or life sciences industries or in the markets in which we operate.
The Board has adopted a retirement policy providing that directors will not be nominated for election to the Board after their
75<SUP>th</SUP> birthday, which was waived by the Board in relation to the election of Dr. Bower at the 2015 Annual Meeting due
to his distinguished experience and unique leadership position with our company and the Board. The Board plans to revisit this
policy in 2018. While we do not have a formal diversity policy, the Governance and Nominating Committee may consider whether the
candidate, if elected, assists in achieving a mix of Board members that represents a diversity of background and experience. The
Governance and Nominating Committee may also consider, among other things, the skills of the candidate, his or her availability,
the candidate&rsquo;s depth and breadth of experience or other background characteristics, and his or her independence. Depending
upon the current needs of the Board, these and other factors may be weighed more or less heavily by the Governance and Nominating
Committee.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Governance and Nominating Committee will consider written recommendations
from stockholders of Anika Therapeutics regarding potential candidates for election as directors. The Governance and Nominating
Committee will review and evaluate the qualifications of director nominee candidates who have been recommended by stockholders
in compliance with procedures established from time to time by the Governance and Nominating Committee and will conduct such inquiries
as it deems appropriate. The Governance and Nominating Committee will consider for nomination any proposed director candidate who
is deemed qualified by the Governance and Nominating Committee in light of the minimum qualifications and other criteria for Board
membership described above or otherwise approved by the Board from time to time.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Stockholders wishing to suggest a candidate for director should write
to the Governance and Nominating Committee in care of our Chief Executive Officer, Anika Therapeutics,&nbsp;Inc., 32 Wiggins Avenue,
Bedford, Massachusetts 01730 and include:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 4%; text-align: center">&#9679;</TD>
    <TD STYLE="width: 94%">the name and address of record of the stockholder;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&#9679;</TD>
    <TD>a representation that the stockholder is a record holder of our common stock, or if the stockholder is not a record holder, evidence of ownership in accordance with Rule&nbsp;14a-8(b)(2) under the Exchange Act;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&#9679;</TD>
    <TD>the name, age, business and residential address, educational background, public company directorships, current principal occupation or employment, and principal occupation or employment for the preceding five&nbsp;full years of the proposed director candidate;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 4%; text-align: center">&#9679;</TD>
    <TD STYLE="width: 94%">a description of the qualifications and background of the proposed director candidate which addresses the minimum qualifications and other criteria for Board membership approved by the Board from time to time;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 4%; text-align: center">&#9679;</TD>
    <TD STYLE="width: 94%">a description of all arrangements or understandings between the stockholder and the proposed director candidate;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 4%; text-align: center">&#9679;</TD>
    <TD STYLE="width: 94%">the written consent of the proposed director candidate (1)&nbsp;to be named in the proxy statement relating to the Annual Meeting of Stockholders, (2)&nbsp;to have all required information regarding such candidate included in the proxy statement relating to the Annual Meeting of Stockholders filed pursuant to the rules of the SEC, and (3)&nbsp;to serve as a director if elected at such annual meeting; and</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 4%; text-align: center">&#9679;</TD>
    <TD STYLE="width: 94%">any other information regarding the proposed director candidate that is required to be included in a proxy statement filed pursuant to the rules of the SEC.</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Governance and Nominating Committee may solicit recommendations
for candidates for directors from non-management directors, the Chief Executive Officer, other executive officers, third-party
search firms, and such other sources as it deems appropriate, including stockholders. The Governance and Nominating Committee will
review and evaluate the qualifications of all such proposed candidates in the same manner and without regard to the source of the
recommendation.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Communications with the Board of Directors</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">If you wish to communicate with any of our directors or the Board
of Directors as a group, you may do so by writing to the Board, or such individual director(s), in care of our Chief Executive
Officer, Anika Therapeutics,&nbsp;Inc., 32 Wiggins Avenue, Bedford, Massachusetts 01730.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">We recommend that all correspondence be sent via certified U.S. mail,
return receipt requested. All correspondence received by the Chief Executive Officer will be forwarded promptly to the appropriate
addressee(s).</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Code of Business Conduct</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">It is our policy that all of our officers, directors, and employees
worldwide conduct our business in an honest and ethical manner and in compliance with all applicable laws and regulations. The
Board of Directors has adopted the Anika Therapeutics,&nbsp;Inc. Code of Business Conduct and Ethics in order to clarify, disseminate,
and enforce this policy. The Code of Business Conduct and Ethics applies to all of our officers, directors, and employees worldwide,
including our Chief Executive Officer and Chief Financial Officer. The Code of Business Conduct and Ethics can be viewed on the
investor relations section of our website at<I>&nbsp;<U>http://www.anikatherapeutics.com</U></I> under &ldquo;Corporate Governance.&rdquo;
Please note that the information contained on the website is not incorporated by reference in, or considered to be part of, this
proxy statement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Majority Voting in Uncontested Director Elections Policy</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">On December 8, 2015, the Board of Directors adopted our &ldquo;Majority
Voting in Uncontested Director Elections Policy.&rdquo; An uncontested election occurs when the number of director nominees is
equal to the number of Board positions to be filled through election and proxies are being solicited for such election of directors
solely by our company. Pursuant to our policy in such an election, if a director receives a greater number of votes &ldquo;withheld&rdquo;
than &ldquo;for&rdquo; his or her election, such director shall promptly offer his or her resignation for consideration by the
Governance and Nominating Committee. The Governance and Nominating Committee shall then consider all of the relevant facts and
circumstances, and the committee shall recommend to the Board whether or not to accept such offer of resignation. The final decision
of whether or not to accept such resignation shall be made by the Board, and, if required or determined by the Board to be desirable,
we shall appropriately disclose the decision of the Board along with the rationale for such decision.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Transactions with Related Persons and Conflict of Interest Policy</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">It is our policy that all employees and directors, as well as their
family members, must avoid any activity that is or has the appearance of conflicting with our business interests. This policy is
included in our Code of Business Conduct and Ethics, and it is supplemented by our Conflict of Interest Policy, which was implemented
by the Board of Directors on October 6, 2015. Both the Code of Business Conduct and Ethics and the Conflict of Interest Policy
are reviewed annually. Among other things, this policy requires each director and officer of Anika Therapeutics to provide written
notice of any potential related party transaction, defined by our policy to mirror the definition of Item 404 of Regulation S-K
(with the exception that our policy includes a monetary threshold of $100,000 as opposed to the threshold of $120,000 set by Item
404 of Regulation S-K) to the Lead Director (or to the Chief Executive Officer if such transaction involves the Lead Director)
including all information that the Lead Director or Chief Executive Officer may request. Upon receiving all relevant information,
the disinterested members of the Board may approve the transaction if they determine that the transaction is in the best interests
of, and fair to, us, may require modifications to the transaction to make it acceptable for approval, or may reject it. The Board
may also establish guidelines for ongoing management of a specific related party transaction. The policy requires that continuing
related party transactions are reviewed on at least an annual basis. Additionally, the policy requires that all of our executives
and directors complete a directors and officers questionnaire in connection with each of our annual proxy statements, in which
they are asked to disclose family relationships and other related party transactions.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">From January 1, 2016 through the date of this proxy statement, we
had one reportable related party transaction. Charles Sherwood III, an adult child of Dr.&nbsp;Charles Sherwood, one of our directors
and our President and Chief Executive Officer, is employed on an at-will basis as our senior corporate legal counsel, a non-executive
position, and received compensation for fiscal year 2016 of approximately $234,000, which included 3,000 incentive stock options
with an initial Black-Scholes value of $49,000, granted under our Second Amended and Restated 2003 Stock Option and Incentive Plan,
as amended (the &ldquo;Second Amended 2003 Plan&rdquo;) with an exercise price of $38.11 on the date of grant and vesting occurring
in four equal annual installments beginning one year from the date of grant. He also received, and continues to receive, benefits
generally available to all employees. In 2017, the Board approved a base salary for Mr. Sherwood III of $240,000, which includes
3,000 incentive stock options under the Second Amended 2003 Plan with a total Black-Scholes value of approximately $55,000 on the
date of grant, as well as a bonus initially targeted to equal 15% of his base salary. The compensation for this employee was determined
in accordance with our standard employment and compensation practices. The 2016 compensation was approved by the Board in accordance
with our Conflict of Interest Policy. In January 2017, the Board approved Mr. Sherwood III&rsquo;s 2017 compensation in accordance
with our Conflict of Interest Policy for ongoing related party transactions.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;<B>BENEFICIAL OWNERSHIP OF COMMON STOCK</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The following table sets forth the beneficial ownership of our common
stock as of March&nbsp;31, 2017, by:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 4%; text-align: center">&#9679;</TD>
    <TD STYLE="width: 94%">each director who served during 2016;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&#9679;</TD>
    <TD>each of the Named Executive Officers named in the Summary Compensation Table set forth under the caption &ldquo;Executive Compensation;&rdquo;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&#9679;</TD>
    <TD>each other person which is known by us to beneficially own 5% or more of our common stock; and</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&#9679;</TD>
    <TD>current directors and executive officers as a group.</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Unless otherwise noted below, the address of each person listed on
the table is in care of Anika Therapeutics,&nbsp;Inc., 32 Wiggins Avenue, Bedford, MA 01730.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid; text-align: left">Beneficial Owner</TD><TD STYLE="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1.1pt; border-bottom: Black 1.1pt solid">&nbsp;</TD>
    <TD NOWRAP COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1.1pt solid">Amount and Nature<BR> of Beneficial <BR> Ownership <FONT STYLE="font-size: 10pt; font-style: normal"><B><SUP>(1)</SUP></B></FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1.1pt; border-bottom: Black 1.1pt solid">&nbsp;</TD>
    <TD NOWRAP COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1.1pt solid">Percentage of <BR> Common Stock <BR> Outstanding <FONT STYLE="font-size: 10pt; font-style: normal"><B><SUP>(2)</SUP></B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">Directors and Named Executive officers<FONT STYLE="font-size: 10pt; font-weight: normal; font-style: normal">:</FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="3" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="3" STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; font-size: 10pt; text-align: left; padding-left: 20pt">&nbsp;Joseph L. Bower</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">41,536</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>(3)</SUP></FONT></TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">&nbsp;*&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 20pt">Raymond J. Land</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">13,524</TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>(4)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;*&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 20pt">Glenn R. Larsen, Ph.D.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,477</TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>(5)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;*&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 20pt">Jeffery S. Thompson</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">16,942</TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>(6)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;*&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 20pt">Steven E. Wheeler</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">36,081</TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>(7)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;*&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 20pt">Charles H. Sherwood, Ph.D.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">613,674</TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>(8)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4.08</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 20pt">Edward Ahn, Ph.D.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">35,036</TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>(9)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;*&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 20pt">Dana Alexander</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">10,000</TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>(10)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;*&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 20pt">Sylvia Cheung</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">206,539</TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>(11)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1.39</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 20pt">Richard Hague</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">36,350</TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>(12)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;*&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 20pt">Stephen Mascioli, M.D., MPH</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-&nbsp;&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>(13)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;*&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 20pt">Current directors and executive officers as a group (10 persons)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,016,159</TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>(14)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6.57</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">5% and Above Stockholders:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 20pt">Blackrock, Inc.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: left; padding-left: 30pt">55 East 52<FONT STYLE="font-size: 10pt; font-weight: normal; font-style: normal"><SUP>nd</SUP> Street</FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 30pt">New York, NY 10055</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,675,840</TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>(15)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">11.44</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 20pt">Wellington Management Group LLP</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 30pt">280 Congress Street</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 30pt">Boston, MA 02210</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,119,957</TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>(16)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7.64</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 20pt">The Vanguard Group</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 30pt">100 Vanguard Blvd.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 30pt">Malvern, PA 19355</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">845,044</TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>(17)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5.77</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 30pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">* Indicates less than 1%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">(1)</TD>
    <TD STYLE="width: 96%">Beneficial ownership is determined in accordance with the rules of the SEC. Accordingly, the number of shares deemed beneficially owned includes (i) shares of common stock owned as of March 31, 2017 and (ii) shares that may be acquired within sixty days of March 31, 2017 through the exercise or vesting of equity awards granted under the Second Amended 2003 Plan. Unless otherwise indicated below, to our knowledge, all persons listed above have sole voting and investment power with respect to their shares of common stock, except to the extent authority is shared by spouses under applicable law.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(2)</TD>
    <TD>As of March 31, 2017, there were 14,654,590 shares of common stock outstanding. Shares not outstanding, but deemed beneficially owned by virtue of the right of a person to acquire those shares are treated as outstanding only for purposes of determining the number and percent of shares of common stock owned by such person or group. </TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 19; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">(3)</TD>
    <TD STYLE="width: 96%">This amount includes (i) 3,217 shares subject to restricted stock units and (ii) 2,000 shares owned by Dr. Bower&rsquo;s spouse. The restricted stock units are unvested and will be fully vested if Dr. Bower leaves our company in good standing.&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(4)</TD>
    <TD>This amount includes 3,217 shares subject to restricted stock units. The restricted stock units are unvested and will be fully vested if Mr. Land leaves our company in good standing.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(5)</TD>
    <TD>This amount includes 1,994 shares subject to restricted stock units. The restricted stock units are unvested and will be fully vested if Dr. Larsen leaves our company in good standing.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(6)</TD>
    <TD>This amount includes 3,217 shares subject to restricted stock units. The restricted stock units are unvested and will be fully vested if Mr. Thompson leaves our company in good standing.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(7)</TD>
    <TD>This amount includes 3,217 shares subject to restricted stock units. The restricted stock units are unvested and will be fully vested if Mr. Wheeler leaves our company in good standing.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(8)</TD>
    <TD>This amount includes 360,969 shares subject to stock options that are exercisable within sixty days of March 31, 2017 and 27,575 shares of restricted stock vesting in four equal annual installments commencing one year from the applicable grant date.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(9)</TD>
    <TD>This amount includes 29,111 shares subject to stock options that are exercisable within sixty days of March 31, 2017 and 5,925 shares of restricted stock vesting in four equal annual installments commencing one year from the applicable grant date.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(10)</TD>
    <TD>This amount includes 10,000 shares subject to stock options that are exercisable within sixty days of March 31, 2017.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(11)</TD>
    <TD>This amount includes 168,931 shares subject to stock options and stock appreciation rights that are exercisable within sixty days of March 31, 2017 and 10,787 shares of restricted stock vesting in four equal annual installments commencing one year from the applicable grant date.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(12)</TD>
    <TD>This amount includes 7,450 shares subject to stock options and stock appreciation rights that are exercisable within sixty days of March 31, 2017 and 21,675 shares of restricted stock vesting in four equal annual installments commencing one year from the applicable grant date.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(13)</TD>
    <TD>Dr. Mascioli&rsquo;s employment as Chief Medical Officer terminated on January 23, 2017, and all shares subject to stock options previously granted to him were forfeited on that date.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(14)</TD>
    <TD>This amount includes 14,862 shares subject to restricted stock units, 65,962 shares of unvested restricted stock, and 576,461 shares in the aggregate subject to stock options and stock appreciation rights that are exercisable within sixty days of March 31, 2017. </TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(15)</TD>
    <TD>Such information is provided based on an amended Schedule 13G filed with the SEC on behalf of Blackrock, Inc. on January 12, 2017. Blackrock, Inc. has sole voting power with respect to 1,642,873 shares and sole dispositive power with respect to 1,675,840 shares.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(16)</TD>
    <TD>Such information is provided based on an amended Schedule&nbsp;13G filed with the SEC on behalf of Wellington Management Group, LLP on February 9, 2017. Wellington Management Group LLP has shared power to vote or direct the vote with respect to 872,939 shares and shared dispositive power with respect to 1,119,957 shares.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(17)</TD>
    <TD>Such information is provided based on an amended Schedule&nbsp;13G filed with the SEC on behalf of The Vanguard Group on February 9, 2017. The Vanguard Group has sole voting power with respect to 26,277 shares and sole dispositive power with respect to 818,467 shares.</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Section&nbsp;16(a) Beneficial Ownership Reporting Compliance</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Exchange Act requires that our officers, directors, and persons
who own more than 10% of our common stock file initial reports of ownership and report of changes in ownership with the SEC and
NASDAQ. Officers, directors, and persons who beneficially own more than 10% of our common stock are also required to furnish us
with a copy of all forms they file pursuant to Section&nbsp;16(a) of the Exchange Act. To our knowledge, based solely upon a review
of Forms&nbsp;3, 4, 5, and other applicable forms as well as amendments thereto furnished to us under Rule&nbsp;16a-3(e) of the
Exchange Act for the year ended December&nbsp;31, 2016, no officer, director, or person who owns more than 10% of our outstanding
shares of common stock failed to file such reports on a timely basis.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>EXECUTIVE OFFICERS</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Board of Directors elects our executive officers annually at
a regular meeting held immediately preceding the Annual Meeting of Stockholders. The Board also elects executive officers throughout
the year as such individuals are hired by us. Such executive officers hold office until the next Annual Meeting of Stockholders
or until their successors are duly elected and qualified, unless they sooner resign or are removed from office. There are no family
relationships between any of our directors, director nominees, or executive officers.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The following table lists the current executive officers of Anika
Therapeutics and certain information concerning the executive officers of Anika Therapeutics. It is anticipated that each of these
officers will be re-appointed by the Board immediately preceding the Annual Meeting:</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="width: 90%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: middle">
    <TD STYLE="font-weight: bold; border-bottom: Black 0.5pt solid; width: 47%; text-align: left">Name</TD>
    <TD STYLE="width: 2%">&nbsp;&nbsp;</TD>
    <TD STYLE="font-weight: bold; border-bottom: Black 0.5pt solid; text-align: center; width: 7%">Age</TD>
    <TD STYLE="width: 2%">&nbsp;&nbsp;</TD>
    <TD STYLE="font-weight: bold; border-bottom: Black 0.5pt solid; width: 42%; text-align: left">Position</TD></TR>
<TR STYLE="vertical-align: middle; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Charles H. Sherwood, Ph.D.</TD>
    <TD STYLE="text-align: right">&nbsp;&nbsp;</TD>
    <TD STYLE="text-align: center">70</TD>
    <TD>&nbsp;&nbsp;</TD>
    <TD STYLE="text-align: left">President and Chief Executive Officer</TD></TR>
<TR STYLE="vertical-align: middle; background-color: White">
    <TD STYLE="text-align: left">Edward Ahn, Ph.D.</TD>
    <TD STYLE="text-align: right">&nbsp;&nbsp;</TD>
    <TD STYLE="text-align: center">45</TD>
    <TD>&nbsp;&nbsp;</TD>
    <TD STYLE="text-align: left">Chief Technology and Strategy Officer</TD></TR>
<TR STYLE="vertical-align: middle; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Dana Alexander</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: center">41</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Chief Operations Officer</TD></TR>
<TR STYLE="vertical-align: middle; background-color: White">
    <TD STYLE="text-align: left">Sylvia Cheung</TD>
    <TD>&nbsp;&nbsp;</TD>
    <TD STYLE="text-align: center">42</TD>
    <TD>&nbsp;&nbsp;</TD>
    <TD STYLE="text-align: left">Chief Financial Officer, Treasurer, and Secretary</TD></TR>
<TR STYLE="vertical-align: middle; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Richard Hague</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: center">57</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Chief Commerical Officer</TD></TR>
</TABLE>


<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><I>Dr.&nbsp;Sherwood&rsquo;s</I>
biography is included above in the section titled &ldquo;Proposal 1: Election of Directors &ndash; Information Regarding the Directors.&rdquo;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><I>Edward Ahn, Ph.D.,</I> was appointed Chief Technology and Strategy
Officer on October 30, 2014. From 2012 through 2014, Dr. Ahn was Managing Director and Chief Science Officer at MedCap Advisors
where he built merger strategies, strategic partnerships, and licensing agreements for emerging medical device, biotechnology,
and biological organizations with a focus on regenerative medicine. Prior to his work at MedCap, Dr. Ahn was Vice President of
Product Development for Pioneer Surgical Biologics from 2007 through 2012. In this role Dr. Ahn directed Pioneer Surgical Biologic&rsquo;s
product development policies, objectives, and initiatives. He has also served as Chief Executive Officer, Chief Technology Officer,
and Founder of Angstrom Medica, Inc., a company based upon his doctoral thesis work and focused on commercializing nanotechnology
in the area of Orthopedics. Dr. Ahn holds a B.S. in chemical engineering from Stanford University and both an M.S. in chemical
engineering practice and a Ph.D. in chemical engineering from Massachusetts Institute of Technology.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><I>Dana Alexander</I> was appointed Chief Operations Officer on April
4, 2016. Mr. Alexander has spent the last 14 years in various leadership roles at Genzyme Corporation. From 2011 through 2016,
Mr. Alexander served as Senior Director of Biologics Manufacturing Operations, heading manufacturing at Genzyme&rsquo;s flagship
biologics plant, with responsibilities including&nbsp;overseeing production planning&nbsp;and execution, bringing new manufacturing&nbsp;capacity
on-line,&nbsp;and&nbsp;implementing new production and quality systems. During his tenure at Genzyme Corporation, Mr. Alexander
also held other leadership roles and provided operational oversight for&nbsp;the construction,&nbsp;start-up, and approval&nbsp;of&nbsp;a
new cGMP cell culture facility, managed&nbsp;Chemistry, Manufacturing and Control (CMC) activities&nbsp;for a variety of&nbsp;late
stage and&nbsp;commercial products,&nbsp;and led operation product&nbsp;teams across complex supply chains to deliver&nbsp;global
clinical and commercial supply&nbsp;requirements.&nbsp;Mr. Alexander holds a B.S. in chemical engineering from Northeastern University
and an M.B.A. from Boston University.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><I>Sylvia Cheung</I> was appointed Chief Financial Officer, Treasurer,
and Secretary on April 1, 2013. Ms. Cheung served as our Vice President of Strategic Processes commencing in 2012. Since October
2014, she has also served as General Manager for our Italy-based subsidiary, Anika Therapeutics S.r.l., and she served in the same
role from 2010 to 2011. Ms. Cheung originally joined our company as its Controller in 2005, and, in addition to fulfilling these
financial responsibilities, she led our integration of Anika S.r.l. subsequent to its acquisition in 2009. Prior to joining Anika,
she held a series of progressively responsible financial management positions at Transkaryotic Therapies, Inc. From 1995 to 2000,
Ms. Cheung worked for PricewaterhouseCoopers LLP as an Audit Senior Associate with a focus in technology companies. Ms. Cheung
holds a B.S. in business administration and accounting from the University of Massachusetts in Amherst and an M.B.A. from Boston
University, and she is a Certified Public Accountant (inactive).</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><I>Richard Hague</I> was appointed Chief Commercial Officer on October
26, 2015. From November 2014 through joining our company, Mr. Hague was the Vice President Sales and Marketing at TEI Medical where
he was responsible for driving the revenue growth of that corporation&rsquo;s dermal scaffold product, as well as for the build
out of its sales and marketing teams. From 2011 through 2014, Mr. Hague was Vice President Sales, Marketing, and Commercial Operations
for Sanofi Biosurgery&rsquo;s Cell Therapy and Regenerative Medicine group. In this role, Mr. Hague was responsible for the global
commercial operations of the group&rsquo;s products in the orthopedic sports medicine and burn markets. Prior to this, Mr. Hague
was the Senior Director and Head of Sales for Genzyme Biosurgery where he headed the U.S. sales team in the orthopedics and sports
medicine market. Mr. Hague holds a B.S. in marketing from the University of Connecticut.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>COMPENSATION DISCUSSION AND ANALYSIS</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">This section describes and analyzes the material elements of the
2016 compensation for our executive officers identified in the Summary Compensation Table hereunder. We refer to these individuals
as the &ldquo;Named Executive Officers&rdquo; or &ldquo;NEOs.&rdquo; The Compensation Committee of the Board of Directors oversees
all decisions regarding the compensation of the NEOs, including base salary, annual bonuses, equity incentives, perquisites, and
other agreements and arrangements.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Philosophy and Process</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The overall objective of our executive compensation policy is to
attract and retain highly qualified executive officers and to motivate them to provide a superior level of performance for the
benefit of our company and its stockholders. The Compensation Committee approves our compensation policies and oversees our overall
compensation program. The Compensation Committee believes that to accomplish these objectives we should provide executive officers
with market competitive compensation packages and the opportunity to earn additional cash and equity compensation based upon our
business progress and financial performance.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In setting the compensation for our executive
officers, the Compensation Committee relies primarily on our financial performance and an assessment of the individual&rsquo;s
performance and contribution to our development and achievements. The Compensation Committee also considers the yearly shareholder
advisory vote on executive compensation, which, given the high approval rate of such compensation at the 2016 Annual Meeting, resulted
in no changes to our executive compensation programs for 2017. Additionally, the Compensation Committee weighs quantitative factors
such as general compensation trends. In this regard, the Compensation Committee periodically reviews surveys of executive compensation
and information concerning compensation at similarly situated companies. The Compensation Committee engaged Radford, an Aon Hewitt
Company&mdash;a business unit of Aon plc, a national executive compensation consulting firm (&ldquo;Radford&rdquo;), to assist
the Company in selecting an appropriate peer group for compensation comparisons and to perform an executive compensation review.
The Compensation Committee, with the assistance of Radford, performed this analysis in 2013, 2015, and 2016, and it generally performs
this analysis at least every two years. In completing its analysis in 2016, the Compensation Committee reviewed competitive data
compiled by Radford from a peer group comprised of 18 companies of similar size and related businesses. The Compensation Committee
also reviewed market data from the&nbsp;2016 Radford Global Life Sciences Executive Survey (the &ldquo;Radford Survey&rdquo;) covering
over 55 public biopharmaceutical and medical device companies.&nbsp;While the Compensation Committee does not determine compensation
based on formulaic criteria, it generally seeks to achieve an overall compensation level approximating the industry median. The
following is the composition of the peer group for 2016:</P>



<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 50%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 100%; border: black 1pt solid; text-align: center"><B>Peer Group Companies</B></TD></TR>
<TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><B><I>Biopharmaceutical Companies</I></B></TD></TR>
<TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center">Exelixis, Inc.</TD></TR>
<TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center">Halozyme, Inc.</TD></TR>
<TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center">Macrogenics, Inc.</TD></TR>
<TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center">MiMedx Group, Inc.</TD></TR>
<TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center">Momenta Pharmaceuticals, Inc.</TD></TR>
<TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center">Repligen Corporation</TD></TR>
<TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center">Spectrum Pharmaceuticals, Inc.</TD></TR>
<TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center">Sucampo Pharmaceuticals, Inc. </TD></TR>
<TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center">Vanda Pharmaceuticals, Inc.</TD></TR>
<TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><B><I>Medical Device Companies</I></B></TD></TR>
<TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center">AtriCure, Inc.</TD></TR>
<TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center">Atrion Corporation</TD></TR>
<TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center">Cerus Corporation</TD></TR>
<TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center">CryoLife Inc.</TD></TR>
<TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center">GenMark Diagnostics, Inc.</TD></TR>
<TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center">Glaukos Corporation</TD></TR>
<TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center">Rockwell Medical, Inc.</TD></TR>
<TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center">STAAR Surgical Company</TD></TR>
<TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center">Vascular Solutions, Inc.</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">With respect to the definition of financial performance, we developed
our 2016 budget with the knowledge that certain events could impact the achievement of the budgeted goals.&nbsp;These events included:
efforts to gain U.S. and international approvals of Cingal; the launch of Cingal in Canada and certain European Union countries;
growing the sales of Monovisc and Orthovisc in the U.S. market as adoption of Monovisc continues to expand in its second full year
of commercialization in the U.S.; the execution of Hyalofast U.S. clinical development; the realization of planned operations and
manufacturing gains; the ongoing international development and improvement of our business; the planned transition of manufacturing
operations for our Italian subsidiary&rsquo;s products from an Italian contract manufacturer to our Bedford, Massachusetts headquarters,
geographic expansion of our existing product franchises, in particular our orthobiologics franchise; and the achievement of CE-Mark
approval for our latest orthobiologics product, which is branded as Orthovisc-T outside of the United States. The Compensation
Committee and the Board of Directors review actual developments to determine executive compensation based on actual performance
and achievements during the year.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 22; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Components of Compensation</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The principal components of the compensation policy for our executive
officers are base salary, cash bonuses, and equity based grants. Decisions regarding each component are made independent of any
other component, provided that overall compensation is an aspect of our benchmark analysis.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><I>Base Salary.&nbsp;&nbsp;</I>The primary component of compensation
for our executive officers is base salary. Base salaries for these individuals are subject to annual review by either the Board
of Directors or the Compensation Committee. In addition, the executive officers are subject to confidentiality, non-disclosure,
non-competition, non-solicitation, assignment and arbitration provisions. Base salary levels for our executive officers are determined
based upon an evaluation of a number of factors, including the individual&rsquo;s level of responsibility, experience, performance
and competitive market practices as determined by our analysis of management compensation surveys, and a review of other published
data relating to executive compensation, including peer group data, and taking into account any contractual obligations.&nbsp;Salaries
are reviewed on an annual basis.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><I>Cash Bonus.&nbsp;&nbsp;</I>The second principal component of our
compensation policy for executive officers consists of discretionary cash bonuses. The Compensation Committee considers the achievement
of financial results, organizational development, business and technical development, and contribution to increasing shareholder
value at its discretion to determine the amounts and the timing of the bonuses awarded to executive officers. Historically, cash
bonuses for the most recently completed year are awarded contemporaneously with annual compensation reviews for the subsequent
year. Bonuses are prorated in the year of hire, provided that the employee begins their employment with us prior to October 1.
The Compensation Committee also grants cash bonuses for executive retention purposes, taking into account, among other things,
general industry practices, special performance bonuses in exceptional circumstances, and any contractual obligations. Bonuses
are not determined based on a formula, but rather by taking into account both company and individual performance as a whole.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">After the completion of the 2016 fiscal year, the Compensation Committee,
with the assistance of the Chief Executive Officer, reviewed our performance, as well as the individual performance of each executive
officer. Accomplishments that factored into the bonus and equity awards for 2016 included: strong financial results, including
achieving 17% product revenue growth from 2015 and exceeding internal net income targets; the maintenance of U.S. market-leading
positions for our Orthovisc and Monovisc products; CE-Mark approval of Cingal; progress on the U.S. FDA approval pathway for Cingal;
continued implementation of our strategic decision to consolidate our manufacturing operations, including for products previously
outsourced to a contract manufacturer, at our Bedford, Massachusetts headquarters; advancements in our research and development
pipeline; organizational development, including the hiring of certain key contributors within the organization; and the achievement
of CE-Mark approval for our latest orthobiologic product, which is branded as Orthovisc-T outside of the United States. For the
year, the Compensation Committee determined that we made excellent overall progress.&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><I>Equity Based Grants.&nbsp;&nbsp;</I>The third principal component
of our compensation policy for executive officers consists of grants under the Second Amended 2003 Plan. Under this plan, executive
officers may be granted stock options or other forms of equity securities, including stock appreciation rights (&ldquo;SARs&rdquo;),
restricted stock awards, and performance-based equity awards. In 2016, the Compensation Committee granted to executive officers
common stock options, performance-based common stock options, and restricted stock awards as described herein. The equity component
of our compensation policy provides the opportunity for our executive officers to be compensated based upon increases in the market
price of our common stock. The Compensation Committee has delegated to our Chief Executive Officer the ability under the Second
Amended 2003 Plan to grant to non-officer employees up to an annual maximum of 50,000 shares per individual and 300,000 shares
per year in the aggregate, provided any such grants comply with all existing plan and statutory requirements.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">In February 2016, the Compensation Committee granted certain executive
officers performance-based stock option awards under the Second Amended 2003 Plan, with the awards to be measured based on our
2016 financial results and certain business criteria, including, among other things, obtaining CE-Mark approval of Cingal and obtaining
approval for a new product in the U.S. or the European Union. In February 2017, the Compensation Committee measured the executive
officers&rsquo; performance in granting such awards under the Second Amended 2003 Plan. The related grants are detailed in the
table captioned &ldquo;Option Grants and Plan Awards in 2016&rdquo; included herein.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><I>Compensation of Chief Executive Officer.</I>&nbsp;In 2016, Dr.&nbsp;Sherwood&rsquo;s
annual salary was $601,586. In determining the compensation for Dr.&nbsp;Sherwood in 2016, the Compensation Committee evaluated
corporate, individual, and organizational accomplishments by Anika Therapeutics in 2015. In addition, the Compensation Committee
took into account information regarding the compensation paid to other Chief Executive Officers in comparably sized, publicly traded
companies in the pharmaceutical and medical device industry and the relative performance of such companies, as well as the data
from the Radford Survey.&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">In recognition of the corporate, individual, and organizational accomplishments
of Anika Therapeutics for 2016, including his leadership and contributions to our performance and financial results for the year,
in January 2017, the Compensation Committee awarded Dr.&nbsp;Sherwood a cash bonus of $496,308, or 110% of his target bonus.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Compensation Committee also factored into its evaluation the
aggregate value of all compensation received by the Chief Executive Officer, including the value of equity awards received by the
Chief Executive Officer as compared to the holdings of other comparably situated Chief Executive Officers, based on data from the
Radford Survey.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><I>Compensation of Chief Technology and Strategy Officer.</I>&nbsp;In
2016, Dr. Ahn&rsquo;s annual salary was $315,675. In determining the compensation for Dr. Ahn in 2016, the Compensation Committee
evaluated corporate, individual, and organizational accomplishments by Anika Therapeutics in 2015. The Compensation Committee took
into account information regarding the compensation paid to other individuals in similar professional capacities in comparably
sized, publicly traded companies in the pharmaceutical and medical device industry and the relative performance of such companies,
as well as data from the Radford Survey.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">In recognition of the corporate, individual, and organizational achievements
of Anika Therapeutics for 2016, including his contributions to our performance and financial results for the year, in January 2017,
the Compensation Committee awarded Dr. Ahn a cash bonus of $156,259, or 110% of his target bonus.&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Compensation of Chief Operations Officer.
</I>Mr. Alexander joined our company on April 4, 2016. Mr. Alexander&rsquo;s salary compensation was $285,000, which reflected
his salary as prorated for the period between his start date and the end of 2016. The Compensation Committee took into account
information regarding the compensation paid to other individuals in similar professional capacities in comparably sized, publicly
traded companies in the pharmaceutical and medical device industry and the relative performance of such companies, as well as data
from the Radford Survey.</P>




<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">In recognition of the corporate, individual, and organizational achievements
of Anika Therapeutics for 2016, including his contributions to our performance and financial results for the year, in January 2017,
the Compensation Committee awarded Mr. Alexander a cash bonus of $76,950, or 80% of his target bonus prorated to his date of hire.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><I>Compensation of Chief Financial Officer.</I>&nbsp;In 2016, Ms.
Cheung&rsquo;s annual salary was $346,942. In determining compensation for Ms. Cheung in 2016, the Compensation Committee evaluated
corporate, individual and organizational accomplishments by Anika Therapeutics in 2015. In addition, the Compensation Committee
took into account information regarding the compensation paid to other Chief Financial Officers in comparably sized, publicly traded
companies in the pharmaceutical and medical device industry and the relative performance of such companies, and data from the Radford
Survey.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">In recognition of the corporate, individual, and organizational achievements
of Anika Therapeutics for 2016, including her contributions to our performance and financial results for the year, in January 2017,
the Compensation Committee awarded Ms. Cheung a cash bonus of $171,736, or 110% of her target bonus.&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><I>Compensation of Chief Commercial Officer.</I>&nbsp;&nbsp;In 2016,
Mr. Hague&rsquo;s annual salary was $315,000. The Compensation Committee took into account information regarding the compensation
paid to other individuals in similar professional capacities in comparably sized, publicly traded companies in the pharmaceutical
and medical device industry and the relative performance of such companies, as well as data from the Radford Survey.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">In recognition of the corporate, individual, and organizational achievements
of Anika Therapeutics for 2016, including his contributions to our performance and financial results for the year, in January 2017,
the Compensation Committee awarded Mr. Hague a cash bonus of $127,575, or 90% of his target bonus.&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Compensation of Chief Medical Officer.</I>&nbsp;&nbsp;Dr.
Mascioli joined our company on April 4, 2016. Dr. Mascioli&rsquo;s salary compensation was $350,000, which reflected his salary
as prorated for the period between his start date and the end of 2016. The Compensation Committee took into account information
regarding the compensation paid to other individuals in similar professional capacities in comparably sized, publicly traded companies
in the pharmaceutical and medical device industry and the relative performance of such companies, as well as data from the Radford
Survey. Dr. Mascioli did not receive a cash bonus for 2016 due to the termination of his employment on January 23, 2017.</P>



<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><I>Deductibility of Executive Compensation.</I>&nbsp;&nbsp;Section
162(m) of the Internal Revenue Code of 1986, as amended (the &ldquo;Code&rdquo;), limits the federal income tax deductibility of
compensation paid to our Chief Executive Officer and to each of the other most highly compensated executive officers, to the extent
such compensation exceeds $1 million per person. There is an exemption from the $1 million limit for performance-based compensation
that meets certain requirements.&nbsp;For this purpose, certain awards made under the Second Amended 2003 Plan qualify as performance-based
compensation. While our Board intends to design certain components of executive compensation to preserve deductibility under Section
162(m) of the Code, it believes that stockholder interests are best served by not restricting our Board&rsquo;s or the Compensation
Committee&rsquo;s discretion and flexibility in crafting compensation programs, even though such programs may result in certain
non-deductible compensation expenses. Accordingly, our Board and the Compensation Committee have from time to time approved, and
our Board or the Compensation Committee may in the future approve, compensation arrangements for certain officers, including the
grant of equity-based awards, that may not be fully deductible for federal corporate income tax purposes.&nbsp;Considering our
current compensation plans and policies, Anika Therapeutics and the Compensation Committee believe that, for the near future, there
is little risk that we will lose any significant tax deduction relating to executive compensation.&nbsp;The Compensation Committee
may approve compensation or changes to plans, programs or awards that may cause the compensation or awards to exceed the limitation
under section 162(m) if it determines that such action is appropriate and in our best interests.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Agreements with Named Executive Officers</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">We have entered into employment agreements with our Chief Executive
Officer and Chief Financial Officer providing severance benefits to be competitive with our peer group, for retention purposes,
and to attract well qualified and talented executives. In exchange for such severance protection, these executives have agreed
to be bound by certain restrictive covenants, including non-competition and non-solicitation provisions.&nbsp;We believe that these
agreements are fair to the executives and to our stockholders because these agreements provide relatively modest severance in exchange
for the restrictive covenants which protect our company.&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><I>Chief Executive Officer</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">On October&nbsp;17, 2008, we entered into an employment agreement
(the &ldquo;CEO Employment Agreement&rdquo;) with Dr.&nbsp;Charles&nbsp;H. Sherwood, our President and Chief Executive Officer.
Effective December 8, 2010, we entered into an amendment to the CEO Employment Agreement to include certain technical amendments
to bring such agreement into compliance with Section 409A of the Code and the regulations thereunder. In addition to his base salary
in existence at the time of the agreement, Dr.&nbsp;Sherwood is eligible to receive cash incentive compensation, with a discretionary
bonus at a target equal to 75% of his annual base salary. Pursuant to the terms of the CEO Employment Agreement, upon any termination,
whether due to death, disability, or for any reason by Dr.&nbsp;Sherwood or us, Dr.&nbsp;Sherwood will be entitled to any accrued
benefits, including any earned but unpaid base salary and incentive compensation, unpaid expense reimbursements, accrued but unused
vacations, and any vested benefits under our employee benefit plans. Under the terms of the CEO Employment Agreement, Dr.&nbsp;Sherwood
would receive a gross-up payment that, on an after-tax basis, is equal to the taxes imposed on the severance payments under the
CEO Employment Agreement in the event any payment or benefit to him is considered an &ldquo;excess parachute payment&rdquo; and
subject to an excise tax under the Code. Notwithstanding the foregoing, the amount of gross-up payment that Dr.&nbsp;Sherwood would
be entitled to receive is limited to $500,000.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Subject to certain conditions, upon an involuntary termination by
us of Dr.&nbsp;Sherwood&rsquo;s employment without &ldquo;cause&rdquo; (as defined in the CEO Employment Agreement) or a voluntary
termination of employment by him for &ldquo;good reason&rdquo; (as defined in the CEO Employment Agreement), Dr.&nbsp;Sherwood
would be entitled to receive a severance amount equal to 1.5 times the sum of his base salary and target annual bonus for the then-current
fiscal year and would be eligible to continue to participate in our group health, dental, and vision program for 18&nbsp;months.
If Dr.&nbsp;Sherwood&rsquo;s termination of employment occurs within 3&nbsp;months prior to or within 12&nbsp;months after a &ldquo;change
in control&rdquo; (as defined in the CEO Employment Agreement) and such termination is made by him for &ldquo;good reason&rdquo;
or by us without &ldquo;cause,&rdquo; (i)&nbsp;Dr.&nbsp;Sherwood would be entitled to receive, in lieu of the severance amount
described above, a severance amount equal to two times the sum of his base salary and target annual bonus for the then-current
fiscal year, (ii)&nbsp;all of Dr.&nbsp;Sherwood&rsquo;s stock options and stock-based awards would immediately accelerate and become
fully exercisable or non-forfeitable as of the effective date of such change in control, and (iii)&nbsp;Dr.&nbsp;Sherwood would
be eligible to continue to participate in our group health, dental, and vision program for 24&nbsp;months, subject to certain conditions.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">According to the terms of Dr. Sherwood&rsquo;s equity award agreements,
if Dr. Sherwood&rsquo;s employment terminates due to the acceptance by the Board of Directors of his retirement in good standing
on or after the date on which Dr. Sherwood has reached the age of 63, on such date of retirement the vesting of all of Dr. Sherwood&rsquo;s
outstanding equity awards shall automatically accelerate and shall become fully exercisable.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><I>Chief Financial Officer</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">On March 22, 2010, we entered into an employment agreement (the &ldquo;CFO
Employment Agreement&rdquo;) with Sylvia Cheung, our Chief Financial Officer, Secretary and Treasurer. Effective December 8, 2010,
we entered into an amendment to the CFO Employment Agreement to include certain technical amendments to bring such agreement into
compliance with Section 409A of the Code and the regulations thereunder. In addition to her base salary in existence at the time
of the agreement, Ms. Cheung is eligible to receive cash incentive compensation, with a discretionary bonus at a target equal to
45% of her annual base salary. Pursuant to the terms of the CFO Employment Agreement, upon any termination, whether due to death,
disability, or for any reason by Ms. Cheung, or us, Ms. Cheung would be entitled to any accrued benefits, including any earned
but unpaid base salary and incentive compensation, unpaid expense reimbursements, accrued but unused vacations, and any vested
benefits under our employee benefit plans. Under the terms of the CFO Employment Agreement, Ms. Cheung would be subject to a modified
economic cutback in the event any payment or benefit to her is considered an &ldquo;excess parachute payment&rdquo; and subject
to an excise tax under the Code.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Subject to certain conditions, upon an involuntary termination by
us of Ms. Cheung&rsquo;s employment without &ldquo;cause&rdquo; (as defined in the CFO Employment Agreement) or a voluntary termination
of employment by her for &ldquo;good reason&rdquo; (as defined in the CFO Employment Agreement), Ms. Cheung would be entitled to
receive a severance amount equal to her current base salary for the then-current fiscal year and would be eligible to continue
to participate in our group health, dental, and vision program for 12&nbsp;months. If Ms. Cheung&rsquo;s termination of employment
occurs within 3&nbsp;months prior to or within 12&nbsp;months after a &ldquo;change in control&rdquo; (as defined in the CFO Employment
Agreement) and such termination is either by her for &ldquo;good reason&rdquo; or by us without &ldquo;cause,&rdquo; (i)&nbsp;Ms.
Cheung would be entitled to receive, in lieu of the severance amount described above, a severance amount equal to 1.5 times the
sum of her base salary and target annual bonus for the then-current fiscal year, (ii)&nbsp;all of Ms. Cheung&rsquo;s stock options
and stock-based awards would immediately accelerate and become fully exercisable or non-forfeitable as of the effective date of
such change in control, and (iii)&nbsp;Ms. Cheung would be eligible to continue to participate in our group health, dental and
vision program for 18&nbsp;months, subject to certain conditions.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Second Amended and Restated 2003 Stock Option and Incentive Plan, as Amended</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">In 2003, the Board of Directors adopted the 2003 Stock Option and
Incentive Plan to provide incentives to officers, employees, non-employee directors, and other key persons. In 2009, the Board,
upon recommendation of the Compensation Committee, adopted the Amended 2003 Plan, which was approved by the stockholders on June
5, 2009. In 2011, the Board, upon recommendation of the Compensation Committee, adopted the Second Amended 2003 Plan, which was
approved by the stockholders on June 7, 2011. In 2013, the Board, upon recommendation of the Compensation Committee, amended the
Second Amended 2003 Plan, which was approved by the stockholders on June 18, 2013. The Second Amended 2003 Plan, as amended, is
administered by the Compensation Committee of the Board, which, at its discretion, may grant stock-based awards, including incentive
stock options, non-qualified stock options, stock appreciation rights, deferred stock, restricted stock, unrestricted stock, performance
shares, and dividend equivalent rights. The Second Amended 2003 Plan provides that in the event of a &ldquo;change of control,&rdquo;
as defined in the Second Amended 2003 Plan, generally all stock options and stock appreciation rights will automatically become
fully exercisable and that the restrictions and conditions on all awards of restricted stock, deferred stock awards, and performance
share awards will automatically be deemed waived. At December&nbsp;31, 2016, a total of 979,569 shares were subject to outstanding
options and SARs issued under the Second Amended 2003 Plan were at a weighted average exercise price of $26.15, unvested restricted
stock awards totaled 88,581 shares, unvested restricted stock units totaled 22,841 shares, and the total number of remaining shares
of common stock available for future grants was 881,084. If our stockholders approve the Anika Therapeutics, Inc. 2017 Omnibus
Incentive Plan in accordance with Proposal 2 at the Annual Meeting, it will replace the Second Amended 2003 Plan and no further
grants will be made thereunder. See section entitled &ldquo;Executive Compensation &ndash; Option Grants and Plan Awards in 2016&rdquo;
for information regarding grants in 2016 to our NEOs.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Risk Considerations in Our Compensation Programs</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Compensation Committee believes that risks arising from our policies
and practices for compensating employees are not reasonably likely to have a material adverse effect on our company.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>COMPENSATION COMMITTEE REPORT</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Compensation Committee of Anika Therapeutics,&nbsp;Inc. (&ldquo;Compensation
Committee&rdquo;) has reviewed and discussed with the management of Anika Therapeutics the section entitled &ldquo;Compensation
Discussion and Analysis&rdquo; contained in this proxy statement. Based on its review and discussions with management, the Compensation
Committee recommended to the Board of Directors that the Compensation Discussion and Analysis be included in the proxy statement
for the 2017 Annual Meeting of Stockholders. This report is submitted by the following independent directors who comprise the committee:</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 24%; text-align: left">&nbsp;Joseph L. Bower, Chairperson</TD>
    <TD STYLE="width: 24%; text-align: left">Glenn R. Larsen, Ph.D.</TD>
    <TD STYLE="width: 24%; text-align: left">Jeffery S. Thompson</TD>
    <TD STYLE="width: 28%; text-align: left">Steven E. Wheeler</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>THE FOREGOING REPORT SHOULD NOT BE DEEMED INCORPORATED BY REFERENCE INTO ANY FILING
UNDER THE SECURITIES ACT OF&nbsp;1933, AS AMENDED, OR UNDER THE SECURITIES EXCHANGE ACT OF&nbsp;1934, AS AMENDED, BY ANY GENERAL
STATEMENT INCORPORATING BY REFERENCE THIS PROXY STATEMENT, EXCEPT TO THE EXTENT THAT ANIKA THERAPEUTICS SPECIFICALLY INCORPORATES
THIS INFORMATION BY REFERENCE, AND SHALL NOT OTHERWISE BE DEEMED FILED UNDER SUCH ACTS.</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>EXECUTIVE COMPENSATION</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Summary Compensation</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The following table summarizes the compensation information in respect
of our NEOs for the year ended December&nbsp;31, 2016.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 95%">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP COLSPAN="29" STYLE="font-size: 10pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 9pt">Summary
    Compensation Table</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP COLSPAN="29" STYLE="font-size: 10pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><FONT STYLE="font-size: 9pt">Name
    and Principal Position</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><FONT STYLE="font-size: 9pt">Year</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1.1pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1.1pt solid"><FONT STYLE="font-size: 9pt">Salary
    <FONT STYLE="font-style: normal"><B><SUP>(1)</SUP></B></FONT></FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1.1pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1.1pt solid"><FONT STYLE="font-size: 9pt">Bonus
    <FONT STYLE="font-style: normal"><B><SUP>(2)</SUP></B></FONT></FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1.1pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1.1pt solid"><FONT STYLE="font-size: 9pt">Option
    <BR> Awards <FONT STYLE="font-style: normal"><B><SUP>(3)</SUP></B></FONT></FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1.1pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1.1pt solid"><FONT STYLE="font-size: 9pt">Stock
    <BR> Awards <FONT STYLE="font-style: normal"><B><SUP>(3)</SUP></B></FONT></FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1.1pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1.1pt solid"><FONT STYLE="font-size: 9pt">All
    Other <BR> Compensation <FONT STYLE="font-style: normal"><B><SUP>(4)</SUP></B></FONT></FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><FONT STYLE="font-size: 9pt">Total</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 30%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">Charles H. Sherwood, Ph.D.</FONT></TD><TD STYLE="width: 2%; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">2016</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="width: 7%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">601,586</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="width: 7%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">496,308</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="width: 7%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">1,519,778</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="width: 7%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">861,286</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="width: 7%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">52,060</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>(10)</SUP></FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="width: 7%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">3,531,018</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">President and Chief</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">2015</FONT></TD><TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">581,242</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">508,587</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">864,043</FONT></TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">535,815</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">52,118</FONT></TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>(10)</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">2,541,805</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">Executive Officer</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">2014</FONT></TD><TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">564,313</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">434,521</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">694,130</FONT></TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">496,310</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">41,093</FONT></TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>(10)</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">2,230,367</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">Ed Ahn, Ph.D.</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">2016</FONT></TD><TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">315,675</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">156,259</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">439,830</FONT></TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">301,069</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">18,720</FONT></TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">1,231,553</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">Chief Technology and</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">2015</FONT></TD><TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">305,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">137,250</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">43,953</FONT></TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">18,720</FONT></TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">504,923</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">Strategy Officer</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">2014</FONT></TD><TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">43,404</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">733,170</FONT></TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>(6)</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">2,164</FONT></TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">778,738</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: left"><FONT STYLE="font-size: 9pt">Dana Alexander<FONT STYLE="font-weight: normal; font-style: normal"><SUP>&nbsp;</SUP></FONT></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">2016</FONT></TD><TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">285,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">76,950</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">759,247</FONT></TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>(7)</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">13,187</FONT></TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">1,134,384</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">Chief Operations Officer</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">Sylvia Cheung</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">2016</FONT></TD><TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">346,942</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">171,736</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">439,830</FONT></TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">301,069</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">18,720</FONT></TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">1,278,297</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">Chief Financial Officer</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">2015</FONT></TD><TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">335,210</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">188,556</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">289,996</FONT></TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">264,931</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">18,720</FONT></TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">1,097,413</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">2014</FONT></TD><TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">307,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">151,965</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">247,519</FONT></TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">195,322</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">13,719</FONT></TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">915,525</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">Richard Hague</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">2016</FONT></TD><TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">315,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">127,575</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">439,830</FONT></TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">301,069</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">84,799</FONT></TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>(11)</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">1,268,273</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">Chief Commerical Officer</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">2015</FONT></TD><TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">48,462</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">727,650</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt"><SUP>(9)</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">24,831</FONT></TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>(11)</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">800,943</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="text-align: left; background-color: rgb(204,238,255); vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">Stephen Mascioli, M.D., MPH</FONT><FONT STYLE="font-size: 8pt"><SUP>(5)</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">2016</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">350,000</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">759,247</FONT></TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>(8)</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">27,473</FONT></TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">1,136,720</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">Chief Medical Officer</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
</TABLE>



<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-align: center">(1)</TD>
    <TD STYLE="width: 95%">The amounts in this column represent the annual base salary approved for the executive by the Board of Directors prorated based on employment dates during the indicated year.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(2)</TD>
    <TD>The amounts in this column represent discretionary cash bonuses earned in the indicated year, but paid in January or February of the following year.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(3)</TD>
    <TD>The amounts in this column reflect the grant date fair value computed with respect to the equity awards issued during the indicated year in accordance with ASC Topic 718. See the information appearing in Note 12 to our consolidated financial statements included as part of our Annual Report on Form 10-K for the year ended December 31, 2016 for certain assumptions made in the valuation of stock and option awards. The Board granted equity awards on February 4, 2016, February 3, 2015, and January 27, 2014, respectively. </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(4)</TD>
    <TD>Unless otherwise noted, these amounts constitute group term life insurance premiums and matching contributions to our Employee Savings and Retirement Plan (401(k) plan).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(5)</TD>
    <TD>Dr. Mascioli&rsquo;s employment as our Chief Medical Officer began on April 4, 2016, and his employment was terminated on January 23, 2017.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(6)</TD>
    <TD>Dr. Ahn&rsquo;s employment as our Chief Technology and Strategy Officer began on October 30, 2014. An equity award of 40,000 shares of incentive stock options was granted in connection with the commencement of Dr. Ahn&rsquo;s employment.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(7)</TD>
    <TD>Mr. Alexander&rsquo;s employment as our Chief Operations Officer began on April 4, 2016. An equity award of 40,000 shares of incentive stock options was granted in connection with the commencement of Mr. Alexander&rsquo;s employment.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(8)</TD>
    <TD>Dr. Mascioli was granted an equity award of 40,000 shares of incentive stock options in connection with the commencement
    of his employment. Upon the termination of Dr. Mascioli&rsquo;s employment, the totality of this award was forfeited.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(9)</TD>
    <TD>Mr. Hague&rsquo;s employment as our Chief Commercial Officer began on October 26, 2015. A restricted stock award of 21,000 shares was granted in connection with the commencement of Mr. Hague&rsquo;s employment. </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(10)</TD>
    <TD>These amounts include reimbursement of life insurance premiums of $15,114, $15,413 and $15,114 in 2016, 2015 and 2014, respectively.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(11)</TD>
    <TD>This amount includes $57,611 and $22,416 of relocation expense reimbursement provided to Mr. Hague in 2016 and 2015, respectively, in accordance with the terms of the Offer Letter we entered into with Mr. Hague prior to the commencement of his employment.</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 28; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Option Grants and Plan Awards in 2016</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The following table sets forth each grant of equity awards made to
the NEOs during the year ended December 31, 2016. All such equity awards vest over a four-year period commencing on the first anniversary
of the grant date, except for performance-based equity awards which vest over a four-year period with the first vesting date occurring
on the performance measurement date and the next three vesting dates occurring on January 1 of each subsequent calendar year following
the calendar year in which the performance measurement date occurs.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 95%">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">Name</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Grant Date</TD><TD STYLE="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1.1pt solid">Exercise Price or <BR> Base of Equity <BR> Awards <FONT STYLE="font-size: 10pt; font-style: normal"><B><SUP>(1)</SUP></B></FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Number of Shares <BR> Underlying Awards</TD><TD STYLE="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1.1pt solid">Grant Date Fair <BR> Value of Awards <FONT STYLE="font-size: 10pt; font-style: normal"><B><SUP>(2)</SUP></B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; font-size: 10pt; text-align: left">Charles H. Sherwood, Ph.D.</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 13%; font-size: 10pt; text-align: center">Febuary 4, 2016</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">38.11</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">125,475</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><SUP>(5)</SUP></TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">2,381,064</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Ed Ahn, Ph.D.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: center">February 4, 2016</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">38.11</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">37,700</TD><TD STYLE="font-size: 10pt; text-align: left"><SUP>(6)</SUP></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">740,899</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">Dana Alexander <FONT STYLE="font-size: 10pt; font-weight: normal; font-style: normal"><SUP>(3)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">April 4, 2016</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">44.54</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">40,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">759,247</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Sylvia Cheung</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">February 4, 2016</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">38.11</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">37,700</TD><TD STYLE="font-size: 10pt; text-align: left"><SUP>(7)</SUP></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">740,899</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Richard Hague</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Febuary 4, 2016</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">38.11</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">37,700</TD><TD STYLE="font-size: 10pt; text-align: left"><SUP>(8)</SUP></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">740,899</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">Stephen Mascioli, M.D., MPH <FONT STYLE="font-size: 10pt; font-weight: normal; font-style: normal"><SUP>(4)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">February 4, 2016</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">44.54</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">40,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">759,247</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; text-align: center">(1)</TD>
    <TD STYLE="width: 93%">The exercise price of each award equals the grant date closing stock price, as reported on the NASDAQ stock exchange.</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(2)</TD>
    <TD>This column represents the full grant date fair value of stock options and restricted stock under ASC 718 granted to each of the NEOs in the fiscal year ended December 31, 2016. Generally, the full grant date fair value is the amount that we will expense in our financial statements over the award&rsquo;s vesting period.&nbsp;For restricted stock, fair value was calculated using the closing price of our common stock on the grant date. For stock options and performance-based stock options, fair value was calculated using the Black-Scholes value on the grant date.&nbsp;See the information appearing in Note 12 to our consolidated financial statements included as part of our Annual Report on Form 10-K for the year ended December 31, 2016 for certain assumptions made in the valuation of these awards.</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(3)</TD>
    <TD>Mr. Alexander&rsquo;s employment as Chief Operations Officer began on April 4, 2016, and this equity award represents incentive stock options granted in connection with such commencement of employment. </TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(4)</TD>
    <TD>Dr. Mascioli&rsquo;s employment as Chief Medical Officer began on April 4, 2016, and this equity award represents incentive stock options granted in connection with such commencement of employment. Dr. Mascioli&rsquo;s employment was terminated on January 23, 2017, and the totality of this award was forfeited on that date. </TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(5)</TD>
    <TD>This includes 22,600 shares of restricted stock awards and 63,500 common stock options, and it also includes 39,375 shares earned in connection with 125% achievement of performance targets related to performance-based stock option awards, all of which vest ratably over four years and were granted during the year ended December 31, 2016.</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(6)</TD>
    <TD>This includes 7,900 shares of restricted stock awards and 18,300 common stock options, and it also includes 11,500 shares earned in connection with 125% achievement of performance targets related to performance-based stock option awards, all of which vest ratably over four years and were granted during the year ended December 31, 2016.</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(7)</TD>
    <TD>This includes 7,900 shares of restricted stock awards and 18,300 common stock options, and it also includes 11,500 shares earned in connection with 125% achievement of performance targets related to performance-based stock option awards, all of which vest ratably over four years and were granted during the year ended December 31, 2016.</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(8)</TD>
    <TD>This includes 7,900 shares of restricted stock awards and 18,300 common stock options, and it also includes 11,500 shares earned in connection with 125% achievement of performance targets related to performance-based stock option awards, all of which vest ratably over four years and were granted during the year ended December 31, 2016.</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Discussion of Summary Compensation and Grants of Plan-Based Awards Tables</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The compensation paid to the Named Executive Officers includes salary
and bonus.&nbsp;See additional information regarding the salary, bonus, and equity incentive compensation of our named executive
officers, as well as a discussion of their employment agreements, under the section captioned &ldquo;Compensation Discussion and
Analysis&rdquo; above.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Outstanding Equity Awards at December&nbsp;31, 2016</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The following table provides information on the holdings of outstanding
stock options and unvested stock awards held by the NEOs as of December&nbsp;31, 2016.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="32" STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Outstanding
    Equity Awards at December 31, 2016</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="16" STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Option
    Awards</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="15" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><FONT STYLE="font-size: 8pt">Stock
    Awards</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD>
    <TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="7" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><FONT STYLE="font-size: 8pt">Equity
    Incentive Plan Awards</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">Name</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1.1pt solid"><FONT STYLE="font-size: 8pt">Number
    of Securities Underlying Exercisable Options <FONT STYLE="font-style: normal"><B><SUP>(1)</SUP></B></FONT></FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1.1pt solid"><FONT STYLE="font-size: 8pt">Number
    of Securities Underlying Unexercisable Options <FONT STYLE="font-style: normal"><B><SUP>(1)</SUP></B></FONT></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><FONT STYLE="font-size: 8pt">Option
    Exercise Price</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><FONT STYLE="font-size: 8pt">Option
    Expiration Date</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1.1pt solid"><FONT STYLE="font-size: 8pt">Number
    of Unvested Shares or Units of Stock <FONT STYLE="font-style: normal"><B><SUP>(1)</SUP></B></FONT></FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1.1pt solid"><FONT STYLE="font-size: 8pt">Market
    Value of Unvested Shares or Units of Stock <FONT STYLE="font-style: normal"><B><SUP>(2)</SUP></B></FONT></FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><FONT STYLE="font-size: 8pt">Number
    of Unearned and Unvested Shares, Units, or Other Rights</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><FONT STYLE="font-size: 8pt">Market
    or Payout Value of Unearned and Unvested Shares, Units, or Other Rights</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 25%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;Charles H. Sherwood, Ph.D</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">102,875</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 2%; font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>(3)</SUP></FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 6%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">38.11</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 7%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">2/4/2026</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">22,600</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 6%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">1,106,496</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 6%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">13,275</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">39,825</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">39.69</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">2/3/2025</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">10,125</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">495,720</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">25,800</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">25,800</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">32.02</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">1/27/2024</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">7,750</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">379,440</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">75,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">25,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">10.87</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">1/29/2023</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">75,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;(*)&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">6.99</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">6/7/2021</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">95,000</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">6.98</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">1/18/2021</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">Total</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">284,075</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">193,500</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">40,475</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">1,981,656</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: red"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: red; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: red; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: red; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;Ed Ahn, Ph.D.</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">29,800</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>(4)</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">38.11</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">2/4/2026</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">7,900</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">386,784</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">831</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">2,494</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">39.69</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">2/3/2025</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">20,000</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">20,000</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">41.15</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">10/30/2024</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">Total</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">20,831</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">22,494</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">7,900</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">386,784</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;Dana Alexander</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">40,000</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">44.54</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">4/4/2026</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">Total</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">40,000</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: red"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: red; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: red; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: red; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;Sylvia Cheung</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">29,800</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>(5)</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">38.11</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">2/4/2026</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">7,900</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">386,784</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">4,256</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">12,769</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">39.69</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">2/3/2025</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">6,675</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">254,718</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">9,200</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">9,200</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">32.02</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">1/27/2024</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">4,575</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">174,582</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">33,750</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">11,250</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">10.87</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">1/29/2023</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">15,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">9.10</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">1/25/2022</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">25,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;(*)&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">6.99</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">6/7/2021</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">25,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">6.98</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">1/18/2021</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">35,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">6.36</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">1/26/2020</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">5,000</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;(*)&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">10.99</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">1/31/2018</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">Total</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">152,206</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">63,019</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">19,150</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">816,084</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: red"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: red; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: red; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: red; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;Richard Hague</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">29,800</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>(6)</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">38.11</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">2/4/2026</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">7,900</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">386,784</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">15,750</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">771,120</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">Total</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">29,800</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">21,000</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">801,360</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: red"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; color: red; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: red; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; color: red; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">Stephen Mascioli, M.D.,
    MPH</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">40,000</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>(7)</SUP></FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">44.54</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">4/4/2026</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">Total</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">40,000</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>



<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">(1)</TD>
    <TD STYLE="width: 96%">Vesting of equity awards commences on the first anniversary of the grant date and continues on each subsequent grant date anniversary until the equity award is fully vested, except as otherwise noted below. Except for those equity awards noted by an asterisk (*), which are subject to a three year vesting period, all equity awards are subject to a four year vesting period, in each case subject to the holder&rsquo;s continued employment with us. The expiration date of each equity award is ten years after its grant date.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(2)</TD>
    <TD>Based on the closing price of our common stock on the NASDAQ stock exchange on December 31, 2016 ($48.96) per share.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(3)</TD>
    <TD>This includes 39,375 performance-based stock options which vest ratably over a four-year period with the first vesting date occurring on February 24, 2017 and the next three vesting dates occurring on January 1 of each subsequent calendar year.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(4)</TD>
    <TD>This includes 11,500 performance-based stock options which vest ratably over a four-year period with the first vesting date occurring on February 24, 2017 and the next three vesting dates occurring on January 1 of each subsequent calendar year.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(5)</TD>
    <TD>This includes 11,500 performance-based stock options which vest ratably over a four-year period with the first vesting date occurring on February 24, 2017 and the next three vesting dates occurring on January 1 of each subsequent calendar year.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(6)</TD>
    <TD>This includes 11,500 performance-based stock options which vest ratably over a four-year period with the first vesting date occurring on February 24, 2017 and the next three vesting dates occurring on January 1 of each subsequent calendar year.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(7)</TD>
    <TD>Dr. Mascioli&rsquo;s employment as Chief Medical Officer was terminated on January 23, 2017 and all unexercisable options were forfeited by him on that date.</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>2016 Equity Award Exercises and Stock Vested</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The following table provides information regarding options and SAR&rsquo;s
exercised and stock awards vested for the NEOs during the year ended December&nbsp;31, 2016.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid; border-top: Black 1.1pt solid">Stock Awards</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Name</TD><TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Number of <BR> Shares <BR> Acquired on <BR> Vesting</TD><TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Value <BR> Realized on <BR> Vesting</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; font-size: 10pt; text-align: left">&nbsp;Charles H. Sherwood, Ph.D.</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">7,250</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">273,881</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;Sylvia Cheung</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,194</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">121,072</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;Richard Hague</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,250</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">224,333</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Potential Payments Upon Termination or Change in Control</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Our Chief Executive Officer and Chief Financial Officer have certain
termination or change in control benefits described in the Compensation Discussion and Analysis sections captioned &ldquo;Agreements
with Named Executive Officers&rdquo; and &ldquo;Second Amended and Restated 2003 Stock Option and Incentive Plan, as Amended.&rdquo;
The following table provides estimates of the potential payments and other post-termination benefits these individuals would receive
assuming a change in control occurred and/or their employment was terminated as of December 31, 2016:</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Termination <BR> Without Cause</TD><TD STYLE="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1.1pt solid">Termination Upon <BR> Change in <BR> Control <FONT STYLE="font-size: 10pt; font-style: normal"><B><SUP>(1) (2)</SUP></B></FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; font-style: normal; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1.1pt solid">Change in <BR> Control Without <BR> Termination or <BR> Death or <BR> Disability <FONT STYLE="font-size: 10pt; font-style: normal"><B><SUP>(1) (3)</SUP></B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; font-size: 10pt; text-align: left">Salary Continuation</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">902,379</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">1,203,172</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">-</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Additional Cash Payment</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">676,784</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">902,379</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Equity Awards Vesting</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">15,281,730</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">15,281,730</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Health Care Benefits</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">23,865</TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">31,820</TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,603,029</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">17,419,101</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">15,281,730</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Salary Continuation</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">346,942</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">520,413</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Additional Cash Payment</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">234,186</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Equity Awards Vesting</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7,605,367</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7,605,367</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Health Care Benefits</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">14,607</TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">21,911</TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">361,549</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">8,381,877</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">7,605,367</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">(1)</TD>
    <TD STYLE="width: 96%">The indicated values for the accelerated vesting of stock options reflect the number of equity award shares that would vest on an accelerated basis, multiplied by the excess, if any, of the $48.96 closing price for our common stock as reported by NASDAQ on December&nbsp;31, 2016 over the applicable exercise price for each option or SAR. This calculation assumes equity awards with an exercise price higher than the closing price of our common stock on December 31, 2016 will not be exercised.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(2)</TD>
    <TD>According to the terms of the CEO Employment Agreement, in the event Dr. Sherwood becomes subject to the excise taxes imposed by Section 4999 of the Code, he would be entitled to a gross-up payment of up to $500,000. According to the terms of the CFO Employment Agreement, all payments otherwise due to Ms. Cheung would be subject to a modified economic cutback.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(3)</TD>
    <TD>According to the terms of Dr. Sherwood&rsquo;s equity award agreements, if Dr. Sherwood&rsquo;s employment terminates due to the acceptance by the Board of Directors of his retirement in good standing on or after the date on which Dr. Sherwood has reached the age of 63, on such date of retirement in good standing the vesting of all of Dr. Sherwood&rsquo;s outstanding equity awards shall automatically accelerate and become fully exercisable.</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 31; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Directors&rsquo; Compensation</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><I>Cash Compensation.</I>&nbsp;&nbsp;For 2016, each of our non-employee
directors was entitled to annual retainers per the following schedule, with such amounts to be prorated based on the actual number
of days served if a director&rsquo;s service to us ended prior to the end of 2016:</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 80%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 59%; border-bottom: Black 1pt solid; text-align: left"><B>Compensation Element</B></TD>
    <TD STYLE="width: 41%; border-bottom: Black 1pt solid; text-align: center"><B>2016 Cash Compensation</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><B>Board of Directors</B></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Lead Director Retainer</TD>
    <TD STYLE="text-align: center">$65,000</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Other Directors Retainer</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">$40,000</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><B>Audit Committee</B></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Committee Chairperson Retainer</TD>
    <TD STYLE="text-align: center">$20,000</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Other Committee Members Retainer</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">$10,000</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><B>Compensation Committee</B></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Committee Chairperson Retainer</TD>
    <TD STYLE="text-align: center">$14,000</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Other Committee Members Retainer</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">$7,000</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><B>Governance and Nominating Committee</B></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Committee Chairperson Retainer</TD>
    <TD STYLE="text-align: center">$10,000</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Other Committee Members Retainer</TD>
    <TD STYLE="text-align: center">$5,000</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>Equity Compensation.</I>&nbsp;&nbsp;The Board
of Directors approved a grant of 2,361 restricted stock units to each non-employee director, valued at $89,987 under the Second
Amended 2003 Plan, based on the fair market value of our common stock on February 4, 2016, the date of grant for the existing directors.
The restricted stock units granted to each non-employee director in 2016 vested in one installment one year from the date of grant,
on February 4, 2017. Each non-employee director is eligible for an annual equity award grant with a value and vesting provisions
as may be determined by the Board based on their review of our compensation policies and general compensation trends.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The following table summarizes the compensation we paid to non-employee
directors for the year ended December&nbsp;31, 2016.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Aggregate Number of Shares <BR> Outstanding</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid; text-align: left">Name</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Fees Earned or <BR> Paid in Cash ($)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Stock Awards
    ($) <SUP>(1)</SUP></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Option <BR> Awards ($)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Total ($)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Options</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Restricted <BR> Stock Units</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%; font-size: 10pt; text-align: left">&nbsp;Joseph L. Bower</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">89,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">89,987</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">-</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">178,987</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">-</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">2,600</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;Raymond J. Land</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">65,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">89,987</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">154,987</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,600</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;Glenn R. Larsen, Ph.D.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">52,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">89,987</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">141,987</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">650</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;Jeffery S. Thompson</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">57,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">89,987</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">146,987</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,600</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;Steven E. Wheeler</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">57,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">89,987</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">146,987</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,300</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">(1)</TD>
    <TD STYLE="width: 95%">An amount of 2,361 restricted stock units were awarded per director on February 4, 2016, based on the closing price of $38.11 per share, and which vest in their totality on February 4, 2017. The amounts in this column reflect the grant date fair value computed with respect to the restricted stock units, made during the indicated year in accordance with ASC Topic 718. See the information appearing in Note 12 to our consolidated financial statements included as part of our Annual Report on Form 10-K for the year ended December 31, 2016 for certain assumptions made in the valuation of these restricted stock unit awards.</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Board of Directors and Executive Officer Stock Retention Guidelines</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Effective October 6, 2015, the Board of Directors adopted stock retention
guidelines that generally require each of our directors and executive officers to beneficially own certain amounts of our common
stock. We believe that ownership of shares of our common stock by directors and executive officers helps align the financial interests
of these individuals with the interests of stockholders, promotes sound corporate governance, and evidences a commitment to our
company. These stock retention guidelines supersede the director stock retention guidelines previously adopted by the Board on
April 22, 2015. Generally, these guidelines require each director to beneficially own, at a minimum, either (a) 3,000 outstanding
shares of common stock or (b) a number of shares (or vested share equivalents) of common stock having a market value equal to three
times the amount of our annual board retainer for the non-lead directors.&nbsp;The minimum shareholding requirement became effective
immediately, except that any director initially elected after January 1, 2015 has three years from the date of their election to
achieve compliance.&nbsp;Compliance by each director will be reviewed annually by the Board&rsquo;s Governance and Nominating Committee,
which is authorized to approve exceptions upon a showing of serious hardship.&nbsp;A non-complying director must retain at least
75% of the shares (net of shares sold or offset to pay the exercise price and taxes) he or she subsequently acquires through exercise
of equity grants, until he or she complies with the guidelines.&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Generally, these guidelines require the Chief Executive Officer to
beneficially own, at a minimum, either (a) 50,000 outstanding shares of common stock or (b) a number of shares (or vested share
equivalents) of common stock having a market value equal to three times the amount of his or her base salary, and they require
any other executive officer to beneficially own, at a minimum, either (a) 10,000 outstanding shares of common stock or (b) a number
of shares (or vested share equivalents) of common stock having a market value equal to the amount of his or her base salary.&nbsp;The
minimum shareholding requirement became effective immediately, except that any individual initially elected as an executive officer
after September 30, 2014 has five years to achieve compliance.&nbsp;Compliance by each executive officer will be reviewed annually
by the Board&rsquo;s Governance and Nominating Committee, which is authorized to approve exceptions upon a showing of serious hardship.&nbsp;A
non-complying executive officer must retain at least 75% of the shares (net of shares sold or offset to pay the exercise price
and taxes) he or she subsequently acquires through exercise of equity grants, until he or she complies with the guidelines.&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Compensation Committee Interlocks and Insider Participation</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Compensation Committee as of December 31, 2016 consisted of Dr.
Bower, Dr. Larsen, Mr. Thompson, and Mr.&nbsp;Wheeler. None of these individuals is or formerly was an officer or employee of our
company, nor have they engaged in any transactions involving our company that would require disclosure as a transaction with a
related person. There are no Compensation Committee interlocks between our company and any other entity involving our or such entity&rsquo;s
executive officers or board members.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">During the fiscal year ended December&nbsp;31, 2016, none of our
executive officers served as: (i)&nbsp;a member of the Compensation Committee (or other committee of the Board of Directors performing
equivalent functions or, in the absence of any such committee, the entire Board) of another entity, one of whose executive officers
served on the Compensation Committee; (ii)&nbsp;a director of another entity, one of whose executive officers served on the Compensation
Committee; or (iii)&nbsp;a member of the compensation committee (or other committee of the Board performing equivalent functions
or, in the absence of any such committee, the entire Board) of another entity, one of whose executive officers served as a director
on our Board.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>PROPOSAL 2:</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 29.5pt 0pt 30pt"><B>APPROVAL OF THE ANIKA THERAPEUTICS, INC. 2017 OMNIBUS
INCENTIVE PLAN</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 29.5pt 0pt 30pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 12.45pt 0pt 6pt">On March 31, 2017, the Board of Directors, upon the
recommendation of the Compensation Committee, adopted the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan (the &quot;Omnibus
Plan&quot;) for officers, employees, non-employee directors, and other key persons of the Company and its subsidiaries, subject
to the approval of the Omnibus Plan by our stockholders. The Omnibus Plan will replace the Company's Second Amended and Restated
2003 Stock Option and Incentive Plan, as amended (the &quot;Second Amended 2003 Plan&quot;), and no new awards will be granted
under the Second Amended 2003 Plan. Any awards outstanding under the 2003 Plan on the date of stockholder approval of the Omnibus
Plan will remain subject to and be paid under the Second Amended 2003 Plan, and any shares subject to outstanding awards under
the Second Amended 2003 Plan that subsequently cease to be subject to such awards (other than by reason of settlement of the awards
in shares) will automatically become available for issuance under the Omnibus Plan. A copy of the Omnibus Plan is attached as Appendix
A to this proxy statement and is incorporated herein by reference.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 12.45pt 0pt 6pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; font-weight: bold">Key Features of the Omnibus Plan</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; font-weight: bold">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 33pt; margin: 0pt 0 0pt 9pt">The following is a summary of key features of the Omnibus
Plan, which are intended to protect the interests of our stockholders:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Limitation on terms of stock options and stock appreciation rights</I>. The maximum term of each stock option and stock
appreciation right (SAR) is 10 years.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Minimum vesting requirement</I>. All awards must be granted with a minimum vesting period of at least 1 year, except that
up to 5% of the share pool can be granted without a minimum vesting period, and awards may be accelerated due to a participant&rsquo;s
death or disability or a change in control of the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>No repricing</I>. The Omnibus Plan generally prohibits the repricing of stock options and SARs without stockholder approval.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>No transferability</I>. Awards generally may not be transferred, except by will or the laws of descent and distribution,
unless approved by the plan administrator.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>No single-trigger vesting on a change in control</I>. In the event of a change in control of the Company, the plan administrator
may provide for accelerated vesting of outstanding awards, but there is no automatic acceleration of awards upon a change in control.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Tax deductible awards</I>. The Omnibus Plan provides flexibility to grant awards that qualify as &ldquo;performance-based&rdquo;
compensation under Section 162(m) of the Code.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>No dividends on options, SARs, or unvested share awards</I>. The Omnibus Plan prohibits the payment of dividends or dividend
equivalents on stock options, SARs, or any other awards that have not vested.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Multiple award types</I>. The Omnibus Plan permits the issuance of incentive stock options, non-qualified stock options,
stock appreciation rights, restricted stock units, restricted stock awards, and other types of share and cash-based awards, subject
to the share limits of the Omnibus Plan. This gives the Company the flexibility to grant different type of awards as compensation
tools to motivate the Company's workforce.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Independent oversight</I>. The Omnibus Plan is administered by the Compensation Committee, which is comprised of independent
members of the Board of Directors.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Director limits</I>. The Omnibus Plan contains annual limits on the value of awards that may be granted to non-employee
directors.</TD></TR></TABLE>

<P STYLE="margin: 0pt 0; font-size: 10pt; font-weight: bold">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; font-weight: bold">Summary of the 2017 Omnibus Incentive Plan</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; font-weight: bold">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 6pt">The following description of certain features of the Omnibus
Plan is intended to be a summary only. The summary is qualified in its entirety by the full text of the Omnibus Plan that is attached
hereto as Appendix A.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 8.2pt 0pt 6pt"><I>Plan Administration.</I> The Omnibus Plan may be administered
by the Board of Directors or the Compensation Committee (the &ldquo;Administrator&rdquo;). The Administrator, in its discretion,
selects the individuals to whom awards may be granted, the time or times at which such awards are granted and the terms and conditions
of such awards. In addition, the Administrator may not reprice outstanding options or cancel stock options or stock appreciation
rights for cash without prior stockholder approval, other than to appropriately reflect changes in the capital structure of the
Company. The Administrator may delegate to our Chief Executive Officer the authority to grant stock options to employees who are
not subject to the reporting and other provisions of Section 16 of the Exchange Act and not subject to Section 162(m) of the Code,
subject to certain limitations and guidelines.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 7.1pt 0pt 6pt"><I>Eligibility. </I>All full-time and part-time officers,
employees, non-employee directors, and other key persons of Anika Therapeutics and its subsidiaries are eligible to participate
in the Omnibus Plan, subject to the discretion of the Administrator. The number of individuals potentially eligible to participate
in the Omnibus Plan is currently approximately 125 persons. The Administrator will use its discretion to select individuals to
participate in the Omnibus Plan who are responsible for, or contribute to, the management, growth, or profitability of the Company.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 7.5pt 0pt 6pt"><I>Plan Limits. </I>The number of shares of common stock
authorized for issuance under the Omnibus Plan is 1,200,000 shares, representing 8% of the fully diluted Company common stock outstanding
as of March 31, 2017. In addition, as of the date of stockholder approval of the Omnibus Plan, any awards then outstanding under
the Second Amended 2003 Plan will remain subject to and be paid under the Second Amended 2003 Plan and any shares then subject
to outstanding awards under the Second Amended 2003 Plan that subsequently expire, terminate, or are surrendered or forfeited for
any reason without issuance of shares will automatically become available for issuance under the Omnibus Plan. Up to 1,200,000
shares may be granted as incentive stock options under Section 422 of the Code. The shares of common stock issuable under the Omnibus
Plan will consist of authorized and unissued shares, treasury shares, or shares purchased on the open market or otherwise.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 7.5pt 0pt 6pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 7.5pt 0pt 6pt">For purposes of determining the number of shares available
for issuance under the Omnibus Plan, the grant of any &ldquo;full value award&rdquo; (<I><U>i.e.</U></I>, a restricted stock award,
deferred stock award, unrestricted stock award, or performance share) shall be deemed an award of two (2) shares for each share
subject to such full value award. For purposes of determining the number of shares available for issuance under the Omnibus Plan,
the grant of any option or stock appreciation right shall be deemed an award of one (1) share for each share subject to such option
or stock appreciation award.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 7.5pt 0pt 6pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 7.5pt 0pt 6pt">If any award expires, terminates, is settled in cash,
or is surrendered or forfeited, the shares subject to such awards will not count against the aggregate number of shares of common
stock available for grant under the Omnibus Plan. Additionally, awards granted in assumption of or in substitution for awards previously
granted by an acquired company will not count against the shares available for grant. Shares issuable upon exercise, vesting, or
settlement or an award, or shares surrendered or tendered to pay the exercise price or taxes required to be withheld with respect
to an award, shall not be available again for the grant of awards.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 7.5pt 0pt 6pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 7.5pt 0pt 6pt">The maximum award of stock options or stock appreciation
rights granted to any one individual will not exceed 400,000 shares of common stock (subject to adjustment for stock splits and
similar events) for any calendar-year period. If any award of restricted stock, restricted stock units, deferred stock or performance
shares granted to an individual is intended to qualify as &quot;performance based compensation&quot; under Section 162(m) of the
Code, then the maximum award shall not exceed 400,000 shares of common stock (subject to adjustment for stock splits and similar
events) to any one such individual in any calendar year. If any cash-based award is intended to qualify as &ldquo;performance-based
compensation&rdquo; under Section 162(m) of the Code, then the maximum award to be paid in cash in any calendar year may not exceed
$1,000,000.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 7.5pt 0pt 6pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 7.5pt 0pt 6pt"><I>Awards to Non-Employee Directors</I>. The maximum
value of plan awards granted during any calendar year to any non-employee director, taken together with any cash fees paid to such
non-employee director during the calendar year and the value of awards granted to the non-employee director under any other equity
compensation plan of the Company or an affiliate during the calendar year, may not exceed the following in total value (calculating
the value of any equity compensation plan awards based on the grant date fair market value for financial reporting purposes): (i)
$500,000 for the Chair or Lead Director of the Board and (ii) $425,000 for each non-employee director other than the Chair or Lead
Director of the Board. However, awards granted to non-employee directors upon their initial election to the Board of Directors
or the board of directors of an affiliate will not be counted towards this limit.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 7.5pt 0pt 6pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 6.1pt 0pt 6pt"><I>Tax Withholding. </I>Participants under the Omnibus
Plan are responsible for the payment of any federal, state, or local taxes that we are required by law to withhold upon any option
exercise or vesting of other awards. Subject to approval by the Administrator, participants may elect to have the minimum tax withholding
obligations satisfied either by authorizing us to withhold shares of common stock to be issued pursuant to an option exercise or
other award, or by transferring to us shares of common stock having a value equal to the amount of such taxes.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 6.2pt 0pt 6pt"><I>Change of Control Provisions. </I>The Omnibus Plan
provides that upon the effectiveness of a &ldquo;change in control&rdquo; as defined in the Omnibus Plan, the Administrator may
take any one or more of the following actions, with or without the consent of a participant: (1) accelerate the vesting or settlement
of awards on the terms and conditions determined by the Administrator (including upon a participant&rsquo;s separation from service
following the change in control), (2) permit the assumption or substitution of outstanding awards by the acquiror in the change
in control, and cancel any awards that are not assumed or substituted for, and/or (3) cancel outstanding vested awards in exchange
for cash, the stock of the acquiror, or other property having a fair market value equal to the consideration paid for shares in
the change in control (reduced by the exercise price of an award, if necessary).</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 6.2pt 0pt 6pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 6.2pt 0pt 6pt"></P>

<!-- Field: Page; Sequence: 35; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 6.2pt 0pt 6pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 6.1pt 0pt 6pt"><I>Adjustments for Stock Dividends, Mergers, etc. </I>Subject
to any required action by our stockholders, in the event of any change in our common stock effected without receipt of consideration
by the Company, whether through merger, consolidation, reorganization, reincorporation, recapitalization, reclassification, stock
dividend, stock split, reverse stock split, split-up, split-off, spin-off, combination of shares, exchange of shares, or similar
change in our capital structure, or in the event of payment of a dividend or distribution to our stockholders in a form other than
our common stock (excepting normal cash dividends) that has a material effect on the fair market value of our common stock, appropriate
and proportionate adjustments will be made in the number and class of shares subject to the Omnibus Plan and to any outstanding
awards, and in the option exercise price, SAR exercise price, or purchase price per share of any outstanding awards in order to
prevent dilution or enlargement of participant rights under the Omnibus Plan. If a majority of our common shares are exchanged
for, converted into, or otherwise become shares of another corporation, the Administrator may unilaterally amend outstanding awards
under the Omnibus Plan to provide that such awards are for new shares. In the event of any such amendment, the number of shares
subject to, and the option exercise price, SAR exercise price, or purchase price per share of, the outstanding awards will be adjusted
in a fair and equitable manner as determined by the Administrator. The Administrator may also make such adjustments in the terms
of any award to reflect, or related to, such changes in our capital structure or distributions as it deems appropriate.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 7.45pt 0pt 6pt"><I>Amendments and Termination. </I>Unless earlier terminated
by the Board of Directors, the Omnibus Plan will terminate, and no further awards may be granted, 10 years after the date on which
it is approved by stockholders. The Board of Directors may amend, suspend, or terminate the Omnibus Plan at any time, except that,
if required by applicable law, regulation, or stock exchange rule, stockholder approval will be required for any amendment. The
amendment, suspension, or termination of the Omnibus Plan or the amendment of an outstanding award generally may not, without a
participant&rsquo;s consent, materially impair the participant&rsquo;s rights under an outstanding award.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 7.45pt 0pt 6pt"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 7.5pt 0pt 6pt"><I>Transferability</I>. Awards are not transferable other
than by will or the laws of descent and distribution, except that in certain instances transfers may be made to or for the benefit
of designated family members of the participant for no value.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 7.5pt 0pt 6pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 6.1pt 0pt 6pt"><I>Types of Awards:</I></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 6.1pt 0pt 6pt"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 6.1pt 0pt 6pt"><I>Stock Options. </I>Options granted under the Omnibus
Plan may be either incentive stock options (&quot;Incentive Options&quot;) (within the meaning of Section 422 of the Code) or non-qualified
stock options (&quot;Non-Qualified Options&quot;). Incentive Options may be granted only to employees of Anika Therapeutics or
any subsidiary. Options granted under the Omnibus Plan will be Non-Qualified Options if they (1) fail to qualify as Incentive Options,
(2) are granted to a person not eligible to receive Incentive Options under the Code, or (3) otherwise so provide. Non-Qualified
Options may be granted to persons eligible to receive Incentive Options and to non-employee directors and other key persons. The
Administrator has authority to determine the terms and conditions of options at the time of grant, including quantity of shares
covered, exercise price, method of exercise, vesting conditions, the term (which cannot exceed 10 years), and other conditions
on exercise. Stock options must be granted with an exercise price not less than 100% of the fair market value of our common stock
on the date of grant (excluding stock options granted in connection with assuming or substituting stock options in acquisition
transactions). The Omnibus Plan prohibits the payment of dividends or dividend equivalent rights on unvested stock options.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 6.1pt 0pt 6pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 8.3pt 0pt 6pt"><I>Stock Appreciation Rights. </I>The Administrator may
award stock appreciation rights, with a term not to exceed 10 years. Upon exercise of the stock appreciation right, the holder
will be entitled to receive an amount equal to the excess of the fair market value on the date of exercise of one share of common
stock over the exercise price per share specified in such right times the number of shares of common stock with respect to which
the stock appreciation right is exercised. This amount may be paid in cash, common stock, or a combination thereof, as determined
by the Administrator. The exercise price is the fair market value of the common stock on the date of grant. The Omnibus Plan prohibits
the payment of dividends or dividend equivalent rights on unvested stock appreciation rights.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 6.6pt 0pt 6pt"><I>Restricted Stock and Restricted Stock Unit Awards.
</I>The Administrator may grant shares of restricted stock, which are shares of common stock subject to specified restrictions,
and restricted stock units (RSUs), which represent the right to receive shares of our common stock in the future. These awards
may be made subject to repurchase, forfeiture, or vesting restrictions at the Administrator&rsquo;s discretion. The restrictions
may be based on continuous service with the Company or the attainment of specified performance goals, as determined by the Administrator.
RSUs may be paid in stock or cash or a combination of stock and cash, as determined by the Administrator.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 6.6pt 0pt 6pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 20.4pt 0pt 6pt"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 20.4pt 0pt 6pt; text-indent: 0.5in"><I>Other Share- and Cash-Based
Awards</I>. The Administrator may also grant awards based on shares of stock, either alone or in addition to or in conjunction
with other awards. Such awards may be granted in lieu of other cash or other compensation to which a participant is entitled from
the Company or may be used in the settlement of amounts payable under any other compensation plan or arrangement of the Company.
The Administrator shall have the authority to determine the persons to whom and the time or times at which such Awards will be
made, the number of shares to be granted pursuant to such Awards, and all other terms of such Awards. The Administrator may grant
cash bonuses under the Omnibus Plan. The cash bonuses may be subject to achievement of certain performance goals.</P>




<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 15.85pt 0pt 6pt"><I>Performance Awards; Performance-based compensation
under Section 162(m) of the Code. </I>The Administrator may grant performance awards, which entitle participants to receive a payment
from the Company, the amount of which is based on the attainment of performance goals established by the Administrator over a specified
award period. Performance awards may be denominated in shares of common stock or in cash, and may be paid in stock or cash or a
combination of stock and cash, as determined by the Administrator.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 15.85pt 0pt 6pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 15.85pt 0pt 6pt">The Omnibus Plan permits the Administrator to grant
performance awards in a manner intended to qualify as performance-based compensation under Section 162(m) of the Code. Under Section
162(m) of the Code, the Company may be prohibited from deducting compensation paid to our principal executive officer and our three
other most highly compensated executive officers (other than our principal financial officer) in excess of $1 million per person
in any year. However, compensation that qualifies as &ldquo;performance-based&rdquo; under Section 162(m) of the Code is not subject
to the $1 million limit. If the Administrator intends to qualify an award under the Omnibus Plan as &ldquo;performance-based&rdquo;
compensation under Section 162(m) of the Code, the performance goals selected by the Administrator may be based on the attainment
of specified levels of one, or any combination, of the following performance criteria:</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 15.85pt 0pt 6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42pt"></TD><TD STYLE="width: 36pt">(i)</TD><TD STYLE="padding-right: 15.85pt">cash flow;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42pt"></TD><TD STYLE="width: 36pt">(ii)</TD><TD STYLE="padding-right: 15.85pt">earnings per share, as adjusted for any stock split, stock dividend or other recapitalization;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42pt"></TD><TD STYLE="width: 36pt">(iii)</TD><TD STYLE="padding-right: 15.85pt">earnings measures;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42pt"></TD><TD STYLE="width: 36pt">(iv)</TD><TD STYLE="padding-right: 15.85pt">return on equity;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42pt"></TD><TD STYLE="width: 36pt">(v)</TD><TD STYLE="padding-right: 15.85pt">total stockholder return;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42pt"></TD><TD STYLE="width: 36pt">(vi)</TD><TD STYLE="padding-right: 15.85pt">share price performance, as adjusted for any stock split, stock dividend or other recapitalization;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42pt"></TD><TD STYLE="width: 36pt">(vii)</TD><TD STYLE="padding-right: 15.85pt">return on capital;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42pt"></TD><TD STYLE="width: 36pt">(viii)</TD><TD STYLE="padding-right: 15.85pt">revenue;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42pt"></TD><TD STYLE="width: 36pt">(ix)</TD><TD STYLE="padding-right: 15.85pt">income;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42pt"></TD><TD STYLE="width: 36pt">(x)</TD><TD STYLE="padding-right: 15.85pt">profit margin;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42pt"></TD><TD STYLE="width: 36pt">(xi)</TD><TD STYLE="padding-right: 15.85pt">return on operating revenue;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42pt"></TD><TD STYLE="width: 36pt">(xii)</TD><TD STYLE="padding-right: 15.85pt">brand recognition or acceptance;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42pt"></TD><TD STYLE="width: 36pt">(xiii)</TD><TD STYLE="padding-right: 15.85pt">customer satisfaction;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42pt"></TD><TD STYLE="width: 36pt">(xiv)</TD><TD STYLE="padding-right: 15.85pt">productivity;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42pt"></TD><TD STYLE="width: 36pt">(xv)</TD><TD STYLE="padding-right: 15.85pt">expense targets;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42pt"></TD><TD STYLE="width: 36pt">(xvi)</TD><TD STYLE="padding-right: 15.85pt">market share;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42pt"></TD><TD STYLE="width: 36pt">(xvii)</TD><TD STYLE="padding-right: 15.85pt">cost control measures;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42pt"></TD><TD STYLE="width: 36pt">(xviii)</TD><TD STYLE="padding-right: 15.85pt">balance sheet metrics;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42pt"></TD><TD STYLE="width: 36pt">(xix)</TD><TD STYLE="padding-right: 15.85pt">strategic initiatives;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42pt"></TD><TD STYLE="width: 36pt">(xx)</TD><TD STYLE="padding-right: 15.85pt">implementation, completion or attainment of measurable objectives with respect to recruitment
or retention of personnel or employee satisfaction;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42pt"></TD><TD STYLE="width: 36pt">(xxi)</TD><TD STYLE="padding-right: 15.85pt">regulatory body approval for commercialization of a product;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42pt"></TD><TD STYLE="width: 36pt">(xxii)</TD><TD STYLE="padding-right: 15.85pt">implementation or completion of critical projects; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42pt"></TD><TD STYLE="width: 36pt">(xxiii)</TD><TD STYLE="padding-right: 15.85pt">any other business criteria established by the Administrator.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 15.85pt 0pt 6pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 15.85pt 0pt 6pt">The Administrator can also select any derivations of
these business criteria (e.g., income will include pre-tax income, net income, operating income). Performance goals may, in the
discretion of the Administrator, be established on a Company-wide basis, or with respect to one or more business units, divisions,
subsidiaries, or business segments, as applicable. Performance goals may be absolute or relative to the performance of one or more
comparable companies or indices. The Administrator may determine at the time that the performance goals are established the extent
to which measurement of performance goals may exclude the impact of charges for restructuring, discontinued operations, and other
extraordinary, unusual, or non-recurring items, and the cumulative effects of tax or accounting changes (each as defined by generally
accepted accounting principles and as identified in the Company&rsquo;s financial statements or other SEC filings).</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 15.85pt 0pt 6pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 15.85pt 0pt 6pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 15.85pt 0pt 6pt; text-indent: 0.5in">In addition, compensation
realized from the exercise of options and SARs granted under the Omnibus Plan is intended to meet the requirements of the performance-based
compensation exception under Section 162(m) of the Code. These awards must have an exercise price equal at least to fair market
value at the date of grant and be granted to covered individuals by a Compensation Committee consisting of at least two outside
directors. The Omnibus Plan limits the number of shares, or amount of cash, that may be the subject of awards, intended to be performance-based
compensation under Section 162(m) of the Code granted to any individual during any calendar year (discussed above under &ldquo;Plan
Limits.&rdquo;)</P>



<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 15.85pt 0pt 6pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 15.85pt 0pt 6pt"></P>

<!-- Field: Page; Sequence: 37; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 15.85pt 0pt 6pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 12.45pt 0pt 6pt">In general, one of the requirements that must be satisfied
to grant awards which qualify as &ldquo;performance-based&rdquo; compensation is that the material terms of the performance goals
under which the compensation may be paid must be disclosed to and approved by a majority vote of our stockholders, generally at
least once every five years. For purposes of Section 162(m) of the Code, the material terms of the performance goals generally
include (1) the individuals eligible to receive compensation upon achievement of performance goals, (2) a description of the business
criteria on which the performance goals may be based, and (3) the maximum amount that can be paid to an individual upon attainment
of the performance goals. By approving the Omnibus Plan, stockholders also will be approving the material terms of the performance
goals under the Omnibus Plan. Although stockholder approval of the Omnibus Plan will provide flexibility to grant awards under
the Omnibus Plan that qualify as &ldquo;performance-based&rdquo; compensation under Section 162(m) of the Code, we retain the ability
to grant awards under the Omnibus Plan that do not qualify as &ldquo;performance-based&rdquo; compensation under Code Section 162(m).</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 12.45pt 0pt 6pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; font-weight: bold">New Plan Benefits</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; font-weight: bold">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 4.75pt 0pt 6pt">A new plan benefits table for the Omnibus Plan and the
benefits or amounts that would have been received by or allocated to participants for the last completed fiscal year under the
Omnibus Plan if the Omnibus Plan was then in effect, as described in the SEC proxy rules, are not provided because all awards made
under the Omnibus Plan will be made at the Administrator&rsquo;s discretion, subject to the terms and conditions of the Omnibus
Plan. Therefore, the benefits and amounts that will be received or allocated under the Omnibus Plan are not determinable at this
time.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; font-weight: bold">Tax Aspects under the U.S. Internal Revenue Code</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; font-weight: bold">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 22.85pt 0pt 6pt">The following is a summary of the principal federal
income tax consequences of transactions under the Omnibus Plan. It does not describe all federal tax consequences under the Omnibus
Plan, nor does it describe state or local tax consequences.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 9.7pt 0pt 6pt">The advice set forth below was not intended or written
to be used, and it cannot be used, by any taxpayer for the purpose of avoiding United States federal tax penalties that may be
imposed on the taxpayer. The advice was written to support the promotion or marketing of the transaction(s) or matter(s) addressed
herein. Each taxpayer should seek advice based upon the taxpayer's particular circumstances from an independent tax advisor. The
foregoing language is intended to satisfy the requirements under the regulations in Section 10.35 of Circular 230.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 8.05pt 0pt 6pt"><I>Incentive Options. </I>No taxable income is generally
realized by the optionee upon the grant or exercise of an Incentive Option. If shares of common stock issued to an optionee pursuant
to the exercise of an Incentive Option are sold or transferred after two years from the date of grant and after one year from the
date of exercise, then (1) upon sale of such shares, any amount realized in excess of the option price (the amount paid for the
shares) will be taxed to the optionee as a long-term capital gain, and any loss sustained will be a long-term capital loss, and
(2) there will be no deduction for the Company for federal income tax purposes. The exercise of an Incentive Option will give rise
to an item of tax preference that may result in alternative minimum tax liability for the optionee. An optionee will not have any
additional FICA (Social Security) taxes upon exercise of an Incentive Option.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 7.75pt 0pt 6pt">If shares of common stock acquired upon the exercise
of an Incentive Option are disposed of prior to the expiration of the two-year and one-year holding periods described above (a
&quot;disqualifying disposition&quot;), generally (1) the optionee will realize ordinary income in the year of disposition in an
amount equal to the excess (if any) of the fair market value of the shares of common stock at exercise (or, if less, the amount
realized on a sale of such shares of common stock) over the option price thereof, and (2) the Company will be entitled to deduct
such amount. Special rules will apply where all or a portion of the exercise price of the Incentive Option is paid by tendering
shares of common stock.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 17.85pt 0pt 6pt">If an Incentive Option is exercised at a time when
it no longer qualifies for the tax treatment described above, the option is treated as a Non-Qualified Option. Generally, an Incentive
Option will not be eligible for the tax treatment described above if it is exercised more than three months following termination
of employment (or one year in the case of termination of employment by reason of disability). In the case of termination of employment
by reason of death, the three-month rule does not apply.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 6.35pt 0pt 6pt"><I>Non-Qualified Options. </I>With respect to Non-Qualified
Options under the Omnibus Plan, no income is realized by the optionee at the time the option is granted. Generally (1) at exercise,
ordinary income is realized by the optionee in an amount equal to the difference between the option price and the fair market value
of the shares of common stock on the date of exercise, and the Company receives a tax deduction for the same amount, and (2) at
disposition, appreciation or depreciation after the date of exercise is treated as either short-term or long-term capital gain
or loss depending on how long the shares of common stock have been held. Special rules will apply where all or a portion of the
exercise price of the Non-Qualified Option is paid by tendering shares of common stock. Upon exercise, the optionee will also be
subject to FICA taxes on the excess of the fair market value over the exercise price of the option.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 6.35pt 0pt 6pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 6.35pt 0pt 6pt"><I>Stock Appreciation Rights</I>. A participant generally
will not recognize taxable income upon the grant or vesting of a SAR with a grant price at least equal to the fair market value
of our common stock on the date of grant and no additional deferral feature. Upon the exercise of a SAR, a participant generally
will recognize compensation taxable as ordinary income in an amount equal to the difference between the fair market value of the
shares underlying the SAR on the date of exercise and the grant price of the SAR.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"><I>Restricted Stock Awards, Restricted Stock Units, and Performance
Awards</I>. A participant generally will not have taxable income upon the grant of restricted stock, RSUs, or performance awards.
Instead, the participant will recognize ordinary income at the time of vesting or payout equal to the fair market value (on the
vesting or payout date) of the shares or cash received minus any amount paid. For restricted stock only, a participant may instead
elect to be taxed at the time of grant.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 22.1pt 0pt 6pt"><I>Other Awards. </I>The Company generally will be entitled
to a tax deduction in connection with an award under the Omnibus Plan in an amount equal to the ordinary income realized by the
participant at the time the participant recognizes such income. Participants typically are subject to income tax and recognize
such tax at the time that an award is exercised, vests or becomes non-forfeitable, unless the award provides for a further deferral.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 11.05pt 0pt 6pt"><I>Parachute Payments. </I>The vesting of any portion
of any option or other award that is accelerated due to the occurrence of a change of control may cause a portion of the payments
with respect to such accelerated awards to be treated as &quot;parachute payments&quot; as defined in the Code. Any such parachute
payments may be non-deductible to the Company, in whole or in part, and may subject the recipient to a non-deductible 20% federal
excise tax on all or a portion of such payment (in addition to other taxes ordinarily payable).</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 19pt 0pt 6pt"><I>Limitation on Anika Therapeutics'
Deductions. </I>As a result of Section 162(m) of the Code, the Company&rsquo;s deduction for certain awards under the Omnibus Plan
may be limited to the extent that the Chief Executive Officer or other executive officer whose compensation is required to be reported
in the summary compensation table receives compensation in excess of $1,000,000 in such taxable year (other than performance-based
compensation that otherwise meets the requirements of Section 162(m) of the Code). The Omnibus Plan is structured to permit the
Administrator to grant awards intended to qualify as performance-based compensation.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 19pt 0pt 6pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"><I>Section 409A of the Code</I>. We intend that awards granted under
the Omnibus Plan will comply with, or otherwise be exempt from, Section 409A of the Code, but make no representation or warranty
to that effect.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; font-weight: bold">Vote Required</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 4.7pt 0pt 6pt">The affirmative vote of the holders of a majority of
shares of Common Stock present or represented at the Annual Meeting and voting on the matter is required to approve the adoption
of the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 4.7pt 0pt 6pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; font-weight: bold">Board Recommendation</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; font-weight: bold">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 6.1pt 0pt 6pt">The Board of Directors believes that stock-based awards
can play an important role in the success of the Company by encouraging and enabling the officers and employees, non-employee directors
and other key employees upon whose judgment, initiative and efforts the Company depends for the successful conduct of its business
to acquire a proprietary interest in it. The Board of Directors anticipates that providing such persons with a direct stake in
the Company&rsquo;s welfare will assure a closer identification of the interests of participants in the Omnibus Plan with those
of the Company, thereby stimulating their efforts on its behalf and strengthening their desire to remain with it.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 6.1pt 0pt 6pt">The Board of Directors believes that the proposed Omnibus
Plan will help us achieve our goals by keeping its incentive compensation program dynamic and competitive with those of other companies.
Accordingly, the Board of Directors believes that the Omnibus Plan is in the best interests of the Company and its stockholders
and recommends that the stockholders approve the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 15.85pt 0pt 6pt"><B>THE BOARD OF DIRECTORS OF THE COMPANY UNANIMOUSLY
RECOMMENDS THAT THE ANIKA THERAPEUTICS, INC. 2017 OMNIBUS INCENTIVE PLAN BE APPROVED, AND THEREFORE RECOMMENDS A VOTE &ldquo;FOR&rdquo;
THIS PROPOSAL.</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 6pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 6pt"></P>

<!-- Field: Page; Sequence: 39; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 6pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>EQUITY COMPENSATION PLAN INFORMATION</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 6pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt">The following table sets forth information concerning
Anika Therapeutics' equity compensation plan as of December 31, 2016.</P>




<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 6pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 6pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 95%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="13" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><FONT STYLE="font-size: 8pt">Equity
    Compensation Plan Information</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; border-bottom: Black 1.1pt solid; vertical-align: bottom"><FONT STYLE="font-size: 8pt">Plan
    category</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><FONT STYLE="font-size: 8pt">Number
    of securities to be issued upon exercise of outstanding options, stock appreciation rights, performance shares and restricted
    stock units <SUP>(1)</SUP></FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><FONT STYLE="font-size: 8pt">Weighted
    Average exercise price of outstanding options, stock appreciation rights, and performance shares</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><FONT STYLE="font-size: 8pt">Number
    of securities remaining available for future issuance under equity compensation plans</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">Equity compensation plans approved
    by security holders</FONT></TD><TD STYLE="width: 2%; font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 12%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 8pt">1,002,410</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 2%; font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 12%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 8pt">26.15</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 2%; font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 12%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 8pt">881,083</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">Equity compensation plans
    not approved by security holders</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 8pt">N/A</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.1pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 8pt">N/A</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 8pt">N/A</FONT></TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 30pt"><FONT STYLE="font-size: 8pt">Total</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 8pt">1,002,410</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 8pt">26.15</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 8pt">881,083</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>



<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 6pt"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 6pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 6pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Excludes 88,581
shares of unvested restricted stock awards as of December 31, 2016.</P>




<P STYLE="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>AUDIT COMMITTEE REPORT</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The following report of the Audit Committee is required by the rules
of the SEC to be included in this proxy statement. The purpose of the Audit Committee is to oversee Anika Therapeutics&rsquo; accounting
and financial reporting process and the audits of its financial statements. During the years 2002 through 2016, the independent
registered public accounting firm of Anika Therapeutics was PricewaterhouseCoopers&nbsp;LLP (&ldquo;PwC&rdquo;). The Audit Committee
operates pursuant to a written charter adopted by the Board of Directors, a copy of which is available on the website of Anika
Therapeutics.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">As set forth in the Audit Committee Charter, management is responsible
for the preparation, presentation, and integrity of Anika Therapeutics&rsquo; financial statements, as well as for its financial
reporting process, accounting policies, internal controls, and disclosure controls and procedures. PwC is responsible for auditing
the financial statements and expressing an opinion as to their conformity with generally accepted accounting principles and as
to the effectiveness of Anika Therapeutics&rsquo; internal control over financial reporting. The Audit Committee&rsquo;s responsibility
is to monitor and oversee this process.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">In the performance of its oversight function, the Audit Committee
has reviewed and discussed with management and PwC the audited financial statements and management&rsquo;s assessment of the effectiveness
of internal control over financial reporting and PwC&rsquo;s evaluation of internal control over financial reporting. The Audit
Committee has also discussed with PwC the matters required to be discussed by Auditing Standards No.&nbsp;16,<I>&nbsp;</I>as adopted
by the Public Accounting Oversight Board. Finally, the Audit Committee has received the written disclosures and the letter from
PwC required by applicable requirements of the Public Company Accounting Oversight Board regarding PwC&rsquo;s communications with
the Audit Committee concerning independence, has discussed with PwC its independence in relation to Anika Therapeutics, and has
considered the compatibility of non-audit services with such independence. Management has represented to the Audit Committee that
the consolidated financial statements of Anika Therapeutics were prepared in accordance with generally accepted accounting principles.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Based upon the review and discussions referred to above, the Audit
Committee recommended to the Board that the audited financial statements of Anika Therapeutics be included in the Annual Report
on Form&nbsp;10-K for the year ended December&nbsp;31, 2016 filed by Anika Therapeutics with the SEC.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>SUBMITTED BY THE AUDIT COMMITTEE</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>OF THE BOARD OF DIRECTORS</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; text-align: center">Raymond J. Land, Chairperson</TD>
    <TD STYLE="width: 33%; text-align: center">Joseph L. Bower</TD>
    <TD STYLE="width: 33%; text-align: center">Jeffery S. Thompson</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><B>THE FOREGOING REPORT SHOULD NOT BE DEEMED INCORPORATED BY REFERENCE
INTO ANY FILING UNDER THE SECURITIES ACT OF&nbsp;1933, AS AMENDED, OR UNDER THE SECURITIES EXCHANGE ACT OF&nbsp;1934, AS AMENDED,
BY ANY GENERAL STATEMENT INCORPORATING BY REFERENCE THIS PROXY STATEMENT, EXCEPT TO THE EXTENT THAT ANIKA THERAPEUTICS SPECIFICALLY
INCORPORATES THIS INFORMATION BY REFERENCE, AND SHALL NOT OTHERWISE BE DEEMED FILED UNDER SUCH ACTS.</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>PROPOSAL 3:</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In April 2017, the Audit Committee of the
Board of Directors completed a competitive process to determine which audit firm would serve as our independent registered public
accounting firm for the year ended December 31, 2017. The Audit Committee invited several firms to participate in this competitive
process, including PwC, our independent registered public accounting firm since 2002. As a result of this process, and following
careful deliberation, on April 24, 2017, the Audit Committee dismissed PwC as the Company&rsquo;s independent registered public
accounting firm effective immediately following the filing of the Company&rsquo;s Quarterly Report on Form 10-Q for the three-month
period ended March 31, 2017. On the same day, the Audit Committee approved the appointment of Deloitte &amp; Touche LLP (&ldquo;Deloitte&rdquo;)
to act as our independent registered public accounting firm for the remainder of 2017 effective immediately following the filing
of the Company&rsquo;s Quarterly Report on Form 10-Q for the three-month period ended March 31, 2017. The Audit Committee is responsible
for the appointment, retention, termination, compensation, and oversight of the work of our independent registered public accounting
firm for the purpose of preparing or issuing an audit report or related work. Although ratification of the appointment of our independent
registered public accounting firm is not required by our By-laws or otherwise, the Board is submitting the appointment of Deloitte
to our stockholders for ratification because we value the views of our stockholders. In the event that stockholders fail to ratify
the appointment of Deloitte, the Audit Committee will reconsider the appointment of Deloitte. Even if the appointment is ratified,
the ratification is not binding and the Audit Committee may in its discretion select a different independent registered public
accounting firm at any time during the year if it determines that such a change would be in the best interests of our company and
our stockholders.</P>


<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Representatives of Deloitte are expected to be present at the Annual
Meeting. They will have an opportunity to make a statement, if they desire, and will be available to respond to appropriate questions.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The reports of PwC on our consolidated financial
statements for the fiscal years ended December 31, 2016 and 2015, and in the subsequent interim period through April 24, 2017,
did not contain any adverse opinion or disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope
or accounting principle, and included explanatory paragraphs. The 2015 report included an explanatory paragraph stating: &ldquo;As
discussed in Note 2 to the consolidated financial statements, we changed the manner in which we classify deferred taxes in 2015
and 2014 due to the adoption of Accounting Standards Update 2015-17, Balance Sheet Classification of Deferred Taxes.&rdquo;</P>


<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">During the fiscal years ended December 31, 2016 and 2015, and through
April 24, 2017, (i) there were no disagreements (as that term is defined in Item 304(a)(1)(iv) of Securities and Exchange Commission
Regulation S-K and the related instructions) between PwC and our company on any matter of accounting principles or practices, financial
statement disclosure, or auditing scope or procedure, which, if not resolved to the satisfaction of PwC would have caused PwC to
make reference to the subject matter of the disagreement in connection with its reports on our consolidated financial statements
for such years, and (ii) there were no &lsquo;&lsquo;reportable events&rsquo;&rsquo; (as that term is defined in Item 304(a)(1)(v)
of Regulation S-K).</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">During the fiscal years ended December 31, 2016 and 2015, and through
April 24, 2017, neither we, nor anyone on our behalf, consulted Deloitte regarding matters or events set forth in Item 304(a)(2)
of Regulation S-K, including either (i) application of accounting principles to a specified transaction, either completed or proposed,
or the type of audit opinion that might be rendered with respect to our consolidated financial statements, in any case where a
written report or oral advice was provided to us by Deloitte that was an important factor considered by us in reaching a decision
as to any accounting, auditing or financial reporting issue; or (ii) any matter that was the subject of a disagreement (as that
term is defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a &lsquo;&lsquo;reportable event&rsquo;&rsquo;
(as that term is defined in Item 304(a)(1)(v) of Regulation S-K).</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We provided PwC with
a copy of the disclosures we made in a Current Report on Form 8-K prior to the time the Report was filed with the SEC. We requested
that PwC furnish a letter addressed to the SEC stating whether or not it agrees with the statements made therein. A copy of PwC&rsquo;s
letter dated April 27, 2017 was attached as Exhibit 16.1 to the Report.</P>


<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">In deciding to  appoint Deloitte, the
Audit Committee reviewed auditor independence and existing commercial relationships with Deloitte, and concluded that
Deloitte has no commercial relationship with us that would impair its independence.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Vote Required</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The affirmative vote of the holders of a majority of the shares of
common stock present or represented at the Annual Meeting and voting on the matter is required for the ratification of the appointment
of Deloitte as our independent registered public accounting firm for the fiscal year ending December 31, 2017. Abstentions, if
any, will not be treated as votes cast and will have no impact on the proposal. Because this proposal is considered a routine matter,
broker non-votes will be counted.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 42; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Board Recommendation</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><B>THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE &ldquo;FOR&rdquo;
THE RATIFICATION OF THE APPOINTMENT OF DELOITTE &amp; TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL
YEAR ENDING DECEMBER 31, 2017.</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><I>Fees Paid to Our Principal Independent Auditor</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The following table summarizes the fees that Anika Therapeutics paid
or accrued for audit and other services provided by its principal independent auditor, PwC, for each of the last two years. PwC
is not expected to be present at the 2017 Annual Meeting.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid; text-align: left">Fee Category</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2016</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2015</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%; font-size: 10pt; text-align: left">Audit fees</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">919,663</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">755,600</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Audit-related fees</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Tax fees</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">86,719</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">85,944</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">All other fees</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">-</TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">-</TD><TD STYLE="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total fees</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,006,382</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">841,544</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">For purposes of the preceding table:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Audit fees consist of fees for the audit of
our consolidated financial statements, the review of the interim financial statements included in our quarterly reports on Form&nbsp;10-Q,
and other professional services provided in connection with statutory and regulatory filings or engagements for those years. Audit
fees also include the audit of the effectiveness of internal control over financial reporting, as required under Section&nbsp;404
of the Sarbanes-Oxley Act of 2002. Audit-related fees consist of the aggregate fees billed by the principal accountant in each
of the last two fiscal years for assurance and related services reasonably related to the performance of the audit or review. Tax
fees consist of fees for tax compliance, tax advice, and tax planning services for those years. All other fees consist of the aggregate
fees billed by the principal accountant in each of the last two fiscal years for products and services other than the services
reported herein.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;In considering the nature of the services provided by the principal
independent auditor, the Audit Committee determined that such services are compatible with the provision of independent audit services.
The Audit Committee discussed these services with the independent auditor and management to determine that they are permitted under
the rules and regulations concerning auditor independence promulgated by the SEC to implement the Sarbanes-Oxley Act of 2002, as
well as the American Institute of Certified Public Accountants.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under its charter, the Audit Committee must
pre-approve all audit and permitted non-audit services to be provided by our principal independent auditor unless an exception
to such pre-approval exists under the Exchange Act or the rules of the SEC. Each year, the Audit Committee approves the retention
of the independent auditor to audit our financial statements, including the associated fee. The Audit Committee evaluates other
known potential engagements of the independent auditor, including the scope of audit-related services, tax services, and other
services proposed to be performed and the proposed fees, and approves or rejects each service, taking into account whether the
services are permissible under applicable law and the possible impact of each non-audit service on the independent auditor&rsquo;s
independence from management. All such services were approved by the Audit Committee pursuant to Rule&nbsp;2-01 of Regulation&nbsp;S-X
under the Exchange Act to the extent that rule was applicable. Since May 2003, each new engagement of PwC had been approved in
advance by the Audit Committee.</P>




<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 43; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>PROPOSAL 4:</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>ADVISORY VOTE ON EXECUTIVE COMPENSATION</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">In accordance with Section&nbsp;14A of the Exchange Act, we are providing
our stockholders with the opportunity to vote on a non-binding, advisory resolution to approve the compensation of our Named Executive
Officers, which is described in the section titled &ldquo;Compensation Discussion and Analysis&rdquo; in this proxy statement.
We currently hold this vote annually.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">As described in the section titled &ldquo;Compensation Discussion
and Analysis,&rdquo; our executive compensation program is designed to attract and retain highly qualified executive officers and
motivate them to provide a high level of performance for the benefit of our company and stockholders. Stockholders are urged to
read the &ldquo;Compensation Discussion and Analysis&rdquo; section of this proxy statement, which more thoroughly discusses how
our compensation policies and procedures implement our compensation philosophy and objectives. The Compensation Committee and the
Board of Directors believe that these policies and procedures are effective in implementing our compensation philosophy and in
achieving our objectives.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Accordingly, the following resolution is submitted for a stockholder
vote at the 2017 Annual Meeting:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&ldquo;RESOLVED, that the stockholders of Anika Therapeutics, Inc.
approve, on an advisory basis, the compensation paid to the Named Executive Officers of Anika Therapeutics, as disclosed pursuant
to Item&nbsp;402 of Regulation S-K, including the Compensation Discussion and Analysis, compensation tables, and narrative discussion
set forth in the Proxy Statement for this Annual Meeting.&rdquo;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">This vote is advisory and will not be binding upon us or the Board.
However, the Board values constructive dialogue on executive compensation, and on other important governance topics, with stockholders
and encourages all stockholders to vote their shares on this matter.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Vote Required</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The affirmative vote of the holders of a majority of the shares of
common stock present or represented at the Annual Meeting and voting on the matter is required to approve this resolution. Abstentions
and broker non-votes, if any, will not be treated as votes cast and will have no impact on this proposal. While this vote is required
by law, it will not be binding on us or the Board of Directors, nor will it create or imply any change in the fiduciary duties
of, or impose any additional fiduciary duty on, our company or the Board. However, the Compensation Committee will take into account
the outcome of the vote when considering future executive compensation decisions.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Board Recommendation</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><B>THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT STOCKHOLDERS
VOTE TO APPROVE THE OVERALL COMPENSATION OF THE NAMED EXECUTIVE OFFICERS BY VOTING &ldquo;FOR&rdquo; THIS RESOLUTION.</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 44; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>PROPOSAL 5:</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>FREQUENCY OF ADVISORY VOTES ON EXECUTIVE COMPENSATION </B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">In accordance with Section 14A of the Exchange Act, we are providing
our stockholders the opportunity to cast an advisory vote, or to abstain from voting, on whether a non-binding stockholder resolution
to approve the compensation of our Named Executive Officers should occur every one, two, or three years. The Board of Directors
recommends that stockholders vote to hold an advisory vote on executive compensation annually, however, stockholders are not voting
to approve or disapprove of the Board&rsquo;s recommendation.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">While our executive compensation program is designed to attract and
retain highly qualified executive officers and motivate them to provide a high level of performance for the benefit of our company
and stockholders, the Board recognizes that executive compensation disclosures are made annually. Holding an advisory vote on executive
compensation annually will give stockholders the opportunity to react promptly to emerging trends in compensation and provide feedback
before those trends become pronounced over time. In addition, an annual advisory vote will also give the Board and the Compensation
Committee more direct and immediate feedback on our compensation disclosures and the opportunity to evaluate individual compensation
decisions each year. However, stockholders should note that because the advisory vote on executive compensation occurs well after
the beginning of the compensation year, in many cases it may not be appropriate or feasible to change our executive compensation
programs in consideration of any one year&rsquo;s advisory vote on executive compensation by the time of the following year&rsquo;s
annual meeting of stockholders. We believe that an annual advisory vote on executive compensation is consistent with our practice
of seeking input and engaging in dialogue with our stockholders on corporate governance matters (including our practice of annually
providing stockholders the opportunity to ratify the Audit Committee&rsquo;s selection of independent auditors) and our executive
compensation philosophy, policies, and practices.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Vote Required </B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The affirmative vote of the holders of a majority of the shares of
common stock present or represented at the Annual Meeting and voting on the matter is generally required to approve this resolution.
Abstentions and broker non-votes, if any, will not be treated as votes cast and will have no impact on this proposal. None of the
frequency options receives a majority of the votes present or represented at the Annual Meeting and voting on the matter, the option
receiving the greatest number of votes will be considered the frequency recommended by our stockholders. While this vote is required
by law, it will not be binding on us or the Board nor will it create or imply any change in the fiduciary duties of, or impose
any additional fiduciary duty on, our company or the Board, the Board will take into account the outcome of the vote in making
a determination on the frequency at which advisory votes on executive compensation will be included in our proxy statement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Board Recommendation </B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><B>THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT STOCKHOLDERS
VOTE TO INCLUDE AN ADVISORY VOTE ON THE COMPENSATION OF THE NAMED EXECUTIVE OFFICERS IN THE PROXY STATEMENT EACH YEAR BY VOTING
&ldquo;ONE (1) YEAR&rdquo; ON PROPOSAL 5 TO INDICATE APPROVAL OF AN ADVISORY VOTE TO INCLUDE A VOTE ON EXECUTIVE COMPENSATION IN
OUR PROXY STATEMENT ON AN ANNUAL BASIS.&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 45; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>OTHER MATTERS</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Board of Directors does not know of any other matters that will
come before the Annual Meeting. However, if any other matters are properly presented at the Annual Meeting, it is the intention
of the persons named in the accompanying proxy card to vote, or otherwise act, in accordance with their judgment on such matters.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>STOCKHOLDER PROPOSALS</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Stockholder proposals intended to be presented at the next Annual
Meeting of Stockholders must be received by us on or before December&nbsp;28, 2017 in order to be considered for inclusion in our
proxy statement. These proposals must also comply with the rules of the SEC governing the form and content of proposals in order
to be included in our proxy statement and form of proxy, and proposals should be directed to: Secretary, Anika Therapeutics,&nbsp;Inc.,
32 Wiggins Avenue, Bedford, Massachusetts 01730. A stockholder who wishes to present a proposal at the next Annual Meeting of Stockholders,
other than a proposal to be considered for inclusion in our proxy statement described above, must have the proposal delivered personally
to or mailed to and received by the Secretary, Anika Therapeutics,&nbsp;Inc., 32 Wiggins Avenue, Bedford, Massachusetts 01730 U.S.A.
We must receive the proposal on or before March&nbsp;20, 2018; provided, however, that such proposal shall not be required to be
given more than sixty days prior to the Annual Meeting of Stockholders. The proposal must also comply with the other requirements
contained in our Amended and Restated By-laws, including supporting documentation and other information. Proxies solicited by the
Board of Directors will confer discretionary voting authority with respect to these proposals, subject to SEC rules governing the
exercise of this authority.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The chairman of the meeting may, if the facts warrant, determine
and declare to the meeting that any proposed item of business was not brought before the meeting in accordance with the foregoing
procedure and, if he should so determine, he shall so declare to the meeting that the defective item of business shall be disregarded.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Pursuant to the rules of the SEC, services that deliver our communications
to shareholders that hold their shares through a bank, broker, or other nominee holder of record may deliver to multiple shareholders
sharing the same address a single copy of our Annual Report and Proxy Statement. We will promptly deliver upon written request
a separate copy of the Annual Report and/or Proxy Statement to any shareholder at a shared address to which a single copy of the
documents was delivered. Written requests should be made to Anika Therapeutics, Inc., 32 Wiggins Avenue, Bedford, MA 01730, Attention:
Secretary. Any shareholder who wants to receive separate copies of the Proxy Statement or Annual Report in the future, or any shareholder
who is receiving multiple copies and would like to receive only one copy per household, should contact the shareholder&rsquo;s
bank, broker, or other nominee holder of record.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">STOCKHOLDERS MAY OBTAIN, WITHOUT CHARGE, A COPY OF OUR ANNUAL REPORT
ON FORM 10-K, INCLUDING THE FINANCIAL STATEMENTS AND SCHEDULES THERETO, FILED WITH THE SEC COMMISSION FOR THE YEAR ENDED DECEMBER
31, 2016, BY WRITING TO OUR SECRETARY, ANIKA THERAPEUTICS,&nbsp;INC., 32 WIGGINS AVENUE, BEDFORD, MA 01730 U.S.A.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><B>THIS PROXY STATEMENT, A FORM OF PROXY AND THE ANNUAL REPORT TO
STOCKHOLDERS ARE AVAILABLE AT <U>www.proxyvote.com</U> and<I>&nbsp;<U>http://www.anikatherapeutics.com/proxy </U>.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">WHETHER OR NOT YOU PLAN TO ATTEND THE ANNUAL MEETING IN PERSON, YOU
ARE REQUESTED TO COMPLETE YOUR PROXY CARD AS INDICATED IN THIS PROXY STATEMENT.<B><I>&nbsp;&nbsp;YOUR PROXY IS REVOCABLE UP TO
THE TIME SET FORTH IN THIS PROXY STATEMENT AND, IF YOU ATTEND THE ANNUAL MEETING, YOU MAY VOTE IN PERSON EVEN IF YOU HAVE PREVIOUSLY
COMPLETED YOUR PROXY CARD.</I></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 46; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><U>Appendix
A</U></FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">ANIKA
THERAPEUTICS, INC.</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0">2017 OMNIBUS INCENTIVE PLAN</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Anika Therapeutics, Inc. sets forth herein the
terms of its 2017 Omnibus Incentive Plan.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">PURPOSE</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Plan is intended to enhance the ability
of the Company and its Affiliates to attract and retain highly qualified officers, Non-employee Directors, employees, consultants
and advisors, and to motivate such individuals to serve the Company and its Affiliates and to expend maximum effort to improve
the business results and earnings of the Company, by providing to such persons an opportunity to acquire or increase a direct proprietary
interest in the operations and future success of the Company. To this end, the Plan provides for the grant of stock options, stock
appreciation rights (&ldquo;<B>SARs</B>&rdquo;), restricted stock, restricted stock units (&ldquo;<B>RSUs</B>&rdquo;), unrestricted
stock, other share-based awards and cash awards. Any of these awards may, but need not, be made as performance incentives to reward
attainment of performance goals in accordance with the terms hereof. Upon the Plan becoming effective, no further awards shall
be made under the Prior Plan.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">DEFINITIONS</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">For purposes of interpreting the Plan and related
documents (including Award Agreements), the following definitions shall apply:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Acquiror<FONT STYLE="font-weight: normal">&rdquo;
shall have the meaning set forth in </FONT>Section&nbsp;15.2.1<FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Affiliate<FONT STYLE="font-weight: normal">&rdquo;
means any company or other trade or business that &ldquo;controls,&rdquo; is &ldquo;controlled by&rdquo; or is &ldquo;under common
control with&rdquo; the Company within the meaning of Rule 405 of Regulation C under the Securities Act, including any Subsidiary.
</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Annual
Incentive Award<FONT STYLE="font-weight: normal">&rdquo; means a cash-based Performance Award with a performance period that is
the Company&rsquo;s fiscal year or other 12-month (or shorter) performance period as specified under the terms of the Award as
approved by the Board.</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Award<FONT STYLE="font-weight: normal">&rdquo;
means a grant under the Plan of an Option, SAR, Restricted Stock, RSU, Other Share-based Award or cash award. </FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Award
Agreement<FONT STYLE="font-weight: normal">&rdquo; means a written agreement between the Company and a Participant, or notice from
the Company or an Affiliate to a Participant that evidences and sets out the terms of an Award. </FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&ldquo;<B>Board</B>&rdquo; means the Board of Directors of the Company<B>.</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Business
Combination<FONT STYLE="font-weight: normal">&rdquo; shall have the meaning set forth in </FONT>Section&nbsp;15.2.2<FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Cause<FONT STYLE="font-weight: normal">&rdquo;
shall be defined as that term is defined in the Participant&rsquo;s offer letter or other applicable employment agreement; or,
if there is no such definition, &ldquo;Cause&rdquo; means, as determined by the Company in its sole discretion and unless otherwise
provided in the applicable Award Agreement: (i) any material breach by the Participant of any agreement between the Participant
and the Company; (ii) the conviction of or plea of nolo contendere by the Participant to a felony or a crime involving moral turpitude;
or (iii) any material misconduct or willful and deliberate non-performance (other than by reason of disability) by the Participant
of the Participant&rsquo;s duties to the Company. A Separation from Service for Cause shall be deemed to include a determination
by the Company in its sole discretion following a Participant&rsquo;s Separation from Service that circumstances existing prior
to such Separation from Service would have entitled the Company or an Affiliate to have terminated the Participant&rsquo;s service
for Cause. All rights a Participant has or may have under the Plan shall be suspended automatically during the pendency of any
investigation by the Company, or during any negotiations between the Company and the Participant, regarding any actual or alleged
act or omission by the Participant of the type described in the applicable definition of Cause.</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 47; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&ldquo;<B>Change in Control</B>&rdquo; shall have the meaning set
forth in <B>Section&nbsp;15.2.2</B>.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&ldquo;<B>Code</B>&rdquo; means the Internal Revenue Code of 1986.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&ldquo;<B>Committee</B>&rdquo; means the Compensation Committee of
the Board, or such other committee as determined by the Board. The Compensation Committee of the Board may designate a subcommittee
of its members to serve as the Committee (to the extent the Board has not designated another person, committee or entity as the
Committee). The Board will cause the Committee to satisfy the applicable requirements of any securities exchange on which the Common
Stock may then be listed. For purposes of Awards to Covered Employees intended to qualify as Performance-Based Compensation, to
the extent required by Section&nbsp;162(m), Committee means all of the members of the Compensation Committee who are &ldquo;outside
directors&rdquo; within the meaning of Section&nbsp;162(m). For purposes of Awards to Participants who are subject to Section&nbsp;16
of the Exchange Act, Committee means all of the members of the Compensation Committee who are &ldquo;non-employee directors&rdquo;
within the meaning of Rule 16b-3 adopted under the Exchange Act.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&ldquo;<B>Company</B>&rdquo; means Anika Therapeutics, Inc., a Massachusetts
corporation, or any successor corporation.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&ldquo;<B>Common Stock</B>&rdquo; means the common stock of the Company.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Consultant<FONT STYLE="font-weight: normal">&rdquo;
means a consultant or advisor that provides bona fide services to the Company or any Affiliate and who qualifies as a consultant
or advisor under Form S-8.</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Covered
Employee<FONT STYLE="font-weight: normal">&rdquo; means a Participant who is a &ldquo;covered employee&rdquo; within the meaning
of Section&nbsp;162(m) as qualified by </FONT>Section&nbsp;12.4<FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Disability<FONT STYLE="font-weight: normal">&rdquo;
shall be defined as that term is defined in the Participant&rsquo;s offer letter or other applicable employment agreement; or,
if there is no such definition, &ldquo;Disability&rdquo; means, as determined by the Company in its sole discretion and unless
otherwise provided in the applicable Award Agreement, the Participant is unable to perform each of the essential duties of such
Participant&rsquo;s position by reason of a medically determinable physical or mental impairment which is potentially permanent
in character or which can be expected to last for a continuous period of not less than 12 months; <I>provided</I>, <I>however</I>,
that, with respect to rules regarding expiration of an Incentive Stock Option following termination of the Participant&rsquo;s
employment, &ldquo;Disability&rdquo; means &ldquo;permanent and total disability&rdquo; as set forth in Code Section&nbsp;22(e)(3).</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Effective
Date<FONT STYLE="font-weight: normal">&rdquo; means June 13, 2017, the date the Plan was approved by the Stockholders. </FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Exchange
Act<FONT STYLE="font-weight: normal">&rdquo; means the Securities Exchange Act of 1934.</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Fair
Market Value<FONT STYLE="font-weight: normal">&rdquo; means, as of any date, the value of the Common Stock as determined below.
If the Common Stock is listed on any established stock exchange or a national market system, including without limitation, the
New York Stock Exchange or the NASDAQ Stock Market, the Fair Market Value shall be the closing price of a share of Common Stock
(or if no sales were reported the closing price on the date immediately preceding such date) as quoted on such exchange or system
on the day of determination. In the absence of an established market for the Common Stock, the Fair Market Value shall be determined
in good faith by the Board and such determination shall be conclusive and binding on all persons. </FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Family
Member<FONT STYLE="font-weight: normal">&rdquo; means a person who is a spouse, former spouse, child, stepchild, grandchild, parent,
stepparent, grandparent, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother, sister, brother-in-law
or sister-in-law, including adoptive relationships, of the applicable individual, any person sharing the applicable individual&rsquo;s
household (other than a tenant or employee), a trust in which any one or more of these persons have more than 50% of the beneficial
interest, a foundation in which any one or more of these persons (or the applicable individual) control the management of assets,
and any other entity in which one or more of these persons (or the applicable individual) own more than 50% of the voting interests.</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Grant
Date<FONT STYLE="font-weight: normal">&rdquo; means the latest to occur of (i)&nbsp;the date as of which the Board approves an
Award, (ii)&nbsp;the date on which the recipient of an Award first becomes eligible to receive an Award under </FONT>Section&nbsp;6
<FONT STYLE="font-weight: normal">or (iii)&nbsp;such other date as may be specified by the Board in the Award Agreement. </FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 48; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Incentive
Stock Option<FONT STYLE="font-weight: normal">&rdquo; means an &ldquo;incentive stock option&rdquo; within the meaning of Code
Section&nbsp;422. </FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Incumbent
Directors<FONT STYLE="font-weight: normal">&rdquo;shall have the meaning set forth in </FONT>Section&nbsp;15.2.2<FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>New
Shares<FONT STYLE="font-weight: normal">&rdquo; shall have the meaning set forth in </FONT>Section&nbsp;15.1<FONT STYLE="font-weight: normal">.
</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Non-employee
Director<FONT STYLE="font-weight: normal">&rdquo; means a member of the Board or the board of directors of an Affiliate, in each
case who is not an officer or employee of the Company or any Affiliate. </FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Nonqualified
Stock Option<FONT STYLE="font-weight: normal">&rdquo; means an Option that is not an Incentive Stock Option. </FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Option<FONT STYLE="font-weight: normal">&rdquo;
means an option to purchase one or more Shares pursuant to the Plan. </FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Option
Price<FONT STYLE="font-weight: normal">&rdquo; means the exercise price for each Share subject to an Option. </FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Other
Share-based Awards<FONT STYLE="font-weight: normal">&rdquo; means Awards consisting of Share units, or other Awards, valued in
whole or in part by reference to, or otherwise based on, Shares.</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Participant<FONT STYLE="font-weight: normal">&rdquo;
shall mean a person who, as a Service Provider, has been granted an Award under the Plan; <I>provided</I>, <I>however</I>, that
in the case of the death or Disability of a Participant, the term &ldquo;Participant&rdquo; refers to the Participant&rsquo;s estate
or other legal representative acting in a fiduciary capacity on behalf of the Participant under applicable state law and court
supervision. </FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Performance
Award<FONT STYLE="font-weight: normal">&rdquo; means an Award made subject to the attainment of performance goals (as described
in </FONT>Section&nbsp;12<FONT STYLE="font-weight: normal">) over a performance period established by the Committee, and includes
an Annual Incentive Award.</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Performance-Based
Compensation<FONT STYLE="font-weight: normal">&rdquo; means &ldquo;performance-based compensation&rdquo; under Section&nbsp;162(m).</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Plan<FONT STYLE="font-weight: normal">&rdquo;
means this Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan. </FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Policy<FONT STYLE="font-weight: normal">&rdquo;
shall have the meaning set forth in </FONT>Section&nbsp;3.2.2<FONT STYLE="font-weight: normal">. </FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Prior
Plan<FONT STYLE="font-weight: normal">&rdquo; means the Anika Therapeutics, Inc. Second Amended and Restated 2003 Stock Option
and Incentive Plan, as amended. </FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Purchase
Price<FONT STYLE="font-weight: normal">&rdquo; means the purchase price for each Share pursuant to a grant of Restricted Stock.
</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Restricted
Stock<FONT STYLE="font-weight: normal">&rdquo; means restricted Shares, awarded to a Participant pursuant to </FONT>Section&nbsp;10<FONT STYLE="font-weight: normal">.
</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Restricted
Stock Unit<FONT STYLE="font-weight: normal">&rdquo; or &ldquo;</FONT>RSU<FONT STYLE="font-weight: normal">&rdquo; means a bookkeeping
entry representing the equivalent of Shares, awarded to a Participant pursuant to </FONT>Section&nbsp;10<FONT STYLE="font-weight: normal">.
</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>SAR
Exercise Price<FONT STYLE="font-weight: normal">&rdquo; means the per Share exercise price of a SAR granted to a Participant under
</FONT>Section&nbsp;9<FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>SEC<FONT STYLE="font-weight: normal">&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Section&nbsp;162(m)<FONT STYLE="font-weight: normal">&rdquo;
means Code Section&nbsp;162(m).</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Section&nbsp;409A<FONT STYLE="font-weight: normal">&rdquo;
means Code Section&nbsp;409A. </FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Securities
Act<FONT STYLE="font-weight: normal">&rdquo; means the Securities Act of 1933.</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Separation
from Service<FONT STYLE="font-weight: normal">&rdquo; means the termination of the applicable Participant&rsquo;s employment with,
and performance of services for, the Company and each Affiliate. A Participant employed by, or performing services for, an Affiliate
or a division of the Company or an Affiliate shall not be deemed to incur a Separation from Service if such Affiliate or division
ceases to be an Affiliate or division of the Company, as the case may be, and the Participant immediately thereafter becomes an
employee of (or service provider to), or member of the board of directors of, the Company or an Affiliate or a successor company
or an affiliate or subsidiary thereof. Approved temporary absences from employment because of illness, vacation or leave of absence
and transfers among the Company and its Affiliates shall not be considered Separations from Service. Notwithstanding the foregoing,
with respect to any Award that constitutes nonqualified deferred compensation under Section&nbsp;409A, &ldquo;Separation from Service&rdquo;
shall mean a &ldquo;separation from service&rdquo; as defined under Section&nbsp;409A.</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 49; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Service
Period<FONT STYLE="font-weight: normal">&rdquo; shall have the meaning set forth in </FONT>Section&nbsp;10.1<FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Service
Provider<FONT STYLE="font-weight: normal">&rdquo; means an employee, officer, Non-employee Director or Consultant of the Company
or an Affiliate. </FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Share<FONT STYLE="font-weight: normal">&rdquo;
means a share of Common Stock.</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Stock
Appreciation Right<FONT STYLE="font-weight: normal">&rdquo; or &ldquo;</FONT>SAR<FONT STYLE="font-weight: normal">&rdquo; means
a right granted to a Participant pursuant to </FONT>Section&nbsp;9<FONT STYLE="font-weight: normal">. </FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Stockholders<FONT STYLE="font-weight: normal">&rdquo;
means the stockholders of the Company.</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Subsidiary<FONT STYLE="font-weight: normal">&rdquo;
means any &ldquo;subsidiary corporation&rdquo; of the Company within the meaning of Code Section&nbsp;424(f). </FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Substitute
Award<FONT STYLE="font-weight: normal">&rdquo; means any Award granted in assumption of or in substitution for an award of a company
or business acquired by the Company or an Affiliate or with which the Company or an Affiliate combines. </FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Ten
Percent Stockholder<FONT STYLE="font-weight: normal">&rdquo; means an individual who owns more than 10% of the total combined voting
power of all classes of outstanding stock of the Company, its parent or any of its Subsidiaries. In determining stock ownership,
the attribution rules of Code Section&nbsp;424(d) shall be applied. </FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Termination
Date<FONT STYLE="font-weight: normal">&rdquo; means the date that is 10 years after the Effective Date, unless the Plan is earlier
terminated by the Board under </FONT>Section&nbsp;5.2<FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Voting
Securities<FONT STYLE="font-weight: normal">&rdquo; shall have the meaning set forth in </FONT>Section&nbsp;15.2.2<FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">ADMINISTRATION OF THE PLAN</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">3.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
General</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Board shall have such powers and authorities
related to the administration of the Plan as are consistent with the Company&rsquo;s certificate of incorporation and bylaws and
applicable law. The Board shall have the power and authority to delegate its responsibilities hereunder to the Committee, which
shall have full authority to act in accordance with its charter, and with respect to the power and authority of the Board to act
hereunder, all references to the Board shall be deemed to include a reference to the Committee, unless such power or authority
is specifically reserved by the Board. Except as specifically provided in <B>Section&nbsp;14</B> or as otherwise may be required
by applicable law, regulatory requirement or the certificate of incorporation or the bylaws of the Company, the Board shall have
full power and authority to take all actions and to make all determinations required or provided for under the Plan, any Award
or any Award Agreement, and shall have full power and authority to take all such other actions and make all such other determinations
not inconsistent with the specific terms and provisions of the Plan that the Board deems to be necessary or appropriate to the
administration of the Plan. The Committee shall administer the Plan; <I>provided</I>, <I>however</I>, the Board shall retain the
right to exercise the authority of the Committee to the extent consistent with applicable law and the applicable requirements of
any securities exchange on which the Common Stock may then be listed. All actions, determinations and decisions by the Board or
the Committee under the Plan or any Award Agreement, or with respect to any Award, shall be in the sole discretion of the Board
and shall be final, binding and conclusive on all persons. Without limitation, the Board shall have full and final power and authority,
subject to the other terms of the Plan, to:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">designate Participants;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"></P>

<!-- Field: Page; Sequence: 50; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">determine the type or types of Awards to be made to Participants;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">determine the number of Shares to be subject to an Award;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">establish the terms of each Award (including the Option Price of any Option, the nature and duration
of any restriction or condition (or provision for lapse thereof) relating to the vesting, exercise, transfer or forfeiture of an
Award or the Shares subject thereto and any terms or conditions that may be necessary to qualify Options as Incentive Stock Options);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">subject to applicable law, delegate its authority and duties to the Chief Executive Officer with
respect to the granting of Options to individuals who are not Covered Employees or &ldquo;insiders&rdquo; within the meaning of
Section 16 of the Exchange Act. Any such delegation by the Board shall include a limitation as to the amount of Options that may
be granted during the period of the delegation and shall contain guidelines as to the determination of the exercise price and the
vesting criteria. The Board may revoke or amend the terms of a delegation at any time but such action shall not invalidate any
prior actions of the Board&rsquo; delegate or delegates that were consistent with the terms of the Plan.;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(vi)</TD><TD STYLE="text-align: justify">prescribe the form of each Award Agreement; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(vii)</TD><TD STYLE="text-align: justify">amend, modify or supplement the terms of any outstanding Award including the authority, in order
to effectuate the purposes of the Plan, to modify Awards to foreign nationals or individuals who are employed outside the United&nbsp;States
to recognize differences in local law, tax policy or custom.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">3.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Separation from Service for Cause; Clawbacks</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"><B>3.2.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Separation from Service for Cause</B></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1.7in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">The Company may annul an Award if the Participant
incurs a Separation from Service for Cause.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"><B>3.2.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Clawbacks</B></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1.7in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">All awards, amounts or benefits received or outstanding
under the Plan shall be subject to clawback, cancellation, recoupment, rescission, payback, reduction or other similar action in
accordance with the terms of any Company clawback or similar policy (the &ldquo;<B>Policy</B>&rdquo;) or any applicable law related
to such actions, as may be in effect from time to time. A Participant&rsquo;s acceptance of an Award shall be deemed to constitute
the Participant&rsquo;s acknowledgement of and consent to the Company&rsquo;s application, implementation and enforcement of any
applicable Policy that may apply to the Participant, whether adopted prior to or following the Effective Date, and any provision
of applicable law relating to clawback, cancellation, recoupment, rescission, payback or reduction of compensation, and the Participant&rsquo;s
agreement that the Company may take such actions as may be necessary to effectuate any such policy or applicable law, without further
consideration or action.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0.5in; margin: 0pt 0">3.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Deferral Arrangement</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Board may permit or require the deferral
of any Award payment into a deferred compensation arrangement, subject to such rules and procedures as it may establish and in
accordance with Section&nbsp;409A, which may include provisions for the payment or crediting of interest or dividend equivalents
as provided in <B>Section 17.10</B>, including converting such credits into deferred Share units.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">3.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
No Liability</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">No member of the Board or of the Committee shall
be liable for any action or determination made in good faith with respect to the Plan, any Award or Award Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 51; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">3.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Book Entry</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Notwithstanding any other provision of the Plan
to the contrary, the Company may elect to satisfy any requirement under the Plan for the delivery of stock certificates through
the use of book entry.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">3.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
No Repricing</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Notwithstanding any provision herein to the
contrary, the repricing of Options or SARs is prohibited without prior approval of the Stockholders. For this purpose, a &ldquo;repricing&rdquo;
means any of the following (or any other action that has the same effect as any of the following): (i) changing the terms or conditions
of an Option or SAR to lower its Option Price or SAR Exercise Price; (ii) any other action that is treated as a &ldquo;repricing&rdquo;
under generally accepted accounting principles; and (iii) repurchasing for cash or canceling an Option or SAR at a time when its
Option Price or SAR Exercise Price is greater than the Fair Market Value of the underlying Shares in exchange for another Award,
unless the cancellation and exchange occurs in connection with a change in capitalization or similar change under <B>Section&nbsp;15</B>.
A cancellation and exchange under clause (iii) would be considered a &ldquo;repricing&rdquo; regardless of whether it is treated
as a &ldquo;repricing&rdquo; under generally accepted accounting principles and regardless of whether it is voluntary on the part
of the Participant.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify">STOCK SUBJECT TO THE PLAN</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">4.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Authorized Number of Shares</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Subject to adjustment under <B>Section&nbsp;15</B>,
the aggregate number of Shares authorized to be awarded under the Plan shall not exceed 1,200,000. The grant of any full value
Award (i.e., an Award other than an Option or a SAR) shall be deemed, for purposes of determining the number of Shares available
for issuance under this <B>Section 4.1</B>, as an Award of two (2) Shares for each Share actually subject to the Award. The grant
of an Option or SAR shall be deemed, for purposes of determining the number of Shares available for issuance under this <B>Section
4.1</B>, as an Award for one (1) Share for each such Share actually subject to the Award. Any Shares returned to the Plan pursuant
to <B>Section 4.2</B> shall be returned to the reserved pool of Shares under the Plan in the same manner. In addition, Shares underlying
any outstanding award granted under a Prior Plan that, following the Effective Date, expires, or is terminated, surrendered or
forfeited for any reason without issuance of Shares shall be available for the grant of new Awards. As provided in <B>Section&nbsp;1</B>,
no new awards shall be granted under the Prior Plan following the Effective Date. Shares issued under the Plan may consist in whole
or in part of authorized but unissued Shares, treasury Shares or Shares purchased on the open market or otherwise.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">4.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Share Counting</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1in; margin: 0pt 0">4.2.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="font-weight: normal">Any Award settled in cash shall not be counted as issued Shares for any purpose under the Plan.</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1in; margin: 0pt 0">4.2.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="font-weight: normal">If any Award expires, or is terminated, surrendered or forfeited, in whole or in part, the unissued
Shares covered by such Award shall again be available for the grant of Awards.</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1in; margin: 0pt 0">4.2.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="font-weight: normal">If Shares issued pursuant to the Plan are repurchased by, or are surrendered or forfeited to
the Company at no more than cost, such Shares shall again be available for the grant of Awards.</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1in; margin: 0pt 0">4.2.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="font-weight: normal">If Shares issuable upon exercise, vesting or settlement of an Award, or Shares owned by a Participant
(which are not subject to any pledge or other security interest), are surrendered or tendered to the Company in payment of the
Option Price or Purchase Price of an Award or any taxes required to be withheld in respect of an Award, in each case, in accordance
with the terms of the Plan and any applicable Award Agreement, such surrendered or tendered Shares shall not be available again
for the grant of Awards.</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1in; margin: 0pt 0">4.2.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="font-weight: normal">Substitute Awards shall not be counted against the number of Shares available for the grant of
Awards.</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 52; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">4.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Award Limits</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"><B>4.3.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Incentive Stock Options</B></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1.7in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">Subject to adjustment under <B>Section&nbsp;15</B>,
1,200,000 Shares available for issuance under the Plan shall be available for issuance as Incentive Stock Options.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"><B>4.3.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Individual Award Limits for Section 162(m) -- Share-Based Awards</B></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1.7in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">Subject to adjustment under <B>Section 15</B>,
the maximum number of each type of Award (other than cash-based Performance Awards) granted to any Participant in any calendar
year shall not exceed the following number of Shares: (i) Options and SARs: 400,000 Shares; and (ii) all share-based Performance
Awards (including Restricted Stock, RSUs and Other Share-based Awards that are Performance Awards): 400,000 Shares.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"><B>4.3.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Individual Award Limits for Section 162(m) -- Cash-Based Awards</B></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1.7in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">The maximum amount of cash-based Performance Awards
intended to qualify as Performance-Based Compensation granted to any Participant in any calendar year shall not exceed the following:
(i) Annual Incentive Awards: $1,000,000; and (ii) all other cash-based Performance Awards: $1.000,000.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"><B>4.3.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Director Awards</B></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1.7in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">The maximum value of Awards granted during any
calendar year to any Non-employee Director, taken together with any cash fees paid to such Non-employee Director during the calendar
year and the value of awards granted to the Non-employee Director under any other equity compensation plan of the Company or an
Affiliate during the calendar year, shall not exceed the following in total value (calculating the value of any Awards or other
equity compensation plan awards based on the fair market value as of grant date for financial reporting purposes): (i) $500,000
for the non-employee Chair or Lead Director of the Board and (ii) $425,000 for each Non-employee Director other than the Chair
or Lead Director of the Board; <I>provided, however</I>, that awards granted to Non-employee Directors upon their initial election
to the Board or the board of directors of an Affiliate shall not be counted towards the limit under this <B>Section 4.3.4</B>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify">EFFECTIVE DATE, DURATION AND AMENDMENTS</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">5.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Term</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Plan shall be effective as of the Effective
Date, <I>provided</I> that it has been approved by the Stockholders. The Plan shall terminate automatically on the 10-year anniversary
of the Effective Date and may be terminated on any earlier date as provided in <B>Section&nbsp;5.2</B>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">5.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Amendment and Termination of the Plan</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Board may, at any time and from time to
time, amend, suspend or terminate the Plan as to any Awards which have not been made. An amendment shall be contingent on approval
of the Stockholders to the extent stated by the Board, required by applicable law or required by applicable securities exchange
listing requirements. No Awards shall be made after the Termination Date. The applicable terms of the Plan, and any terms applicable
to Awards granted prior to the Termination Date, shall survive the termination of the Plan and continue to apply to such Awards.
No amendment, suspension or termination of the Plan shall, without the consent of the Participant, materially impair rights or
obligations under any Award theretofore awarded.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.</TD><TD STYLE="text-align: justify">AWARD ELIGIBILITY AND LIMITATIONS</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">6.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Service Providers</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Subject to this <B>Section&nbsp;6</B>, Awards
may be made to any Service Provider as the Board may determine and designate from time to time.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 53; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">6.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Successive Awards</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">An eligible person may receive more than one
Award, subject to such restrictions as are provided herein.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">6.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Stand-Alone, Additional, Tandem, and Substitute Awards</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Awards may be granted either alone or in addition
to, in tandem with, or in substitution or exchange for, any other Award or any award granted under another plan of the Company,
any Affiliate or any business entity to be acquired by the Company or an Affiliate, or any other right of a Participant to receive
payment from the Company or any Affiliate. Such additional, tandem or substitute or exchange Awards may be granted at any time.
If an Award is granted in substitution or exchange for another award, the Board shall have the right to require the surrender of
such other award in consideration for the grant of the new Award. Subject to the requirements of applicable law, the Board may
make Awards in substitution or exchange for any other award under another plan of the Company, any Affiliate or any business entity
to be acquired by the Company or an Affiliate. In addition, Awards may be granted in lieu of cash compensation, including in lieu
of cash amounts payable under other plans of the Company or any Affiliate, in which the value of Shares subject to the Award is
equivalent in value to the cash compensation (for example, RSUs or Restricted Stock).</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0.5in; margin: 0pt 0">6.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Minimum Vesting</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">All Awards shall be granted subject to a minimum
vesting period of at least one (1) year after the Grant Date; <I>provided</I>, <I>however</I>, that up to five percent (5%) of
the Shares eligible for issuance pursuant to <B>Section 4.1</B> may be issued in respect of Awards that are not subject to the
minimum vesting period requirement; <I>provided</I>, <I>further</I>, that this <B>Section 6.4</B> shall not apply to Awards that
vest upon a Participant&rsquo;s death, Disability, or following a Change in Control<B>. </B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.</TD><TD STYLE="text-align: justify">AWARD AGREEMENT</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The grant of any Award may be contingent upon
the Participant executing an appropriate Award Agreement, in such form or forms as the Board shall from time to time determine.
Without limiting the foregoing, an Award Agreement may be provided in the form of a notice which provides that acceptance of the
Award constitutes acceptance of all terms of the Plan and the notice. Award Agreements granted from time to time or at the same
time need not contain similar provisions but shall be consistent with the terms of the Plan. Each Award Agreement evidencing an
Award of Options shall specify whether such Options are intended to be Nonqualified Stock Options or Incentive Stock Options, and
in the absence of such specification such options shall be deemed Nonqualified Stock Options.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">8.</TD><TD STYLE="text-align: justify">TERMS AND CONDITIONS OF OPTIONS</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">8.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Option Price</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Option Price of each Option shall be fixed
by the Board and stated in the related Award Agreement. The Option Price of each Option (except those that constitute Substitute
Awards) shall be at least the Fair Market Value on the Grant Date; <I>provided</I>, <I>however</I>, that in the event that a Participant
is a Ten Percent Stockholder as of the Grant Date, the Option Price of an Option granted to such Participant that is intended to
be an Incentive Stock Option shall be not less than 110 percent of the Fair Market Value on the Grant Date. In no case shall the
Option Price of any Option be less than the par value of a Share.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">8.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Vesting</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Subject to <B>Section&nbsp;8.3</B>, each Option
shall become exercisable at such times and under such conditions (including performance requirements) as stated in the Award Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">8.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Term</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Each Option shall terminate, and all rights
to purchase Shares thereunder shall cease, upon the expiration of the Option term stated in the Award Agreement not to exceed 10
years from the Grant Date, or under such circumstances and on such date prior thereto as is set forth in the Plan or as may be
fixed by the Board and stated in the related Award Agreement; <I>provided</I>, <I>however</I>, that in the event that the Participant
is a Ten Percent Stockholder, an Option granted to such Participant that is intended to be an Incentive Stock Option at the Grant
Date shall not be exercisable after the expiration of five years from its Grant Date.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 54; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">8.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Limitations on Exercise of Option</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Notwithstanding any other provision of the Plan,
in no event may any Option be exercised, in whole or in part, (i)&nbsp;prior to the date the Plan is approved by the Stockholders
as provided herein or (ii)&nbsp;after the occurrence of an event which results in termination of the Option.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">8.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Method of Exercise</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">An Option that is exercisable may be exercised
by the Participant&rsquo;s delivery of a notice of exercise to the Company, setting forth the number of Shares with respect to
which the Option is to be exercised, accompanied by full payment for the Shares. To be effective, notice of exercise must be made
in accordance with procedures established by the Company from time to time.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">8.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Rights of Holders of Options</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Unless otherwise provided in the applicable
Award Agreement, an individual holding or exercising an Option shall have none of the rights of a Stockholder (for example, the
right to direct the voting of the subject Shares) until the Shares covered thereby are fully paid and issued to him or her. An
individual holding an Option shall not have the right to receive cash or dividend payments or distributions attributable to the
subject Shares until the Option has been exercised and the Shares covered thereby are fully paid and issued to him or her. Except
as provided in <B>Section&nbsp;15</B> or the related Award Agreement, no adjustment shall be made for dividends, distributions
or other rights for which the record date is prior to the date of such issuance.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">8.7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Delivery of Stock Certificates</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Subject to <B>Section&nbsp;3.5</B>, promptly
after the exercise of an Option by a Participant and the payment in full of the Option Price, such Participant shall be entitled
to the issuance of a stock certificate which evidences, or electronic notice of a book entry which records, his or her ownership
of the Shares subject to the Option.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">8.8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Limitations on Incentive Stock Options</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">An Option shall constitute an Incentive Stock
Option only (i)&nbsp;if the Participant of such Option is an employee of the Company or any Subsidiary of the Company; (ii)&nbsp;to
the extent specifically provided in the related Award Agreement; and (iii)&nbsp;to the extent that the aggregate Fair Market Value
(determined at the time the Option is granted) of the Shares with respect to which all Incentive Stock Options held by such Participant
become exercisable for the first time during any calendar year (under the Plan and all other plans of the Participant&rsquo;s employer
and its Affiliates) does not exceed $100,000. This limitation shall be applied by taking Options into account in the order in which
they were granted. No Option shall be treated as an Incentive Stock Option unless the Plan has been approved by the Stockholders
in a manner intended to comply with the stockholder approval requirements of Code Section 422(b)(1); <I>provided</I>, <I>however,
</I>that any Option intended to be an Incentive Stock Option shall not fail to be effective solely on account of a failure to obtain
such approval, but rather such Option shall be treated as a Nonqualified Stock Option unless and until such stockholder approval
is obtained.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.</TD><TD STYLE="text-align: justify">TERMS AND CONDITIONS OF STOCK APPRECIATION RIGHTS (SAR<FONT STYLE="text-transform: none">s)</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">9.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Right to Payment</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">A SAR shall confer on the Participant a right
to receive, upon exercise thereof, the excess of (i)&nbsp;the Fair Market Value on the date of exercise over (ii)&nbsp;the SAR
Exercise Price, as determined by the Board. The Award Agreement for a SAR (except those that constitute Substitute Awards) shall
specify the SAR Exercise Price, which shall be fixed on the Grant Date as not less than the Fair Market Value on that date. SARs
may be granted alone or in conjunction with all or part of an Option or at any subsequent time during the term of such Option or
in conjunction with all or part of any other Award. A SAR granted in tandem with an outstanding Option following the Grant Date
of such Option shall have a grant price that is equal to the Option Price; <I>provided</I>, <I>however</I>, that the SAR&rsquo;s
grant price may not be less than the Fair Market Value on the Grant Date of the SAR to the extent required by Section&nbsp;409A.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 55; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">9.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Other Terms</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Board shall determine at the Grant Date
or thereafter, the time or times at which and the circumstances under which a SAR may be exercised in whole or in part (including
based on achievement of performance goals or future service requirements), the time or times at which SARs shall cease to be or
become exercisable following Separation from Service or upon other conditions, the method of exercise, whether or not a SAR shall
be in tandem or in combination with any other Award and any other terms of any SAR.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">9.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Term of SARs</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The term of a SAR granted under the Plan shall
be determined by the Board; <I>provided</I>, <I>however</I>, that such term shall not exceed 10 years.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">9.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Payment of SAR Amount</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Upon exercise of a SAR, a Participant shall
be entitled to receive payment from the Company (in cash or Shares, as set forth in the Award Agreement) in an amount determined
by multiplying:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the difference between the Fair Market Value on the date of exercise over the SAR Exercise Price;
by</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">the number of Shares with respect to which the SAR is exercised.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.</TD><TD STYLE="text-align: justify">TERMS AND CONDITIONS OF RESTRICTED STOCK AND RESTRICTED STOCK UNITS (RSU<FONT STYLE="text-transform: none">s)</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">10.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Restrictions (applicable to Restricted Stock and RSUs)</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">At the time of grant, the Board may establish
a period of time (a &ldquo;<B>Service Period</B>&rdquo;) and any additional restrictions including the satisfaction of corporate
or individual performance objectives applicable to an Award of Restricted Stock or RSUs. Each Award of Restricted Stock or RSUs
may be subject to a different Service Period and additional restrictions. Neither Restricted Stock nor RSUs may be sold, transferred,
assigned, pledged or otherwise encumbered or disposed of during the Service Period or prior to the satisfaction of any other applicable
restrictions.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">10.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Delivery of Shares (applicable to Restricted Stock and RSUs)</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Subject to <B>Section&nbsp;3.5</B>, upon the
expiration or termination of any Service Period and the satisfaction of any other conditions prescribed by the Board, the restrictions
applicable to Shares of Restricted Stock or RSUs settled in Shares shall lapse, and, unless otherwise provided in the applicable
Award Agreement, a stock certificate for such Shares shall be delivered, free of all such restrictions, to the Participant or the
Participant&rsquo;s beneficiary or estate, as the case may be.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">10.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Rights of Holders of Restricted Stock (applicable to Restricted Stock, not RSUs)</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Unless otherwise provided in the applicable
Award Agreement, holders of Restricted Stock shall have rights as Stockholders, including voting and dividend rights; <I>provided</I>,
<I>however</I>, any dividends with respect to the Restricted Stock shall be withheld by the Company for the Participant&rsquo;s
account, and interest may be credited on the amount of the dividends withheld at a rate and subject to such terms as determined
by the Committee. The dividends so withheld by the Committee and attributable to any particular share of Restricted Stock (and
earnings thereon, if applicable) shall be distributed to the Participant in cash or, at the discretion of the Committee, in Shares
having a Fair Market Value equal to the amount of such dividends, if applicable, upon the release of restrictions on such Share
and, if such Share is forfeited, the Participant shall have no right to such dividends.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 56; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0.5in; margin: 0pt 0">10.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Purchase of Restricted Stock (applicable to Restricted Stock, not RSUs)</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Participant shall be required, to the extent
required by applicable law, to purchase the Restricted Stock from the Company at a Purchase Price equal to the greater of (i)&nbsp;the
aggregate par value of the Shares represented by such Restricted Stock or (ii)&nbsp;the Purchase Price, if any, specified in the
related Award Agreement. If specified in the Award Agreement, the Purchase Price may be deemed paid by services already rendered.
The Purchase Price shall be payable in a form described in <B>Section&nbsp;11</B> or, if so determined by the Board, in consideration
for past services rendered.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">10.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Restricted Stock Certificates (applicable to Restricted Stock, not RSUs)</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Subject to <B>Section&nbsp;3.5</B>, the Company
shall issue, in the name of each Participant to whom Restricted Stock has been granted, stock certificates or other evidence of
ownership representing the total number of Shares of Restricted Stock granted to the Participant, as soon as reasonably practicable
after the Grant Date. The Board may provide in an Award Agreement that either (i)&nbsp;the Secretary of the Company shall hold
any stock certificates for the Participant&rsquo;s benefit until such time as the Restricted Stock is forfeited to the Company
or the restrictions lapse or (ii)&nbsp;such certificates shall be delivered to the Participant; <I>provided</I>, <I>however</I>,
that such certificates shall bear a legend or legends that comply with the applicable securities laws and regulations and make
appropriate reference to the restrictions imposed under the Plan and the Award Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">10.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Rights of Holders of RSUs (applicable to RSUs, not Restricted Stock)</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"><B>10.6.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Settlement
of RSUs</B></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1.7in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">RSUs may be settled in cash or Shares, as set
forth in the Award Agreement. The Award Agreement shall also set forth whether the RSUs shall be settled (i)&nbsp;within the time
period specified in Section 409A for short term deferrals or (ii)&nbsp;otherwise within the requirements of Section&nbsp;409A,
in which case the Award Agreement shall specify upon which events such RSUs shall be settled.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"><B>10.6.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Voting
and Dividend Rights</B></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1.7in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">Unless otherwise provided in the applicable Award
Agreement, holders of RSUs shall not have rights as Stockholders, including voting or dividend or dividend equivalents rights.
Dividend equivalent rights may be granted with respect to RSUs pursuant to <B>Section 17.10</B>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"><B>10.6.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Creditor&rsquo;s
Rights</B></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1.7in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">A holder of RSUs shall have no rights other than
those of a general creditor of the Company. RSUs represent an unfunded and unsecured obligation of the Company, subject to the
terms of the applicable Award Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">11.</TD><TD STYLE="text-align: justify">FORM OF PAYMENT FOR OPTIONS AND RESTRICTED STOCK</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">11.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
General Rule</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Payment of the Option Price for the Shares purchased
pursuant to the exercise of an Option or the Purchase Price for Restricted Stock shall be made in cash or in cash equivalents acceptable
to the Company, except as provided in this <B>Section&nbsp;11</B>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">11.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Surrender of Shares</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">To the extent the Award Agreement so provides,
payment of the Option Price for Shares purchased pursuant to the exercise of an Option or the Purchase Price for Restricted Stock
may be made all or in part through the tender to the Company of Shares, which Shares shall be valued, for purposes of determining
the extent to which the Option Price or Purchase Price for Restricted Stock has been paid thereby, at their Fair Market Value on
the date of exercise or surrender. Notwithstanding the foregoing, in the case of an Incentive Stock Option, the right to make payment
in the form of already-owned Shares may be authorized only at the time of grant.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 57; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">11.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Cashless Exercise</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">With respect to an Option only (and not with
respect to Restricted Stock), to the extent permitted by law and to the extent the Award Agreement so provides, payment of the
Option Price may be made all or in part by delivery (on a form acceptable to the Company) of an irrevocable direction to a licensed
securities broker acceptable to the Company to sell Shares and to deliver all or part of the sales proceeds to the Company in payment
of the Option Price and any withholding taxes described in <B>Section&nbsp;17.3</B>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">11.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Other Forms of Payment</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">To the extent the Award Agreement so provides,
payment of the Option Price or the Purchase Price for Restricted Stock may be made in any other form that is consistent with applicable
laws, regulations and rules, including the Company&rsquo;s withholding of Shares otherwise due to the exercising Participant.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.</TD><TD STYLE="text-align: justify">TERMS AND CONDITIONS OF PERFORMANCE AWARDS</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">12.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Performance Conditions</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The right of a Participant to exercise or receive
a grant or settlement of any Award, and the timing thereof, may be subject to such performance conditions as may be specified by
the Board. The Board may use such business criteria and other measures of performance as it may deem appropriate in establishing
any performance conditions, and may reduce the amounts payable under any Award subject to performance conditions, except as limited
under <B>Section 12.2 </B>in the case of Performance-Based Compensation.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">12.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Performance Awards Granted to Designated Covered Employees</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">If and to the extent that the Board determines
that a Performance Award to be granted to a Participant who is designated by the Board as likely to be a Covered Employee should
qualify as Performance-Based Compensation, the grant, exercise or settlement of such Performance Award shall be contingent upon
achievement of pre-established performance goals and other terms set forth in this <B>Section&nbsp;12.2</B>. Notwithstanding anything
herein to the contrary, the Board may provide for Performance Awards to Covered Employees that are not intended to qualify as Performance-Based
Compensation.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"><B>12.2.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Performance
Goals Generally</B></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1.7in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">The performance goals for Performance Awards shall
consist of one or more business criteria and a targeted level or levels of performance with respect to each of such criteria, as
specified by the Board consistent with this <B>Section&nbsp;12.2</B>. Performance goals shall be objective and shall otherwise
meet the requirements of Section&nbsp;162(m), including the requirement that the level or levels of performance targeted by the
Board result in the achievement of performance goals being &ldquo;substantially uncertain.&rdquo; The Board may determine that
Performance Awards shall be granted, exercised or settled upon achievement of any one performance goal or that two or more of the
performance goals must be achieved as a condition to grant, exercise or settlement of the Performance Awards. Performance goals
may be established on a Company-wide basis, or with respect to one or more business units, divisions, Affiliates or business segments,
as applicable. To the extent consistent with the requirements of Section&nbsp;162(m), the Committee may determine at the time that
goals under this <B>Section&nbsp;12 </B>are established the extent to which measurement of performance goals may exclude the impact
of charges for restructuring, discontinued operations, extraordinary items, debt redemption or retirement, asset write downs, litigation
or claim judgments or settlements, acquisitions or divestitures, foreign exchange gains and losses and other extraordinary, unusual
or non-recurring items, and the cumulative effects of tax or accounting changes (each as defined by generally accepted accounting
principles and as identified in the Company&rsquo;s financial statements or other SEC filings). Performance goals may differ for
Performance Awards granted to any one Participant or to different Participants.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"><B>12.2.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Business
Criteria</B></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1.7in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">One or more of the following business criteria
for the Company, on a consolidated basis, or specified Affiliates or business units of the Company (except with respect to the
total stockholder return and earnings per share criteria), shall be used exclusively by the Board in establishing performance goals
for Performance Awards: (i) cash flow; (ii) earnings per share, as adjusted for any stock split, stock dividend or other recapitalization;
(iii) earnings measures; (iv) return on equity; (v) total stockholder return; (vi) share price performance, as adjusted for any
stock split, stock dividend or other recapitalization; (vii) return on capital; (viii) revenue; (ix) income; (x) profit margin;
(xi) return on operating revenue; (xii) brand recognition or acceptance; (xiii) customer satisfaction; (xiv) productivity; (xv)
expense targets; (xvi) market share; (xvii) cost control measures; (xviii) balance sheet metrics; (xix) strategic initiatives;
(xx) implementation, completion or attainment of measurable objectives with respect to recruitment or retention of personnel or
employee satisfaction; (xxi) regulatory body approval for commercialization of a product; (xxii) implementation or completion of
critical projects; or (xxiii) any other business criteria established by the Board; <I>provided</I>, <I>however</I>, that such
business criteria shall include any derivations of business criteria listed above (<I>e.g.</I>, income shall include pre-tax income,
net income and operating income).</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 58; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"><B>12.2.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Timing
for Establishing Performance Goals</B></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1.7in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">Performance goals shall be established not later
than 90 days after the beginning of any performance period applicable to Performance Awards, or at such other date as may be required
or permitted for Performance-Based Compensation.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"><B>12.2.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Settlement
of Performance Awards; Other Terms</B></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1.7in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">Settlement of Performance Awards may be in cash,
Shares, other Awards or other property. The Board may reduce the amount of a settlement otherwise to be made in connection with
such Performance Awards.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">12.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Written Determinations</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">All determinations by the Board as to the establishment
of performance goals, the amount of any Performance Award pool or potential individual Performance Awards and the achievement of
performance goals relating to Performance Awards, shall be made in writing in the case of any Award intended to qualify as Performance-Based
Compensation to the extent required by Section&nbsp;162(m). To the extent permitted by Section&nbsp;162(m), the Board may delegate
any responsibility relating to Performance Awards.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">12.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Status of Section&nbsp;12.2 Awards under Section&nbsp;162(m)</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">It is the intent of the Company that Performance
Awards under <B>Section&nbsp;12.2</B> granted to persons who are designated by the Board as likely to be Covered Employees within
the meaning of Section&nbsp;162(m) shall, if so designated by the Board, qualify as Performance-Based Compensation. Accordingly,
the terms of <B>Section&nbsp;12.2</B>, including the definitions of Covered Employee and other terms used therein, shall be interpreted
in a manner consistent with Section&nbsp;162(m). The foregoing notwithstanding, because the Board cannot determine with certainty
whether a given Participant will be a Covered Employee with respect to a fiscal year that has not yet been completed, the term
Covered Employee as used herein shall mean only a person designated by the Board, at the time of grant of Performance Awards, as
likely to be a Covered Employee with respect to that fiscal year. If any provision of the Plan or any agreement relating to such
Performance Awards does not comply or is inconsistent with the requirements of Section&nbsp;162(m), such provision shall be construed
or deemed amended to the extent necessary to conform to such requirements.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">13.</TD><TD STYLE="text-align: justify">other SHARE-based awards</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">13.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Grant of Other Share-based Awards</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Other Share-based Awards may be granted either
alone or in addition to or in conjunction with other Awards. Other Share-based Awards may be granted in lieu of other cash or other
compensation to which a Service Provider is entitled from the Company or may be used in the settlement of amounts payable in Shares
under any other compensation plan or arrangement of the Company, including any other Company incentive compensation plan. The Board
shall have the authority to determine the persons to whom and the time or times at which such Awards will be made, the number of
Shares to be granted pursuant to such Awards, and all other terms of such Awards. Unless the Board determines otherwise, any such
Award shall be confirmed by an Award Agreement, which shall contain such provisions as the Board determines to be necessary or
appropriate to carry out the intent of the Plan with respect to such Award.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 59; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">13.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Terms of Other Share-based Awards</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Any Common Stock subject to Awards made under
this <B>Section&nbsp;13</B> may not be sold, assigned, transferred, pledged or otherwise encumbered prior to the date on which
the Shares are issued, or, if later, the date on which any applicable restriction, performance or deferral period lapses.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">14.</TD><TD STYLE="text-align: justify">REQUIREMENTS OF LAW</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">14.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
General</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Company shall not be required to sell or
issue any Shares under any Award if the sale or issuance of such Shares would constitute a violation by the Participant, any other
individual exercising an Option or the Company of any provision of any law or regulation of any governmental authority, including
any federal or state securities laws or regulations. If at any time the Board determines that the listing, registration or qualification
of any Shares subject to an Award upon any securities exchange or under any governmental regulatory body is necessary or desirable
as a condition of, or in connection with, the issuance or purchase of Shares hereunder, no Shares may be issued or sold to the
Participant or any other individual exercising an Option pursuant to such Award unless such listing, registration, qualification,
consent or approval shall have been effected or obtained free of any conditions not acceptable to the Company, and any delay caused
thereby shall in no way affect the date of termination of the Award. Specifically, in connection with the Securities Act, upon
the exercise of any Option or the delivery of any Shares underlying an Award, unless a registration statement under such Act is
in effect with respect to the Shares covered by such Award, the Company shall not be required to sell or issue such Shares unless
the Board has received evidence satisfactory to it that the Participant or any other individual exercising an Option may acquire
such Shares pursuant to an exemption from registration under the Securities Act. The Company may, but shall in no event be obligated
to, register any securities covered hereby pursuant to the Securities Act. The Company shall not be obligated to take any affirmative
action in order to cause the exercise of an Option or the issuance of Shares pursuant to the Plan to comply with any law or regulation
of any governmental authority. As to any jurisdiction that expressly imposes the requirement that an Option shall not be exercisable
until the Shares covered by such Option are registered or are exempt from registration, the exercise of such Option (under circumstances
in which the laws of such jurisdiction apply) shall be deemed conditioned upon the effectiveness of such registration or the availability
of such an exemption. The Committee may require the Participant to sign such additional documentation, make such representations
and furnish such information as it may consider appropriate in connection with the grant of Awards or issuance or delivery of Shares
in compliance with applicable laws, rules and regulations.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">14.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Rule 16b-3</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">During any time when the Company has a class
of equity security registered under Section&nbsp;12 of the Exchange Act, it is the intent of the Company that Awards and the exercise
of Options will qualify for the exemption provided by Rule 16b-3 under the Exchange Act. To the extent that any provision of the
Plan or action by the Board or Committee does not comply with the requirements of Rule 16b-3, it shall be deemed inoperative to
the extent permitted by law and deemed advisable by the Board, and shall not affect the validity of the Plan. In the event that
Rule 16b-3 is revised or replaced, the Board may modify the Plan in any respect necessary to satisfy the requirements of, or to
take advantage of any features of, the revised exemption or its replacement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">15.</TD><TD STYLE="text-align: justify">EFFECT OF CHANGES IN CAPITALIZATION</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">15.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Adjustments for Changes in Capital Structure</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Subject to any required action by the Stockholders,
in the event of any change in the Common Stock effected without receipt of consideration by the Company, whether through merger,
consolidation, reorganization, reincorporation, recapitalization, reclassification, stock dividend, stock split, reverse stock
split, split-up, split-off, spin-off, combination of shares, exchange of shares or similar change in the capital structure of the
Company, or in the event of payment of a dividend or distribution to the Stockholders in a form other than Shares (excepting normal
cash dividends) that has a material effect on the Fair Market Value, appropriate and proportionate adjustments shall be made in
the number and class of shares subject to the Plan and to any outstanding Awards, and in the Option Price, SAR Exercise Price or
Purchase Price per Share of any outstanding Awards in order to prevent dilution or enlargement of Participants&rsquo; rights under
the Plan. For purposes of the foregoing, conversion of any convertible securities of the Company shall not be treated as &ldquo;effected
without receipt of consideration by the Company.&rdquo; If a majority of the Shares which are of the same class as the Shares that
are subject to outstanding Awards are exchanged for, converted into, or otherwise become (whether or not pursuant to a Change in
Control) shares of another corporation (the &ldquo;<B>New Shares</B>&rdquo;), the Board may unilaterally amend the outstanding
Awards to provide that such Awards are for New Shares. In the event of any such amendment, the number of Shares subject to, and
the Option Price, SAR Exercise Price or Purchase Price per Share of, the outstanding Awards shall be adjusted in a fair and equitable
manner. Any fractional share resulting from an adjustment pursuant to this <B>Section 15.1 </B>shall be rounded down to the nearest
whole number and the Option Price, SAR Exercise Price or Purchase Price per share shall be rounded up to the nearest whole cent.
In no event may the exercise price of any Award be decreased to an amount less than the par value, if any, of the stock subject
to the Award. The Board may also make such adjustments in the terms of any Award to reflect, or related to, such changes in the
capital structure of the Company or distributions as it deems appropriate. Adjustments determined by the Board pursuant to this
<B>Section 15.1</B> shall be made in accordance with Section 409A to the extent applicable.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 60; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">15.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Change in Control</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"><B>15.2.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Consequences
of a Change in Control</B></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1.7in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">Subject to the requirements and limitations of
Section 409A if applicable, the Board may provide for any one or more of the following in connection with a Change in Control,
which such actions need not be the same for all Participants:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<B>Accelerated Vesting</B>. The Board may provide in any Award Agreement, or in the event of a Change in Control may take such
actions as it deems appropriate to provide, for the acceleration of the exercisability, vesting or settlement in connection with
such Change in Control of each or any outstanding Award or portion thereof and Shares acquired pursuant thereto upon such terms,
including a Participant&rsquo;s Separation from Service prior to, upon, or following such Change in Control, to such extent as
determined by the Board.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<B>Assumption, Continuation or Substitution</B>. In the event of a Change in Control, the surviving, continuing, successor or purchasing
corporation or other business entity or parent thereof, as the case may be (the &ldquo;<B>Acquiror</B>&rdquo;), may, without the
consent of any Participant, either assume or continue the Company&rsquo;s rights and obligations under each or any Award or portion
thereof outstanding immediately prior to the Change in Control or substitute for each or any such outstanding Award or portion
thereof a substantially equivalent award with respect to the Acquiror&rsquo;s stock, as applicable. For purposes of this <B>Section
15.2.1</B>, an Award denominated in Shares shall be deemed assumed if, following the Change in Control, the Award confers the right
to receive, subject to the terms of the Plan and the applicable Award Agreement, for each Share subject to the Award immediately
prior to the Change in Control, the consideration (whether stock, cash, other securities or property or a combination thereof)
to which a Stockholder on the effective date of the Change in Control was entitled; <I>provided, however</I>, that if such consideration
is not solely common stock of the Acquiror, the Board may, with the consent of the Acquiror, provide for the consideration to be
received upon the exercise or settlement of the Award, for each Share subject to the Award, to consist solely of common stock of
the Acquiror equal in Fair Market Value to the per Share consideration received by Stockholders pursuant to the Change in Control.
If any portion of such consideration may be received by Stockholders pursuant to the Change in Control on a contingent or delayed
basis, the Board may determine such Fair Market Value as of the time of the Change in Control on the basis of the Board&rsquo;s
estimate of the present value of the probable future payment of such consideration. Any Award or portion thereof which is neither
assumed or continued by the Acquiror in connection with the Change in Control nor exercised or settled as of the time of consummation
of the Change in Control shall terminate and cease to be outstanding effective as of the time of consummation of the Change in
Control.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<B>Cash-Out of Awards.</B> The Board may, without the consent of any Participant, determine that, upon the occurrence of a Change
in Control, each or any Award or a portion thereof outstanding immediately prior to the Change in Control and not previously exercised
or settled shall be canceled in exchange for a payment with respect to each vested Share (and each unvested Share, if so determined
by the Board) subject to such canceled Award in (i) cash, (ii) stock of the Company or of a corporation or other business entity
a party to the Change in Control or (iii) other property which, in any such case, shall be in an amount having a Fair Market Value
equal to the Fair Market Value of the consideration to be paid per Share in the Change in Control, reduced by the exercise or purchase
price per Share, if any, under such Award. If any portion of such consideration may be received by Stockholders pursuant to the
Change in Control on a contingent or delayed basis, the Board may determine such Fair Market Value as of the time of the Change
in Control on the basis of the Board&rsquo;s estimate of the present value of the probable future payment of such consideration.
In the event such determination is made by the Board, the amount of such payment (reduced by applicable withholding taxes, if any)
shall be paid to Participants in respect of the vested portions of their canceled Awards as soon as practicable following the date
of the Change in Control and in respect of the unvested portions of their canceled Awards in accordance with the vesting schedules
applicable to such Awards. For avoidance of doubt, if the amount determined pursuant to this <B>Section 15.2.1(c) </B>for an Option
or SAR is zero or less, the affected Option or SAR may be cancelled without any payment therefore.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 61; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"><B>15.2.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Change
in Control Defined</B></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1.7in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">Unless otherwise provided in the applicable Award
Agreement, a &ldquo;<B>Change in Control</B>&rdquo; means the consummation of any of the following events:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
the acquisition, other than from the Company, by any individual, entity or group (within the meaning of Section&nbsp;13(d)(3) or
Section&nbsp;14(d)(2) of the Exchange Act), other than the Company or any subsidiary, affiliate (within the meaning of Rule 144
promulgated under the Securities Act) or employee benefit plan of the Company, of beneficial ownership (within the meaning of Rule
13d-3 promulgated under the Exchange Act) of more than 50% of the combined voting power of the then outstanding voting securities
of the Company entitled to vote generally in the election of directors (the &ldquo;<B>Voting Securities</B>&rdquo;); or</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
a reorganization, merger, consolidation or recapitalization of the Company (a &ldquo;<B>Business Combination</B>&rdquo;), other
than a Business Combination in which more than 50% of the combined voting power of the outstanding voting securities of the surviving
or resulting entity immediately following the Business Combination is held by the persons who, immediately prior to the Business
Combination, were the holders of the Voting Securities; or</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
a complete liquidation or dissolution of the Company, or a sale of all or substantially all of the assets of the Company; or</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
during any period of 12 consecutive months, the Incumbent Directors cease to constitute a majority of the Board; &ldquo;<B>Incumbent
Directors</B>&rdquo; means individuals who were members of the Board at the beginning of such period or individuals whose election
or nomination for election to the Board by the Stockholders was approved by a vote of at least a majority of the then Incumbent
Directors (but excluding any individual whose initial election or nomination is in connection with an actual or threatened proxy
contest relating to the election of directors).</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Notwithstanding the foregoing, if it is determined
that an Award is subject to the requirements of Section&nbsp;409A and payable upon a Change in Control, the Company will not be
deemed to have undergone a Change in Control for purposes of the Plan unless the Company is deemed to have undergone a &ldquo;change
in control event&rdquo; pursuant to the definition of such term in Section&nbsp;409A.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">15.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Adjustments</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Adjustments under this <B>Section&nbsp;15</B>
related to Shares or other securities of the Company shall be made by the Board. No fractional Shares or other securities shall
be issued pursuant to any such adjustment, and any fractions resulting from any such adjustment shall be eliminated in each case
by rounding downward to the nearest whole Share.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">16.</TD><TD STYLE="text-align: justify">No Limitations on Company</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The making of Awards shall not affect or limit
in any way the right or power of the Company to make adjustments, reclassifications, reorganizations or changes of its capital
or business structure or to merge, consolidate, dissolve or liquidate, or to sell or transfer all or any part of its business or
assets.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 62; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">17.</TD><TD STYLE="text-align: justify">TERMS APPLICABLE GENERALLY TO AWARDS</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">17.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Disclaimer of Rights</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">No provision in the Plan or in any Award Agreement
shall be construed to confer upon any individual the right to remain in the employ or service of the Company or any Affiliate,
or to interfere in any way with any contractual or other right or authority of the Company or any Affiliate either to increase
or decrease the compensation or other payments to any individual at any time, or to terminate any employment or other relationship
between any individual and the Company or any Affiliate. In addition, notwithstanding anything contained in the Plan to the contrary,
unless otherwise provided in the applicable Award Agreement, no Award shall be affected by any change of duties or position of
the Participant, so long as such Participant continues to be a Service Provider. The obligation of the Company to pay any benefits
pursuant to the Plan shall be interpreted as a contractual obligation to pay only those amounts described herein, in the manner
and under the conditions prescribed herein. The Plan shall in no way be interpreted to require the Company to transfer any amounts
to a third party trustee or otherwise hold any amounts in trust or escrow for payment to any Participant or beneficiary under the
terms of the Plan.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">17.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Nonexclusivity of the Plan</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Neither the adoption of the Plan nor the submission
of the Plan to the Stockholders for approval shall be construed as creating any limitations upon the right or authority of the
Board or its delegate to adopt such other compensation arrangements as the Board or its delegate determines desirable.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">17.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Withholding Taxes</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Company or an Affiliate, as the case may
be, shall have the right to deduct from payments of any kind otherwise due to a Participant any federal, state or local taxes of
any kind required by law to be withheld (i)&nbsp;with respect to the vesting of or other lapse of restrictions applicable to an
Award, (ii)&nbsp;upon the issuance of any Shares upon the exercise of an Option or SAR or (iii)&nbsp;otherwise due in connection
with an Award. At the time of such vesting, lapse or exercise, the Participant shall pay to the Company or the Affiliate, as the
case may be, any amount that the Company or the Affiliate may reasonably determine to be necessary to satisfy such withholding
obligation. Subject to the prior approval of the Board, the Participant may elect to satisfy such obligations, in whole or in part,
(i)&nbsp;by causing the Company or the Affiliate to withhold the minimum required number of Shares otherwise issuable to the Participant
as may be necessary to satisfy such withholding obligation or (ii)&nbsp;by delivering to the Company or the Affiliate Shares already
owned by the Participant. The Shares so delivered or withheld shall have an aggregate Fair Market Value equal to such withholding
obligations. The Fair Market Value of the Shares used to satisfy such withholding obligation shall be determined by the Company
or the Affiliate as of the date that the amount of tax to be withheld is to be determined. A Participant who has made an election
pursuant to this <B>Section&nbsp;17.3</B> may satisfy his or her withholding obligation only with Shares that are not subject to
any repurchase, forfeiture, unfulfilled vesting or other similar requirements.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">17.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Other Provisions; Legends</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Each Award Agreement may contain such other
terms not inconsistent with the Plan as may be determined by the Board. Any stock certificates for any Shares issued under the
Plan shall be subject to such stop-transfer orders and other restrictions as the Company in its sole discretion may deem advisable
under the rules, regulations and other requirements of the SEC, any securities exchange on which the Common Stock may then be listed
and any applicable federal or state securities law, and the Company in its sole discretion may cause a legend or legends to be
placed on such certificates to make appropriate reference to such restrictions.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">17.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Severability</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">If any provision of the Plan or any Award Agreement
shall be determined to be illegal or unenforceable by any court of law in any jurisdiction, the remaining provisions hereof and
thereof shall be severable and enforceable in accordance with their terms, and all provisions shall remain enforceable in any other
jurisdiction.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 63; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">17.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Governing Law</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Plan shall be governed by and construed
in accordance with the internal laws of the Commonwealth of Massachusetts without regard to the principles of conflicts of law
thereof or principles of conflicts of laws of any other jurisdiction that could cause the application of the laws of any jurisdiction
other than the Commonwealth of Massachusetts. For purposes of resolving any dispute that arises directly or indirectly in connection
with the Plan, each Participant, by virtue of receiving an Award, shall be deemed to have submitted to and consented to the exclusive
jurisdiction of the Commonwealth of Massachusetts and to have agreed that any related litigation shall be conducted solely in the
courts of Middlesex County, Massachusetts or the United States District Court for the District of Massachusetts, where the Plan
is made and to be performed, and no other courts.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">17.7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Section&nbsp;409A</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Plan is intended to comply with Section&nbsp;409A,
and, accordingly, to the maximum extent permitted, the Plan shall be interpreted and administered to be in compliance therewith.
Any payments described in the Plan that are due within the &ldquo;short-term deferral period&rdquo; as defined in Section&nbsp;409A
shall not be treated as deferred compensation unless applicable laws require otherwise. Notwithstanding anything to the contrary
in the Plan, to the extent required to avoid accelerated taxation and tax penalties under Section&nbsp;409A, amounts that would
otherwise be payable and benefits that would otherwise be provided pursuant to the Plan during the six-month period immediately
following the Participant&rsquo;s Separation from Service shall instead be paid on the first payroll date after the six-month anniversary
of the Participant&rsquo;s Separation from Service (or the Participant&rsquo;s death, if earlier). Notwithstanding the foregoing,
neither the Company nor the Committee shall have any obligation to take any action to prevent the assessment of any excise tax
or penalty on any Participant under Section&nbsp;409A and neither the Company nor the Board shall have any liability to any Participant
for such tax or penalty.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">17.8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Separation from Service</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Board shall determine the effect of a Separation
from Service upon Awards, and such effect shall be set forth in the applicable Award Agreement. Without limiting the foregoing,
the Board may provide in the Award Agreements at the time of grant, or any time thereafter with the consent of the Participant,
the actions that will be taken upon the occurrence of a Separation from Service, including accelerated vesting or termination,
depending upon the circumstances surrounding the Separation from Service.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">17.9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Transferability of Awards</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"><B>17.9.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Transfers
in General</B></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1.7in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">Except as provided in <B>Section&nbsp;17.9.2</B>,
no Award shall be assignable or transferable by the Participant to whom it is granted, other than by will or the laws of descent
and distribution, and, during the lifetime of the Participant, only the Participant personally (or the Participant&rsquo;s personal
representative) may exercise rights under the Plan.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"><B>17.9.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Family
Transfers</B></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1.7in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">If authorized in the applicable Award Agreement,
a Participant may transfer, not for value, all or part of an Award (other than Incentive Stock Options) to any Family Member. For
the purpose of this <B>Section&nbsp;17.9.2</B>, a &ldquo;not for value&rdquo; transfer is a transfer which is (i)&nbsp;a gift,
(ii)&nbsp;a transfer under a domestic relations order in settlement of marital property rights or (iii)&nbsp;a transfer to an entity
in which more than 50% of the voting interests are owned by Family Members (or the Participant) in exchange for an interest in
that entity. Following a transfer under this <B>Section&nbsp;17.9.2</B>, any such Award shall continue to be subject to the same
terms as were applicable immediately prior to transfer. Subsequent transfers of transferred Awards are prohibited except to Family
Members of the original Participant in accordance with this <B>Section&nbsp;17.9.2</B> or by will or the laws of descent and distribution.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">17.10.&nbsp;&nbsp;&nbsp;
Dividends and Dividend Equivalent Rights</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">If specified in the Award Agreement, the recipient
of an Award may be entitled to receive, currently or on a deferred basis, dividends or dividend equivalents with respect to the
Common Stock or other securities covered by an Award; <I>provided</I>, <I>however</I>, that no dividends or dividend equivalents
may be paid or granted with respect to an Option or SAR or the Shares subject thereto until such Award has been exercised. The
terms of a dividend equivalent right may be set forth in the Award Agreement. Dividend equivalents credited to a Participant may
be paid currently or may be deemed to be reinvested in additional Shares or other securities of the Company at a price per unit
equal to the Fair Market Value on the date that such dividend was paid to Stockholders. Notwithstanding the foregoing, in no event
will dividends or dividend equivalents on any Award that is subject to vesting conditions (including the achievement of performance
criteria) be payable before the Award has become vested.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 64; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">17.11.&nbsp;&nbsp;&nbsp;
Data Protection</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">A Participant&rsquo;s acceptance of an Award
shall be deemed to constitute the Participant&rsquo;s acknowledgement of and consent to the collection and processing of personal
data relating to the Participant so that the Company and the Affiliates can fulfill their obligations and exercise their rights
under the Plan and generally administer and manage the Plan. This data shall include data about participation in the Plan and Shares
offered or received, purchased or sold under the Plan and other appropriate financial and other data (such as the date on which
the Awards were granted) about the Participant and the Participant&rsquo;s participation in the Plan.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">17.12.&nbsp;&nbsp;&nbsp;
Plan Construction</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">In the Plan, unless otherwise stated, the following
uses apply: (i)&nbsp;references to a statute or law refer to the statute or law and any amendments and any successor statutes or
laws, and to all valid and binding governmental regulations, court decisions and other regulatory and judicial authority issued
or rendered thereunder, as amended, or their successors, as in effect at the relevant time; (ii)&nbsp;in computing periods from
a specified date to a later specified date, the words &ldquo;from&rdquo; and &ldquo;commencing on&rdquo; (and the like) mean &ldquo;from
and including,&rdquo; and the words &ldquo;to,&rdquo; &ldquo;until&rdquo; and &ldquo;ending on&rdquo; (and the like) mean &ldquo;to
and including&rdquo;; (iii)&nbsp;indications of time of day shall be based upon the time applicable to the location of the principal
headquarters of the Company; (iv)&nbsp;the words &ldquo;include,&rdquo; &ldquo;includes&rdquo; and &ldquo;including&rdquo; (and
the like) mean &ldquo;include, without limitation,&rdquo; &ldquo;includes, without limitation&rdquo; and &ldquo;including, without
limitation&rdquo; (and the like), respectively; (v)&nbsp;all references to articles and sections are to articles and sections in
the Plan; (vi)&nbsp;all words used shall be construed to be of such gender or number as the circumstances and context require;
(vii)&nbsp;the captions and headings of articles and sections have been inserted solely for convenience of reference and shall
not be considered a part of the Plan, nor shall any of them affect the meaning or interpretation of the Plan or any of its provisions;
(viii)&nbsp;any reference to an agreement, plan, policy, form, document or set of documents, and the rights and obligations of
the parties under any such agreement, plan, policy, form, document or set of documents, shall mean such agreement, plan, policy,
form, document or set of documents as amended from time to time, and any and all modifications, extensions, renewals, substitutions
or replacements thereof; and (ix)&nbsp;all accounting terms not specifically defined shall be construed in accordance with GAAP.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: middle">
    <TD STYLE="width: 8%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; width: 34%"><FONT STYLE="font-size: 10pt">Adopted by the Board:&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; width: 58%"><FONT STYLE="font-size: 10pt">March 31, 2017</FONT></TD></TR>
<TR STYLE="vertical-align: middle">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: middle">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; font-weight: bold"><FONT STYLE="font-size: 10pt">Approved by the Stockholders:&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 10pt">_________________________,
    2017</FONT></TD></TR>
<TR STYLE="vertical-align: middle">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: middle">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; font-weight: bold"><FONT STYLE="font-size: 10pt">Scheduled Termination Date:&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 10pt">_________________________,
    2027</FONT></TD></TR>
</TABLE>


<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 65; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img src="card_1.jpg"></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 66 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img src="card_2.jpg"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>cheung_sig.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cheung_sig.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_VP!#  ," @," @,# @,# P,#! <%! 0$
M! D&!P4'"@D+"PH)"@H,#1$.# P0# H*#A0/$!$2$Q,3"PX4%A02%A$2$Q+_
MVP!# 0,# P0$! @%!0@2# H,$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2
M$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A+_P  1"  > '@# 2(  A$! Q$!_\0
M'    04! 0$             !P $!08( P()_\0 +1   00!! $$ 0,$ P
M     @$#! 4&  <1$B$($R(Q%#)!4146(R1A@8/_Q  4 0$
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MDX[53)]?.F5E>_-J4-*^2Y% G(G9$$O:)4Y#E$1%Z\<HFI'2T'AMEMEI&V@
M&T3A $41$_ZUD^CK*_-O4QN9MOCTF/ P&2S#R+)(U>RK!6U@HI#D0T<'A%C\
M165?Z?(C56R5$5Q"U1;.2FJJ8=4+!30CN%&&02BVKB"O5#5$54'GCE415XUG
M_P!(>U=E08]#R_+W*];.?0QZV&Q">-]!91YV3)DO.F *<B3*?=><X!!'@!3M
HPI$&AHL5F#%9C0F6H\>.V+;++0( -@*<"(BGA$1$1$1-+772T'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>card_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 card_1.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_X1"617AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    F    <@$R  (    4    F(=I  0    !    K    -@   $L
M 0   2P    !061O8F4@4&AO=&]S:&]P($5L96UE;G1S(#$Q+C @5VEN9&]W
M<P R,#$W.C T.C(U(#$R.C P.C4Q   #H $  P    $  0  H ( !     $
M  ,6H , !     $   /H          8! P #     0 &   !&@ %     0
M 28!&P %     0   2X!*  #     0 "   " 0 $     0   38" @ $
M 0  #U@         2     $   !(     ?_8_^  $$I&248  0$! 2P!+
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M,E)Q@9$C,T)48I*4H:*QP=+P)#0U4V-R=(*RX0861)/")4-SE?'_Q  4 0$
M                    _\0 %!$!                     /_:  P# 0 "
M$0,1 #\ _5-8O^8&^F.V_1EA2,7$7FH,'JQR/2*VJ^+6Q=7%XM%NH!>-90D/
MX9S.7M6F1_OK0:W^9&Y5%HX4I$E6_9@#X_IJ5G;R'U.(8MEO.I&)+;;K:E+$
MC,<4<^?4>R<Y.Q;](@)F4@E1N$XBKF#[%ISK=V>RM"W%/6ELR1DA31DJ'.<A
M%!;:45MI4I)02)*3J.RNJ4H%*4H,"[8";Q:\*\2E$Y8S.?FCE43-JAM:'$(=
M"TY G>$3ZNS6I;QZV#[V*T>6<1F%,@$R1EB4#RY]=1*N;7"5&SN%:*\=C+Z7
MF]8H.>AYQCNRDY3OWQ_\KIJU6@MN W6+%(!=>.?60?MRJRY>V:4#_IX4F.19
M^_VGU&O.GVI5A5LT@F#FIC,Q^_RTH)1=W1B 8_\ &H3U^YH;JZ#:C*I /_:5
M]VHD[0M,02K9I0%0)*F(ZN2_15X^#1"3T,=0X>4_WH);!QUQM>^G$%1XI'(=
M@JS4-J;<H/12U@!SW<1/HJ:@4I2@4I2@4I2@4I2@Q7RL72R Y..1 7&7HBN,
M3F227<, $PLG/7E2X<4F\<QM6>'$2"ID%1$ZSB]'GJ-EU4K#C>SU0G+ TD0>
MT8Z#H*=*50'8! B%_=[*[2'(C"\3IFE?;!TJMOWEI.,;,!C/$T(D$?M- *U&
M-HM)90DH2" !"5( GL&*@J)WA2A4/Y9$PY]6'/G7@2M*,DO8N1(7U>:K_A-D
MJ( DCX:,_I43M-A1@:D@#C09G^:@ZV9.Z<Q!8X\@K%.@ZZN5#:W"+E"E-Z Q
MXP/U$U-0*4I0*4I0*4I0*4I08SSSG2'@;24)5XV^=!.<2 $=7('OJ2U<2M!%
MY;J:<Q:-K<<'KPCNJTYL]AQPK(.*29RUKGP9;_"TP\NZ@Y"K3(@/:SHYR^S/
M\12;/R7LCY+G+\>FND[-82DCB@CL[JE39L)43@!G*#F/500IZ(1*0[$]2QG^
M#7(<LVUA0#P4/@N5;-K;JF6&C/6@4-LP3)9;)[4B@]9>0\DJ1BC3B24_74E<
MMMH:3A:0E"9F$B*ZH%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*J*MU%95@.
MI/MZAYLOQ%<"T(CA7K[Y6==?JH+U*H]%5F<"I(]\KUT^JO3:'3"N)/\ J5_C
MG07:5G7*$V["G74N!"!)PON*/J DU53?VN_ 2'\8X@"7H,Z>YCNH-NE9:=LL
M*6I(GAB>!S[M<^&V,&*#R'B.:DQ'B4&M2LH[:8#A1A5(DYMN1 $ZX.VJR]MJ
M4M2FG&DM) 40JW>*HR!Y"<SI0;U*Q;?;!QX'U-J40("&G4B3IF4GD16MB>GV
MM$3Y9[J"2E9CMU?!UP(MT! &4I49//[?FK@7>TBH?D[<'X"J#6I62;O:,)BV
M1V\*OQU58L7[MUY0N64(;PR" 9GJSH,-RP94VS=NINGENO*2I+8Q>Z5F>$F,
MHU%5K:RMG74I-MM%"E*B%HPIUZ\&E?3;' -@W/):X^,JLQ>)M)<WK 25J3!8
M$Y'KW@%!Y:;(0VZE3EDXH!&&%N(()F9R$SRJP;-N,MC(/\Z:E3=V=NL%+*D*
MC+-([(UJ^VZI:H++B!UJCOH,XV+,&-DH)$0,2<Z#9K+J7T*L&6.'V-<A6?FC
M*,JUJ\6D+0I*A*5"".L4'SSG^'PM-LI-S@,)2[A0WA5EJ)1J3Z.RNQL.+Y)!
M:5;@I)0I*02 F#HGF<]>ZMDVS1;:;*.%HA2!)R(TKO<HW^^P^RX<&*>4S%!@
MW.RSOE!FS&"3! 1$3VB:#99Q3T0P"(&%LR.<UMJ945$A]T3R$9?-7FX5[X>^
MCW4&*C9BL22JSX9$C"W/X[Z\;V4MQ:4JM@V ,U%+<$^KS"MO<*]\/?1[J;A7
MOA[Z/=00-[*L@A(7:LE0&9PZFNO!5C[T9^+5P" !)/::4&5<;.0ER+?9MFXB
M-5N%!GS!)J/9H9Z7L]ZW9#";BT6XI"3E,MD3UQ)S[36S6:VRFVVCL]AN<#5H
MZA,ZP"T*!LY]#&SFBL.$*<6D8&U+]TK6 8';4HVFP4X@B[B)_-79]6&N=DF+
M)H8HE;F77Q*ITA.,CI[8S(B!EV4'?A%B)PW/R9S[M>#:=N2!ANO3:NC_ (UX
MJX0#GM!M(G0X:\2^)GI[:@.6$4':]I,(22471@ \-JX=?Y:>$K<KPA-R3('Y
MLY'KPQ7)?1(_+VQ*<O%S[:\-PA)*5;1:!G0X9%!+TYG$A.%^5:>P+C6,S&7I
MJU5%%TTA8+E^TH8<TG"/34_3+;/\H:RR/$*">E0INK=2@E+S9)R "A4U I2E
M J%ZX0RJ%)=/"5<#:E#+S#7LJ:H'51=L#?800KV/#./T\HH(4[384V7 W=E,
M@?FKLYSRPSRJ)#R;C:UHX@.)2;=[)QM2#XS7)0!JPE?YU-Q.'X/M>7S_ -JK
MMF=I6!*]X>BN\9$3Q-9QRH)-D3T%N"(QKGXRJGBYQ'B9P\N$]]4]GL(?V>R'
M$DA+BU A920<2NJO!L]L2CHSI3D)-TH_6:"[%SEQ,_%/?0"ZG-3$3Y)[ZI]"
M 20+=[D<KM??7@L$R#T=^<_]6OJ\]!=(N8\9F?W3WT(NL(A3&+]TQ]=5#:"%
M3;.+D88-RHR/2:\38I"0!;.#"92.DJUS[>V@N1<R>)GXI]'.I&@Z =Z4$\L(
M(K-\'H$!-N^!'*[6(^>I&+8V[I6U;NDB0,=RI0S["2*#1I4!=?Y6X_W!4R22
MD$B#S%![2E*!43B7#<-*2&]V K%(XNR*BV@PEUG%N \X@@I3CP\^NN%V;8NT
MJ3;XDN!6\7C(B>SG,T$R4O W$AKB/! .>7NJJI2I.U+%+@0%BU=!"-)Q-:=E
M>= :4V^VJTA 5B0-Z>,QY\JY8;#6T;!(;W?Y,\2C%B@E34Y\Z")I+*]F,"X0
MZI.]7 ;<*,\2M8(FNDOL*1DQ>"!$;XZ?'KNR6A&S6BNYZ.-XOBE(GB5UBI2\
MT#)VF(G0J;[J"!M]E<)2S>2H@QOLY^/VU8W0!(#%X0#KO]?IU[O6QBG:(R'E
M(RY3IUUQOF0,]J#JDJ;[J"R+1H&07O\ >7WT%HV/=/:1[<OOJ-FY81(5>H=.
MO$I(('HBO7KRV+*L-RU)28PN)GT2:#OHC6>;V?[9??4>Z;Z1N<-S&$+Q[U>'
M729UJLJ[0+6U&]5O4K3C3O48HYXN*(\Q)\]7V[EAQ82V^TM1Y)6":#@6C8GB
M?S_;+[Z]%HT"2"]F9]N7WU/2@B:MT-+Q)+I,1Q.*4/434M*4"E*4"J3WZ:M/
MX=[^IJKM4GOTU:?P[W]35!4MV5/;,:2E800XLYJB>)78:\38.IF+A/QQGI\'
MLJ-%V]:6R6FV7M\AQ84#;.+$%1,@@0>7.O#M6^C)DGSV;W=02] <"82^@'2<
M8^[0V#BE E](SSASEEV5$=J7TF&C$Y39O9_-73.T[M2H=0I C46+RLZ"WT%K
M*+IP*ZY3/U5[X/0O(7+I/7PSV\NVJKNT;@*06PM7(S8/"*L-;0 42\+A>4#!
M8O)^PT'?@Q!20IYXCSCNKMBP#3R7 \ZK"2<)B,Q'57GA-C]7>?)'?NT\)L?J
M[SY([]V@MXT^4GUTQH\I/KK%5M.Z#JPVTYN\1PE5D],5YX4O(]J5\B>H-O&C
MRD^NF-'E)]=92=HO%(*BX#&8\'O&*]\(.^6Y_P"N>H-3>(\M/KKH&1(TK%9V
MC<9A86D)R218/&1]E6T;292A(+=V2!!(M'1_QH+]4GOTU:?P[W]35/";'ZN\
M^2._=J%I]-UM=E;2'@AIAQ*BXTI$%2FR!Q 3H=*#_]D
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                  #_X1"7:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[
MOR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B \>#IX;7!M971A
M('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @
M0V]R92 U+C(M8S P,2 V,RXQ,SDT,SDL(#(P,3 O,3 O,3(M,#@Z-#4Z,S @
M(" @(" @("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO
M<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z1&5S8W)I<'1I
M;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+R(@>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]M;2\B('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(B!X;6QN<SIS=$5V=#TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C
M(B!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B
M('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(@>&UL
M;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q
M+C O(B!X;7 Z0W)E871E1&%T93TB,C Q-RTP-"TQ.%0Q-CHU-SHP-BTP-#HP
M,"(@>&UP.DUE=&%D871A1&%T93TB,C Q-RTP-"TR-50Q,CHP,#HU,2TP-#HP
M,"(@>&UP.DUO9&EF>41A=&4](C(P,3<M,#0M,C54,3(Z,# Z-3$M,#0Z,# B
M('AM<#I#<F5A=&]R5&]O;#TB061O8F4@26Y$97-I9VX@0T,@,C Q-R H5VEN
M9&]W<RDB('AM<$U-.DEN<W1A;F-E240](GAM<"YI:60Z,D8R03 Y-4)$,#(Y
M13<Q,3DU1D9",3%!.3@W1CA#0D8B('AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)
M1#TB>&UP+F1I9#HX,T$U0D,V,S-$0CE%,#$Q.#9%-CDQ,S,V,C$U131!-B(@
M>&UP34TZ1&]C=6UE;G1)1#TB>&UP+FED.C R,S8Y-6$U+3=E,S8M968T8RUB
M,CDV+3@W.6%D,&4R-V%F-"(@>&UP34TZ4F5N9&ET:6]N0VQA<W,](G!R;V]F
M.G!D9B(@9&,Z9F]R;6%T/2)I;6%G92]J<&5G(B!P9&8Z4')O9'5C97(](D%D
M;V)E(%!$1B!,:6)R87)Y(#$U+C B('!D9CI4<F%P<&5D/2)&86QS92(@<&AO
M=&]S:&]P.D-O;&]R36]D93TB,R(@<&AO=&]S:&]P.DE#0U!R;V9I;&4](G-2
M1T(@245#-C$Y-C8M,BXQ(CX@/'AM<$U-.D1E<FEV961&<F]M('-T4F5F.FEN
M<W1A;F-E240](G5U:60Z96(X,CDR-&8M-&-D,2TT,C$W+6(V838M,#@T96$S
M8C-C9F-F(B!S=%)E9CID;V-U;65N=$E$/2)X;7 N:60Z,#(S-CDU834M-V4S
M-BUE9C1C+6(R.38M.#<Y860P93(W868T(B!S=%)E9CIO<FEG:6YA;$1O8W5M
M96YT240](GAM<"YD:60Z.#-!-4)#-C,S1$(Y13 Q,3@V138Y,3,S-C(Q-44T
M038B('-T4F5F.G)E;F1I=&EO;D-L87-S/2)P<F]O9CIP9&8B+SX@/'AM<$U-
M.DAI<W1O<GD^(#QR9&8Z4V5Q/B \<F1F.FQI('-T179T.F%C=&EO;CTB8V]N
M=F5R=&5D(B!S=$5V=#IP87)A;65T97)S/2)F<F]M(&%P<&QI8V%T:6]N+W@M
M:6YD97-I9VX@=&\@87!P;&EC871I;VXO<&1F(B!S=$5V=#IS;V9T=V%R94%G
M96YT/2)!9&]B92!);D1E<VEG;B!#0R R,#$W("A7:6YD;W=S*2(@<W1%=G0Z
M8VAA;F=E9#TB+R(@<W1%=G0Z=VAE;CTB,C Q-RTP-"TQ.%0Q-CHU-SHP-BTP
M-#HP,"(O/B \<F1F.FQI('-T179T.F%C=&EO;CTB8V]N=F5R=&5D(B!S=$5V
M=#IP87)A;65T97)S/2)F<F]M(&%P<&QI8V%T:6]N+W!D9B!T;R!A<'!L:6-A
M=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P(B\^(#QR9&8Z;&D@<W1%=G0Z86-T
M:6]N/2)D97)I=F5D(B!S=$5V=#IP87)A;65T97)S/2)C;VYV97)T960@9G)O
M;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+VIP
M96<B+SX@/')D9CIL:2!S=$5V=#IA8W1I;VX](G-A=F5D(B!S=$5V=#II;G-T
M86YC94E$/2)X;7 N:6ED.C)&,D$P.35"1# R.44W,3$Y-49&0C$Q03DX-T8X
M0T)&(B!S=$5V=#IW:&5N/2(R,#$W+3 T+3(U5#$R.C P.C4Q+3 T.C P(B!S
M=$5V=#IS;V9T=V%R94%G96YT/2)!9&]B92!0:&]T;W-H;W @16QE;65N=',@
M,3$N,"!7:6YD;W=S(B!S=$5V=#IC:&%N9V5D/2(O(B\^(#PO<F1F.E-E<3X@
M/"]X;7!-33I(:7-T;W)Y/B \+W)D9CI$97-C<FEP=&EO;CX@/"]R9&8Z4D1&
M/B \+W@Z>&UP;65T83X@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" \/WAP86-K
M970@96YD/2)W(C\^_^T8+E!H;W1O<VAO<" S+C  .$))300$       /' %:
M  ,;)4<< @   @   #A"24T$)0      $,W/^GVHQ[X)!7!VKJ\%PTXX0DE-
M!#H      ),    0     0      "W!R:6YT3W5T<'5T    !0    !#;')3
M96YU;0    !#;')3     %)'0D,     26YT965N=6T     26YT90    !#
M;')M     $UP0FQB;V]L 0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP
M<FEN=&5R3F%M951%6%0    !    .$))300[      &R    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    2     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M  H  0         ".$))30/U      !( "]F9@ ! &QF9@ &       ! "]F
M9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    ! "T    &
M       !.$))30/X      !P  #_____________________________ ^@
M    _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@  #A"24T$
M"       $     $   )    "0      X0DE-!!X       0     .$))300:
M      .Y    !@             ,#   "80   !" $$ 3@!) $L 00 @ %0
M2 !% %( 00!0 $4 50!4 $D 0P!3 "  20!. $, +@!? %  .0 P #8 -P X
M %\ ,0 W "@ (P S #$ ,0 R #( *0 @ "T ( !0 $, ,P @ $8 20!. $$
M3  @ '  <@!O '@ >0 @ &, 80!R &0 +0 Q     0
M       !              F$   ,#                      !
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M;&]N9P  # P     4F=H=&QO;F<   F$     W5R;%1%6%0    !
M;G5L;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$58
M5     $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$58
M5     $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@
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MA<1^D=_9.W^7_P"!IFXY$>QW+>;GGD#?S^YM24VDE4]!T3Z9F)CUG\_0#?\
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M?I7'3Z(C<DIM[<F/ILF/W#S_ -N)@W*G5]<3K[#Q_P!N*M]A8 1Z','^>?\
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M:'ADG:32\F.T^\)OVAU'3]"?/]!9_P"E$E.GO;XI;V^*SAGYL:L>#X?9G_\
MI=+[=F?N/_\ 85__ *724Z.]OBGYU"S&YV?J#6X1]$C'L,_^#-VH[>H@- ./
MD$@?Z)R2FZJ=O_*^-_X7R/\ J\1+]I-_[CY'_;103DNLSF9(Q[Q7138Q\UD$
MNL?C^FUC3_.?S5F[9]!)3__9.$))300A      ![     0$    8 $$ 9 !O
M &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  10!L &4 ;0!E &X = !S
M'0!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $4 ; !E &T 90!N
M '0 <P @ #$ ,0 N #     ! #A"24T$!@      !P '     0$ _]L 0P #
M @(# @(# P(# P,# P0'!00$! 0)!@<%!PH)"PL*"0H*# T1#@P,$ P*"@X4
M#Q 1$A,3$PL.%!84$A81$A,2_]L 0P$# P,$! 0(!04($@P*#!(2$A(2$A(2
M$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2_\
M$0@#Z ,6 P$B  (1 0,1 ?_$ !T  0 " P$! 0$            %!@0'" ,!
M @G_Q !9$  ! P0! P$#! H/!@,' @<! @,$  4&$1('$R$Q"!0B%3)!40D6
M&",U6&&5L=,7&3A"4U5Q<W9WDY2RTN,D,U)7@9%BEM$E-#9#<G6S=(*AHB:C
M*&.2_\0 %0$! 0                    '_Q  9$0$! 0$! 0
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MK/%M4= ^;\[:AH^G+UK LWLH8)BK-H3B;F18\+"Y.7#<MMZ>84VF8XVX^V5
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M[:R'G(UN@N1#(0Z68K32 ^&4+/9"E.H"OB\*'E0) 35HRKJM]K3MT:,2.X[
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MVK>RF0U'>+8$="4;20D_-(0H$#0(2KZC64B3B^5N.6[C:;HKM-NNQELH= 2
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M<;"_4D>E;NZ*9EEL3K9U!Z;9ID?VZ1,8MUNN,*\NP&8LECWD.;C/AD);4K2
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MN:9*)*5ON*"DR%]QY(VKX0I9*M)UHDD:W7A&Z:8_#D-28L:6U+:?6_[VFY2
M^M:PV%\W>YS6E09:VE1*3VT['@5:*4%75TTQU2'$B"ZDK<#B7$3'DN,J#BW
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MJD_"%^J1Z:\5NJE!K(>S?T]9MF)0K;CT2VIPF=$FVE^$A++R78R2EON. <G
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MDKGPXK62$*)"?2LN[NXA8UW"3-CVDOO/-Q;B$(;4X/?'&FOOH]0E9#7+?J$
M^=5G0(V,6ZX-W&VILT>9>AIJ0RIM*IG@;XD?/.DI]-_-'U"@ICG5FX6RXWUA
MZUM3H]G?F/O/"0&"S$84R"$IXJYN??20"4@\3M0\;\'>M%UM:4LW''%W">]+
MNY9CVCWB251(,E+).DL$]Y1<0 D\4'1)6G8%7N5"QAIN0_-:LB&[@@A]QT-@
M2$O$?.)^<%E(_P#JXCUU6%?+3AD&Y6]N_P 2R,SKQ<%^XA]M 7(E%')?#?DJ
M*6]GZ]#>R105N9UAGQ(C\HXXV8S#-WEDFY@*]TMSS;3B]=LCN+*R4(WK21R6
MDG0QKGUGNCZIZ,8QQQU$6Y&$U,G^\,QUJ:GMPW0ISL\ HJ6LHX*7L(45<2.)
MOT>V8]=8[Z(D>T3&6TR8CZ6TMN)2'E!4AI6O3FH K2?4@;K#FV3#VA-DW"+8
M6TW8(]Z<=#:1)YJVDJ)\$J4@$'U)2/JH)Z:P]+@NM19*X3[B-)?;0E:FS]8"
M@0?^HK5%AZGW:T89!G7<*R*8[8W[[/6XMJ&&(S/$+0T$HTM9)) 5H>O):=IW
ML&W9'C<8W2/;KA:F/DF6&KBA+R$!A]P!8"_J4KF#^4GZP:_4[#L<G,0(MQM%
MI>9A@MPF78R"EL$ E" 1Z'B"0/!XC?I08^39@K'GK,4Q N%<Y"6GIKZUMM1>
M12$\BEM9"E%6D\N*=C16DE(-+@]:W7+5!FM6A<J!N+&DR7YR$/B0[!3+&FTM
MA*D\%H!4"GXB=(TG=7B\?:[>I,1%R;MMTD1'67F6BIMU3)6I/!WB3X&PE0/Y
M 1Y JN3L(PR==HE_?E6=,*P\&$M(1%2PR4MJ;2A;G#F $NG2"L#R/&O!"<PK
M,9&4>\-W*W)MDEF/&E!M$KO@LOH*D;5Q3I8XJ"D@$#7A1W4 YU=]XC6+Y-M
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M2^]X_P#K0-?4/%!7;+U1CO\ RX[?VG;>S;G;@MAM497(QH)0EYPD$A1Y+!
M'@ZT=$UFPL^M=ZNUUM%P@R6%6^>J(GWI@*1*+<=J25I]? 2X"-_4#]-?+[TL
MM%^AOQG'[E$3+$U$A<60$+=:F$&0T20=)44I.TZ4GB.*AYW^[CTU@7";+EIG
M76(_,E"2I49Y"2A1C)C+"24$@+:0@'UT4A2>)\T&"OK1C26UK0N>M ?9CMJ$
M)8#SKL82@A!( 40P0L_0-ZWR\5+R^HEAAV^%.7,*XMQMB[E#=;:4H2&$]KRC
MQY4>\UQ3ZGEX'K4>]TDL2[;'B,>]1U0YC<N*^E2'%LNHBIB@@.)4A0+*>)"D
MD;._4 CWRK V\FEXFA_M^Y8Y<43U$K*7'%--J2T@!( X\RE9V=;;2.)WM(8T
M7K%C<^-/>@/O2$6]M#RN+7'NLJ6I =05$ HY(5Y)'C1]%))_,?K'CDU;(MJI
M\M$F1&CQW6X:PV\Z_&$IM"%*T">PH+/U; ^<0*_#71NR1HK$:$_.C,09:9-O
M0VEG_8E)2XD)02V2I/%U8 <YE/P\2DI!'LOI'9/M3?QN,Y/CVJ7V4R6TNI6I
MYMJ,W&2@J6E1 [;+?Q)TL*3R"@:"ZZIJO*+',9M22\\]R<6ODZ02.2BKB- >
M!O0_(!ZU[4&)=+7%O5O?@W-H/Q)2.#S140'$GU2=>H/H1Z$;!\&LI*0E(2D
M) T !X%?:4"HV\8Y;K_V1>(XDH8)*6U+4$*WK86D'2T^!X4"/ \5)4H/FJ^T
MI0?-5]I2@^4K[2@^:I7VE!\I7VE!\U7@_ CR9,:0^RVX]$4I3"U#9;*DE)(_
ME!(K(I0?-5BW6U1;W;WX-T9#\22G@\RHD)<3]*5:]4GT(]"-@[!-9=*#X!H
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M[0O4*\Y3GL.PN3(US4+U%Q>UN& AB+\GNL)6Z\AQ(=0\6W"M"G7 TI2^)0
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MUGZ<7.S9'\NM7R([<93K_OX<MA[3C3JFE%+:0[R;4GM !14H$'X@H@$ Z?C
M\NQ]^3B=IQM#5\C,R;K"CQ6.2BZGD!)2@:4K?(?%ORE7U&O.1>>F>30I<V['
M$I3%QF+AR7+@RQ_M3L19;*5\Q\?;.]$[ "@1H&LJR]*H%LB0(TJ5*?9M]F@6
MU 8=<B%7NG<XN$MK!^+NG:=Z\?34=<.DDJ4B8F+>V&$S476,YSMW=(BW!\/N
MI&W .XE>PE>N)! 4A1 -!9;;DF)V=I^TVBXV&"U9&'%/0X[[328331 <)0"
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M0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*YANV:YI$Z]R>E\*?<G7)E_9RN',42
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M%3= I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E
MI2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E
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M:"G&$N:YA"M;2%<4[UZZ'U5%/]/\9DPHL-^P6=R)!#B8S"H3?;:#AY.!*=:
M4H D?20"?(%!AXOGS>3WVX6IF&MB1: X+AR<!["^^XTTG6O/-+*W!Z:24?\
M$*CKW?KQ^RE;K-;UW%-M3;FY4@0V(ZD\B\I)[JG#R"-)_P#E^?7\E2T7I];&
M9%QD2.])D76\-764XHI07'F4MI9!X!.TH2RUH'?E.R2:DKABEFNUUBW.YVN!
M*N,$ 1I3L=*G60%<AQ41L>?/\M!K:'UANDNY0Y2+4TF!>[7!D6>*J</OIER>
MVVMY7;VT0D@J2 L?0DJ5XK+@];7YURC6]G&9S\U+Q;N"(A=DHC#Y0?A!:5H9
M*2D*C.N**RWI \<CM-6J=TSQV1#N#,&U6RWNW,)$B0Q;V%*<"7.X H+0I)'/
M:M$>"HD:/FE@Z:8]CT&VQX]NBON6E;BXTEZ.WW$*<=+RR.*0$@N**N*0$@ZT
M!H4%6MW7B'<)+,?Y)E-NR&H_;070I2GB$JF,Z ^=&;<0I7_$>21HBO:'U@E3
M)%K@BQ-(NE^9BR+6T;EMI;3[4AT%YP-GMJ2B*[L)2L$E(2I6R4W>/BEEB269
M$6TVYE^/(?D,NMQ4)4V\^27G$D#84LD\CZJV=[K$;Z?8RS"?ALV"T-Q9"T+=
M:1#0$J4@DH.M?O=G7U;.M4%%F]7Y]W8C?:];1%2Q<[3'N;[TI/)DR+D(KC;:
M"@AQ/P. KY)\*!3L^!;>J5YN]BPUV3B3D1J[.3X$6,J6V5M OS&63S \ZXN'
MT\CU%9[F!XV\] >=L5H4[:TM)A*,-O<8-*Y-!'CX>"O*=?-))&MUE0<9ML"R
MQK4B,EZ%$4A;:)'WTEQ"PXEPE6]K#@"^7KR&_6@U@CJ]=Y$*]7^W0S*M]BN;
M,*79R$(D(4XPTE3?,D)[C<I92K9XE//6R$[NN2R\@L?2^YS$S8 R.#:G9"I!
MBE;"74H*U<6^0)2-$)V?J)WYW-C&;0#<"+9 !NTA$B?J.G_:GDI0E+CGCXE!
M+;8!.R A/U"LZ5%9G1GHTQIM^/(;4VZTXD*2M"AHI(/J"#K5!4+I?[M'O>!B
M/(BI@7V0XQ<&3')<6KW)Y])2OEI("FAL<23OU&O.#;)>0R+[E\>!???(MICM
ML,.S8+12S.4DNJ3IL(*DH:6QZGR5D;!2:O+EMB.JB*<C,*5 7SBDM@EA7!2-
MH_X3P4I/CZ%$?32+;HL%IUJ'&88;?=6ZZEML)"UK45+40/4J)))^DF@UM)R&
M_7/#<"N%MO+D.\Y,W 08S<5E33RW&P](</))("64/* "AOB$[V16TJP6+);X
MI@F-"BM&V,&/"*&4CW9HA(*$>/A3I"!H?\(^JLB-#8A(6B(RVREQQ;J@A(2%
M+42I2C^4DDD_230>U*4H%*4H%*4H%?$I"1I( 'Y!7VE I2E I2E I2E!\4D*
M!"@"#Z@_37VE*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E
M*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E
M*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E
M*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E
M*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E
M*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E
M*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E
M*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E
M*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E
M*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E
M*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E
M*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E
M*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E
M*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E
M*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E
M*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E
M*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E
M*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E
M*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E
M*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E
M*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E
M*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E
M*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E
M*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E
M*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E
M*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E
M*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E
M*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E
M*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E
M*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E
M*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E
M*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E
M*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E
M*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E
M*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E
M*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E
M*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E
M*!2E*!2E*!2E*#QES8\!DNSGV8[0.BMU80G?\IKQ3>8"T1U(G1%)EJ*(Y#Z2
M'5#U"?/Q'P? J%ZFV,Y)T\R2VM0VYTB7:93<9A:$JYNJ:4$:WX!Y$:-4#)</
M3$EWUE_#5WUJZV)B):/=66@B,XD.<V"21V/OBDN]P:!)]=H2*#<?<3SX<D\]
M;X[\Z^NO W&('VF#*CAY\$M-ET<G /4I'J=?DJA9I9,DM]KQ^Z8PGY3R>VQ5
M6Q]T\0'$2&TH4ZH*('%$A$=Y7T\$.  DZ-2G].W+-#R"P6S&Y4V=,=AHQR]\
M6UB&TU'8;;6IXD*;+#K;CI3KXN1*>2EJ #<0R.TD+(N=O(:&UD2D?#YUY\^/
M/BLYMYMUE+K2T+:6GDE:5 I*?78/U5I/+.GCS)R.1;+&EL2LR@S&UQ+>R^M<
M5$*(A:@V?"@'&W/A/T@G7TUL5F:F\8Q=;9;X\M,B# $927HHCA3BXX4$I3Z
M@+3L#P"=?0=!9?>F2VVX'6^V]KMJYC2]^FC].Z^.S8[#;KC[[+;<<Z=4I8 ;
M.@?B/T>"#Y^L5H"#@.2P+)C%HD6F2Y:<$EVZ;;FVW$*4^5.-J4A(Y?#[LV)#
M0!\%+B-;(HYT[S5N%<8]QMMO)RY<.9<W(4GWD,SF[@TZMQ:'$)!'86I'JH<(
MC2?JV&_Q-CEH.!]DMEON!86-</\ BW]7Y:^/3HT=UEM^0RVY(.FD+< +A_\
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M0[%E34=RS29*D3(JY<?WB _%+S".WR<2'4)*D??6_(\'?C>CKR8ZFXY+7&1
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MQM*1XJ^X#)N&<>P!#>&;IQB==;6]QR:Z3UM)9!G+ [KY4%H2M.FBH':0OQY
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M/>W2WXVDGZ0I05:;?B1CW>WW2Y72?=)]NB2HK;TA#*.3;ZV%JV&T)&P8Z-:
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ME!HSJKT@G]0_:#P*\J8838\?L-Q,B7(ML::@2%2H2VV0AY*N"E);=(<0 I/
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M#SB>*0!I7IX&HYOI58VTP@KW]WY/0AF.'9BUI;80MM:64H)X)3]Y:2>*05!
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MY[\*/,L%PM[J+BF/%<F1X[R0ZW-8B.A 0Z2DA4A("_36R.6N)L0Z8XT)1?\
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M,LHDNWZ3;(W88BJT1(6A,@O!OB0H_>^0&R1X-;R2H*2"D@@C8(^FN2>IW6K
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M I2E I2E I2E I2E I2E I2E KCC[)#^#^BO]94#_"JNQZXX^R0_@_HK_65
M_P *J+QV/2E*(Y ^RH?N4Y']((/Z5UUO;OP?&_F4?H%<D?94/W*<C^D$']*Z
MZWMWX/C?S*/T"B^,BE*40I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E
M I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E
M I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E
M I2E I2E I2E I2E I2E I2E KCC[)#^#^BO]94#_"JNQZXX^R0_@_HK_65
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M$J^)('D5TU2@YYNOLEKO4NY(GY;_ .RYDR[7-EAJSI0^U<+C#=BOK4_W25L
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MQA+@4D)^)2C].JE?N4L<?NL.Z7:_9-<[E'R).029LH0?>)DQ(82CDZB,E;2
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M0X=(4!0;_I6I;3F>4*]SM=\4?E.=-B);DV^ XMLQ%M'N/!:V@D$+2=\D@!1
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M<9!!5RU\WYOPUZ,=&K>U?'Y+DVX+@R8S"9$7OG_;'42WY2UO^-*"G'P=)X^
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M#B?0;^D5\;Z-V%NX,S2NXKDH>:?D+5(!,MUJ4J4A;AUOP\M2M)XI((204I2
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MJ+*CO.LJXN(;="E(.DG1 /@Z4D__ +A]=9- I2E I2E I2E I2E I2E I2E
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M6SO#5-4% LDB[V/.)\*<_?;W:O=6NU*=C+2F*O;* V=-A#Q45N.EQ!^ !:5
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MM7>=:0PJ.\$"(A)#VW5!!=</T%#1'$[0P'+NJ$CJS&:RDS7L8N=\R.#[JY9
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MTI0\ !"3Y]*K./=#6L48MOR!<F(\VRI;8@S%P"XXJ,AEUI+;^W-.$)>404\
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M?DX-D-DR&/&6$/.VN>U*2THC8"BA1T=?0:">I2E I2E I2E I2E I2E I2E
MI2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E
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MM"G]I"0E(3M0\#P!XH-8W#I3?)=RB65'9<NJVUF3DXC2.]$Y6-</BEU380M
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M%+*2GD A*5'?C1\['I0:.D]#KK'M\!BTN0FF6DQC<8K;B>-P+:I/PK[K3B%
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MW"E7."S.>>4TACOA1_WZV$DD>!R<;4@;U\0X^3XK)LF:6/))LB)8KI$FR8J
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M3LC=!;:5'6G(;;?79K=GF,2U6Y]4>5VE<@TZDD*03Z<@001]%2- I2E I2E
MI2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E
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MI"0E*1ZXMXP1S&+3%F_+#-N19X:K7#<CPG%NOM.*<9BM.\-EX([[92WP)+B
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M]3@!ZDOV_P ?_P!^@]I7-R 1[/\ U.(/I]_M_P"OH-_TK0'W2F;_ (OW4_\
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M\7[J?_;0/U]!O^E: ^Z4S?\ %^ZG_P!M _7T^Z4S?\7[J?\ VT#]?0;GD?\
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M&_Z5H#[I3-]Z^Y^ZG[_G[?\ KZ?=*9O^+]U/_MH'Z^@W_2M ?=*9O^+]U/\
M[:!^OI]TIF_XOW4_^V@?KZ#?]*T!]TIF_P"+]U/_ +:!^OI]TIF_XOW4_P#M
MH'Z^@W_2M ?=*9O^+]U/_MH'Z^@]I3-SZ>S]U/\ [>W_ *^@W_2M ?=*9O\
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M[K>O90N4Z/R"NU(O(<3L>AT6/6LACVK>O\5AMF+[+%W9990$-MMWP)2A(&@
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MD@A*.:9^RK6^)'GX14+$RC-)B+:MR/<9SWNS<BXIEV,-BV3BT]R98^]CD@*
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FN0UDDVYO@(1-@1F2T'E+X.-J>*M ^ -.)\C6]'Q2E!,TI2@__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>card_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 card_2.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_X2<"17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    F    <@$R  (    4    F(=I  0    !    K    -@   $L
M 0   2P    !061O8F4@4&AO=&]S:&]P($5L96UE;G1S(#$Q+C @5VEN9&]W
M<P R,#$W.C T.C(U(#$R.C Q.C Q   #H $  P    $  0  H ( !     $
M  ,6H , !     $   ,5          8! P #     0 &   !&@ %     0
M 28!&P %     0   2X!*  #     0 "   " 0 $     0   38" @ $
M 0  )<0         2     $   !(     ?_8_^  $$I&248  0$! 2P!+
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M(S)4<8&1DI2ATP8S-%-5=*.STO D0E*Q)6*R\19#<H+!X35$<__$ !0! 0
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M(<&4E+BAF (,;^H>BIN^)=<27[@I3(20\T-=8'5_ZKO;.:I"7ERA,Y;A'-(
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M*9GOJV_7/901YV_&_>GLKU*DJ(";HDG@"GLKO,]]6WZY[*]279&9" .I9/\
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M[I/?9=_^'^NJN(7+]ZAFW1AUVVHOLK*G-F$A*74J),*/ &@__]D
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M;W-H;W @,RXP #A"24T$!       #QP!6@ #&R5'' (   (    X0DE-!"4
M     !#-S_I]J,>^"05P=JZO!<-..$))300Z      "3    $     $
M  MP<FEN=$]U='!U=     4     0VQR4V5N=6T     0VQR4P    !21T)#
M     $EN=&5E;G5M     $EN=&4     0VQR;0    !-<$)L8F]O; $    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M #A"24T$.P     !L@   !     !       2<')I;G1/=71P=71/<'1I;VYS
M    $@    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M  !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V
M8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M  $       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D
M;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2
M;'0               !";&0@56YT1B-2;'0               !2<VQT56YT
M1B-0>&Q <L            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M    4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O
M<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9        .$))
M30/M       0 2P    !  $!+     $  3A"24T$)@      #@
M   _@   .$))300-       $    >#A"24T$&0      !    !XX0DE- _,
M      D           $ .$))32<0       *  $          CA"24T#]0
M    2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M 0!:    !@       0 U     0 M    !@       3A"24T#^       <
M_____________________________P/H     /______________________
M______\#Z     #_____________________________ ^@     ________
M_____________________P/H   X0DE-! @      !     !   "0    D
M    .$))300>       $     #A"24T$&@     #N0    8
M"8    F$    0@!! $X 20!+ $$ ( !4 $@ 10!2 $$ 4 !% %4 5 !) $,
M4P @ $D 3@!# "X 7P!0 #D ,  V #< . !? #$ -P H ", ,P Q #$ ,@ R
M "D (  M "  4 !# #, ( !& $D 3@!! $P ( !P '( ;P!X 'D ( !C &$
M<@!D "T ,@    $                          0             )A
M"8                       0                         0     0
M     &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M"8      4F=H=&QO;F<   F$    !G-L:6-E<U9L3',    !3V)J8P    $
M      5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L
M;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O
M1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M*       #     (_\        #A"24T$%       !     (X0DE-! P
M)>     !    H    *    '@  $L    )<0 &  !_]C_X@Q824-#7U!23T9)
M3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P
M35-&5     !)14,@<U)'0@                  ]M8  0    #3+4A0("
M
M !%C<')T   !4    #-D97-C   !A    &QW='!T   !\    !1B:W!T   "
M!    !1R6%E:   "&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD
M   "5    '!D;61D   "Q    (AV=65D   #3    (9V:65W   #U    "1L
M=6UI   #^    !1M96%S   $#    "1T96-H   $,     QR5%)#   $/
M" QG5%)#   $/   " QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H
M8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2
M<U)'0B!)14,V,3DV-BTR+C$              !)S4D="($E%0S8Q.38V+3(N
M,0
M        6%E:(        /-1  $    !%LQ865H@
M %A96B        !OH@  ./4   .06%E:(        &*9  "WA0  &-I865H@
M        )*    ^$  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE
M8RYC:               %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                                  !D97-C
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(              "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O
M;&]U<B!S<&%C92 M('-21T(                             9&5S8P
M       L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V
M+3(N,0              +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I
M;B!)14,V,3DV-BTR+C$                                  '9I97<
M     !.D_@ 47RX $,\4  /MS  $$PL  UR>     5A96B       $P)5@!0
M    5Q_G;65A<P         !                         H\    "<VEG
M(     !#4E0@8W5R=@        0     !0 *  \ %  9 !X (P H "T ,@ W
M #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0
MJ0"N +( MP"\ ,$ Q@#+ -  U0#; .  Y0#K /  ]@#[ 0$!!P$- 1,!&0$?
M 24!*P$R 3@!/@%% 4P!4@%9 6 !9P%N 74!? &# 8L!D@&: :$!J0&Q ;D!
MP0') =$!V0'A >D!\@'Z @,"# (4 AT")@(O C@"00)+ E0"70)G G$">@*$
M HX"F *B JP"M@+! LL"U0+@ NL"]0,  PL#%@,A RT#. -# T\#6@-F W(#
M?@.* Y8#H@.N [H#QP/3 ^ #[ /Y! 8$$P0@!"T$.P1(!%4$8P1Q!'X$C 2:
M!*@$M@3$!-,$X03P!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%
M]@8&!A8&)P8W!D@&609J!GL&C :=!J\&P ;1!N,&]0<'!QD'*P<]!T\'80=T
M!X8'F0>L![\'T@?E!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24)
M.@E/"60)>0F/":0)N@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB
M"SD+40MI"X +F NP"\@+X0OY#!(,*@Q##%P,=0R.#*<,P S9#/,-#0TF#4 -
M6@UT#8X-J0W##=X-^ X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S
M#\\/[! )$"800Q!A$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D42
M9!*$$J,2PQ+C$P,3(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/ 5$A4T
M%585>!6;%;T5X!8#%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$ 8
M91B*&*\8U1CZ&2 911EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR
M&]H< APJ'%(<>QRC',P<]1T>'4<=<!V9'<,=[!X6'D >:AZ4'KX>Z1\3'SX?
M:1^4'[\?ZB 5($$@;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X
M(V8CE"/"(_ D'R1-)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG
M>B>K)]PH#2@_*'$HHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K BLV*VDKG2O1
M+ 4L.2QN+*(LURT,+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C U,&PP
MI##;,1(Q2C&",;HQ\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'
M-<(U_38W-G(VKC;I-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z
M[SLM.VL[JCOH/"<\93RD/.,](CUA/:$]X#X@/F ^H#[@/R$_83^B/^) (T!D
M0*9 YT$I06I!K$'N0C!"<D*U0O=#.D-]0\!$ T1'1(I$SD42155%FD7>1B)&
M9T:K1O!'-4=[1\!(!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR
M3+I- DU*39--W$XE3FY.MT\ 3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3
M$U-?4ZI3]E1"5(]4VU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX
M6@=:5EJF6O5;15N56^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@
M_&%/8:)A]6))8IQB\&-#8Y=CZV1 9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_
M:)9H[&E#:9II\6I(:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P
M*W"&<.!Q.G&5<?!R2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1
M>&YXS'DJ>8EYYWI&>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$>
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M.="ZT3S1OM(_TL'31-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N
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M-?A9]'?_ #;^/\SZ?_!?SB1RJQ.EFC0_^;LX/]CZ>O\ -_SBK^CUO_N7B_\
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MZ;%0_9M][&MMZ?EBP;[FV/SM1;L9%3K:KG6^FZZBEM'L_1^GZ_IUI[^FY+F
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M^NWUGN_2>K9[:OS_ ,Q6/UK:9.0"1.X_9YELG8T?0W/_ /17\XD\W&(;>3M
M'NH!D^_0EW\XWW4?]N?\8DIJ_LOZLQM+VZ-V']8LF-=N\^MN=]/V;UJ?;,,
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MW[C/\X_^02_3?N,_SC_Y!)3'<S_N1^+/_(I;F?\ <C\6?^14OTW[C/\ ./\
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M*W&^BPOL],,:VJZJ^QSG-M?^94DI_]DX0DE-!"$      'L    ! 0   !@
M00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !% &P 90!M &4 ;@!T
M ',    = $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  10!L &4
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M-&-T@B:#DJ/P_\0 %0$! 0                    '_Q  9$0$  P$!
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M%EMT2&.T]_JU]P<5^-^#\_@;K4Y;G%BP;$YN395<H\&Q6Z.9$B:K:T); WR
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M&BX0K[GGQ&]5;N$)R)&)6I/41=I<R41D_*:K2%B*7OY7:"_BX_1OS1&\I2E
MI2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E
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MI*P21OPV:8C[-&<8Q?V+39(%QCW*X]!9\"3>EMJ0T+],F+?<:6]Z!SFZ?GV
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M&Z(EN.VYP@>JBI3B/^":Z3]AKIRUTCZY];,/8">5BL^'L2%)]')!MBE/+_\
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M'+GU5#^*G(_M!!_O776]N_V?&_Y*/[A7)'U5#^*G(_M!!_O776]N_P!GQO\
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M4-'8?1JO)KVFL?,9X2XPCW$F)[K#-TAK#OO)<X!;J72VTI(9=*PI7PA/CGL
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M-O\ \2BNK*Y3^J<?Q1,C_K&W_P")118ZZ0P;^!./_P!51O\ M)I3!OX$X_\
MU5&_[2:41RY]50_BIR/[00?[UUUO;O\ 9\;_ )*/[A7)'U5#^*G(_M!!_O77
M6]N_V?&_Y*/[A1?&12E:?+K\SC..3[E*E,PTQV](>>86\D.*(2V.VCXUDK4E
M(0GXE$@#R11&KLO3>W6.#BD6+(F+;Q#G[F7%))<Y,K:/<T//PK)\:\ZK3(Z+
MPX%Q;GV"\7*VRBAYJ4L,QWQ):7*=DA*DNMJ *')#W$IUX60KEXU6N4]0[KE%
MGFMSU.1I=BF7B"MYJ"_;?>1\@JE(68[JBXV1WTC14?* H:WH6WEN52L,Z33;
M_;V&9LRV6=,AIF0Z6T.K"!H*7Y(!/J?FH)!D^.Q<LQJYV2Y%U$2ZQ'(KJF5<
M5H2M)22DZ.E#>QX/D5%8725E-[5>+W?;Q=[FN1">6Z^&6T[B]_MI2A#:0$GW
MA>Q\Y\^/-1Z\]2,OL-YDXV^SCTV]K?M?NLQMEYF,EF<Y(:^-HK4HJ:5&6KPL
M=P$?<'>OJWYQ?I^5OXOCB+1#NCLNXOR9\UM^0QPB"&A7!GNI5R6N6C0#@2A*
M2=$D;"1R^E$<W072R7BZVB["9+?$QA++AX2NUWF>+B%)*"6&5#QL*;'G6P==
M8NAT'%EVU6.WN[QC#MT>WRB\W'DF<TPM:FU++C1TY]M<!4G6PKR"0DCQP#J9
M?<]R>/%:A6JWVZ%:&I=V*E+?<7(5)FQE-,*!2. <B<PXH':3KCM6T[;+LER5
M.;P,;PT6-A<FS2KBY*N;;CH"FG66TM!M"T'2B[Y7OX>/W*MZH,F=TW;>Q698
M;;=9D&+<)\V5+48T>07A+>=>=:*76U)X\GCKQO24[WYW&[MTH8Q:W17\.1DT
MFXQ;@R_'>@2HADL!%O;A'9E:;<0IIAOD%;)4>0\@:TD/KG?[Y:F[Q:+7:8]N
MD6^Q*CL2G'%N+EW93:&DJ6D@(;:4XDJ/%16#H!)&SE9=UHO/36'?7,LB6R['
M%W83LU=M2J,J7$F!U#19;<<4$O)>;^)!6H%O:@02$T&[Z;=)CCN/Q_E^5*<N
MKT*?'E#OI=XIF3')2MKXCFXDN<2K0!()XC=9UBZ11<8NZ)EANUPC1W$Q??8:
MV([J)3D=AMA#A4ILK0I33+25<5 'M@@).R8A>.K%UQVY)@+AQ/ER[2K?$5)A
MQI=SCM+7">DN+0PT>;B0EA24A/#ER"E$ &MC8NJ>0S;M8$9/ 1C-MN.V!(FV
M>3_I\H2GV>VDJ4@Q.:&V'6P\E17[P$#XDG89S?1MZR",_C.0W,O8]#FM8U F
M!KW2"I]LI0%\6^:T(^$)Y$D)&O.SNPHT)Q-H:ASY3DQX1@T])4E*%/*XZ4LA
M( !)V= :\UF5SMB?5C(>G_2G&9F2QX%T9EX49\!J.EXOI<8$5M"7G-K+G<]Y
M2HE* 4:(TYZT%C7KHG9[U8K+;'IMQ:18;.BUQ'4EM1*$/1'DK6E2"E1"X36P
M1Q(*P00?'A<.A=KO=HGPL@NMXN#USO;=WE2UJ:;6M8C(BN,@)0$AER,A3*DZ
MWP<7H[((T<;JCF,N5;K1'MT-,^YWI$%B[7"R3;=&4TJ%)DK6(SR@XI:%1B@@
M+XJ"TGDG9"8GE_6B_P"2]-LTDP[7)3;)>-7U45UNU3(AMZH[+O96Y+<'9<[G
M _<:X**0"X-J 70GIU;TY0;Z'Y9E&[FZ<.2>'=,!,+CK6^/;2%>N^7SZ\5",
MTZ83+9&*<!;R-=PGL7%E^5"G0V4*3*DKD=N07DE00EQYSBME)<2DJULFLB;U
M/R'$<J1:<Q9LDF,ARW/2IT%#C*8\>:X_&2"E:U;4B2AD%9("D.*/%)1YF.&Y
MB;]@<;)[RF/;HDQAV>VI2B$MPBI2V'%D_<J+';4KZ"5?10>]HQ%$'I_"Q>4^
MIQN/9V[:X\V.)4$LALJ&_0^-UII?2F.;K"N-GNT^V2HUK8MD@H8COIEQV5*4
MUR#K:@E:2XYI2=?ZQ6P?AU!F^N%_4BZ1H<>WSY;;UA]PE2;3+M+2V[G.7%\M
MO**UA 05A:2 O>N*=;.S3U*RUW*D8BTG'!>6[P]!?NBH[WNY:3!:EH=3'[O+
MEIT-EON_-RY:^&@D,SI!$F1+[:S>+JWCN0.27W[2A+/!A]]16XZRX4=Q![I4
M]KD0%DGT^&L^W=/ RY9WKQ>)ETDV2YJGQG51H\?DHQ7HW!26FT@IXOK5]/+7
MD#X:AEBZIY5F:IL+'HN/P;ECL%YZ[&:'7693[<Z9##;!2I);0I<!Y?<5S*0M
ML<%'=8]EZL73)GX2L,@P83F47V,P'KDIU\1FG+$W/[A:"T[4-!O@E2$G[K>]
MDAOX?06RVJQ1(%EGW.&_;KPNZ0II[3RV5EHL)9XK04*93'*6 DIV$H2=\@%5
M[Y#T;;R"+*;&1WNWO76R_(]W?A-QFU3XP+I3L=HAM:2^]I383X<5O9XD1N)G
MV:WG(L><MGR2M"K/D F6A+*@)TV!+9C@H>4O[6E:R>/('B%JY<CHIG?3/*G\
MLL;[USEQG[C$E%B9':M;UO7"<X(5V7677%J"@%A7+>E)4E2?!!(;2]8K%OF&
MS\;E./HA7"V.6YQQ! <#:VBV2"1KEH_1K?S5I\EZ7V_)9[\YV9<(<Y<>"W'D
M1E("HJXC[CS+J I)!5R=4%!0*5)\$:)W6/.;:<,O6:Q+]D(OD',KA':COWB0
M_%EM)O#D=N&(SBU-)"F^+22A*5)/$@^N[0Z?9'><I<ODN\-VZ/;HMVF6^WLQ
MTK+JA&D.LJ=<65:^+@-)"?&B>1Y:2&".DK7'WIV^W5V^*O35V<NJT,<U.ML=
MA+8;X< V&2I(2$[V2K9422C=)6;//;GXO?+M9YI]X1*=;0RZ);3LIV3P6E;9
M'P./N\%#1 6H'ENOG/5OWK.,6Q=V?/MEIND6?-EN092XKTM<<L);C!Y!"T A
M];AX%*B&-;X\@=1D5INF/9SA-HP.9V@Y!NRG'KW+E7(-IW&5R(6[W'#LA(!<
M2$A1(\#B0DV)=.&L-N4ARUW28NV.OR'V;:['8*(ZWG"XL)<#8=XA2E\4E1T%
M:\@ #*RG"3D%VMUVMEVN%CN]M8?C-2XB&G.;#Q;+C:D.H4DCDTVH'0(*!YT5
M UQ<NO$QFPV*ZPDQ%ONP84J\6IJU2I1:2^Z&S_I2"&V!X64=Q)*N/HD>:7/.
M[U-D66]WI,2-9X&:W.'&C0@X7GFH3%T:6MU15H\BPDA 3X*=[.P$A8F+].+9
MB,FWO6MV8I5NM:K>GO.!9="G0ZMU9ULN*7M1/@$J/BLS(L53?[G89Z)TJ#)L
M$XR6BRE"@\E3:FUM+"DGX5)6?(T00-&JIL_6;,[S8C-AX\Z^)D"-/1);QR>A
MNWMN.H#K90YP5-4AM?-)9*"OBK2!I/*QI.0&Z=+)EYMERCS%O61Z0S/@H4RA
M:NTHA:$E2E(\C[DJ)3Z$[%!KI?1>Q3\9M-BFO7!V#:+"_96OMJ4K4RZAI)65
M!/AP=E!!&@#OQ4CQ3'9&.1'69UUD7=QQ0(>?BQV%  : TRV@'YR21ZDZT/%5
M=CN>9#=[ITGC7.RY)9F+@A9ERYLV*MNX$6UU8"@R^M9)4 OXTCRG?@ZJXKLQ
M*E6J8S:I*8<UV.M$:0IL+#+A20E92?71T=?/J@B,_HIAE]NEYN.6X]9\CFWI
MX+>?NUO9DK:;#2&TLMJ4G:6P$; !^Z4H^I-?%OZ06V#CDRSN7&[2VYS<%#\F
M0XA3R_=$-H;43Q *E!I)4=>23Z56;TZXV3'V;"RS>(.;0K[853TW>_2;E&D(
M=E]M,EEQ2SME9;>V@):4>'%24CB:WMRZRW^!=F\94S#5?F9DYN3<(MBFSXZF
MHS<5P*3&84IQ)6)K(/)PI3Q6=J^$$+ 8Z<VYAJWMI>EJ3;K_ "[VWM2?B?D*
MD*6D^/N![TYH>OA/D^=Q17L]VZ3;6;?<<@O\R' LJ[-;&7/=^,.*78[B1H-:
M<4#%93MSD%)3I0.SO6)ZPY4[!N%XD62!:;7C]NMDZ[PIJ'3+;3("%RD^J0@L
M-!U7Q))60!I&CO(;ZYREW:Y056U@+5=V6[,4*4HRX 6^F0\?_>E,"8M('@@L
M_P"]02BR=*8UKO*+O.N]TN=R%W-T6Z^&D)4[[B800$(0D)0&M: \[&R3YW(+
MYBT3(+G8YLY3O.PRW93#:=<'%.1W8Z@L$'8X/*/C7D#_ (554OK5D>/6"RWB
M_P "R2V\NM!FVF+#4XV8;ZNSVF7W25!QLA\<GDI1QX'X#R&ME=.I646"_KQ.
M>BPR\@ENVT0+BS&=:BH;EJE!1=9+BE<FQ"=( < <*D#:/BT&QMWL_P",V_'H
M5D<7<)L"(N:5IE/A:I+<F.N,6W%:!*4,*2TG6B$MHV3KS[KZ/IDV1B#<LCNT
MR1;Y+$FVSUQ8B7HKC04D*/%D)<*D+6E?-)!"CH))W7UT@EW.4YFHR-R,[-CY
M0ZRI492NT4IC1@"A*B2@$?%PV>)41M6MF*9%UVFV6X7Q=L3$O5MC6F\2X*T6
MF5$0E^ CEVS)6HMR$J(6DEL)XE/CEYT$^5T]+DFPRW;S.,ZRIDMK?3'80);+
MY27&UH2V$I&VV]%("AQ]3LDX,/H[:(>-3[(U*N!BW"T0K6XM2T<PU%;+:% \
M=<B#Y\:WZ 5H;EU*RBP2[A9[FQ89-Y7\BF ^PTZW'9-QE/Q^+J2LJ7VO=UJY
M H[G)*=-GS6WZ32KL_>^HC>3/17YD3)VV><3DEDH%L@D%"%*46][Y%')6B3Y
M/J0T$GIM=7^H-L%K1?8&.VW(W;X\W(EQ#"6ZMMTK+*4 R"I;SI64N$(!4XH;
M/ "P\OQ!O*V[:M$Z7;+A9IHF6^;%"%+9=[:VE;2M*DJ2IMUQ!!'HK8T0"*BQ
MSJ1<<)R#/GLFF3KK;YMQGNV*.\\5E$J,XEHPFB?N0X'(_;0/Y0>/SUY8%FF5
M8G8[=%RNZID1OK@NL:[Y#<(CTYM#R)W!MCX'$^[MJY.!#B]MH"$HUY%!:%CZ
M8P;+)MTQ4VX3;A"GRK@]+D%'.9(D-EM:G E(  1I*0D  (2/FK>Y%:IUW@H9
ML]YF6-]#H69$9AETJ3H@H*74*&CO?@ [ \ZV#M:HU^]7;II<LAD9#%O5TR)Q
M%PN%JD*O$A^!<X3;O>,9N-SX,2&X^D!/;&RDJ"U[< "6CHE9Q"@0ESKD]$9M
MMRMUP:>+:OE-J>XEV272$ I6IU//;? #DH :T!\R>BT>[-K7DV1W^[W!J,RQ
M;K@]V&WK?VGVY"'&^#02IPO,,K45I4%=I(*>/(&'Y%U1N-POZ+]BT9FX6VS)
MO MJ&G5$75$:/&4\1HZY=WWAI/\ [F]^=ZK=2>KL>1?1<%F"SCD1V>F)=EON
M<%-QX:'7GE)2=*0'%+;T02.THCR:#>W?H_%R1^'.R6\72;>K;'<:@75M#,=Z
M&M3B5AUO@@ +3PX^04J2I25!25$5M'.G,!YB:V])F*-POT2]/+VD'WB.8Y2D
M?#X03&1L>OE6B/&M7TOSZX99<K];;VV%/V?W9QN2+/)M?>;?2L@&/(4I:2"V
MH;WH@CP#L5@0+..HF:YFG([G?6F,<N;-NM]OMMXDVY#39AQY!>7V'$*<6M;Z
M@"HD!*$A(!YE0?9Z%6YZVM6J;>KU)L=OC2X]IMRRR$6X2&'&"4*#86HH9><;
M1S*@E*SOD=$9%TZ,Q+C/>6S?;W"MTNZ0+K,MT<L]N1*B%@MJ*BV5A*A&9"DI
M4 >&_&U;CJ<HR'&\US67'-O>L3696>W+CR XN0OWN-;6"6U\@EL(4^E>BE?,
M\A\'W1U@Z_WUVSWN^1+(Y(M4:W7>5&2JS36$Q##0XIHO2E@-.AWM$$-\2A2@
MD%?E0":,=%X4>R7NQ(N]R^0;Q%EQD0>Q'!AHDE14&W>UW"$\E! 43H'1WH:W
M608"G)<FLUTN5TF&/8Y29D2"AED)2^$+1R[G#N@$+.TA0WZ'X24F/YOU)NUD
MR"=9[!$MSTEI%B##DI2^*57";)CK4H).R$)8"P!KD=C8]1@QNHF3W&]L8K%%
MA9R!%QG,2;FY$=5$+,9IAWFA@.A?-0ELIX%WX>+BMJ  (3+,<&1E<ZS3V;E,
MM5PL3[CL21':9=UW&RVO:74*3OB?"@-CZ=%0.EM_1:SV[&+G8VYMT=C77&&<
M=>===0IP1VA)"5@\==P^]N;)&O"?'KO<=,LIFYGA-ON]Y8B1ITA3R'VHCA<:
M2IMY;9X*/DCX-[_IJ,]7>JLC "\JSNQY3UJM_P HW"W?(\F4M<<J4$DOM*#<
M8*[;H2IP*!*#H:2J@SKAT=BSKJMYN^7J+;7KW%O;MJ9+/97,86TL$J+97P4I
ME"E(Y:Y;4-&I/F.,-YA87;8]*D0BI^/(:DQPDK:=8>0\TH!0*3I;:20001L5
M!HW4?(C?4O2X]G38592]80PVAPRB$I7QD=PJXCXTA);X>FU!?\FM/A67Y%EV
M<]/+Q>C:V;7D^*7&Z0XD/N)<C)6J"MMMWDHAU00X-K2$ 'D..B#03X]-X+D>
M6W(ES7%3;[%O3SFT F1'+!2  G023&1L?TJT1XU\8+TX:P%(C6RZ3)%IC-%F
M# ?CL 1&^6TH#B6PXH) XIY*/P^O(^:C74WJM>,8R=VRXI;7)TJ!9A=76Q9I
MD\S.;CB&HR#'!#)467-N+V$[3I"O.L*\=<5VC+(;:$^_623(DQ9#35EE-N0W
M8]O?EN)]Z*NRZX#&6V6DI!25>5;200LJ1C,:1EL#(5N/"9;[=)@-M@C@6WW&
M'%$C6^0,=&O.M$^#XUIKMTQ@7079QN;<(4VY7IB\M3&%([D.4U'9826PI)24
MEM@!25!6PM8]"-0F^77-;E&Z=W!V3CS,N^7]IR-&CLO%J(VY;9JU)=7W?])"
M1Q(XI:"E(_D[!%A=/LBF9-CJI-X1&1.B7&; D&,E26G%QI3K!<2E1)2%=L*X
MDGCRUM6MD(S,Z$6:]-2!E-QNUX=F27ILIUU;;17,6RVPU)2&T)"%LM-A+7'7
M$DK/)>E#ZQ;IZ_'ZM7?+;DB4GMV:/:HJY#K9,QT*W(F%#?PI*TMQ4>='[2?A
M2-;UEGZEY-=XN+7)2+&Q;>H"GV;,T([JGK<L1'Y3"Y![@#P4W'5S2D-E"E!(
M*AM5;?H+"EQ^B6)+DN057"X66/,>D,QU(2Z\\TE9<<!65+62K:U<MJ5L^-^
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M/@Z!'IXU7L]:($F8W+D0HCLII!;;?6PE2T(/@I"B-@'9\5SA;,#O,C"+ZN9
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M)4V021\:?4!OHG5>#+R-JW)MEV1;Y-S?M4:]*2U[H_-9"^XR-.=P:4TZCDI
M25ME(.RG?OF$##;9<8E]SJ9 @+;>;]W7<[J6(RGD'DVKM+6&E.)(Y)44E0(V
M"-5#[?@^1MW"WV"1;VD62V9?,R W@2T$/,NR)$IMA+?W8=#KZ4*V./!LJ"B5
M<1(<RM-TB9Y:<EMEE7D<>/:)EN<AM/LMO,+=<96'$=U24%"@T4K^+D-(T%>=
M!)I^9V"U3(L.Z7RSPY<XH$5B1.;;<?*SI'!)4"K9\#7K\U8^=Y:Y@^.2KRFS
M7*],06UO2FH#C"7&FD(4M3GVYQ ( 3K0).R-#UU4]MZ*7FWX-E%L=CVYVYW'
M!(5FA+;<'!N0U[XKM(4H AMM3[02H@>$@Z!%6WGMHD9!@N16NVI2J7<K3*C1
MTJ5Q!<<:4E()^8;(\T'GC69M7RS.7"Z0WL?+2$NN1[C*CEQMI2=H<66G5I2E
M0WK:@?A/BLSZ[;'\KR;5\LVKY4A,EZ3"]\;[S+8 )6MO?)*=$'9&O(JJ<OPK
M*?<\CMMDLR;@,GQ^!"1*]]:::B.L!U+H="B%>4K24%"5 JV%< .1P(O2&<[<
MKO"S*!DE\MHNMYN49,:; ;ARVYJ)"0R3I$D.=J2IG2E< 4I5S   "VCU$Q06
MEJZG)L?%L??]W:F_*;/9<=UOMI7RXE6AZ;W6%CO4^PWNU6"3-N-MM<W(V$/0
M;?*G-I>=Y'0"$D@K\^/ J 6C'<T@7FU7Z]VB=D$>U)N5O@VZ9*ABX-19*8:F
MW7UI4&%K2N.^V2E15VG4$\U<P8Q'Z7Y^SA>/XP_$<:C6RVV=#$>VS8S<&,['
M?#D@/*6.^L@(3VP@<3H;X'9H.B&+O!E"*8LR*\)J%+C%MY*N^D>I1H_$!L>1
M]-8F49+%Q.VM3KBAYQIZ?#A)#0!/<DR&V$'R1X"W4D_T ^OI5-8"B39^I-Z=
MAQ3>K';+TNR8\N$KFF,)RA/N"W%:XI0TH-MCZ.T$;V=58_4^TW/(X=FM-FM[
MCZ';Y;IDJ:7FT-1&HDQB0KD"KFI2DM%*0A*O/W12/-!*?EB!VVG/?8G;>=6T
MVKOITMQ 45H!WY4D-N$CU'!6_0U@0<WQVZ-3W;9?[++:M2>4];$]IQ,0:)VZ
M0KX!I)/Q:]#]%5>C"\I=>LUG59DMP;'D=ZN3ES5,:X2&Y;-P2P&T E>P9J O
MFE/$I^'F/(P,HZ,7R9B>/0,>9CPGK1B\&$\VPZVCN.Q9D*1V 5)4C2D,/H!4
MDI!7Y&B:"[+/?+=D5O;GX_/A7."Z2&Y,.0EYM9!T=*22#H@CUK2VO/XEWRG(
M[#$M]V$W&XL>2ZIZ,&D2TO*?2GLE1!5\49Q/(@))UHD>:P^F&.N62#=Y4UF_
ML3;W<?>Y:;T[$6\I89:9"M1?M0!0T@:!)\;/DU]MV2XV_J-E&0LQ4R8TS&[;
M$B-)>2E3S\=ZX.+1Y\)&I#6B?'D_0:#WQ7/#D-[N%FN5DNU@NMOC,RU1IZF%
M]QAU3B4.)6RZXG[II8()!&O31!.YOMSD6BW*D6^U3KR^%)2F)#6TEQ6SK>W5
MH0 /4[5_PWZ55F*VFX8#=LFR:+BMQMT2]FVQ6K.N>)LM^67UMKD+4%N);:"7
MV_ 60$MK40GSN<]3)>3Q<4>'3J")MYDNH92HN-),5M1^-]*7%)2M24[*4D@%
M6M^-T&HC]9(EPMMO79[%?9]WN$J;&^16Q'1)87#<+<DK4MT-!*%\4\@X0HN(
MX[Y5E.=7+1[KB,B-%N\EC,9"6(KC<,A,51'D2%$@-D*^#CLJWO0(2HB,6S%;
MKBWUI7G&,6GJ-A@W*VR[1*N,<RWDRW8[RI1>YEM;BGHP4O:P3W5J]0$G-A=.
M[O"PK"[<\(KEPMF0-W6Z=IW[6V5NNO/!LD J2E;I \ D >!Z4&\R'J1(QJ_0
M+?.Q6_.1;G<V;?%N++T-33CCG\H([_=XI 6I7VO82A1UH5-JB$S')UXZG0+K
M<4(39<>MJS;D\P2[.?44..%/S=ME'!)^?WESZ*VN/7R3DE@7/1 ?MCSCLAN.
MS-20HI0ZM#;BAZA*TI2L#U 6/GH-7=^K6&V6R76[2\ELBX5D($];$YMTQU$D
M!"@%>%$@@ ^3HU(7+O%19U71APRX0C&2AR&@R"\WQY MI0"5['H$@D[&M[J@
MV^F^<WRVWV1D4:<_=)V'&W."?,B:D3PX'"EA+ "$,$\@@K(5Y/()]3T# ?7)
MA,.O1GH3CC:5*C/%!6R2/*%%"E)V/0\5$>/!-!!G^H5DNW3N-GLNRWEYFS./
MRHT(1.Y,9?1W8RP$)44A6E.I)*N(2HE1 !(E<3)8DVW09,<E3UR@F;$A%:$O
MOMA*5'BDJ )'- )WH%0V1NHKC^'7.W])+I8)+;0N4I%U#: X"DF0^^MOXO3R
M'$[^BMO:X]PL-ALD9%H3/E6^RE"W$R&T%#S;;8#*2K_\0@_%Z#@-^HH-,KK%
M&@INS.06"_6BZ6M$-:+:\([KLSWMY3$8-*:>6V2MU"D:4M/$C9TGXJD>(9>U
MEK-P28,ZU3[3+]TN$";VR['=[:'4@EM2D*"FW6U@I41I6CH@@5+'Z67HO7^[
MV"PJL27YUGN$6T7&ZB2_+DPI*G7E+="G$MAQHH;0 M0!3R(3L[L7I[9[HS<<
MHOF0PODN1D=Q;?8@*>2ZN,PU&:92'%()05E3:UGB2 %)&R0:"00,JLMUNLNV
M6N[VN9<H&_>X<>8VX]'T='F@'DGSX\@>:Q966XQCT\V^=>;%;)KJENF*[,:9
M<6KCW%JX$@D\3R)UZ>3598UC6<M9]%R')(DZ8_:K9=V'$NS8C<=]UYYA;#<1
M#8Y);*6=%3VE \=\O*JV61=,)=_>RE]^VPG%WS([!.2'5(451X;L-3H4?_:&
MG]#Y]^/NJ"S+/>K?D-O;GV"?#N4%[8;DPWTO-KT2#I220=$$>OJ*\,HOB<8Q
MF[WEUI3Z+3!>EJ:2K1<#:"LI!^8GCJH_C=LN.+77(W78(<@WF_NS ZTZG[0Q
M[FR.91ZDJ=:4GB//Q<J^KL9_4#I#/[-N>MMRR/'70U;Y:@ER.Z_'/%MP^@4"
MH _0=T&U^O"PNSHMIFW6TM72Y,)<:M;TQL/NH4DGPT3R4- ^@^8U^+SC&8DJ
M="<O]B9DVAGNSHZK@TE<1L:')Q/+:$_$D;.A\0^FJOF=/LA[=YL3=G;?3?,B
MM]V1?_>6@F(VS[J5!:2>[WF_=E);XI4DCM[4GX@,BWV7-,;P%W&;)9I3-P@3
M>XN]1'X:A<F%S0MY;0=5M,IQI2U'NMA <W\9^%1"P8F>6VZ7ZRP+(_&N<6]V
M^;,8GPY*'6=1G&&U)!3L*V9'J#XX&O*\]2[#:+[,L*KC 7?XEK<N(MRY;;*U
M-(!/DJ("?0G9\ ?$?'FH/TQZ>W^QY<Q=KVP\U&[EZ7J5,;>?2)2X"FN91\/,
M^[NE7'8!]"K8)SNJ>&7B_P!POR;+;O>T7_"I]G;D!YM"8\E046^YR4%<5<N(
M*0K1'D >:";3L]QJUSG(5TR&Q0YK+2G7(S]Q:;<0A(Y*44E6P /)/IKS7U)S
MK&X5M@W"9D%D8@7-03"E.7!I+4HGT#:RK2S_ ,":@+W2V5(NDJ2_ @N!_/(M
M\Y**22RU#9:"S_[@IL@#UT!47NO2;(HUY5,#%VE6V9\NQGX5F?@!U#4RX*D(
M5J6DH+;C9 6$J"@4H\*\\0Z"J/3[SB]VO L\^YV:1=;2M,TP%36^_&* %!U3
M?+DD *!V1KR*^<-E%#,RS-PKA'BXTIBW,2IJN1FA,9I9<2=?$!SX%7SJ0OZ*
MJZ]X1F^29E&?NK<QQBW7:Z/(<5+BH@B(["EL14LMH'>+FGF>X7=:5SXE2=<0
MMF%F^.W-BX/6V_666S:4\K@XQ/:<3$&B=ND*T@:2H_%KT/T5BXGGMLS6X7AG
M'WXTZ):G&4)FQ9*'VI'<;"]I4G8\;T?/J*K6_=(KL[9+%'L\& !:,<ML9Z)W
M4MHE.0YL63[J3K7!:&7F]D<1W#OP34PZ;62Z1LFS6]WFR)L+>1SXS\:.I]IQ
M]:6XK;2EO=M2D!94@^$J4.(3YWL -A OV%XK(OT>'>;-'F,N.7&]-KN:7'VS
MI*5.O<EE:0$AM(WH)2$)&@ *VV.9)9LTQZVY#8I46=;)C E1)25)4$I4D@G?
M\E0!4D_./(/SU5D3#,TN^?PI^2HF*9M\R[!;KDF,(GN[Z7$11':;'=/P=KN%
MW2N0\<AY$MQRVY);>B$6V6N$U:\LM^.>Y1&9RVW&DS&F.VVI1;4I);*TA7T\
M3Y .P D$?/\ &)EK>N<3(["_;H[A;>F-W)I3+:PGD4J6%<0>/G1/IYK,MV36
MB[QVY%INMNFL/,&0V['E(<2MH$I+@()!2""-^FQ5-6?IAD5RRSY5OD.XKB*N
M5FDZODN*[)/N@F=Q:DQQVDZ4\T4A._0'Q]R-9U"P:XQ)EO@6QV)%N66Y+<[8
MXPEX!:[+/T[+<0D>BT]A+F_F._.U>0OR=?K9;+2;K<KC!B6Q*$N&:_(2VR$J
MT$JYD\='8T=^=BL)_.<<BP($Z3D%D:A757"!)<N#26Y:OH;45:6?_P NZUG4
M6'??K<B,8.E]LM3&!+;@>[ID^Z)WR3'+_P!J"]A'W6OAY:(5Q(K+%NGF3XF8
M\Z?CPOZI3%\B+@OSV%+C";<#);4ZM12A2%H(#W#:@4IXI7YH++QGJ;;+WB,3
M([LY#L=NDVR%/4Y,GM)2RF2TEQ*5DD<2.03M6N7S5(K??K9=FHKMJN$&8U.9
M4]%7'D)<2^VDI"EH()Y)!4D$CP.0^FN>,$PV[07+.U%B1[Q-Z?*L2+K;(TEL
M]UUFT/1G&VUJ(;[C:WT. *4D?"/()!J6V3$<GQG)6<H8Q_WCW]V\\K+&FLH7
M;Q,7"6V5*4H-D$PUK=X%1"WSQ#FB2%H/9GC\=Z.T_?+.V[+C&5'0N<V%/,!!
M674@J^) 0"KD/&@3Z5\1LZQN9;Y<^'D%D?@P'>U+DMW!I34=SQ\*UA6DJ\CP
M3OS516KHU>F>F^06R?"@&\7+I=;L;;4EX$&6S&EMN-\OF1S>1Y^?>_FJ19=T
MQEWC)9KT*#"-L?&+A#1*4I(M]R?D/#C]"6EMZ^GT'I03JV9YC5[EQHMFR&QS
MY4QHO1V(MQ:=6\V"05H2E1*D@I()'CP?HKZCYQCDMF<[$O\ 97VK6X&IRVY[
M2DQ5E7$)<(5\!*O&CKSXJO)/2NXJD/+M[4: [(S65=S*94D+0T[ =CAT:]5\
ME@:]=5%<>Z,7=[%[9!O\"[JN5F:LL%:9TF J ]&C7"*^\& PA*U("8ZBGO)2
MK2R-;4J@MN?U9PZW1K/)?R2RJBWZ:85OD-3FUMOO **DA85KQQ(/GP2!ZD5O
M[S?+;CD!<[(;A"MD)H@+DS)"66TDG0!4H@#9\56MVP>[Q;[<KM"M@GH.<QKR
MU&8=:2X[&%K8B+4.:DI"@XE:M%0V$[&R0#(NH=EN,F[XI>[1;S>DXY<77W[:
MAUMMQQ+D=UD.-%Q24%Q!<\!2DCBISSO0(;\YA84IMRE7JTA-X*1;B9K>IA5]
MR&O/Q[^;CO=?M^RVQXJAM>3WFU6A#H);5/FMQPO6@=%9&];'_P BJZZ==-;E
M9LOB7Z]P(<4*CWE:(R'$N&WF;.:?2RDCQOB@E93\/,J )&B?OJ [,A]:,5E6
MW'?KC6C%;TVIAMYEMUOG(MXVDNJ2CB=<5>=Z/@*\@A.KYD.-<FK)D-VL[3M]
M9+3$&3-;;<FMK^$A""H%8.]>/IK6WOJAAF%VVX&YY#98K5@0A$R.F:V7(P\)
M2E2.7($^  :J6%T@RC'\!OF(?)<:\2,GL,&WM7I$IM+5I<:AHCJ2L+(<+32T
M*?:[:5**G% A!^([N^8-DLJ/F=KQNV3XUAN$26^U"N<J,L/W%<@.\XBD*4I#
M;NWE+#Q2 I:.*4CG06F,ZQM4Z)"3D-C,R>4B+'%P:[CY4A*T\$\MJVA25#7J
M% ^A%8C$[$WLXE*8N=J?RF-#++T?Y12X_&C[2I0#)4>VDD-E1"1RXHWO2=5&
MY9;QE]\ZDVVW8P6%7K);0M=S>DL)5;"S MSJ@Z LDK;'EOM<TE9.RD?$=I$Z
M>Y#V;+8G+,VP+#D%PNKE_P#>6BF6AX2N/!(/=[SGO*4N<TI2!W-*5\.PM6W9
MMCMW;G+M5^LTU%K3SG*CSVG!%3HG;A"CP&DJ.SKT/T5XJZA8LBS(NZ\DL";2
MZI243S<F0PH@Z(#G+B2#X]:J3(>BU]E85CMKL346$_:,/BV]]#3K: X]'E07
M_=]J2I/%:8[Z-J2I([AV""0=UC/3:4<HLU_FPKT'DWB3.G_+ST);Z5F (J'$
MIB_:QM*0GQ\6ALT%D0<SQ^Z.RV[9?+/,<M[0=EH8G-N&.V1L*6 ?A21YV=#5
M> Z@XNJS)NZ<DL)M*G"V)XN378*QZI[G+CL?1NJ=NG0Z^/8!CUFLS$*!)MN'
MSK?(2VXA"%R7)<!\-$\5)*7!&?2I12H#GY!WH[_'^FLQ_)+'?I\*^)D,Y J?
M<!?GX*W1QMKT9MU"8OVO>W$)W]UI.SH 4$]'4G&%9):+"W?+8Y<[[ <GVYEN
M4A7O,=!0.:"#\0/<!3K[H)61OB=?EQS?&\6R&!C,B=;X5WN<61,AP.XAM3R4
M*3S(3]*E.>/&U$+/GB:A^*81>,7RK'I;ML#\2.O)(SACO-?Z(U-N;<F*LA2A
M\ ::XD(VI)4D<=;(D.6V2X/YWCEV@0%SHL>VW&WR5-N-I5',A492'2%J&T#W
M=0/':MJ3I)&R RL+ZFX_FN-,W>WW2UIXV]F;<(Z9[;BK<EQOGQ>T?@T.6RK7
MW)^BLY.>XRJU,71.16(VV2YVF9@N+79<7R">*5\N)/(@:!]3JJ>O?1.^O8%B
MMHL+,6#(L>'1K?(;9=;0''V)5O?[ *DJ24K3&D(Y*2I([AV""0=[C?3*4O)[
M/?IT.])>1=Y4^<;\]"6^EQ4%,9MQ*8OVH;2D)\;/C9H++BYA89[UQ9@WJTR'
M;/OY1;:FMK5#UO?= /P:XJ^ZUZ'Z*BN;=8<7LN$JO,*[X]=HLV<Q;(Y^66FH
M[KS[J&N*GAR"0D.<U$ D)23HU5UEZ(9",.BVJ[-WB5><;M;<)AR=+@BVW-")
M<9]YI/90'^+XBI"B\G:>XK?/9)F,S"+YE-ZNM[<LWR(FX7''2BW27V5.J1 G
M%Y^0X6E*;"E-KX) 4HE+*=ZV  G5MZ>V*!;)D9B(^GY42W[X^;@^Z^YP\H'O
M"E]W2"3QTH<=G0&S7OC+&.V"'#@XV_"0W=$KF1N,OO.3Q\)6_P U**WO"D;6
M2KU3L^E9..WQR_(N"W($J"W#N#T1DR!Q,E+1XEU(]0@J"@/I"0H>"*I&?T>S
M& FX3<9$!-UQF<N/A?<D (1"?5(+Q5X^ );F)0$>=F T?G%!:MTZK8U8GF!?
M+O:X;,^X-P;>\J>TI,EQ;27 1I7PC2M>?Z#Z*&_7$>I%ERU^1#CS8#-VC3)T
M==L,QM4@)C2G(Y=+8/()46^0\> H"H(>F%PQ?E\@6PSH%LR.V2H,1I]L.N1(
M]O9BJT7%)2% I4=*4-A/TD [2Q=.)UJ.-+3$BLNP,YO5YG+0M.U1Y7RCVU;_
M )2B),<$>HU_[:"PKED-KLTB&Q>+E @OW!T-1&I,E#2I"R0 EL*(*E;4D:&S
MLCZ:UZ.H6+.6Z9<$9+8%0+>Z&9DH7)DM1W"=!#B^6DJ)\:)!J.]0>G\S+LGC
M3(*FHW;Q.]VMF<3\<21+7#[:TCU\!AP['IH#YZ@=HZ8SVK.W+O-ESDWZVQ84
M2(J'<+2@QE,=PH<B\>VVIM!6L /I!*72.WY4*"X7,[QIF3"CO9#8T2+EP]R:
M5<&@N3S *.V.6U\@I)&M[!&O6LIG*+-)O<BS1KM;';O%;[C]O1+0J0TCQ\2F
MP>0'Q)\D?./IKGY&.Y;DBL\L-VL4"9?\BL]H@W&\Q7VFVH$H11S=4%$+*&U+
M+C?;2HE8(T@:56:_T3O]UCY#9KA(O[;SLR_3+/=$R80MZ%STR4ME02E,OFE$
MHI4D[3M (40$@!:%PZM8$W+M+<G)<<DO3+D8<)3<]EWA*#2U$;"CP5P"AOQ]
MV!_* ,WJL+A%O5X@XG);PV5;'<7O33SUM1*B$.->ZOL*,=0=XE""\D@+[:BE
M)TG>@;/H%<I_5./XHF1_UC;_ /$HKJRN4_JG'\43(_ZQM_\ B446.ND,&_@3
MC_\ 54;_ +2:4P;^!./_ -51O^TFE$<N?54/XJ<C^T$'^]==;V[_ &?&_P"2
MC^X5R1]50_BIR/[00?[UUUO;O]GQO^2C^X47QD5'\_R]K ,)O>1RHLJ<U98+
MLM4>,VI:W>"2K0"02!X\JUH#9/@&I!6ES7'?KOPV_6(/^Z_+5LDPN_PY]KNM
M*1RX[&]<MZV/2B-%.ZPXY:U!-Q7=& U&9DSEFU2"BW-N[X*DJX:9]"3SUQ2.
M2M)\UG9OGT?")./LRH-RFF_W(06S#BN/=DEM:^2N"3_N>GC?D_,:B5YZ5Y%=
MX>20DWBSQ8><PVV;^E,)QQ;*^P([JXRBL?=L(0D!8/%2>?Q;*:E^:8O+OL>R
MKLDB-&EV.Z-361);4MMP)0MM2%:((^!Q1!^D"@T&%=8[=?5OQ;VIV',1=[M!
M;?,)YJ(Y[G*?1Q#RAP*PRSS4 K^2O7W) D.)]0[-FCSK-E7-2ZW';E);F0'H
MJG8[A4&WD!Q*2I"BA7D>FO.MC<:G]&V[K8(-HN%PW%8O=YN$@MM<5.MW!$])
M;2=_"I(G?=>=]OT&_&3TMZ9*P,.+N+&/N34Q&HB)UNB.,NOH3LJ+@6M83R/$
M\$^ 0?)V-!Z2NMV+QKDJ"%WA^09[UN9]WLTEU,B8R5=R.VH(TMQ(0M1 .N*%
MJWI*B,V5U5L$6R0+PI5S7:I[?=]\;M;ZFXR KBHOD(^U<5;"@O13I6P DZQ8
M/39<-^R.&>A7R1E=QOI'9UW!*1-2&O7P4^^ \OGX>@WX@N2^SI/OMNEV]=WM
M4J'+@OQVA<;>M\6YUR5(?4_';[@0'%!]""HCD.RD@_R:"1W3KW;[6J_I78\B
M=^0<F@V)9;M<A7>5)$<AU.F_1/O'IYY<4Z/VQ&Y$KJMCJ+PY;ER)B'&WG8_O
M"H#PCK?::4ZXRE[CP4XE"%DI!W\"AZI(&FO736[37<J5 N-N0B]9!;+["[T=
M9+3\00P6G-*\H5[BGXAHCN'P>/G4V[H4F#?;G(>18)4>?.FW!F2[$=,N(_*#
MA6$GN<" XZX0KB"$'AK8Y$)38NKV/Y,_;VK&F\RS<FD2&%)M$A*?=W%%+;ZB
M4#BTLA7%9\*"21X!-;BZ9E;[5?X=E<3.D7&8V'0U$A./AEHKX!QU200A)5XV
MHCT)] 2(A<^E4Z5]9K=OF6R&O%FH;?RJB.XF;P96@NLH4E8':>2V$*0K8 ).
ME$#6RZ@8%.R^\V27;9%MMSEJDM/)N09<]^82EU"W6FEI6D<'4HX*2K:3O92K
M0%!A7[KOCEHL5\N,1%TGFT6Z7.9;;MSZ4W!$8A+I8<*.+B4J4D%2=@!7+RGS
M6PZ@=0U8MTJNF5VZ',6\Q;U/QH[UO>4M+A2>'<: "PD'6_3Q\X]:AM@]G=FT
M8_=;$LV,QWK--M=ONC<-SWUII])0.?)PH)2@@**0.9 /P^E3^_XM/RKIU-L%
MVE1&+A<;>J,](C-*+2%$:Y)2H[U_030:]GJO9;:J/!O<J<Y,9$5FX3$V:0U'
MBR'TH+:'CHI86KN(/!:MI#B.6N0)PKOUTL<%Q*;;#OET2F_"RO/1K3(4TB0'
M5M.!*PV0LH6VH'COSH;KQR'I7=+K+R6%!NT%C'LQGLS+HT[#4N2T4M,LNMLK
M"PGBXB.C14G:"I9'+:0G*E=-)S.+MP;1<(@GQ<I?OK#DB.HM*+L]V26E!*M^
M$NE'('U .OFH&%=7(607!ZUW5+[%P-^N=KCK3 >3&=5%??"6P\1P+O89YD!7
MS*UK1 W>4=2+)B$TQ+JJ>[(;B&9(1!MSTLQHP)'>=[:5<$DI5K?D\%:!XJUK
M8/39<,68>_H5\E97<+ZK3.NX)1F$->O@I]['Q?/P]!OQ^91A%]D9+<;SAMUM
ML%^]V=FUS4SX2I :2RM];3S7%:?B'O+P*%>%?!Y3Q/(,A?5[&1>E6UN5*>6U
M+BPWI3,%YR*R])0VJ.A3X3VP7 \UQ^+U6D'6QO*RG/H^+9+C%GD0+E*<R:8N
M,V]&BN.-L%+2W.2U)20/N->2- E7HDU';9T9:LN/R[/;;@4Q7+W9+A'+C7)3
M;5N3 2&U'?Q*6('W7C7<]#KS)LLQJ;>;OC%QM4F,R[8+FJ2XW(;4I+S2X[K*
MT@@CBH!WD#Y&TZ(\[ 1? NN%GR'&(<W(G7+;*-I>N,IUV"\Q%*&-"06G%CBH
M-E0WHD^?&]'4NQ?-K;ERI;=L$YB3!#:I$6?!=B/(0X"6UEMQ*5<5!*M'6MI4
M/5) @]UZ%(O6$VG&YMUXLV_'IUH=>;C^5^\-H0' "KQQ*-\3O>]5(^G&"'#D
M37ID/'V)\U+3;K]JCNM]Y#?+CS[BU'PIQ9"=Z3R/D[W08L3K%BJH_P#](3=9
M*%3'HS#<.RR%F2XTI7?+24H^-*%)4%K'PA6D[Y$ [*#U4Q>YVTSX%T0]$$N)
M$#B6E_$Y*;:<8T-;*5(?;5R] .6R.*M0Z[=#%R86-JCR;9,FXZY<0&KA&<[$
MAF8\'5CX%A2%I4AK2OB! 4-?%M.4>A<)>0VN6EZ-#M$2S)AR;1"C%II<A#3S
M+3S9Y'@$M2Y*>)V3]J._@\AM4]<<1^3'[@]+GL16FX[S2GK7(0J6U(>2RRXP
MDHY.I4XM"04 _=I^922<UCJO8'6KF\Z;I%BV:.7KA)DVQ]MJ,0VAQ32E%/\
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M"0OBX@.O.$'23Q(3YUR(9N2]7X%KEXZJT%VX0;ED+UHDN1X3SZG5HAR7B(_
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M6AST=;\GBKZ#47NW66VHRS'[-9E/.)N-_D6N7+>@O)C$L19+KR&GR VIQ#C
M21L_<N#U2KCB]",,=QR#D%QEIF(;NUU>1:&9D94=V':FG'/=8Y;4 I*4EQY2
M0H!02X 0#L5C/]&+I+DV^VR+U!^M6W7RXW5,=$)0EO":U+2ME3G/B A4UQ04
M$[(2D'6B5!LKAUHMDRU,OXH7ER'I]I2VF? >CID0YD]F,7VN83S3Q<40H; /
M$D:4-[2U]4[&];;@_.N33CEJ2ER5V8CJ $.2'6&>*2"I14XRMOX=[4DZ]141
MQKH,JT66-!E*Q]$NWO6OLW.%!<0](:B3&)*@X%.*">Y[N@:3X"OB\C21G,=#
MRU=<8E*NJ2Q9Y,EVY1Q&T+DDRE2XJ2>7PEE\A0/G>U#QOP&\>ZTXG%;N;TR=
M)C0[7$F2W)CT%Y##S,0ZDJ:<*>+H1\_$G?DC8!-9<+JGCTV%(D%Z;$]UEQ(K
MK$RWO1WTN2EI1'':6D+TM2T@'6O7>M'5?P/9S;A8]?+'NPEB7:KA MMT]R=,
MQA,D*2GGMPH/%"RE12 5Z!^'R#NK_ASF0==[#<HJ)K5NM%N4]>.<5:6)<ALJ
M$!*7% )64>\S'"$[XE+?+1X["89/G]IQ*6Q$N(N,F9(8<DB-;[<],<2R@@+=
M4EI*BE(*@//J3H;-:&R=2CE'5!RR6-PN62-C\.Z)E)MKJT3?>E/<%(D;#80$
MM)(\*YE2@".!K.R7$;TO*TY#A=QMD.:];/DZ4U<8BWVU(2X5M.)X+20I"EN;
M3Z+"@-IT#7S@/31O 937N<U<J-&QJUV1I+C>ED0U23W5$>-J]X'@ :XGZ? ;
M:=F]MMF11+-/1<69$YT,QY"X#HC..E"EAL/<>'(I2KY_4:^Z\5XY%U Q_%3>
M7+[++"\?MK4^;J.MQ28[JW$(* E)*RI;*T\4;5L)&O*=PV?T8FW+J(UD4RX6
MN2W&OK=TCO2(2W9C+:6>W[HVX5\6FM[7M"1O?D$[49#F73899F&-WD34QX]I
M4I-QB%GD+@T%MO,I*MCB6WV6U@Z/@K3KXMT'K?.K>,V!^.Q*ER9,B8(WNK,&
M$[*7(,A#[C*4!M)Y%2(KRM#T"03H$$ZUOK!#:R2!9EQKA<7+@+LL2K?:Y"VV
MO<I094T1Q.U@DI)WK:=@:6FL#"^B2L339.Y=A-<LN0+N"%JC\28J+>] C1A\
M1T6V5MDJ_E*2LZ'/QL;5TVG6.^VBY6^X1'3"N%Z=DMO,*'-BXS!)(00KPM!2
MA.SL'XCH>*#'LG77'Y^*VB^2XEYA+O4-<XPTVF0\\TRV$]QY:4M[[:>2!SUH
M[ &ZV_V7L95>UVQF5*><:F1H3TIJ"\N*T_(;;<CMJ?">V"XEYKC\7JXD>"H;
M@AZ S@S8U/2,>N3UDMCMH#<Z&\6GXO-*F7#Q<!2ZG2N0\I5R_DZ!J6?8G0S"
MNL2!)CQ(T_)+1=V&6HVD1FX*8"0P!OT(@Z!^;F/!UY"1Y#G%JQB[6FV71<HS
M[V7/<V(\1Q\J2V4!Q:N"2$(3W4%2E: !WNM/:^LN+7=^(TQ+F,FXJ9$%<JWO
ML(EH>44M.MJ6@!3:E:2%#QM:/]]&]CD&%MY#DL"XRG^,>+:+A;G6$I^)Q,I4
M<E05OQH,$>GGE_1YKZP= #:\1E6EY>/M7*/;6HEJO<2 XE]+K*T.-/.)4X1X
M=9864((!*/4#0 3&X=8<:@.O-)>N,YR,9'O"(%KD2BPB.Z6G7%AM!T@.)6C?
M\HH6$[XJUGQ.HUEN5Z;MEG<F7-U2&EN2(,-U^.P'4!QON/)24)*D%*@-[XJ2
M3H*23%(/2F]8F([V$7FVMS7["Q:;F]<H*W@^MIQYU,M(0XGXRY*DJ4DG2RL?
M$GCY^+!TAN^#VRXV+"+ZS$LEUA,LEY^.I4V"\U!:AI>:6E02H\&&5:4D:4%'
M9! 2&??NN%FLMJE2D6_('I,.7 9>@KL\EI]*)C_9:>X%OEP)2YYUY*"GPH@5
ML7NJ%JM[\IF:](ERC<51(L&!;'W9.TQVGE)4V 2>*7 I2]!(YI2?B\&%6KH)
M.MT6]NL2\?A3[G&M"&Q#M[@;4];Y:Y(=?6MQ3CJG%+ 4HG8 ]5$;.]5TPO,#
M*',HL5TMJ;TY+DK6S*BK5'4Q)CPVW6O"PH*#D%I:5^?&TD>>0#/F=<L1AQD2
M/?)TADVXW)U4:UR'?=HH6M"W7@E&VPA;3B5)5I22D@CP:DV297;L4MS4R[..
ME$E]#$9J,PM]V2ZO[E#;: 5*) )\#P 2= $B"6GHH[;;/D<5V\-OR<EL3\"2
M^(G!*9+\B;(>>2GD=(+DU7%&R0$ %1]:DV68;+O%OQ]5FFQXMUQF<W-A.2&"
MXRXL,.,+0M(4#I33S@!!VDE*O.M$,=KJ_C;[MM88=N+DVZRGHK,)-L?]X0ZR
MI =2XWPY-\ XA1*@!Q/($C1K;9?FUNP>%[Y?F[C[FAMQU^1%M[TAN,TV 5N.
MJ0DA"0#OS\P)&]'4:Q?I?+M67)R:\W*-*NDIZ=(GHCQBVT5OMQ&6TM@J)"4-
M0FTDG9425?#O0UW63HY-ZI&4TB?;/<IME?MON]TAKE-PG7-_Z6TV%I07=$#:
MP=<4E)'Q!03O)<NM^*,PEW(2WG+C(]WAQX<5<AU]S@MPA*$ GPAM:B?323_1
M7BK.K,AJ8X[)<;$"YQ+9)"XZTJ;E20P66R"-^?>F//H.?G6CK ZAX;(S#%V[
M5%;L[JTK2H.7%IU784$D)>:4VM*T.I)!"DJ!]0"-[$55TAR!"S%1DL23;YEY
MLUXN,F5!4J7(?@"&E200L( =$%M1.B4E:QH[!2&1B_7BR2[8\[E3SMM6Q+NK
M)E*M[Z(BQ!=?[B4/%)2I:66%+*023P<T/A4!(975*SPHD1V5%OZ'YRG?=X(L
MLE4I:&PDN.=D(*^"0M.U:UM24_=$ Q6V](K_ !_<8ERO%EG6NR7>YW>WMKMJ
MPMUZ6)00T_\ ;"E32!,<WQ *])^YT>6G1[/4QIV#.]ZL;[MO>F)BV=Z.^8$*
M)(1&VPQ]MYH"7(H<'\D=UQ(0D<2D)M/ZW8A;PEQ4^3)AEF*\N=$@/R(S296O
M=PMU""E)6%)(!.]*23H*3O?-YQ971#*9FDS[I)M;!4TH!4F.'R\@['@)$9[X
MCX/'P?(W5F:=)[W8,4OD+ 7+8U:KL;<](MD>VK4XTY&1'8*(VEZ2VIF,T-$$
MHXJ(*N7P[M_H_=)MTB1IEW@G&H=^N5W$=$-8E/&:Q+;6TISGQ2$JF.*"@G9"
M4CQHE0;=OK;B'R<_<5R9T>.E$9UM;MJD(5+:D/)88<924<G4J<6A(* ?ND^@
M4DGXG=:K1'?LS42#?)+MTOBK.^R+6^EV ^(Y?^VHX;3M'!0WK:5\@2 :CN-=
M U6>R18$I6/IE6YVV!BZ0X+B'Y#428Q(4' IQ03W/=T A/@*^+TTD2.Y]-IR
M[Q*NMIN$1,IW*V;ZTW(CJ* E-M;@K:44JWLI2I84/G(&O4T5^8UU>MLFQ7>5
MDLEJ+*L9E/S&VF'"!&1-E1F5)'DK4KW50XIV>7C0Y)!L*J/N?2IY6:X3;XSL
MQYFWS[A<;V^F$M$=^(Y-,Z.R73\/=3+;C:2"3P#I( 55X40KE/ZIQ_%$R/\
MK&W_ .)175E<I_5./XHF1_UC;_\ $HHL==(8-_ G'_ZJC?\ :32F#?P)Q_\
MJJ-_VDTHCESZJA_%3D?V@@_WKKK>W?[/C?\ )1_<*Y(^JH?Q4Y']H(/]ZZZW
MMW^SXW_)1_<*+XR*TN992QA>-3KQ+8?E)B)2&X[&NY(=6H(;;3L@<E+4E()(
M&SY-;JM7D^.0\ML,VT78.^ZS6^"E-+X.-D$%*T*^925 *!^8@&B*W8ZF7FU9
M!F2LJC6NT"T1+4&(]QO:&(06^J1R<3)+>]$!"?+>^39 21HGPC]>W9DRRW1%
MOA-X@_CUZNETG"<'7&%6Y]EITM<04N-@J7H@_&%)(XZ(.[7T1B.W)5VDY)DS
M]^,R/+1=7%12XTXRR^PCBWV.R$]J2ZDCM^IY>%?%7NWT5LJ(4"(Y,NS\:)'N
MD62V^ZVY\H,7%T/2FWB4;TIQ*2"CB1K6]$["/6CVC85Z*X5OM\*;?'EPTP8-
MOO;$MMPRE.!*77F]AI;89<4XD!6DC:"YO5;/&.H5QBXSU'ON5PI+:L6N4M7R
M>'4N%#3$)APH;6 .25*YJ22 2%C82? VZNE_O%C;MMSR?);@J&_'?MLV0J-[
MQ <9)X*0I+("R02%=T+Y D'>SO%N'2[W'IMG%CLLV=<KCED:<X[)N3R2IV4_
M&[6R4)2E*?A3X2D!/S #0 :^X]:I5B:=1?\ %9L>X/,P7[9"9FMNJF-RI;45
M*2H\4MNH<>:YI)*0%C2U>=9 ZNRV5.R9V.J;L]NN<>TW2<U/2X6)CJFT*[:.
M(+C+;CJ4*<)2=A1""!NLF#T<@!+;M]NU\O$MKY/##TUYHJC-PY*)+;2.#:=I
M+K:"M2N2U@#:O UDSNDUOG7>3)5<[PU;IUS9NDNS-N-"(_+:*%(<.VRX!R:;
M44)6$J4G92>2N0:B)USBR+A)BN62XL?(]TC6J^NN*2$VZ7(>#3*-_P#J!04T
M[R&M-OM*/W1 R<KZG3F>D&5Y?A]N:?D66/<EPD37N#;XBJ<3WOA!)02T5 >"
MI.O(WL:S*.BL6)B.01<-:EOW?(K4];I;S\Q+8DO.N+<3.?5QV76G''%@HT=+
M*0/" F9*Z?6Q739>$$OHLZ[*;0I3:P' P6>T2%$'XN))V0?/F@CMVZNRK1\L
MR'L>6[;<3#(R24W.23#6ME#S@904_;@TTZAQ9)1\*OA"U;2-ME>5WJSYSB-H
MM%NARK;?'9"9LAV24.-!MLK^!/$@_3Z^?3QZUA7#H[#NCDP3K[?UQKREGY=B
M)5'0U>%-H2CD\ SM)4A"$+#1;"DI (J27[%6K]<[)</?)L&58I2GV51NWIU*
MD%"VEA:%#@I)\ZTH:&E"@JO#.NLFR]-[+=.H]ND,I=Q!5Y;F^]MK<FB.&$.\
MT?"EI2UR&RCXB"%?$4$:J;=.NJ,7J&+Q'@BUFX6;M%T6^Z(N$90=2HMD/( \
M[2M*DE((*3Z@I4?U_H[C\NPVRSRO?G(5IL#]C8'?XK]W=[')14D AP&,V4J&
MM'9^C4BQ^QRK-!=8N%]NM[<<5M,B>B.EQL: T.RTVGYM[()V3YUH *FL75U>
M&8I.G=2;U<G<H8,)B?8KJU%MS,&4^YVTEAT-I"HI65:>+CP"6SY*PI-;S'^N
M0S%UFW8;:X=WO@<E)E(:NZ%0641^SR<$I*%<TJ]X:X:;V25!01Q5K82.B\.Y
MJD2<AR'([O=5(CHB7.0N.V_ [+P>;+(:90WON)2I14A7+02K:?%;"9TV7,>M
MLTY/D+5\MC;[*+PVF('G6'E(4ME;?8[)1R;;(^U\@4#1\JV$;OG7INPNS!<+
M3'@LMWOY#B2KE=VHC$B8&E/+VL@\&4MI4>9VHJ!2$$ZVQ?K--S+*,=18[;;U
M8[=+3=I$N6;BE:FY$&6S'6&U)!0MOFM6E;^-*DJ^'6C)9W2VWRXO&//NL*<W
M>57B/<([C?>CRE-EM2DA2"@I4VI:"E22"%G^@CSR#I7$REF*B_7B]2EMVF=:
MI;NV$*G19@1WD.<6@$G;39!;""./T$["+P_:$CSFYC%MML"\72/+@1VF;+>V
MIL=SWU;J&2I\)2$%*F5\QQ/$:(Y[%2:Q=4F;Q=8%H7;GX]X?N,Z',B!T+]S3
M%2"IY2M#:%!R,4^ =24'0\U\6_I! C7+Y1N=WOEWG\X![\M;*="&IY3*0AII
M" G;[F] ;V*^,5P-R'U2RS,9\41'+JQ'@Q&>_P!SDAH?;)&AX0IT)821Z\8S
M>_/@!\7+JRJ!<;BXW97G\=LUV9M5PN@E)2M#[A:3R0SKXVD*>0E:BI)!"M)4
M$[KPZ5W?(+Q#RZYWR,3-%[F1H<8W,N,\([BVT-I' !H?"-J )425'YA6QN'2
M:WW&[RY*[E>&K=<;BQ<IUF:<:$63*:[90XK;9<2"66BI"5I2HHV0>2^4EL&/
MQ<<CRV;>IU2)DZ1-<[B@3W'G"XO7@>.2CH?104_C?53-+T[A4TV%B3*OF(S+
MG+M[%P#4?DAR)Q7S4@D*(<6E*-$;5Y4 .0V3GM,XXJ\0H\0PU1'S;4O&1<V6
M):5STM+9#<4_&Z$H?94L@C05\/,I4!,<6Z96_%#;S'G7.9\DV]^W0A)4W]IB
MNK:5V_@0G?'LH"2=JUO94?-8N.=)HF(2HB\6O5\ML5F/$9E0D*8<:G>[,H9;
M6[S:4H++3;:%%M2-A"?HW0?.37&\WW/&,6Q^[.X_'CVOY2N$^/':=D+YNEMI
MIKNH6VD;0XI:BA1\( URV/JX99=<?N#.-V.#,S"\0K:)\^1*E,0U=E2U(;\I
M;"%.K*' E(2A'VM7)2/&]KE.#,9)<(5SB7*YV.\V]MQEBXVU3?<[3A25M+2Z
MA;:T$H0=*0=%(((.ZU]QZ9F>_&F-Y/DD*[MP# E7.*J,AZ<P5%02Z"R6P4J4
MHI4A"%)Y*T?)H(R_U_$F";IC6-3[M94MVM?O(E-LN._**6_=DMMJ]3MYOGR4
M@)"M@J\@9_V7+BY<(]EC8R7<C<N4BWO1OE$"*PXU':D<U/\ #D6U-/-Z(;Y<
ME<2GYZW$7I+8+?:W+;;FY,6"MRV+0PV[X:$ M>[H3L$\?M" =[)&_(K3Y+TE
M=N.:VV\6&Z7*TJ^4)5PF2HSK9<;><ALQDA"'&U(4@H9&TJ2KR=C1UHK!O/M!
MVZRX[;KS-CVZ(T\I]$Z#.O+4>8RN/(5'?0PUHB0I#B%CPI(/'P22!6S/5N6;
MNZRUC;ZK:B]/61N89J MV6A"E)(;U_JE%(1S*N04?N"D%58TCV?K(Y#E18MV
MR"''N=N$&ZI9?9*KBD///%;JU-%0679+ZU%LH"BL@@C0J4*Z?VU#(#9EK+=[
M5>DI[H'*223KT^XV3X__ $T1CX5U*@YW)8198\CM.6.'=777- ,B27 VRH?_
M (@[2RH?R?'TBJ_QKKI)QK!K9=^I-ME,6R1#GN-W7WE#CK[D1MYY:5M  (YM
M,.J;(4=A'Q!!(!F?2# 58/:KV]+CB).R2^2[K(C!_O",'5_:V0KTTE 3L#X0
MHJUX\G B] [$BWIMEUN5]N]E9CS&8MLFR&RU&]Z2M#RD*0VEPJ*'74IY+/ .
M*"=>-%0_(^MTW+\;EP,.9MYNK-ULK,Q5JR-M]"(LZ8&@$R&T'BZ>#C:@!M'(
M*2I0XDS>+U66)++JK+(&-*O9L*;NJ8E3GO:7S&Y*9UOM&0GLA?+D5$'AQ/*M
MRU@!>M+<"_Y!?;ZAB=$F,NS?=TN-KC/(=;&VF4 @K;3RY D^?(K#1TFMZ+LF
M1\IWA5K1=E7=%D+C7N:9JEEPN_ZONG[:HN\"YP"SRX^!HB&/>TM'CVFSS)MH
MA6QV_0';G!CW6_,0RY";#?Q<E#7=6IS2&_0A.U*;]!*LJZBW%JR89=<&M\6Y
M0\IGQ$$RWRP4QWVRM) XGXB->OI]!K('2:%"BV!&.WB]V.5CEM-LC3(BF%N.
MQ3PVVXEUI:%>6T*!X@@@Z(!4#O,HQ-K*;;#C/3IT)^!+9EQID7M]U#K9V#I:
M%(.P2""D^%'6CH@*^Q/JQ/MZ7?KQ@NIM,C)K];XUV7)25#W1^:ZD%D)\-)8B
MK0%<N14WHIT0H[7IAUMMO4RY.082(+;Z[<BXQTQ+JS.(86KCQ>[?^J>22GDC
MXA\0XJ5I6MZ>F=F7%@QGQ(>8@WB?=4MN+!#CTQ,I+R5^/*-37M#QKX?)T=Y.
M&8>O#80A)OMZN\)AEMB&Q<2POW5M (2E*T-)6OQH%3BED\1YWLD(;;>K-W8Q
MF[W3*H6,VI<3(9-LBF;?Q$86AMU:1R=4V=+TC6@D\B=Z WK7XOUO;R7/8L6S
MMRIWURXI:+I;+4E:/]&0Y(FIE2%K&TA" EA)()Y'@$@E52:3T@B.7/W^!?K]
M;Y#5T?N,0L>[*$1R0A27TH#C*MI7R*CRY$'[DI&P?&%T)QVW(@*A/75J;:8<
M*) GB2#(C)BK?4A25E/DJ]Y=2L*VE:3HCUV&&SU5G&5\G8Y8YM]G+<O3ZE2Y
MS49+;<&<8ZT!00=DE0#8X^@'-0(*J\;EUW M<R\XSCTN\6.U0(<RX2?>D,.M
MB4VEU"6VR#S*6G&UKVI.@L<>9VD2ZS].K79+F9T-<LOE-P&EN C4V5[T]XU_
M^)]S] \>?6JXS'HG*?AM8[AJ;I#M4NWV^#.E?*C2&7FHVD)6\WVRXIU+20!V
MRE+FDI7\(U06-E.92[1?+;8\=M0N]XN461,2T[+$5EJ.PIM*U+<XJ/(J>;2E
M(2=DG9 22(=C^=W+.^IN.N0(TJ)CQQ^1,6RN=VUID]T,K0\TD$+4VH+;US*0
M25#>A4VRC"&\CN5ON<2Z72QW:VLO1V9UN+1667B@N-*2ZVX@I*FFE>4[!0-$
M>0?G&NGEIQ1^ [:!)2JW6PV]L..\^;9<#BEK)&U.*6"HJ)\DGZ:"O\VZE95
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M]!<;S6Z9+>+1*&,1KE/%JBQ%*GONQVU\$I>9< 4IP\4I3K96!Y\:E:;_ #<
MZ4HN_426F?=+-9DOW5YI"$>\2$M@K2A*0$[4OX4@ ;V*]6NFMI:Q3%\<[DQ=
MKQ14(Q6E.@E_W1(# >.OB"5(;<\:^)"3Z;!V658E;\SM[$"_H,B"U,9E.12
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M@:BN$^S]&BX%8;1G%SO%S?MN.(M;<=<I';MJE(:[JHZT-I65!;2."UJ4I(2
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M6N:RPI;2R]\'(@E *5E(4L$K*@4W(G%[2FZ*N*8$83E2_>R_P^(O]@,=S?\
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MJV-[/@:\_76W*_K;PY$1A^;&FY),:M4=Z"PZ\^PEW9?>;2VE2^3;"7G 0/5
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M#B' RT'&T\$+"!M*?H!^84'.-[RF?>NF"KLS>C?,V-]M:GL6?FLL-PI*+S%
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M,IY;3L7E"M\>!&2Q%:0AL) /PC:] #9^DZ%>K3#4=M#;#;;;:/N4(2 $_P#
M4',]TZ@Y@ZXQ:D9'&MIB1[PW!N=QNC%N$V3%N<B*A3JE,+2Z6VF65+0D("N\
M20?'&12YV67"\R79&5W*WK^O.+9E1(*&3':C+@LN/)1S;*BHN+64N$['PZ &
MP;U>BLR$I2^RTX$*Y)"T Z5](W\]>G$?0/7?I0<T7C/<K1*B68Y&W;H\?Y=;
MC76?=&+>J2]%GJ99"W%L+0LM-!*BC2>>RI7( U)$WW*VW[O>+MD#Z)-GRZQ6
MKY-AALP>W);MJ9*?*.:P5S'E)42"-)UKR#=[T5F0D)D,M.I"@H!: H CT/GY
MZ].(^@>3OTH*SZ(Q4L6;)X2KY-N,MG)KJAY$A]M;L3<MXH\)2./))"QR'G8(
M\57. V1R[7C$[?%RN\%V/(RM,U]I]E4ALIGLCLE01]K\\%GQR_X ZKI!#+;:
MUK;0A*W2"M02 5$#0W]/BOQMAMI2E--H0I:N2BE(!4?I/]/@?_%!S+'ZDYM?
M9%J89OMLMT]..6R5 5<+JS;VKE)<<<2\XMLL*[R5*0A!0@IX<]@ J01L[UEF
M40X<.:_D4A,6_9K=K:^Y(G,V]B#&BR)J(["'NROME9:1M:@5**0@$$BNAG(K
M+RFU.LM+4T>394@$H/TCZ*_78[3[2FGVVW&UC2D+2"%?\10<YR\ZOL6U7/Z]
M<[CV6X6C&&YUD=MLB.\U>'5.20'=EH"2K3<9"FVTI')PZ&UMD3[I1"F'-\[N
M%UE3Q)ER(*GH#RT*;C.*@L+4E.D@_"24C9/@?3YJS5165]KFRTKL';6T \#K
M7CZ/%>@ &] >?6@YZNG5?(,9O,TW>YN_)O36YNJRTF.C_2X4QXB"K83X[498
M=64Z\M^?4BO6-=K_ "\EQR)F4A3DUN=9);S*FT)]W?D,W%;C8*0-A.DH&]^$
M#YR2;_*$G>T@\O7QZU^\03L@;^G5!35JN5PM?LPX*[C\YRVSG[3CD5N6VVA:
MF@^Y$:60E8*2>+BO4&M=<<ENEDR1['+OE=Q@X^WE"8CUZD.,H?::7;$2$1B\
M4<4A;Y5I9'+T0""I-7MQ&@-#0]!JOAUAM]M;;[:'$.#2TK2"%?\ $?/04'AM
MVDWOJ/A=QO&437X?NN10+;*4ZRTU>&VIT0,*(" %J6V%>4:YAD+2 "=R'J9D
M=[B95<[;8[J]:TN-8RVV\RRVM;/O=W>COJ3S202IH!(Y @$; ]=VVJ.TOM\V
MVU=H\F]I!X'6MCZ/%?92"=D G_A00? KE,A+S6!=9TZZL8Q>O=XKT@!R0IA4
M"+)XJ*0.9"Y"T@ZWH)!V?)IBV]5;]?')+>/Y"XS&O;-B?BN?*4>Y2('O=U98
M7R"64MM+++VBUMQ(*01KR5=/@ ;T/7UKS:C,L@AEIML*45$)0!LD[)_X[H*-
MN627.SY YCMXRNX0+!'RSW)Z\R'64/H95:FY3<=3Q1Q2%/K5I9'(@!&_(KWP
M?(I]K]F[(+UB\U5XGQIF1R(4_P!W"S((N<PI?[:0 HD?'Q2 %>@'FKL=8;?;
M4V^VAQ"_NDK2"%?\17V$A(TD #Z *#F[,;BN^V^]6?'<VN.1V-EJR3%W)F3'
M?5'DN7!*>WW4-\2'$:<X:^'@"-)6!5O9Q+EV^7A4"'-D-)N5[,.2_P 4%Q;?
MN$M>]E) 5S;0K8 \CZ"14P:C-,(*6&FVTJ45%*$@ D^2?^-?9 .M@'7I0<T8
MGE#F)8C@CSF6R+C;F7/=;C;6KI'1/$I<I#:?M?#;R4$E*F@4J'(D<U<0-9+S
M#*LJP/-7[Q=[8M+F-7X7BS+N[3C\-:$J2VE$5+*5M=HZ;45+4%!8)*B4FNI!
M!C!Q+@CL!Q*BM*^V-A1]3OZ37T(K*75NI9:#KH 6L(')0'H"?GH*^Z9VI<+.
M^J#Z[C<):7LC8 9?4@H;W;(2OATD'^5Q\D^$I^?9,&=SV;]:5WN[V8OQ<C3>
M%0KG;NXQJP0OE)#+KP8*-CLQCW.ZODD\NX=H*0+^  )( \^M>?NK/>4]V6N\
MM/%3G <BGZ"?HH*(:R6ZW++8>.8SF,^X8](R2/%^665L/NZ-LG2'X:7@CBKB
MJ/'7RT5I[Q&_ UY(SJZV>58GL@R1Z9 B7Z7:%PV9S#$^04W5<:.\IHH_TA'!
M*4+2DH/A2@%J.DWZS':CMI;8;;;;1]RE"0 G_@!7XJ,RMU#JVFU.-[X+* 2G
M?KH_-04!ACLN)"@V*'DMSDO3LPR:-.YNLN2(P#L];6O@^ GBAP;'GEX^$ZK$
MPWJ2WAO36S(EY6V8@Z:M2[>_+?94IV<VDAQ*" .:T%;*. V?*002?/1:&&T+
M6M#:$K<.UJ"0"HZULGY_'BO@0HX" ([.FUE:!VQ\*CO9'T'R?/\ 30<W9#D]
MVQF=E=WM^0ROE6=8<:<<:DR66T18S\I;<F4D%I7!+:%+5W"E24;*E @:%J=,
M[E>7\2OC]YNEON:&);OR7(B7-%P4VP&6SP=>2VA*EI=[NOAWPX;).R; ,=I3
MG<4VV5\"CD4C?$_-OZ/Z*,1VHS0:C-MM-I]$(2$@?]!0<POY?FL>VX]%<RY$
M>9=,-CWJ/<;M=8]N:DW%X'N)T8ZDK99XLGM#7B02HJ.BF0Y#U#S6W.919(,A
M2[UB$2XWB2ZW&#P=C.LA4)L(X[6E*WGP-:4LVX@[Y'=^/1F9 0'VFG VH*0%
MH!XD>A&_0UZ<1O>AL_/0<\W?J!*M-S=@XQG3]YQ=Y-L5=<C4]&DFR]YY:5J#
MR4=L=U*4?= AKEST$D"OGJCU..,QE1L*R=Z6_8;8W<4S9=]82W-#DAU ;0@,
MK5*4"PXA2=H"04_$%;4GH1N*RRVIMIEI#:R2I*4 !1/J2/Z:^40(S8:#<=A(
M9!2T$M@< ?4#Z*"B8-TFXUF&2L6J\R[G.DY^TVY;I3K2BEI5I2XA(' % 4H
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MSV#ST1Q5L>*#X]H_IE>NL/0:[XU:F[4,CE)A264R%E+'?8DLOJ0%Z)2%=I2
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M;KPN'MA.P\ENC4;!Y4K%+'ET'&Y^0)NS:>+DL,]EUN.4<E@%]'(;&@005;(
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M^<##?9=RCHUCL[[%]UPL9,]&A6J%>6<81!D,PQ);5(=?67'4ON%I!TD(0DK
M.AOQ@Y3]4#Q?';A #-I;=@&SVJZW-4J\LQ9;#4]M+J$1XQ!,E;;:TK6 I( .
M@2?%8'57VELFR2Z6R/@EBN5IQFV]6K=BTG)&[JA*YCK<I*)3*HP3R#"OB0%\
MCR(\I&Z&N@.L'2T=6+!9K8NYJMGR1D-NO/=$;O=TQ'TN]O7).N7'7+SK>]'T
MJ"0?9<;A1+,R,D4OY(ZG2<ZY?)P'=4\M]7NO^L\ =_7<\[X_<C?C=>T#U['0
MZ#;WF+=9KL_,9DOF),R!%N>4VRE)/906UJ=40H^@"1H<E)V*CF+^UI#S'JGC
MV)6FQM08N066#=H\^\W9,)V4W*C]Y*8C!;5[RI TE8"TD'>@=;H:D77KH(OK
M5.Q>1\KV^,QCSLDO6V[69-U@S4O(2CFN.I:4EUO1+:E<@DJ.TG=0[IU[)UWZ
M0W'&IW3W.8[#]OQ^-8;ZB=8 ^U=(S#ZW6UMI#R2PZ ZM&^2TZ(/'QYWW5CVB
M[Q@74"YXGB6"2,LF6?$OKGF/B\-PD(B!YUM:!R0HES[7M('W6R/AULQJ1[;%
MO[UPG6S$;I,Q:S8C!RFYWCWUILQH<MAUQIOLGRIXK0AL)!T>2B5)"?B&OJ+[
M(MUB].G\ ;SP)Q6U7!-SQ'5C3[Y9Y;<P2FE..EWC(0A7)/$H05!7W0(%9)]D
MV;>KP_D6;YDBYY5<,LLE]G2XUF$>,IJUA08BM,]U10#S42X5J.SZ>-5D1O:>
MR%DWNVY#TVDVW*H6)G*K5:$7YJ0FYP$K"'4]Y+8#;Z.0^UE)!) "OGK1I]J6
M%U1Q;%,GQ6'DEMQBZ]1+58[7/C3FH[MS+@/>[S2VEZCI<VVI((4O@2%) \C6
M5G7LAW3*;GF$>QY[\C8IFV10\BN5I78TR71.84RI7!_NITVLQVR4\=@@:.M@
M_K/L=*3U@CYQ)R>!)<AY>YD3*GL>0NXK2XA:#"7.+O+L(YCMI2E*4\?(4=$:
MK&O;ZQ_);_+AV^P.38KD2[/VA-MNK4N?+,!MQQ2'8:4A3!=0TLM[4K>@"$DB
MK0Z+]?8O53I=/S>YQ[1:H-O2X[(9M]Z%S5';;:2XL/:;06G4@D*:*21K>R"*
M&H7:/8UM\3#NG&-7?)'YUOP.PWJS2.W #*KDU<F"RM0/<5VB@*)'W>S]%8=Y
M]D:]Y7T]QK&<SS6SWQ>!RHZ\9?DXL.T&&F%L%F8S[QI_DVI(Y(+924 CU->M
ML]L9_P"3K=<\KP*?8K7E6,W'(,2?5=VI"KFS#C>\J;>0E/\ H[BF=+'E8T=;
MV-5).C?M(3>IV90<?R##)6+.7S$&<JLSJ[HW+]Y@K<0V0XE*1VG IQ!X[5L'
MU!&J&IYTFZ<1^F&!1,=;19R6EO.2#:K6($9Q;BU*44L<U\1Y \J43K9.S7/3
M_P!3Z@_6+=<?M^<7"')E7LR+?<T6X%VWVKW=^.+8D=SXD=F4^GGL?=[X^*L+
M-/:FB85UDMN$R[7;)D2X7F%9U3(E_;=EQI$I*>V7(8;VA'-02>3@5KX@DC1.
MDPSVO+CEUYQIE73Z5!M.7W*ZVFS7%R]M++\Z"'B4*:#>TMK["@'"=A6P4Z 4
M1K=9G[*=ORQ'4IAB]KMD+/\ &K98V([,($6Q,'N=I8)7]L!*T_#I.@G6_.QC
M77V7+CE%LZC#*\PCR+MU'Q.%8)DJ+9.RW%5'#X[Z&R\HJY!X?!R&N/J=^-KT
MF]IR%U>O&(VZP6.4S(ON/2KQ=TNR1NR=F3[KV%CC\:U/I>2/N?#*CKYJTV7^
MUK]:]VRJ9'PZ;<,%P2^,67),D3<FFUQ9+A:"BU%*>3K;9?:"E<DGR>(5JAJR
M>I72ECJ3T:O/3^;/=ALW>S?)QG-M!2FSP #G GSY /'?GTV/6J[F^R]<LB@9
MVK+,QCRKMGF$,8O+E1+)V&X_:[^I"6R\K>P^!PY#RC?+SH5-U5]HSJ:[C_6!
ME5H18F\'RNS0+=)M%R2J2H.R(95'.P.9=;>6>6T@!7 CU55AW[VSF\,M&3M9
MYB:;%E&.9) L7R:]?FC%<<FQ_>&'5S. 2VCLA:E_ KCQT.1-!\3_ &*K:]U$
M&2,3L<FQIWR:JZQKUC0G.E<-IMKE%=[R>SW$-)V%)<XJ^(?173-<R6;VT3EC
M&(1<&PE[(+]E=TNUK$*+?&1'8?MZ&G'%IE%/%QE33H6E8 )  X[.JZ;HA7*?
MU3C^*)D?]8V__$HKJRN4_JG'\43(_P"L;?\ XE%%CKI#!OX$X_\ U5&_[2:4
MP;^!./\ ]51O^TFE$<N?54/XJ<C^T$'^]==;V[_9\;_DH_N%<D?54/XJ<C^T
M$'^]==;V[_9\;_DH_N%%\9%:'/,*MO4?#+SB^2I>7:K]#<AS$LN=M9:6-*XJ
M^8Z^>M]5=^T/U"N72?HEF.7XVU"?N>/VM<J*W-;4ME2TD:"TI4DD>?F4*(BL
M+V/>GC-HO4*[-Y#?GKY"CP7KA=[V_*EQV([@<80PZ5;9#;@"T\-?$ 3NO4^R
M9A;MKFM3)N53+U/NT.[.Y))O+CES$J(DIC+2\1H!M*EI">/'2U>-G=4SE?M)
M]8<+=Z@+N:^G\N/TX38+A-2S:I2%38]T6$^[-DR"$*;TY]M(5R^'X$^:E.2>
MTOE$7K1!LV+/VFY8M<,P.)*<=L#C0B31'4I7^DF4"\MMU(Y)2PE/'8"PKR2Z
MM'$_9KPW#;S9KK:A>'9UBN]QNT9Z9<5R%+E3V@U)6XI6RODE._)\$DUJ[7[)
M6#6;++=?8#N2(%FOKM\M=K-X<5 @RW>9=4TP?A2%E:B1YT?30)!YMC=2>M+G
M2BTW16?V$/RNL(L3CJK0_P!U*?E);7;6KWG7NVTC[4 #PTGGO:C9T#VDNI%U
MZQ7"RV?'6;GCV/9;'QRZHC6-[D4*;;[T[WLO\6]+<YI9+:MMC[O9!H+?ZF>S
MWC/5*^HO5UE9#9[JJV+M4J78[JY!7-@K5R5&>X_=M\B3\Q&SHC=;?'^C>+8I
ME5IOV/05P95CQI.-P&6G3V68"7$N)0$'U4%(3\1.]5SG$]H7K7>.CRL]MUJQ
M9^W/Y _"6+9:'YDBUV^*_*;D3%1U24=]1+30"$+'$!2CRWI,U]H?J7D+OL8W
M#.^E^30F)[N/Q[A\L1[>ZSWVEH3S5'07.3"U%0*>964#8()\@)AG_LO8?U)S
M"Y9'?Y>51Y5Z@,V^Z1K9?7X4>?&:Y<6GD-%)4GXU;&_.S61?O9DP*_QWXR[:
M_!AO8@K$A%@OEEMJVJ<#G!"1Z*Y)'Q>M<W9GF/4CIWU;ZHY7C]RPZ9=<8Z8V
MFZ7EV1:W^Q/2TY+7VF&P_MKDGEM:EKT4CQYV)OG'M79#:<WM2\4%NGXZB\V.
MU7N$NRN Q7;B&B4>^F2D%U*'DK"$,+&A\2A\P7+EG0*P93>H-XCW+)\=N\*U
MIM2IUANRX3LF&E7)++I&PH!140=!0*CHC=>D+H1C]JZC3<RLD[(;;,NZDKN]
MNBW1:8%S=2SV4NOL'84OAH;!&RD$[(W4#]E[(\[R#+NK;/43([7>HMCS%^W1
M&(\!QA4<H985]K*GEA+/%?A&B>7)16=Z%?I]HWJW=LJB,6A6!1K7>.I=WPB$
MV_:I3CK C!U3<QQ0D +(2T06P$A1'W2>7PA:</V0\,M=@LELLMSS*VKQB1)7
M8KA$OKC<NULOI2EV*RYKPP0D? H*T?.]^:D^%>SWAG3VZ6&?B4*5"?QRR2;-
M"_TI2QV)#Z7WE+Y;*W%.H"BLG>R?IJ@7?:QS6X=+[+(M;]B;SAMJ_/W2)'QY
MV8R_'MDI4<R!REM)CLDI'(J6M6U?"DZK(N/M@9A&;M\-NT6%-ZZA8KC]UP".
MIEU2'I4YQMF6R^>X.X&5.!WX>![?K]-#5^]..B5CZ:Y!>[]!G7^]7[(&F&)M
MSO=Q5+?4RSR[30)  2GFH^FSOR36\OW3RSY'FN+Y5<D2%7;#TS$VQ2'>*$B4
MVEMWDG^5\*1KZ*KWV@^J.5=/;ATWM&$/8VQ.SC(OD>1-O49QQF.#'<6'$(0Z
M@E7- TDJ^+?'8WR%3V#VF>I^777$L2L#>$(R*Z95D>/7&\/0Y"X3@M;;;B93
M#:7>6E)4I)05*^+7D &@NZR>SEBU@DW-J!+R,X]=DS$OXN[=G%VH>]\O>.,?
MY@HN+/'?$%1*0*T[/LGXHSC-NLIO6;N-V&6U)Q^8Y?W%2K$6VU-I1$=UM#?;
M44%*N0(T#O0U6^)^U%FMWN.&Y%<6\55B6<YQ(Q6/C\>,\+K;N#CS:)#CI=*5
M*!8Y.([:>*5IT:C6 >V+U!?Q_I]EF:,89=K1GMOOBQ9K#%?:F0G;<P\[RYK>
M6%A?9*5)XCAS3Y5\XUT+BOLW87AT_&I]G8N)GXQ(N4IB7(G+>=ER+@E*93\A
M:MEUQ82/)]->/&A6N9]E+ F,;L]B;8NGN%BQFX8W$29IY"#.UWP3KRL\1I7S
M51<#VNNJD3I/DV8WC&[<]%:Q!F_VB>Y8WX41M]3[2%1"3(69".V\%)=26]\%
M;3Z5ZYCD_4C"NLF39&AO&;KG=FZ-?*2HL>*][DZVB[K<4RE/<YE08"DA7+RL
M ZT>-"E^W?V:<*OD.\Q9[-Q4U?<4BXM,XRRDFWQRHMI3X\+VM6U?/63$Z V"
MU9HO(\?N>465V5)8E7"W6Z[N,PKB^RA"$./,CPI10VA*M$!82.0-:WH+UHE=
M<I^67NS(@G!(4B)$Q^4AM0?EN^[(=E+6HJ*2E*W4MITD>6U[)^:I(OM0YX[T
M4NO5)PX>(%UO M%AL:XCR5VAQ5Q$1+]PD=[XDI&UK0EM'DI 4-T%U6[V=,-M
M<+'(D>/-5'Q:_P R^P$.22K_ $J5WN]S\?$@^\.:3\VQ]%1BR>QCT[L<N$M)
MR6=#M4.X0+;;9U[>>BP(DUI3<B.RV3\""E:OGY#QY\#5=9%[3'4C$+I?L/?.
M%7K*+-E>.6EJ\,0'VH+S-V4I.G&0^I2'6RG?AP@I4#H5\8Y[1_5*+D=N1ERL
M+G6B-U1>P&X(M]KD,R)B@TIQ,QLJ?4EK0X)[9"]_$>0V-#5LV+V4,(LT.[1I
M3V1WIN]8P<8E&ZW9R0?DW9XLH]. 2"0"G7T^22:^OW*6#2K9*@Y#\N9 B;C;
M>.ONW6Y*==7#;D*D-?& "'$.$%*QH@(3]%5[[./M']0NKN4V65?<;2C$,HC3
MG6I#%G=C)M*V5_:FU25/*3)Y)"DJ(;;XK &M&H1U+ZBY=TNZ\>T%D^!S\38;
MQO'+#<Y\*]L...7!MMET=EDH<1VR>2AS(7\10->2:"]X_LHX4+==6;S(R6^S
MKU+M\F;=KM=UR9CGN+J78S7</HVA:=\0!O9WL^:V>0= <=R"9ECL6\9+99F8
MS&)=Z<M%U,=;_;C&,EL^#ILM^J=>2 ?! JFHWM3]0\GZI3(>'8HM_'+1?+;:
MYT%5E==?#4EEEQV2N6'DH:4CO[2V6E<TH/Q D:K[IWF.8=,)O4&^!S"YV69U
MUE.')O4FTOMHAN>27729!4J,E*0EICDDI4KRL\O =8],^B\7I=?)KUCND]5A
M19[?:;+8E.++%KCQDJ"B-K(6XXI?)2R ?A \ZK21/95PJ#E+5\CO9$%Q;W*O
M4. J[.*AQ)<I#B9"VV3X'/O+)WO1/P\1L&I9?M-=2FY36)6QK"IN5L=2$X>_
M>3$D"WR&W(*Y*7TM!TJ0XV0D+;YJ&TD CD"G-P3VD.I>4]6';8,=9GXU;<PD
M8O=/=+&\CW<, H5-,LOE(VZD*[/:\-K!YDC9"V(OLR8)&L^*VEV#+E6_#[%/
ML=OCR)14E<.:A+<A#O\ ODI0 #XUYKXZ9>S1BO2O*8V162=D]RNL*R&QQ7;Q
M>')@CP.:%I80E7A*4EL:U])WO=13K#D>=VWVG^C]DQG([7;L:O\ $N[DRWOP
M'%^\F,VPISN*#R0HE#FFO "%<E*#FP$TE[-/6/,^E73?I7$NS5BNF(9-;<F=
MB0HL5U$]A< R)(4IXN%"^X4K3Q#8X[3Y)W0=9S^AV)7+K%;NITN"ZK++7;S!
M8?#Q#7#3@"U-^A6$NN)"O4!1%1_'/9:P?%LL@7NV_+BV+/<'[E:+)(NCCEMM
M<M_EW'F(Y/%*CW'"/4)*R4@5#/9AZ[=0NJUWAKSJPM(Q^_8XB\0;E%LSL%J,
M\5H_T4+6\Y[PDH<!#H"/*%;3Y&J=]K3KE=XO6N5*PZ?E2(_1B+#EF#:8$MZ)
M=ISS[3LMB6ZRA3:$(@I_]4C2G3KT-!T<CV4<.C17F+9.RJW%%\>O5K=B7A;:
M[+*>[G>,0Z^UH<[SG-!Y)5R\CP->F3>RWBF6KMC]WNN9&XP+4_:)%R9O[S<J
MYP7EEQR/*<'EQ!62=>-;T-#Q53]4/:BSN/.ZA73I4YAKN*8)B5HR9I=Q@/O/
MW-F8EQ?:"T/)2@%#9(5Q.O T=['SU ]IWJ-8[[U(N>/LX@C$^F]TQ]IR'*@O
MN3;@S<68JW$]T/!#:D&0HA7 [\ CP2H:OJX="\6N71^W]-)34TXO;8T*.PVF
M20\$1'&W&=KULGDTC?T^:Q9/L\XA*9GM/,SRBXYDSE[^I1&[DTIM2%#QX1MI
M'P_\:JN\^U%D-KC9,"UCJ9EIZQPL,ALN-.!3L![W8J<*>YLO:>=(4-)^$?"=
M'>GF>TSD-XZG,V"*Y;KMA.6R+_:H4I%D<A*9<@Q7W"6WUR5&1I3*D+/80G9!
M23\X7EU)Z$8WU2OD&[WZ1?(,^';Y%M6]:KDN(94)\I+L=WC]TVHH2?&CX]:T
M]J]E_$,?O-CN>-RLDL[]FM4&TOMP;JMMJ[1(8XL-36]%+P"=I)T"4J()T=53
M?RG,L_U+Z-.M,N3"FQNG;*V9,=U33C:N"?*5)((/](JB>K.?Y<[T;E]*XN1W
MZ/?.E"KO=KY=&ISK<J1;V4MFUE;H/)0=%P:V-^?=E?10=F1/9(PJ'BSN-M3L
MM-C:F,3+-#5?72G'WV7%+:<@*^Z94E2U:\GQX]/%;.R>S)AED1;%CY9G7"W9
M,G)5W.=<5ORIMQ2TIE+C[A^[ ;44A( 2 !H"JF3[2O4.9U:G63$\:-RQS&;_
M &VRW%A-G==><:>:94]+5+[P0T4][DALM*YI2?B!4-8W3OVDNJG5'(5&QV*'
M#Q^\RKQ!BRG\>?+=D<B]T,.//^\ 22I3)2MM*&BDJ&E'1V%I7'V2L&N67.WY
MQW)&0[DC63&U,7AQ$!-U0I*C*#'IS44_%O8.SH#=?5K]DW![1?(MRBO9(I-N
ME7&1;H#MW<7%@*GMNHE!IH^ %]Y:O.R#K1T-5S]TMZKY:[BO0*^9W(L>57N]
M0,HFQ;H_'D(D0TL6]2TH40_P<6I:5I4HIUP*4I2@@J.T@>U[U(QG$[;DN>V_
M$[K&R7IC,RZVP;1#D1UQ'X_9TVZM;J^;:@^%*("2G1 WK9&K]/LQX&[:[#;9
MMOE3(&.XO(QB)'D2E*2NWOI;2XA>M%2B&D:5L$?-6&W[+N.MV2TP3D6=N2\=
MDJ?L=W<OZU3K6E30:4RRZ1_J2A(!0H*!UL^=&HCT@Z[Y9/ZJ2,5ZGWSI_<+8
MS@T7)3=;(RY%0TM]\(#2U./K3Q"?0^.0*3XWJND 00"#L'T-$1U>!VV7@4C$
M+RY/N]JF6YVWRUW&4J0_*:<04+[CBO*E$*/FJ\L_LD].K&KI^J%;YQ7TU=D/
M65;DQ2BI;SO>6I\_^J>[\8WZ*\U<U*"IKS[,N'7FR3K=SO<!4W+W,N1-@W!3
M,F+=%_=.M+U\(T5#CHC2C66W[.V((BA@MW%21FZ<T)5+))NB5!063K[C8'PU
M9U*"%9]TELW42^8O>;I(NT"[8?,<DVN;;)ACN([B0AUM1&PIM:0$J&O('J*T
MEF]G+#+';\1@PXTU<;";C<+A:VWI)6.[-+W?[FQ\:3[PYH'TV/HJT*4%>],^
MB=HZ4/\ '%[OE3EK9C&+!L\^\.285O:*@K@RVKT X@)*BHI3L @$BHQD_LE8
M-E>3W*\SW<DCIN]VC7B;;(EX<9@O7!@H*)*F!\)<(0D'YCZZWHU=-*"G\@]E
MW%,ALE\LR[CE,"TY->)UUO<.!=E,MW%R84%]MT >6SP&@-$;5H^37M^YFQ&-
MD5SNECD9#9&;Y"]TNUIMUU6U!GI$8QDK=9.P5AH@!0UY2DG9&ZMJE!5=R]G'
M&)=JQ*+:IN1V"7A-J%IM-TL]T5&EIA<$)+#BP"'$GM()Y ^4[&C7MD7L]XUD
MU_M]YG3,B;N,+'7<>?>9NBP;C 6""W)WLND*)7R/GD=DFK.I04C>/9!P*[Q8
MD5MS);9&;L,:P7!FVWEV,F\6^.GBTQ+"?]8 DJ3OPHA1&]'5;N\>S5@]ZMF9
MV]^'+8A9VQ;F+HS'DEM*6X*$HCI: 'P )0D>/756G2@A'4SI#8^J;%H-\=NM
MON./RC*M-VM,U429!=4@H66W$_,I!*5)(((]1X%:>Q>SGA>.PL3CVR-/!P^\
MOWJ&^[-6Z])G/H<0\_(6K9=4H.K)W\^M:  JSZ4$*ZB=)K-U+G8Y/N\B[0+E
MBD]4VUSK7,,9YE:D%MQ/(;VA:"4J&O(^BM-:O9TPVSPL8BQ(\Y3&(WN;>;<E
MR45#WF7WN]S\?$D^\.:3\VQ]%6=2@KOIKT0LW2B83BEURDVMJ.N-!LDR[N2(
M%O;4M*REEI7W.BD!.R>*20- D56:?9$A95U/ZBY!U'FSW[+E=_@7"-:+==WF
MXTYJ-'92A$UC02KB\TI0 )V"-GYATA2@KFS]"['CN<3,DQZYY/;!<;BY<YMF
MBW9:+=)F.)TX\MCTY*/Q$ A)5\1&_-:N3[-.,N=++;T\MUSRFU8Q;VI#*H\"
MZEI4ME]2E.M/*T>:"5J^@C?@BK:I04G?/9!Z>7N2K3-\MMLEPH4*Z6>WW=UB
M%=F(:$HCHE- _;."$)3O8)  .ZWT_P!G7#KC#OL5]B<EC(LEBY%-2W)*?]-C
M%DM%/CX4#L-_#\^C]-6=2@KS%^A]CQGJ-.SE<_(+SD4N$Y 9?NUQ5(3"BN/!
MY3#"= )05A)\[("0 =>*QKA[/.(72-?6);,\MY'E,;)IW&41N>P62V4^/"/M
M#>T_/Y^FK,I04W;?92PFU9)&O$5[(R8%SG7&! 7=W%1(3TU#J9/:9/@!?>6K
MSL@ZT0/%9]I]FG"K-#M,6$S<0U9<1DXI%"IA)%O?*2XD^/*]H3I7S5:M*"HX
MGLR8M9YMKE8O<LLQYRWVN#:Y M-Z<C)N4:&GA'3) ^[*4[3R'%1!(WKQ6%</
M9)P:XY>[?ENY(R'<D:R;Y*9O#B( NJ%)4908^YYJ*?BWL'9T!NKII05QU*Z#
M8WU2OD.[WU^^09\:VR+6Z[:KFY$,N"^4J=C.\?*FRI"3XT?'K6LA^S/BL:[8
MA*?G9+-AX(B+\A6F5=5+A178['8:>#>AMP(^?>B23K=6U2@Y_P"I/LQ*ZJ==
M)^3Y!=;E;<<F82W8%ILUV=ARWE^].N/-N!*>*F%MN $$D['H-;J;0O9VP6"B
M_L-6CE;\EQZ'CTZ MY18,"*VXVRVD>J=)<4.6]^AWL595*"DX?LD87'M=ZAS
MI^775R^6ENROS;A?77Y+5L0L+]R:</E#*B-* \J!\DULH_LOX)!EK<M4.9;X
MBLFA9*W;8DDMQ6+A%1Q0XVT!I 4-<TCPH@&K:I05=COL]6/$9%P&+7S,K5;)
MR9?9M$6^.(AP%R2HN.1V_P#TU<EJ4GR0E1VD"MITZZ+8[TUMU_C6TW&[/95+
M5*O<V\2C*?N#BFPW]L) &N"0G0 &O^)J>TH*3L7LB8%8DNM)7D=PBHLTRS6N
M+<;R[):LL*4@H?:B)5_J^2-)V>1   .O%3+&NC6-XGDMCOMH;F)GX_BJ,7A%
MR05)$!+C:P%#YU\FD?%_QJ=4H*AN7LO8;<\S=R-U[(FW7LBBY(JWM79Q,+Y3
M8*.,GL^A40VE)!V-;T ?-9]J]GK%,<@XLU9H\U2L)NTZ\6=+LPZ]ZE][N]PZ
M\I/?<T->-CUU5GTH*.]FOH7*Z77//LHR>%:K=D74&^KGO0;;+7*8@1]J4AE#
MJT(*MN./N'24C;N@/&ZV62>RSA&4Y9/O5R%\0Q>;A'N-XLD>Z.-VVZ2V./:>
MD1Q\*U MMD^@44)Y ZJWZ4%29'[,6'Y1?\FN=P=OS:<OD0I5U@,7)2(KTF(M
ME;+X;T>+G^CMI)!\I!&O)-9>3>SGAV57/)KE<6[HS<\HN5ON;\Z)/6P]$F0F
M0S'>CJ3Y;4E T?4'9V""15H4H*]M?1*RP+SB=XGW+(KW=\-7/7;IUUN2I#JC
M,0$/=PD:4.*0$@ !.O JPJ4H%<I_5./XHF1_UC;_ /$HKJRN4_JG'\43(_ZQ
MM_\ B446.ND,&_@3C_\ 54;_ +2:4P;^!./_ -51O^TFE$<N?54/XJ<C^T$'
M^]==;V[_ &?&_P"2C^X5R1]50_BIR/[00?[UUUO;O]GQO^2C^X47QD5K\@Q^
MV9799EHR6!$NEKN#1:E0Y;0=:?0?5*DGP1_0:V%*(C-QZ98E=Q=Q=<;LLL9
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MO]BJ8TH(=]8MY_"%F'YO:_V*GUBWG\(68?F]K_8JF-*"'?6+>?PA9A^;VO\
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M^S=P_P ,Y4PJ']9/_M#G']F[A_AG*F% I2E I2E I2E I2E I2E I2E I2E
MI2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E
MI2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E
MI2E I2E J']4_P"#MN_M)9?_ -91JF%0_JG_  =MW]I++_\ K*-0A,*4I0*4
MI0*4I0*Y3^J<?Q1,C_K&W_XE%=65RG]4X_BB9'_6-O\ \2BBQUTA@W\"<?\
MZJC?]I-*8-_ G'_ZJC?]I-*(Y<^JH?Q4Y']H(/\ >NNM[=_L^-_R4?W"N2/J
MJ'\5.1_:"#_>NNM[=_L^-_R4?W"B^,BE*40I2E I2E!#^LG_ -H<X_LW</\
M#.5(+Y=U66%[PB!<+D>83V8+0<<\_/HD#7_6H_UD_P#M#G']F[A_AG*F%!#_
M +(COWI9A^8M_K*?9$=^]+,/S%O]94PI00_[(COWI9A^8M_K*?9$=^]+,/S%
MO]94PI00_P"R([]Z68?F+?ZRGV1'?O2S#\Q;_65,*4$/^R([]Z68?F+?ZRGV
M1'?O2S#\Q;_65,*4$/\ LB._>EF'YBW^LI]D1W[TLP_,6_UE3"E!#_LB._>E
MF'YBW^LI]D1W[TLP_,6_UE3"E!#_ +(COWI9A^8M_K*?9$=^]+,/S%O]94PI
M00_[(COWI9A^8M_K*?9$=^]+,/S%O]94PI00_P"R([]Z68?F+?ZRGV1'?O2S
M#\Q;_65,*4$/^R([]Z68?F+?ZRGV1'?O2S#\Q;_65,*4$/\ LB._>EF'YBW^
MLI]D1W[TLP_,6_UE3"E!#_LB._>EF'YBW^LI]D1W[TLP_,6_UE3"E!#_ +(C
MOWI9A^8M_K*?9$=^]+,/S%O]94PI00_[(COWI9A^8M_K*?9$=^]+,/S%O]94
MPI00_P"R([]Z68?F+?ZRGV1'?O2S#\Q;_65,*4$/^R([]Z68?F+?ZRGV1'?O
M2S#\Q;_65,*4$/\ LB._>EF'YBW^LI]D1W[TLP_,6_UE3"E!#_LB._>EF'YB
MW^LI]D1W[TLP_,6_UE3"E!#_ +(COWI9A^8M_K*?9$=^]+,/S%O]94PI00_[
M(COWI9A^8M_K*?9$=^]+,/S%O]94PI00_P"R([]Z68?F+?ZRGV1'?O2S#\Q;
M_65,*4$/^R([]Z68?F+?ZRGV1'?O2S#\Q;_65,*4$/\ LB._>EF'YBW^LI]D
M1W[TLP_,6_UE3"E!#_LB._>EF'YBW^LI]D1W[TLP_,6_UE3"E!#_ +(COWI9
MA^8M_K*?9$=^]+,/S%O]94PI00_[(COWI9A^8M_K*?9$=^]+,/S%O]94PI00
M_P"R([]Z68?F+?ZRGV1'?O2S#\Q;_65,*4$/^R([]Z68?F+?ZRGV1'?O2S#\
MQ;_65,*4$/\ LB._>EF'YBW^LI]D1W[TLP_,6_UE3"E!#_LB._>EF'YBW^LI
M]D1W[TLP_,6_UE3"E!#_ +(COWI9A^8M_K*?9$=^]+,/S%O]94PI00_[(COW
MI9A^8M_K*?9$=^]+,/S%O]94PI00_P"R([]Z68?F+?ZRGV1'?O2S#\Q;_65,
M*4$/^R([]Z68?F+?ZRGV1'?O2S#\Q;_65,*4$/\ LB._>EF'YBW^LI]D1W[T
MLP_,6_UE3"E!#_LB._>EF'YBW^LI]D1W[TLP_,6_UE3"E!#_ +(COWI9A^8M
M_K*?9$=^]+,/S%O]94PI00_[(COWI9A^8M_K*?9$=^]+,/S%O]94PI00_P"R
M([]Z68?F+?ZRO6+GKLJ4RR<6RM@.N)1W78;80C9UR4>YX ]34KI0*A_5/^#M
MN_M)9?\ ]91JF%0_JG_!VW?VDLO_ .LHU"$PI2E I2E I2E KE/ZIQ_%$R/^
ML;?_ (E%=65RG]4X_BB9'_6-O_Q**+'72&#?P)Q_^JHW_:32F#?P)Q_^JHW_
M &DTHCESZJA_%3D?V@@_WKKK>W?[/C?\E']PKDCZJA_%3D?V@@_WKKK>W?[/
MC?\ )1_<*+XR*4I1"E*4"E*4$/ZR?_:'./[-W#_#.5,*AW63QT@SG?WMW#_#
M.5D?94PK[[\7_3#'^>@E-*BWV5,*^^_%_P!,,?YZ?94PK[[\7_3#'^>@E-*B
MWV5,*^^_%_TPQ_GI]E3"OOOQ?],,?YZ"4TJ+?94PK[[\7_3#'^>GV5,*^^_%
M_P!,,?YZ"4TJ+?94PK[[\7_3#'^>GV5,*^^_%_TPQ_GH)32HM]E3"OOOQ?\
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M3"OOOQ?],,?YZ?94PK[[\7_3#'^>@E-*BWV5,*^^_%_TPQ_GI]E3"OOOQ?\
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M "0_\4^3HO\ -H_Y(?\ BLBE!C_)T7^;1_R0_P#%/DZ+_-H_Y(?^*R*4&/\
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M5&_[2:4P;^!./_U5&_[2:41S1]5 M$JZ>R;=W8+2G46V[09,CB-\&^YP*O\
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6X3Q2ZI*E#_AM"=?0!H4I09E*4H/_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
